taug_10q.htm

0001354488-14-000819.txt : 20140219 0001354488-14-000819.hdr.sgml : 20140219 20140219165523 ACCESSION NUMBER: 0001354488-14-000819 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140219 DATE AS OF CHANGE: 20140219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAURIGA SCIENCES, INC. CENTRAL INDEX KEY: 0001142790 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 651102237 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53723 FILM NUMBER: 14626320 BUSINESS ADDRESS: STREET 1: 39 OLD RIDGEBURY ROAD CITY: DANBURY STATE: CT ZIP: 06180 BUSINESS PHONE: 917-796-9926 MAIL ADDRESS: STREET 1: 39 OLD RIDGEBURY ROAD CITY: DANBURY STATE: CT ZIP: 06180 FORMER COMPANY: FORMER CONFORMED NAME: Immunovative, Inc. DATE OF NAME CHANGE: 20120503 FORMER COMPANY: FORMER CONFORMED NAME: Novo Energies Corp DATE OF NAME CHANGE: 20090626 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC WINE AGENCIES INC DATE OF NAME CHANGE: 20040622 10-Q 1 taug_10q.htm QUARTERLY REPORT taug_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2013

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 000-53723

TAURIGA SCIENCES, INC.

(f/k/a Immunovative, Inc.)

(Exact name of registrant as specified in its charter)

Florida		65-1102237
(State or other jurisdiction of Identification No.)		(I.R.S. Employer or organization)

39 Old Ridgebury Road

Danbury, CT 06180

(Address of principal executive offices) (Zip Code)

(917) 796-9926

(Registrant's telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.00001 Par Value

(Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). þ Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer o Accelerated Filer o Non-Accelerated Filer o Smaller Reporting Company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

As of February 18, 2014 the registrant had 522,934,923 shares of its Common Stock, $0.00001 par value, outstanding.

TABLE OF CONTENTS

		Pages
PART I. FINANCIAL STATEMENTS

Item 1.	CONSOLIDATED FINANCIAL STATEMENTS:	3

	Consolidated Balance Sheets as of December 31, 2013 (unaudited) and March 31, 2013	3

	Consolidated Statements of Operations and Comprehensive Loss for the nine months ended December 31, 2013 and 2012, and for the period December 12, 2011 (inception of development) to December 31, 2013 (unaudited)	4

	Consolidated Statements of Cash Flows for the nine months ended December 31, 2013 and 2012, and for the period December 12, 2011 (inception of development) to December 31, 2013 (unaudited)	5

	Consolidated Statement of Stockholders’ Equity (Deficit) for the period December 12, 2011 (inception of development) to December 31, 2013 (unaudited)	7

	Notes to Consolidated Financial Statements (unaudited)	9

Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK	19

Item 4.	CONTROLS AND PROCEDURES	19

PART II. OTHER INFORMATION

Item 1.	LEGAL PROCEEDINGS	21

Item 1A.	RISK FACTORS	21

Item 2.	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS	21

Item 3.	DEFAULTS UPON SENIOR SECURITIES	25

Item 4.	MINE SAFETY DISCLOSURES	25

Item 5.	OTHER INFORMATION	25

Item 6.	EXHIBITS	25

ITEM 1 FINANCIAL STATEMENTS

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS

	December 31,			March 31,
	2013			2013

ASSETS
Current assets:
Cash	$	57,628		$	143,034
Other receivables		1,991			7,906
Investments - available for sale securities		50,000			-
Prepaid expenses		-			19,534
Total current assets		109,619			170,474

Equipment, net of depreciation		26,853			28,382

Other assets:
Deferred financing costs		85,434			-
Advance to acquire Pilus Energy LLC		70,000			-
License agreements, net of amortization		1,373,431			-

Total assets	$	1,665,337		$	198,856

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Notes payable	$	96,425		$	225,000
Convertible notes, net of discounts		558,773			106,425
Accounts payable		302,488			277,053
Accrued interest		51,343			8,004
Accrued expenses		143,737			148,348
Accrued professional fees		233,965			418,668
Total current liabilities		1,386,731			1,183,498

Stockholders' equity (deficit)
Common stock, par value $0.00001; 1,000,000,000 shares
authorized, 401,363,096 and 226,449,077 issued and
outstanding at December 31, 2013 and March 31, 2013		4,013			2,264
Additional paid-in capital		37,943,812			31,000,267
Accumulated deficit from prior operations		(16,244,237	)		(16,244,237	)
Accumulated deficit during development stage		(21,230,874	)		(15,741,675	)
Accumulated other comprehensive loss		(194,108	)		(1,261	)
Total stockholders' deficit		278,606			(984,642	)

Total liabilties and stockholders' equity (deficit)	$	1,665,337		$	198,856

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

													Period from
													December 12,
													2011
													(Inception of
	For the Three Months ended						For the Nine Months Ended						Development)
	December 31,						December 31,						to December 31,
	2013			2012			2013			2012			2013

Operating expenses
General and administrative	$	1,162,138		$	2,703,686		$	4,460,880		$	5,479,420		$	16,602,528
Impairment of advances to Immunovative
Therapies, Ltd. for future stock ownership		-			885,000			-			2,714,049			3,533,214
Depreciation and amortization expense		32,077			587			48,084			8,245			94,671
Total operating expenses		1,194,215			3,589,273			4,508,964			8,201,714			20,230,403

Loss from operations		(1,194,215	)		(3,589,273	)		(4,508,964	)		(8,201,714	)		(20,230,413	)

Other income (expense)
Interest expense		(7,540	)		(3,410	)		(57,839	)		(5,922	)		(74,249	)
Loss on conversion of debt		-			-			(321,000	)		-			(321,000	)
Gain on settlement of law suit		-			-			-			-			20,000
Amortization of debt discount		(397,404	)		-			(601,396	)		-			(625,212	)

Total other income (expense)		(404,944	)		(3,410	)		(980,235	)		(5,922	)		(1,000,461	)

Net loss		(1,599,159	)		(3,592,683	)		(5,489,199	)		(8,207,636	)		(21,230,874	)

Other comprehensive income (loss)
Translation adjustment		5,627			(5,706	)		7,153			-			7,153
Impairment on available for sale investments		(77,500	)		-			(200,000	)		-			(200,000	)
Total other comprehensive income (loss)		(71,873	)		(5,706	)		(192,847	)		-			(192,847	)

Comprehensive loss	$	1,671,032		$	(3,598,389	)	$	(5,682,046	)	$	(8,207,636	)	$	(21,423,721	)

Net loss per share (basic and diluted)	$	(0.00	)	$	(0.02	)	$	(0.02	)	$	(0.05	)

Weighted average common shares outstanding
Basic and diluted		347,748,207			196,957,424			258,387,696			156,677,929

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

							Period from
							December 12, 2011
							(Inception of
	For the Nine Months Ended						Development)
	December 31,						to December 31,
	2013			2012			2013

Cash flows from operating activities
Net loss	$	(5,489,199	)	$	(8,207,636	)	$	(21,230,874	)
Adjustments to reconcile net loss to cash provided
by (used in) operating activities:
Stock-based compensation		3,101,043			2,924,227			11,498,376
Shares issued in Settlement Agreement		-			-			153,000
Impairment of advances to Immunovative
Therapies, LTD, for future stock ownership		-			2,665,050			3,533,214
Amortization of debt discount to interest expense		539,001			3,410			562,817
Depreciation and amortization		48,083			8,245			94,670
Loss on conversion of debt		321,000			-			321,000
Decrease (increase) in assets
Other receivables		5,915			(109,900	)		(1,991	)
Prepaid expenses		19,534			(14,928	)		16,758
Increase (decrease) in liabilities
Accounts payable		85,435			147,524			232,977
Accrued salaries and wages		-			7,846			-
Accrued interest		53,339			(31,600	)		41,191
Accrued expenses		(4,611	)		96,678			86,277
Accrued professional fees		(184,703	)		(98,832	)		(96,437	)
Related party payables		-			90,000			(96,884	)
Cash used in operating activities		(1,505,163	)		(2,519,916	)		(4,885,906	)

Cash flows from investing activities
Purchase of equipment		(5,134	)		(2,940	)		(28,954	)
Purchase of intangible asset - domain name		-			(7,893	)		(7,893	)
Purchase of license		(168,750	)		-			(168,750	)
Advance to acquire Pilus Energy, LLC		(70,000	)		-			(70,000	)
Advances to Immunovative Therapies LTD, for
future stock ownership		-			(2,665,050	)		(3,533,214	)
Cash used in investing activities		(243,884	)		(2,675,883	)		(3,808,811	)

Cash flows from financing activities
Proceeds from notes payable		136,425			150,000			361,425
Repayment of note payable to former chief
executive officer		-			(52,364	)		(125,503	)
Sale of common stock		141,350			5,191,123			7,402,827
Proceeds from convertible debentures		1,378,713			-			1,553,713
Commissions paid on sale of common stock		-			(643,956	)		(643,956	)
Cash provided by financing activities		1,656,488			4,644,803			8,548,506

Foreign currency translation effect		7,153			2,243			34,296
Net increase / (decrease) in cash		(85,406	)		(548,753	)		(111,915	)

Cash, beginning of period		143,034			619,624			169,543
Cash, end of period	$	57,628		$	70,871		$	57,628

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

							Period from
							December 12, 2011
							(Inception of
	For the Nine Months Ended						Development)
	December 31,						to December 31,
	2013			2012			2013

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Interest and Taxes Paid	$	-		$	-		$	-

NON CASH ITEMS
Conversion of accounts payable to common
stock	$	-		$	(65,000	)	$	(95,559	)
Conversion of convertible notes payable to common stock	$	(1,378,354	)	$	(179,572	)	$	(1,557,926	)
Issuance of common stock to settle commissions
on private placement offering	$	-		$	(689,000	)	$	(689,000	)
Conversion of accrued interest on Caete Invest
& Trade, S.A. to common stock	$	-		$	(46,247	)	$	(46,247	)
Purchase of intangible asset - domain name with
common stock	$	-		$	(25,000	)	$	(25,000	)
Investments in available for sale securities	$	(250,000	)	$	-		$	(250,000	)
Impairment of available for sale securities	$	(200,000	)	$	-		$	(200,000	)
Comprehensive loss	$	200,000		$	-		$	200,000
Investment in Green Hygienics, Inc.	$	(106,250	)	$	-		$	(106,250	)
Issuance of common stock	$	778		$	88		$	876
Additional paid in capital	$	2,788,242		$	1,004,731		$	3,823,522
Beneficial conversion features	$	(848,014	)	$	(37,500	)	$	(940,405	)
Additional paid in capital	$	848,014		$	37,500		$	940,405
Deferred financing costs	$	85,435					$	85,435
Licensing Agreement - Warrant	$	(1,139,851	)				$	(1,139,851	)

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

For the period from inception December 12, 2011 to December 31, 2013

											Deficit
								Deficit			accumulated			Accumulated
					Additional			accumulated			during the			other			Total
	Number of				paid-in			from prior			development			comprehensive			stockholders'
	shares		Amount		capital			operations			stage			income (loss)			deficit
Balance at December 11, 2012 (inception)		82,924,466	$	829	$	15,602,529		$	(14,593,526	)	$	-		$	(31,157	)	$	978,675
Sale of common stock under private placement
agreements at $0.05 per share		6,624,332		66		331,150												331,216
Issuance of shares under consulting agreements
between $0.10 and $0.14 per share		14,845,000		148		2,008,152												2,008,300
Issuance of shares in connection with settlement
agreements at $0.14 per share		1,565,000		16		199,484												199,500
Vesting of stock-based compensation						137,247												137,247
Conversion of accrued expenses to common
stock		709,090		7		77,993												78,000
Conversion of convertible debt to common
stock		10,000,000		100		1,013,950												1,014,050
Issuance of stock options						1,400,000												1,400,000
Net loss for the period April 1, 2011
to December 11, 2011									(1,650,711	)								(1,650,711	)
Net loss for the period December 12, 2011
(inception of development) to March 31, 2012												(4,595,168	)					(4,595,168	)
Translation adjustment															28,914			28,914

Balance March 31, 2012		116,667,888	$	1,166	$	20,770,505		$	(16,244,237	)	$	(4,595,168	)	$	(2,243	)	$	(69,977	)
Sale of common stock under private placement
agreements at $0.10 to $0.15 per share		48,844,286		489		5,190,633												5,191,122
Amendment to former chief executive officer's
employment agreement at $0.10 per share		2,500,000		25		249,975												250,000
Issuance of shares under consulting contract for
strategic planning officer at $0.10 per share		2,500,000		25		249,975												250,000
Issuance of shares to purchase domain name at
$0.125 per share		200,000		2		24,998												25,000
Issuance of shares under consulting contracts
at $0.10 to $0.29 per share		30,878,983		308		4,505,881												4,506,189
Issuance of shares to convert Caete Invest &
Trade, S.A. debt under conversion agreement		2,720,000		27		225,792												225,819
Conversion of accounts payable at $0.10 per
share		1,592,920		16		95,559												95,575
Stock issued for commissions under private
placement agreements		5,335,000		53		688,947												689,000
Commission expense paid with stock issuances
under private placements						(689,000	)											(689,000	)
Commission paid under private placement
agreements in cash						(643,956	)											(643,956	)
Issuance of shares to CEO under employment
contract for achieving capital raise goal of
$7,500,000 at $0.25 per share		2,500,000		25		624,975												625,000
Issuance of shares to former CEO under employ-
ment contract for achieving capital raise
goal of $7,500,000 at $0.25 per share		2,500,000		25		624,975												625,000
Issuance of shares to CEO in lieu of salary at a
price of $0.04 to $0.24 per share		360,000		4		47,396												47,400
Issuance of shares to JMJ Financial to obtain
loan at $0.15 per share		200,000		2		29,998												30,000
Beneficial conversion feature related to JMJ
Financial						92,391												92,391
Issuance of shares to CEO as signing bonus
under employment contract at $0.20 per share		1,500,000		15		299,985												300,000
Issuance of shares to CEO as additional
compensation at $0.04 per share		4,000,000		40		159,960												160,000
Issuance of shares to CFO under consulting
agreement at $0.06 to $0.20 per share		2,000,000		20		246,480												246,500

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

For the period from inception December 12, 2011 to December 31, 2013

											Deficit
								Deficit			accumulated			Accumulated
					Additional			accumulated			during the			other			Total
	Number of				paid-in			from prior			development			comprehensive			stockholders'
	shares		Amount		capital			operations			stage			income (loss)			deficit

Issuance of shares to company attorneys for
services rendered at $0.10 to $0.25 per share		2,150,000		22		287,478												287,500
Consulting contract vesting amortization
adjustment						(2,082,680	)											(2,082,680	)
Translation adjustment															982			982
Net loss for the year ended March 31, 2013												(11,146,507	)					(11,146,507	)

Balance at March 31, 2013		226,449,077	$	2,264	$	31,000,267		$	(16,244,237	)	$	(15,741,675	)	$	(1,261	)	$	(984,642	)

Issuance of shares to former chief financial
officer at $0.04 to $0.07 per share		360,000		4		15,896												15,900
Issuance of shares for cash at $0.01 to $0.06
per share		4,569,848		46		141,304												141,350
Issuance of shares to chief executive officer
at $0.02 to $0.08 per share		7,790,000		79		465,921												466,000
Issuance of shares to chief operating officer
at $0.02 to $0.09 per share		5,250,000		53		342,447												342,500
Issuance of shares to convert convertible debt
at $0.02 to $0.09 per share		63,635,121		636		1,202,718												1,203,354
Issuance of shares to consultants at $0.02 to
$0.09 per share		80,461,224		803		2,134,435												2,135,238
Contribution of 2,500,000 shares by chief
executive officer to finalize licensing agreement
at $0.04						106,250												106,250
Issuance of shares to settle accounts payable
at $0.04 per share		1,500,000		15		59,985												60,000
Issuance of shares for loan commitment fee
at $0.03 per share		7,000,000		70		209,930												210,000
Issuance of shares for available for sale
investments $0.06 per share		4,347,826		43		249,957												250,000
Beneficial conversion feature of convertible
notes						848,014												848,014
Stock-based compensation vesting						26,837												26,837
Strategic alliance warrant valuation						1,139,851												1,139,851
Impairment of available for sale securities															(200,000	)		(200,000	)
Net loss for the nine months ended
December 31, 2013												(5,489,199	)					(5,489,199	)
Translation adjustment															7,153			7,153

Balance at December 31, 2013		401,363,096	$	4,013	$	37,943,812		$	(16,244,237	)	$	(21,230,874	)	$	(194,108	)	$	278,606

See accompanying notes to unaudited consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

NOTE 1 – NATURE OF BUSINESS AND GOING CONCERN

Nature of Business

The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies.

In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (“ITL”) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the “License Agreement”) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (“Licensed Products”). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments.

On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.

On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction. The Company traded under the symbol “TAUG” beginning on April 9, 2013.

On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (“GHI”) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, Green Innovations Ltd. (“GNIN”) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8.

On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the “Parties”. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.

On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (“Pilus”), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry). Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (“EBR”) platform. This transformative technology is the basis of the Pilus Cell™. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current (“DC”) electricity, and produce economically important gases. The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules. Pilus’ highly metabolic bacteria are non-pathogenic. Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range. Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD. On January 28, 2014, the acquisition was completed. Pilus will operate as a wholly-owned subsidiary of the Company. As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000. In addition, the Company paid Bacterial Robotics, LLC (“BRLLC”), formerly the parent company of Pilus, $50,000 at closing. In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on June 12, 2013.

Going Concern

As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Management’s plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders’ deficit.

Cash Equivalents

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.

Equipment and Depreciation

Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Asset

Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.

Consolidated Financial Statements

The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

Net Loss Per Common Share

The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.

Stock-Based Compensation

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders’ equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterparty’s performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.

Comprehensive Income

The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income.

Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

Income Taxes

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

Impairment of Long-Lived Assets

Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Research and Development

The Company expenses research and development costs as incurred.

Fair Value Measurements

ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements.

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments classified as Level 1 - quoted prices in active markets include cash.

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.

Uncertainty in Income Taxes

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.

Recent Accounting Pronouncements

Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

NOTE 3 – EQUIPMENT

The Company’s equipment is as follows:

	December 31,		March 31,
	2013		2013		Estimated Life

Computer and office equipment	$	55,085	$	49,951	5 years
Less: accumulated depreciation		28,232		21,569
	$	26,853	$	28,382

NOTE 4 – INTANGIBLE ASSETS

Intangible assets consist of the cost of: (1) a license fee with Green Hygienics, Inc. (see Notes 1, 5 and 8). The Company has paid cash of $143,750 and the chief executive officer contributed 2,500,000 shares of the Company's common stock valued at $106,250 for a total license fee value of $250,000 and (2) A strategic alliance agreement to utilize technology owned by Bacterial Robotics in the cleansing of nuclear wastewater created by the operation of a nuclear power plant. The company paid cash of $25,000 and issued a warrant for up to 75,000,000 shares of the Company's common stock valued at $1,139,851. The Company’s intangible assets are as follows:

	December 31,		March 31,
	2013		2013		Estimated Life

Licensing fee	$	1,414,851	$	-	5 years
Less: accumulated amortization		41,420		-
	$	1,373,431	$	-

NOTE 5 – LICENSE AGREEMENT

Immunovative Therapies, Ltd.

On December 12, 2011, the Company entered into a License Agreement (the “License Agreement”) with Immunovative Therapies, Ltd., an Israeli Corporation (“ITL”), pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all product candidates (the “Licensed Products”) based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covers two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vaz TM (“Licensed Products”).

On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013 and that the Company had complied in all material respect with the License Agreement therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated. No value has been assigned to the ITL shares as they are deemed to be worthless.

Green Hygienics, Inc.

On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1 and 8). The Licensing Agreement with GHI will enable the Company, on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products to commercial entities including medical facilities, schools, and more. The Company agreed to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, GNIN, issued the Company 625,000 shares of common stock of GNIN. The terms of the Licensing Agreement provides the equal recognition of profits between the Company and GHI on the sales by the Company.

As of December 31, 2013, the Company has paid $143,750 of the $250,000 licensing fee in cash and the Chief Executive Officer contributed 2,500,000 shares of common stock of the Company in lieu of the remaining $106,250. The Company will amortize the licensing fee over the five year life of the licensing agreement.

Bacterial Robotics, LLC

On October 29, 2013, the Company entered into a strategic alliance agreement between the Company and Bacterial Robotics, LLC (the Parties) to develop a relationship for the research and development of the NuclearBot Technology that will be marketed and monetized pursuant to a Definitive Agreement. Accordingly, subject to the terms of this agreement, (a) Bacterial Robotics agrees to develop a whitepaper which may be delivered as a readable electronic file, on the subject of utilizing the NuclearBot Technology in the cleansing of nuclear wastewater created in the operation of a nuclear power plant (the "Whitepaper"), which Bacterial Robotics shall deliver to the Company within ninety (90) days of the agreement, which may be extended upon mutual agreement based upon unexpected complexities, and (b) the Parties agree to use commercially reasonable efforts in good faith to (1) identify prospective pilot programs, projects and opportunities for the NuclearBot Technology for the Parties to strategically and jointly pursue, (2) enter into a joint venture, in which the Company will be the majority and controlling owner, for the purpose of (A) marketing and selling products and services utilizing the NuclearBot Technology, (B) sublicensing the NuclearBot Technology and (C) owning all improvements to the NuclearBot Technolgoy, and other inventions and intellectual property, jointly developed by the Parties and (3) negotiate its terms and conditions of Definitive Agreements. As consideration for the Strategic Alliance, the Company issued a $25,000 deposit upon signing the agreement. Additionally, the Company issued a 5 year warrant for up to 75,000,000 shares of the Company's common stock with a value of $1,139,851.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

NOTE 6 – CONVERTIBLE NOTES AND NOTES PAYABLE

Convertible Notes Payable

During the period of February 22, 2013 to December 31, 2013, the Company entered into 8% convertible promissory notes with various individuals aggregating $361,425. The notes are unsecured and are due 180 days from the date of issue. Should the notes not be repaid at the respective maturity date, the lender has the right to convert the unpaid principal and interest into common stock of the Company at $0.025 per share. During the nine months ended December 31, 2013, $265,000 of the notes were converted into 10,600,000 shares of the Company's common stock. The balance at December 31, 2013 was $96,425.

On October 19, 2012, the Company entered into a one year convertible promissory note agreement for $445,000 with JMJ Financial, a California based institutional investor. The note is non-interest bearing for the first 90 days and subsequent to that, the note has an interest rate of 5% per annum. The note, at the holder’s option, is convertible at $0.15 per share and if the price per share at the time of conversion is greater than $0.15 per share, on average for the previous 25 trading days, the conversion rate shall have a 25% discount, with the minimum price of $0.15 per share. The Company paid an origination fee of 200,000 shares of its common stock to secure the loan. On November 14, 2012, the Company received $150,000 and an additional $25,000 on March 27, 2013. The 25% discount created a beneficial conversion feature at the commitment date aggregating $37,500 representing a discount which is being accreted monthly from the issuance date of the note through maturity and is recorded as additional interest expense. At March 31, 2013, the loan balance is $106.425, net of unamortized discount of $68,575. During the nine months ended December 31, 2013, the Company issued 9,900,000 shares of its common stock to convert the note. Under the terms of the original agreement, approximately 4,125,000 shares were required to be issued. To entice the conversion, the Company issued an additional 5,775,000 shares resulting in a loss on conversion of $321,000.

The Company during the nine months ended December 31, 2013 and at various times has entered into convertible debt instruments with interest rates ranging between 8 and 10% per annum. The total proceeds from the notes aggregated $1,378,713. The notes are convertible into shares of the Company's common stock with varying price ranges. During the nine months ended December 31, 2013, the Company recorded a beneficial conversion feature of $848,014. At December 31, 2013, the Convertible notes were carried at $558,773 net of unamortized discount of $377,589.

NOTE 7 – RELATED PARTIES

On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1, 4, 5 and 8). The Company’s former CFO, Bruce Harmon, is the CFO and Chairman of GNIN, the parent company of GHI.

NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock

During the year ended March 31, 2012, the Company sold for cash under private placement agreements 6,624,452 shares of its common stock at $0.05 per share.

During the year ended March 31, 2012, the Company issues to various consultants 14,485,000 shares of its common stock at prices ranging between $0.10 and $0.14 per share. These shares were valued at the market price of the stock on the date of the commitment. These consulting agreements were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions, and other mutually agreed upon services. The aggregate value of the shares has been recorded as stock based compensation.

The Company issues 1,565,000 shares of its common stock in connection with the settlement agreements. The shares were valued at $0.14, the value at the date of settlement

During the year ended March 31, 2012, the Company converted unpaid rent on the corporate office in the amount of $78,000. Accordingly, 709,090 shares of the Company’s common stock were issued at $0.1098 per share. The rent was payable to a party related to the former chief executive officer.

On July 11, 2011, the Company converted a $500,000 debenture along with accrued penalties for being in default and accrued unpaid interest into 10,000,000 shares of the Company’s common stock and recognized a loss on extinguishment of $336,836.

During the year ended March 31, 2013, the Company sold for cash under private placement agreements, 48,844,286 shares of its common stock at an average price of $0.10 per share.

On May 15, 2012, the former chief executive officer’s employment contract was amended to award him an additional 2,500,000 shares of the Company’s common stock at $0.10 per share, the value at the date of commitment. Additionally, his employment contract was amended to award him an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.

On May 15, 2012, the strategic planning vice president was issued a consulting agreement for 36 months. In connection with the agreement, he was issued 2,500,000 shares of the Company’s common stock and an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

The Company issued 200,000 shares of its common stock at $0.125 per share to obtain the rights to a domain name.

On May 21, 2012, the Company issued 2,720,000 shares of its common stock to convert the Caete Invest & Trade, S.A. debt plus accrued interest. The note principal and accrued interest aggregated $225,819.

During the year ended March 31, 2012, the Company converted $95,575 of accounts payable by issuing 1,592,920 shares of its common stock at an average price of $0.06 per share.

On October 19, 2012, the Company issued 200,000 shares of its common stock to obtain a loan at $0.15 per share.

On August 22, 2012, a signing bonus in the amount of 1,500,000 shares was issued to the chief executive officer in connection with his employment contract. The shares were valued at $0.20 per share, the value at commitment date.

In December 2012, the board approved the issuance of an additional 4,000,000 shares to the Company’s chief executive officer. The shares were valued at $0.04 per share, the value at the date of commitment.

In connection with the chief financial officer consulting agreement dated September 1, 2012, and subsequent modification, 2,000,000 shares were awarded at a price ranging from $0.06 to $0.20 per share.

The Company, during the course of the year has issued 2,150,000 shares of its common stock at prices ranging from $0.10 to $0.25 per share for legal services.

Commencing October 2012, the chief executive officer received 360,000 shares (60,000 per month) of the Company’s common stock as salary in lieu of cash. These shares were valued between $0.04 and $0.24 per share. His employment agreement was subsequently modified in December 2012 to begin cash compensation in addition to the 60,000 shares award per month.

During the year ended March 31, 2013, the Company issued to various consultants 30,878,983 shares of its common stock at prices ranging between $0.10 and $0.29 per share. These shares were valued at the market price of the common stock on the date of commitment. There consulting agreement were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions and the mutually agreed upon services. The aggregate value of the shares has been recorded as stock-based compensation.

The Company issued 5,335,000 shares of its common stock and 643,956 in cash as commissions related to the private placement agreements.

During the nine months ended December 31, 2013, the Company issued to its chief financial officer 360,000 shares of its common stock at $0.04 to $0.07 per share for services rendered in accordance with his consulting contract.

During the nine months ended December 31, 2013, the Company issued 4,569,848 shares of its common stock in exchange for $141,350.

During the nine months ended December 31, 2013, the Company issued to its chief executive officer a total of 7,790,000 shares of its common stock at prices ranging from $0.02 to $0.08 per share for services in lieu of cash compensation.

During the nine months ended December 31, 2013, the Company issued to its chief operating officer a total of 5,250,000 shares of its common stock at prices ranging from $0.02 to $0.09 per share for services in lieu of cash compensation.

During the nine months ended December 31, 2013, the Company issued collectively 63,635,121 at prices ranging from $0.02 to $0.09 per share for the conversion of a $1,203,354 convertible debt.

During the nine months ended December 31, 2013, the Company issued to various consultants collectively 80,461,224 shares of its common stock at prices ranging from $0.02 to $0.09 per share.

During the nine months ended December 31, 2013, the Company issued 1,500,000 at $0.04 per share in settlement of legal fees.

During the nine months ended December 31, 2013, the Company issued 7,000,000 shares at $0.03 per share for a commitment fee relating to a convertible debt arrangement.

During the nine months ended December 31, 2013, the Company issued 4,387,826 shares of its common stock to Green Hygienics in connection with a license agreement.

During the nine months ended December 31, 2013, the chief executive officer contributed 2,500,000 shares to the Company to fully pay up the Green Hygienics license fee. The shares were valued at $0.04 per share totaling $106,250.

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

In connection with the consulting agreements and the board advisory agreements, the agreements have as part of the compensation arrangements, the following clauses: a) the consultant will be reimbursed for all reasonable out of pocket, b) to the extent the consultant introduces the Company to any sources of equity or debt arrangements, the Company agrees to pay 8% to 10% in cash and 8% to 10% in common stock of the Company of all cash amounts actually received by the Company and 2% for debt arrangements, and c) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant’s performance.

Warrants for Common Stock

The following table summarizes the activity of the warrants for common stock issued in 2010 in connection with consulting agreements outstanding as at December 31, 2013:

	Number of Warrants		Exercise Price		Expiration Date

Balance March 31, 2013		394,465	$	0.75		8/2014
Exercised		-

Balance December 31, 2013		394,465

The warrants were valued utilizing the following assumption employing the Black-Scholes Pricing Model:

Volatility	241.65% to 244.92%
Risk-free rate	1.34% to 0.41%
Dividend		-
Expected life of warrants		3

Stock Options

On February 1, 2012, the Company awarded 5,000,000 options to purchase common shares to its former Chief Executive Officer and 5,000,000 options to purchase common shares to the vice president – strategic planning, currently the Chief Executive Officer. These options vested immediately and were for services performed. The Company recorded stock-based compensation expense of $1,400,000 for the issuance of these options. The following weighted average assumptions were used for Black-Scholes option-pricing model to value these stock options:

Volatility	220	%
Expected dividend rate	-
Expected life of options in years	10
Risk-free rate	1.87	%

A summary of option activity as of December 31, 2013, and changes during the period then ended, is presented below:

				Weighted
	Weighted			Average
	Average			Remaining	Aggregate
	Exercise		Number of	Contractual	Intrinsic
Options	Price		Shares	Term	Value

Balance March 31, 2013	$	0.10	10,000,000	8.92	$	400,000
Options granted		-	-	-		-
Options exercised		-	-	-		-
Options cancelled/forfeited		-	-	-		-
Balance at December 31, 2013	$	0.10	10,000,000	8.92	$	400,000
Exercisable at December 31, 2013	$	0.10	10,000,000	8.92	$	400,000

TAURIGA SCIENCES, INC. AND SUBSIDIARY

(Formerly Immunovative, Inc. and Subsidiary)

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2013

(unaudited)

In connection with the strategic alliance with Bacterial Robotics, LLC, the Company isued on October 29, 2013 a warrant to acquire up to 75,000,000 shares of the Company’s Common stock. The warrant was valued at $1,139,851 utilizing the Black-Scholes option-pricing model. The assumptions utilized in the claculations are as follows:

Volatility	168.32	%
Expected dividend rate	-
Expected life of warrant in years	5
Risk-free rate	1.27	%

A summary of Warrant activity as of November 31, 2013 is presented below:

	Number of Warrants Outstanding		Exercise Price		Exercise Date
Balance March 31, 2013		-		-		-
Granted - October 29, 2013		75,000,000	$	10.026	October 29, 2018
Exercised		-
Cancelled		-
Balance December 31, 2013		75,000,000

NOTE 9 – COMMITMENTS

On August 22, 2012, the Company entered into an employment agreement with Seth M. Shaw, its chief executive officer. The agreement provides for annual compensation of $132,000. Mr. Shaw previously elected to forgo cash compensation and receive 60,000 shares of the Company’s common stock on a monthly basis. However, as the only principal officer and director, he decided to take the cash compensation as well and is in the process of modifying his employment agreement.

The Company is liable for an additional $25,000 in connection with the strategic alliance agreement with Bacterial Robotics, LLC.

NOTE 10 – SUBSEQUENT EVENTS

On January 28, 2014 (the "Closing Date"),the Company completed its acquisition of Pilus Energy LLC, an Ohio limited liability company (“Pilus Energy”), pursuant to the terms of an Agreement and Plan of Merger, as amended by Amendment No.1 to the Agreement and Plan of Merger, dated January 28, 2014 (collectively, the “Merger Agreement”) by and among the Company, Pilus Acquisition, LLC, an Ohio limited liability company (“Pilus Acquiror”), Bacterial Robotics, LLC, an Ohio limited liability company (“BR”), Pilus Energy, Daniel J. Hassett, PhD, (“Hassett”) and Cody Harrison (“Harrison”), and such other individuals who joined as parties to the Merger Agreement by execution of a joinder agreement prior to the closing of the merger transaction.

Pursuant to the terms of the Merger Agreement, on the Closing Date, Pilus Acquiror merged with and into Pilus Energy, with Pilus Energy being the surviving entity and becoming a wholly owned subsidiary of the Company. The Company will pay BR a total cash consideration of $50,000, payable by February 20, 2014, in connection with the Merger Agreement, and issued Warrants exercisable for up to 100 million shares of Common Stock of the Company (the “Warrants”) to BR, its members and Pilus Energy’s members, who each exchanged, on a pro-rata basis, their membership interests in BR and Pilus Energy for the Warrants.

In addition, the parties to the Merger Agreement, dated November 25, 2013, agreed to amend certain covenants and closing conditions thereto prior to the closing of the Merger. The material changes set forth in the Amendment No. 1 to the Merger Agreement included: (i) the elimination of the covenant that the Company complete a reverse stock split as a condition to closing of the Merger, (ii) a replacement of the requirement to raise $2.25 million by the Company within 180 days of execution of the Merger Agreement, with a requirement that the Company instead agreed to pay BR (a) $75,000 upon the receipt by the Company of the first $1 million of funding for pilot programs or other projects utilizing the intellectual property assigned to the Company by Pilus Energy as part of the Merger and (b) $100,000 upon receipt by the Company of a second $1 million in funding by the Company for the purpose of funding projects that use the intellectual property acquired in the merger, (iii) revise certain Intellectual Property sections of the Merger Agreement to reflect the right to use certain Trademarks and Trade Secrets by Tauriga, (iv) add a covenant that the Company will cover the costs related to Pilus Energy’s intellectual property following the consummation of the Merger, (v) add a covenant that Tauriga shall establish a stock option plan for BR, (vi) add a guarantee that key man insurance is in place by the closing of the Merger, (vi) address a plan for management of Pilus Energy following the merger, and (vii) revise the Merger Agreement to reflect the Assignment (and ownership) of certain Pilus Energy intellectual property, rather than the granting of a License to use such intellectual property.

In connection with the closing of the merger, BR, Jason E. Barkeloo, the Chief Executive Officer of BR, Hassett, Harrison and each member of Pilus Energy entered a Release and Covenant Not to Sue in favor of the Company, and a Standstill and Voting Agreement with the Company, agreeing to restrictions on acquisition of additional Company capital stock, transactions involving Company or proxy solicitations. The BR and Pilus Energy members that were not previously a party to the Merger Agreement (at the time of initial signing on November 25, 2013), also signed a Joinder Agreement binding them to the terms of the Merger Agreement prior to the Closing.

Subsequent to December 31, 2013, the Company issued 54,557,827 shares in connection with the Conversion of Convertible Notes and issued 67,014,000 in connection with consulting agreements.

PART I - FINANCIAL INFORMATION

SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS

We believe that it is important to communicate our future expectations to our security holders and to the public. This report, therefore, contains statements about future events and expectations which are “forward-looking statements” within the meaning of Sections 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934, including the statements about our plans, objectives, expectations and prospects under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You can expect to identify these statements by forward-looking words such as “may,” “might,” “could,” “would,” ”will,” “anticipate,” “believe,” “plan,” “estimate,” “project,” “expect,” “intend,” “seek” and other similar expressions. Any statement contained in this report that is not a statement of historical fact may be deemed to be a forward-looking statement. Although we believe that the plans, objectives, expectations and prospects reflected in or suggested by our forward-looking statements are reasonable, those statements involve risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements, and we can give no assurance that our plans, objectives, expectations and prospects will be achieved.

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of and elsewhere in our Form 10-K dated March 31, 2013 for the fiscal year ended March 31, 2013 and in our subsequent filings with the Securities and Exchange Commission.

THIS REPORT CONTAINS FORWARD LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934. THESE FORWARD LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM HISTORICAL RESULTS OR ANTICIPATED RESULTS, INCLUDING THOSE SET FORTH UNDER "RISK FACTORS" IN THIS “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND ELSEWHERE IN THIS REPORT. THE FOLLOWING DISCUSSION AND ANALYSIS SHOULD BE READ IN CONJUNCTION WITH "SELECTED FINANCIAL DATA" AND THE COMPANY'S FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED ELSEWHERE IN THIS REPORT.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

We are a Florida corporation formed on April 8, 2001. We were originally organized to be a blank check company.

On June 8, 2009, the Board of Directors approved the change of name to “Novo Energies Corporation”. As described in a report filed with the United States (“U.S.”) Securities and Exchange Commission on June 26, 2009, a majority of shareholders executed a written consent in lieu of an Annual Meeting (the “Written Consent”) effecting the change of the name of our business from “Atlantic Wine Agencies, Inc.” to “Novo Energies Corporation” on June 8, 2009 to better reflect what we then intended to be our future operations. We filed an amendment to our Articles of Incorporation on June 8, 2009 with the Florida Secretary of State to affect this name change after receiving the requisite corporate approval.

On June 23, 2009, the Board of Directors approved a 3-for-1 forward stock split. Accordingly, all share and per share amounts have been retroactively adjusted in the accompanying financial statements.

On July 30, 2009, Novo Energies Corporation (“Novo”) formed a wholly-owned subsidiary, WTL Renewable Energy, Inc. (“WTL”). WTL was established as a Canadian Federal Corporation whose business is to initially research available technologies capable of transforming plastic and tires into useful energy commodities. Simultaneously, WTL also intended to plan, build, own, and operate renewable energy plants throughout Canada utilizing a third party technology and using plastic and tire waste as feedstock. On May 8, 2012, the name was changed to Immunovative Canada, Inc.

On May 17, 2011, Novo entered into an exclusive memorandum of understanding with Immunovative Clinical Research, Inc. (“ICRI”), a Nevada corporation and wholly-owned subsidiary of Immunovative Therapies, Ltd. (“ITL”), an Israeli corporation pursuant to which the Company and ICRI intended to pursue a merger resulting in Novo owning ICRI.

In April 2012, the Board of Directors approved the change of name to “Immunovative, Inc.” As described in a report filed with the United States (“U.S.”) Securities and Exchange Commission on April 30, 2012, a majority of shareholders executed a written consent in lieu of an Annual Meeting (the “Written Consent”) effecting the change of the name of our business from “Novo Energies Corporation” to “Immunovative, Inc.” on April 2, 2012 to better reflect what we then intended to be our future operations. We filed an amendment to our Articles of Incorporation on April 30, 2012 with the Florida Secretary of State to affect this name change after receiving the requisite corporate approval.

On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.

On March 13, 2013, the Board of Directors approved the change of name to “Tauriga Sciences, Inc.” from “Immunovative, Inc.” We filed an amendment to our Articles of Incorporation on March 13, 2013 with the Florida Secretary of State to affect this name change after receiving the requisite corporate approval. The Company’s symbol change to “TAUG” was approved by FINRA effective April 9, 2013.

In March 2013, the Company signed a Memorandum of Understanding (“Marvanal MOU”) with Marvanal, Inc. (“Marvanal”), a company who is an approved vendor with the State of Connecticut public school food lunch program (“CT Food Program”). Marvanal’s lactose-free dairy products are authorized for the 2012-2013 CT Food Program and is currently developing a comprehensive line of dairy products utilizing a specific food-protein concentration-based technology. The Marvanal MOU was for the Company to acquire the exclusive marketing rights within the State of New York for Marvanal’s lactose-free, dairy product line. The Company is not pursuing the Marvanal MOU.

In May 2013, the Company signed a Memorandum of Understanding (“Constellation MOU”) with Constellation Diagnostics, Inc. (“Constellation”). Constellation is a developer of camera-based technology with the goal of preventing skin cancer through early detection. Under the terms of the Constellation MOU, the Company and Constellation will establish a joint venture partnership to develop and commercialize a novel, imaging-based diagnostic technology for use in predictive and preventative oncology. Constellation has already begun product development in collaboration with professors at the Massachusetts Institute of Technology (“MIT”) and Harvard University. The Company made an initial investment in Constellation of $100,000 for a 2% equity stake. The Constellation MOU provides the potential of the Company earning an equity stake in Constellation of up to 35% with up to $1,000,000 in investments.

On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the "Parties". Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.

On November 25, 2013, the Company executed a definitive agreement to acquire Pilus, a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry). Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (“EBR”) platform. This transformative technology is the basis of the Pilus Cell™. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current (“DC”) electricity, and produce economically important gases. The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules. Pilus’ highly metabolic bacteria are non-pathogenic. Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range. Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD. On January 28, 2014, the acquisition was completed. Pilus will operate as a wholly-owned subsidiary of the Company. As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000. In addition, the Company paid Bacterial Robotics, LLC (“BRLLC”), formerly the parent company of Pilus, $50,000 at closing. In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.

The Company has signed Memorandum of Understandings (“MOU”) and/or Letter of Intents (“LOI”) with various groups and/or companies and is currently negotiating for completion of the respective agreements to include one or more operations into the Company. These MOUs and/or LOIs have all been released as public information through a Form 8-K and/or a press release. There are no guarantees that the outstanding MOUs and/or LOIs will be finalized.

The following Management Discussion and Analysis should be read in conjunction with the consolidated financial statements and accompanying notes included in this Form 10-Q.

RESULTS OF OPERATIONS

Three months ended December 31, 2013 compared to the three months ended December 31, 2012

Revenue. The Company is currently developing its business, and as a result has no products or services to offer and no revenues.

Selling, General and Administrative Expenses. For the three months ended December 31, 2013, selling, general and administrative expenses were $1,162,138 compared to $2,703,686 for the same period in 2012.

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership. For the three months ended December 31, 2013, the impairment expense was $0 compared to $885,000 for the same period in 2012. The Company, under the license agreement with Immunovative Therapies, Ltd., advanced funding to facilitate research and development. The Company impaired the advances as the value was undeterminable at the time.

Net Loss. We generated net losses of $1,599,159 for the three months ended December 31, 2013 compared to $3,592,683 for the same period in 2012, a decrease of 43.8%.

Nine months ended December 31, 2013 compared to the nine months ended December 31, 2012

Revenue. The Company is currently developing its business, and as a result has no products or services to offer and no revenues.

Selling, General and Administrative Expenses. For the nine months ended December 31, 2013, selling, general and administrative expenses were $4,460,880 compared to $5,479,420 for the same period in 2012. The expense for 2013 is primarily composed of a stock-based compensation ($3,101,043), accounting fees ($103,015), legal fees ($207,748), and consulting fees ($272,568).

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership. For the nine months ended December 31, 2013, the impairment expense was $0 compared to $2,714,049 for the same period in 2012. The Company, under the license agreement with Immunovative Therapies, Ltd., advanced funding to facilitate research and development. The Company impaired the advances as the value was undeterminable at the time.

Net Loss. We generated net losses of $5,489,199 for the nine months ended December 31, 2013 compared to $8,207,636 for the same period in 2012, a decrease of 33.2%.

Liquidity and Capital Resources

We continue to fund our operations through private placement offerings and other financings.

During the nine months ending December 31, 2013, the Company sold 4,569,248 shares of common stock for a total of $141,350.

During the nine months ending December 31, 2013, the Company issued Convertible Notes aggregating $1,515,138.

At December 31, 2013, we had cash and cash equivalents of $67,628 compared to $143,034 at March 31, 2013.

Cash Flows

Net cash used in operating activities amounted to $4,885,906 for the period from December 12, 2011 (inception of Development Stage) to December 31, 2013. Net cash used in operating activities for the nine months ended December 31, 2013 and 2012 was $1,505,163 and $2,519,916, respectively.

During the nine months ended December 31, 2013, we used $243,884 in investing activities, primarily the acquisition of the license agreement.

During the nine months ended December 31, 2012, we used $2,675,883 in investing activities primarily related to the advances to Immunovative Therapies LTD, for future stock ownership.

During the period from inception December 12, 2011 (inception of the Development Stage) to December 31, 2013, we generated $8,548,506 net of $643,956 in cash paid for commission and issued 5,335,000 shares of the common stock for commission paid with stock.

During the nine months ended December 31, 2013, we generated cash from financing activates of $1,656,488 primarily from the sale of common stock. During the nine months ended December 31, 2012, we generated cash from financing activities of $4,644,803 primarily from the sale of common stock.

We do not believe that our cash on hand at December 31, 2013 will be sufficient to fund our license agreement requirements if all the conditions of the license agreement required of the licensor are met. We will continue to seek additional equity financing. However, there is no assurance that we will be successful in our equity private placements.

Going Concern Qualifications

The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company had no revenue and net losses of $5,489,199 for the period ended December 31, 2013 compared to sales of $0 and net loss of $8,207,636 for the nine months ended December 31, 2012. As discussed in Note 1 to the financial statements, since inception of the Development Stage (December 12, 2011) the Company had losses of $21,230,874 and there are existing uncertain conditions which the Company faces relative to its obtaining financing and capital in the equity markets. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company had working capital deficit and accumulated deficit during the development stage of $1,277,112 and $21,230,874, respectively, at December 31, 2013, and used cash in operations of $1,505,163 in the nine months ended December 31, 2013. The Company is highly dependent on its ability to continue to obtain investment capital from future funding opportunities to fund the current and planned operating levels. The unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to bring in income generating activities and its ability to continue receiving investment capital from future funding opportunities. No assurance can be given that the Company will be successful in these efforts.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean a company's controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its chief executive and chief financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC's rules and forms and that information required to be disclosed is accumulated and communicated to the chief executive and interim chief financial officer to allow timely decisions regarding disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are not effective as of such date. The Chief Executive Officer and Chief Financial Officer have determined that the Company continues to have the following deficiencies which represent a material weakness:

1.	The Company does not have an Audit Committee;
2.	Lack of in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;
3.	Insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting;
4.	Insufficient written policies and procedures over accounting transaction processing and period end financial disclosure and reporting processes.

To remediate our internal control weaknesses, management intends to implement the following measures:

●

The Company will add sufficient number of independent directors to the board and will form an Audit Committee with a qualified person to chair the committee.

●

The Company has hired a part-time chief financial officer and will add sufficient accounting personnel to properly segregate duties and to effect a timely, accurate preparation of the financial statements.

●

The Company will hire staff technically proficient at applying U.S. GAAP to financial transactions and reporting.

●

Upon the hiring of additional accounting personnel, the Company will develop and maintain adequate written accounting policies and procedures.

The additional hiring is contingent upon the Company’s efforts to obtain additional funding through equity or debt and the results of its operations. Management expects to secure funds in the coming fiscal year but provides no assurances that it will be able to do so.

Changes in Internal Control over Financial Reporting

Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

The Company’s management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of the control system must reflect that there are resource constraints and that the benefits must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of December 31, 2013, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.

The Company, as of the date of this report, has funded ITL approximately $3.7 million under the Licensing Agreement and other related costs in connection with raising the capital and fulfillment of the Licensing Agreement by the Company.

ITEM 1A. RISK FACTORS.

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the nine months ended December 31, 2013, the Company issued 4,569,808 shares of its common stock in exchange for $141,350.

During the nine months ended December 31, 2013, the Company issued to its chief operating officer a total of 5,250,000 shares of its common stock at prices ranging from $0.02 to $0.04 per share for services in lieu of cash compensation.

During the nine months ended December 31, 2013, the Company issued collectively 63,635,121 at prices ranging from $0.02 to $0.09 per share for the conversion of convertible notes.

During the nine months ended December 31, 2013, the Company issued to various consultants collectively 87,461,264 shares of its common stock at prices ranging from $0.02 to $0.09 per share.

The Company issued 4,347,826 shares of its common stock to Green Hygienics, Inc. (“GHI”) as part of the licensing agreement with GHI.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None

ITEM 4. MINE SAFETY DISCLOSURES.

None

ITEM 5. OTHER INFORMATION.

None

ITEM 6. EXHIBITS.

Exhibit 31.1		Certification of Chief Executive Officer and Interim Chief Financial Officer

Exhibit 32.1		Certification of Chief Executive Officer and Interim Chief Financial Officer

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Exhibit 101

101.INS		- XBRL Instance Document

101.SCH		- XBRL Taxonomy Extension Schema Document

101.CAL		- XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		- XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		- XBRL Taxonomy Extension Label Linkbase Document

101.PRE		- XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TAURIGA SCIENCES, INC. (formerly Immunovative, Inc.) (Registrant)

Date: February 19, 2014	By:	/s/ Seth Shaw
		Seth Shaw
		Chief Executive Officer and Interim Chief Financial Officer

EX-31.1 2 taug_ex311.htm CERTIFICATION taug_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Shaw, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Tauriga Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 19, 2014	By:	/s/ Seth Shaw
		Seth Shaw
		Chief Executive Officer and Interim Chief Financial Officer

EX-32.2 3 taug_ex321.htm CERTIFICATION taug_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Seth Shaw, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(a)	the quarterly report on Form 10-Q of Tauriga Sciences, Inc. for the period ended December 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 ; and

	(b)	information contained in the quarterly report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Tauriga Sciences, Inc.

Date: February 19, 2014	By:	/s/ Seth Shaw
		Seth Shaw
		Chief Executive Officer and Interim Chief Financial Officer

GRAPHIC 4 img001.jpg begin 644 img001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WXD`9--\Q M?6B3[AJ&@";S%]:/,7^]4-%`$WF+Z_I1YB_WOTJ&B@";S%]:/,7UJ&B@"?S% M]:3S%_O5#10!-YB^M'F+ZU#1Q0!-YB^M'F+ZU#10!-YB^M'F+_>J&B@";S%] M:/,7UJ&B@":3[AJ$=*FD^X:A[4`%%%%`!1124`+17-^*O%:^&Q;CR!*TI^9F M8@*/P%=!%*)H(Y5&!(H89R.HS0!)111^=`!32V`2<`#KGM]>:IZQ?-INESW2 M[-Z+\@HQVI:Y# MP#J$TVF7&FWAF%Y8R^6ZS=0#T&>^.:Z_.10`4444`%%%%`$TGW#4/:II/N&H M>U`!1110`?@>F?K5>ZOK6SA>:YN(XHT4LQ9AT')QS576]*;6-,DM4NY[5STE MA;:<^_M7`7GP]M=+1;W4]5EN+=0-T'\$!)Z'CWZT`8'BC5WUW58+UG2V MMIGV0KCYO*!QYC>O/\J[[PQ.D]U-;V_B'^TI8T&<;@%'3GC'Y5RVLZ=I=YJ! MCU2_GAN8@L3&UM@;:T_NHS=3U&36]X`TZ+0FU:UNYX1>+,%(#?>3&00#V.>* M8'9!+H8S*GXGGI]*P-?\56OA^.+[3=>9++RD=NNXX'4YZ>U9_C?QG:6FD26> MFW4<]Y^",#U%("UX MH\;2Z[;?8XHY([8L&S(1N8]N!TKGM*NY-/U6UNHB%>*0,"PX..H_*N]T[X96 M0;F!Z')/\`2@#( MTWQH9KB:[ELK6.T>9(I#$V9HV;(5W!`RI]:[@=*Q)]%ANO$?VZ54>(6PA*8S MN(;()'UK;Y[]:`"BBB@`HHHH`FD^X:@J>3[AJ"@`I:2FRB0PL(G".1\K,NX# M\,B@&/K.U#2+._E$\T"-=1X,4KY)1A]TCMUK/:YUA=>ATS[9;$/;M,9?LYXP M<8^]5?7-6U33_L]O:-'-Z\\RWD5\QO`^UP,8VG(P<8& M*TM2U1X8-(FLW0Q7=W$A)'6-@3Q^E/UF_N+&YTM(&`%S=B*0D9RNTG\^*%%[ M#]JK7.7LO!.D:"HUB\\^YV?/Y;KDJ3T^7G<016EI.@";2)FN+.$?;C+--'(A M\S+'*#/L/7I3--D\1:II\M]!JML")I42W>U&T[6(&6!SVJS9>(IKZ?19"%BA MO+>9YD(SM9,=#[N>M!T&*Y?4/$%W!XB58BG]EV\L=O M=$C)\R0'!![!?ES]:ZC_`#S2E%K4J,U+8*6DHJ2@HHHH`GD^X:@J>3[AJ"@` MHZ&BB@#!G?\`XKJV7//V!^I_VA69IL6KZK=:AK%E+9""]V*VM;N8+W5M!M[>5)9?M? MG%8V#84(V6X[-N.>]5SJ>FV6KQ:8++9+"RQ0D*`,."3M^F.11[770?L=+%'2+L3Z#!I3 MZ@=,U*P`AF7"AOE&,@-QM(PZ?90O+>.\:!,X^5`R@9 M.>>/:M;5TL[K4DMY-%3498XP\KD*/*4G`P3R>_'M3[^:PTE++3%TZ-H+MBHB M`"HN""20!R>:.>*U#V4[6N8EMH>O7GAZ>"2>RC_M#=-()(G\P,_(R0<9'`_" MNB\/Z@VHZ)#+*<7"9AF!_AD4[2/TI]YJ:V6IV5DT)/VDD>9D!01Q@>I[XJ]% M!#"7,4:IO8NV!C<3W-3*?,BH4N5W).YHHHK,U"BBB@">3[AJ"IY/N&H*`"BB MB@`JK>6%M?\`EBYCWB-MRC)'/OCK^-6J*`*5]I5GJ/E_:8B6CR$*L5(!ZC(( MX]JEDLX)/(#1@B!@T?)^4@8JQ10!5-C;?V@+XJ?M&W9N#'!'/4=#U-,DTRRF MN$N)(`TJ2B56. EX-101.INS 5 taug-20131231.xml 0001142790 2013-04-01 2013-12-31 0001142790 2013-12-31 0001142790 2013-03-31 0001142790 2012-03-31 0001142790 TAUG:NumberOfSharesMember 2012-03-31 0001142790 TAUG:NumberOfSharesMember 2013-03-31 0001142790 TAUG:NumberOfSharesMember 2013-12-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2013-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001142790 TAUG:DeficitaccumulatedfromprioroperationsMember 2012-03-31 0001142790 TAUG:DeficitaccumulatedfromprioroperationsMember 2013-03-31 0001142790 TAUG:DeficitaccumulatedfromprioroperationsMember 2013-12-31 0001142790 TAUG:DeficitaccumulatedduringthedevelopmentstageMember 2013-03-31 0001142790 TAUG:DeficitaccumulatedduringthedevelopmentstageMember 2013-12-31 0001142790 TAUG:AccumulatedothercomprehensiveincomelossMember 2012-03-31 0001142790 TAUG:AccumulatedothercomprehensiveincomelossMember 2013-03-31 0001142790 TAUG:AccumulatedothercomprehensiveincomelossMember 2013-12-31 0001142790 2012-12-31 0001142790 2011-12-11 0001142790 2012-04-01 2012-12-31 0001142790 2011-12-12 2013-12-31 0001142790 TAUG:NumberOfSharesMember 2012-04-01 2013-03-31 0001142790 2012-04-01 2013-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2012-04-01 2013-03-31 0001142790 TAUG:NumberOfSharesMember 2013-04-01 2013-12-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2013-04-01 2013-12-31 0001142790 us-gaap:WarrantMember 2013-03-31 0001142790 us-gaap:WarrantMember 2013-04-01 2013-12-31 0001142790 us-gaap:StockOptionMember 2013-04-01 2013-12-31 0001142790 us-gaap:WarrantMember 2013-12-31 0001142790 TAUG:DeficitaccumulatedduringthedevelopmentstageMember 2012-04-01 2013-03-31 0001142790 TAUG:AccumulatedothercomprehensiveincomelossMember 2013-04-01 2013-12-31 0001142790 2013-10-01 2013-12-31 0001142790 2012-07-01 2012-09-30 0001142790 2014-02-18 0001142790 TAUG:DeficitaccumulatedduringthedevelopmentstageMember 2012-03-31 0001142790 TAUG:Warrants1Member 2013-04-01 2013-12-31 0001142790 TAUG:Warrants1Member 2013-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure TAURIGA SCIENCES, INC. 0001142790 10-Q 2013-12-31 false --03-31 No No Yes Smaller Reporting Company Q3 2014

0.00001

1000000000

Nature of Business   The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies.   In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (ITL) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the License Agreement) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITLs current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (Licensed Products). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments.   On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the ITL Notice), along with alleged damages. It is the Companys position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITLs share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.   On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction.  The Company traded under the symbol TAUG beginning on April 9, 2013.   On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (GHI) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHIs parent company, Green Innovations Ltd. (GNIN) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8.   On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the Parties. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.   On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (Pilus), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry).  Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (EBR) platform.  This transformative technology is the basis of the Pilus Cell.  The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots, that remediate water, harvest direct current (DC) electricity, and produce economically important gases.  The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules.  Pilus highly metabolic bacteria are non-pathogenic.   Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range.  Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD.  On January 28, 2014, the acquisition was completed.  Pilus will operate as a wholly-owned subsidiary of the Company.  As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000.  In addition, the Company paid Bacterial Robotics, LLC (BRLLC), formerly the parent company of Pilus, $50,000 at closing.  In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.   Basis of Presentation   The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.   These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on June 12, 2013.   Going Concern   As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Managements plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Companys ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates   The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Foreign Currency Translation   Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders deficit.   Cash Equivalents   For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.   Equipment and Depreciation   Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.   Intangible Asset   Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.   Consolidated Financial Statements   The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.   Net Loss Per Common Share   The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (EPS) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.   Stock-Based Compensation   The Company accounts for Stock-Based Compensation under ASC 718 Compensation-Stock Compensation, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.   The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period.   The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterpartys performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.   Comprehensive Income   The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income.   Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.   Income Taxes   The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.   Impairment of Long-Lived Assets   Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.   Research and Development   The Company expenses research and development costs as incurred.   Fair Value Measurements   ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements.    The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:   Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);   Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and   Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).   Financial instruments classified as Level 1 - quoted prices in active markets include cash.   These consolidated financial instruments are measured using managements best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.   Uncertainty in Income Taxes   Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.   ASC 740 Income Taxes clarifies the accounting for uncertainty in income taxes recognized in an enterprises financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.   As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.   Recent Accounting Pronouncements   Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

The Companys equipment is as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">March 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Computer and office equipment</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">55,085</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">49,951</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: accumulated depreciation</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">28,232</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">21,569</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">26,853</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">28,382</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> </table>

Intangible assets consist of the cost of: (1) a license fee with Green Hygienics, Inc. (see Notes 1, 5 and 8). The Company has paid cash of $143,750 and the chief executive officer contributed 2,500,000 shares of the Company's common stock valued at $106,250 for a total license fee value of $250,000 and (2) A strategic alliance agreement to utilize technology owned by Bacterial Robotics in the cleansing of nuclear wastewater created by the operation of a nuclear power plant. The company paid cash of $25,000 and issued a warrant for up to 75,000,000 shares of the Company's common stock valued at $1,139,851. The Companys intangible assets are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">March 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Licensing fee</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">1,414,851</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: accumulated amortization</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">41,420</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">1,373,431</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> </table>

On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1, 4, 5 and 8). The Companys former CFO, Bruce Harmon, is the CFO and Chairman of GNIN, the parent company of GHI.

On August 22, 2012, the Company entered into an employment agreement with Seth M. Shaw, its chief executive officer. The agreement provides for annual compensation of $132,000. Mr. Shaw previously elected to forgo cash compensation and receive 60,000 shares of the Companys common stock on a monthly basis. However, as the only principal officer and director, he decided to take the cash compensation as well and is in the process of modifying his employment agreement.   The Company is liable for an additional $25,000 in connection with the strategic alliance agreement with Bacterial Robotics, LLC.

The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies.   In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (ITL) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the License Agreement) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITLs current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (Licensed Products). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments.   On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the ITL Notice), along with alleged damages. It is the Companys position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITLs share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.   On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction.  The Company traded under the symbol TAUG beginning on April 9, 2013.   On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (GHI) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHIs parent company, Green Innovations Ltd. (GNIN) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8.   On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the Parties. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.   On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (Pilus), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry).  Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (EBR) platform.  This transformative technology is the basis of the Pilus Cell.  The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots, that remediate water, harvest direct current (DC) electricity, and produce economically important gases.  The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules.  Pilus highly metabolic bacteria are non-pathogenic.   Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range.  Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD.  On January 28, 2014, the acquisition was completed.  Pilus will operate as a wholly-owned subsidiary of the Company.  As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000.  In addition, the Company paid Bacterial Robotics, LLC (BRLLC), formerly the parent company of Pilus, $50,000 at closing.  In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.   These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on June 12, 2013.

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders deficit.

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.

Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.

The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.

The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (EPS) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.

The Company accounts for Stock-Based Compensation under ASC 718 Compensation-Stock Compensation, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.   The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period.   The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterpartys performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.

The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income.   Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

The Company expenses research and development costs as incurred.

ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements.    The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:   Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);   Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and   Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).   Financial instruments classified as Level 1 - quoted prices in active markets include cash.   These consolidated financial instruments are measured using managements best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.   ASC 740 Income Taxes clarifies the accounting for uncertainty in income taxes recognized in an enterprises financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.   As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.

Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">March 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Computer and office equipment</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">55,085</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">49,951</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: accumulated depreciation</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">28,232</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">21,569</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">26,853</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">28,382</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Number of Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Expiration Date</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">394,465</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">0.75</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">8/2014</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercised</td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Balance December 31, 2013</td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">394,465</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> </table>

The warrants were valued utilizing the following assumption employing the Black-Scholes Pricing Model:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Volatility</td> <td style="text-align: right; line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%">241.65% to 244.92%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Risk-free rate</td> <td style="text-align: right; line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%">1.34% to 0.41%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 115%">Dividend</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 9%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life of warrants</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3</td> <td style="line-height: 115%"> </td></tr> </table>   Stock Options     <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 88%; line-height: 115%">Volatility</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">220</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected dividend rate</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected life of options in years</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Risk-free rate</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.87</td> <td style="line-height: 115%">%</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Weighted</td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Average</td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Remaining</td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Aggregate</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Number of</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Contractual</td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Intrinsic</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Options</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Term</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.10</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">10,000,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">8.92</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">400,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options granted</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options exercised</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options cancelled/forfeited</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2013</td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">0.10</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">10,000,000</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">8.92</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at December 31, 2013</td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">0.10</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">10,000,000</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">8.92</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td></tr> </table>

109619

170474

19534

50000

1991

7906

26853

28382

1373431

1665337

198856

1386731

1183498

233965

418668

143737

148348

51343

8004

302488

277053

96425

225000

1665337

198856

278606

-984642

-69977

1166

2264

4013

20770505

31000267

37943812

-16244237

-15741675

-21230874

-2243

-1261

-194108

-4595168

-194108

-1261

21230874

15741675

16244237 16244237

37943812

31000267

4013

2264

401363096

226449077

401363096

226449077

-5489199

-8207636

-21230874

-5489199

-1599159

-3592683

P5Y

28232

21569

55085

49951

P5Y

1373431

41420

1414851

10000000

394465

0.1

0.75

75000000

August 2014

2.4165

2.4492

1.6832

2.20

.0127

0.0187

0.0041

0.0134

0.00

P5Y

P3Y

P10Y

75000000

10000000

10.026

0.1

P8Y11M1D

400000

558773

106425

-200000 -200000 -200000

116667888

226449077

401363096

48844286 489 5191122 5190633 2500000 25 250000 249975 2500000 25 250000 249975 200000 2 25000 24998 30878983 308 4506189 4505881 2720000 27 225819 225792 1592920 16 95575 95559 5335000 53 689000 688947 -689000 -689000 -643956 -643956 2500000 25 625000 624975 2500000 25 625000 624975 36000 4 47400 47396 360000 200000 2 30000 29998 92391 92391 522934923 1500000 15 300000 299985 4000000 40 160000 159960 2000000 20 246500 246480 2150000 22 287500 287478 -2082680 -2082680 7153 -11146507 -11146507 7153 360000 15900 4 15896 4569848 141350 46 141304 7790000 466000 79 465921 5250000 342500 53 342447 63635121 1203354 636 1202718 80461224 2135238 803 2134435 106250 106250 1500000 60000 15 59985 7000000 210000 70 209930 4347826 250000 43 249957 848014 848014 26837 26837

4460880

5479420

16602528

1162138

2703686

2714049 3533214 885000

48084

8245

94671

32077

587

4508964

8201714

20230413

1194215

3589273

-4508964

-8201714

-20230413

-1194215

-3589273

57839

5922

74249

7540

3410

321000

20000

601396

625212

397404

-980235

-5922

-1000461

-404944

-3410

7153

5627

-5706

200000

77500

-192847

-71873

-5706

-5682046

-8207636

-21423721

-1671032

-3598389

-0.02

-0.05

-0.00

-0.02

258387696

156677929

347748207

196957424

1139851 1139851

As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Managements plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Companys ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">December 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">March 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%">Licensing fee</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">1,414,851</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">5 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: accumulated amortization</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">41,420</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">1,373,431</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td></tr> </table>

Immunovative Therapies, Ltd.   On December 12, 2011, the Company entered into a License Agreement (the License Agreement) with Immunovative Therapies, Ltd., an Israeli Corporation (ITL), pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all product candidates (the Licensed Products) based on ITLs current and future patents and a patent in-licensed from the University of Arizona. The license granted covers two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vaz TM (Licensed Products).   On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the ITL Notice), along with alleged damages. It is the Companys position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013 and that the Company had complied in all material respect with the License Agreement therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITLs share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated. No value has been assigned to the ITL shares as they are deemed to be worthless.   Green Hygienics, Inc.   On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1 and 8). The Licensing Agreement with GHI will enable the Company, on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products to commercial entities including medical facilities, schools, and more. The Company agreed to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHIs parent company, GNIN, issued the Company 625,000 shares of common stock of GNIN. The terms of the Licensing Agreement provides the equal recognition of profits between the Company and GHI on the sales by the Company.   As of December 31, 2013, the Company has paid $143,750 of the $250,000 licensing fee in cash and the Chief Executive Officer contributed 2,500,000 shares of common stock of the Company in lieu of the remaining $106,250.  The Company will amortize the licensing fee over the five year life of the licensing agreement.     Bacterial Robotics, LLC   On October 29, 2013, the Company entered into a strategic alliance agreement between the Company and Bacterial Robotics, LLC (the Parties) to develop a relationship for the research and development of the NuclearBot Technology that will be marketed and monetized pursuant to a Definitive Agreement. Accordingly, subject to the terms of this agreement, (a) Bacterial Robotics agrees to develop a whitepaper which may be delivered as a readable electronic file, on the subject of utilizing the NuclearBot Technology in the cleansing of nuclear wastewater created in the operation of a nuclear power plant (the "Whitepaper"), which Bacterial Robotics shall deliver to the Company within ninety (90) days of the agreement, which may be extended upon mutual agreement based upon unexpected complexities, and (b) the Parties agree to use commercially reasonable efforts in good faith to (1) identify prospective pilot programs, projects and opportunities for the NuclearBot Technology for the Parties to strategically and jointly pursue, (2) enter into a joint venture, in which the Company will be the majority and controlling owner, for the purpose of (A) marketing and selling products and services utilizing the NuclearBot Technology, (B) sublicensing the NuclearBot Technology and (C) owning all improvements to the NuclearBot Technolgoy, and other inventions and intellectual property, jointly developed by the Parties and (3) negotiate its terms and conditions of Definitive Agreements. As consideration for the Strategic Alliance, the Company issued a $25,000 deposit upon signing the agreement. Additionally, the Company issued a 5 year warrant for up to 75,000,000 shares of the Company's common stock with a value of $1,139,851.

Convertible Notes Payable   During the period of February 22, 2013 to December 31, 2013, the Company entered into 8% convertible promissory notes with various individuals aggregating $361,425. The notes are unsecured and are due 180 days from the date of issue. Should the notes not be repaid at the respective maturity date, the lender has the right to convert the unpaid principal and interest into common stock of the Company at $0.025 per share. During the nine months ended December 31, 2013, $265,000 of the notes were converted into 10,600,000 shares of the Company's common stock. The balance at December 31, 2013 was $96,425.   On October 19, 2012, the Company entered into a one year convertible promissory note agreement for $445,000 with JMJ Financial, a California based institutional investor. The note is non-interest bearing for the first 90 days and subsequent to that, the note has an interest rate of 5% per annum. The note, at the holders option, is convertible at $0.15 per share and if the price per share at the time of conversion is greater than $0.15 per share, on average for the previous 25 trading days, the conversion rate shall have a 25% discount, with the minimum price of $0.15 per share. The Company paid an origination fee of 200,000 shares of its common stock to secure the loan. On November 14, 2012, the Company received $150,000 and an additional $25,000 on March 27, 2013. The 25% discount created a beneficial conversion feature at the commitment date aggregating $37,500 representing a discount which is being accreted monthly from the issuance date of the note through maturity and is recorded as additional interest expense. At March 31, 2013, the loan balance is $106.425, net of unamortized discount of $68,575. During the nine months ended December 31, 2013, the Company issued 9,900,000 shares of its common stock to convert the note. Under the terms of the original agreement, approximately 4,125,000 shares were required to be issued. To entice the conversion, the Company issued an additional 5,775,000 shares resulting in a loss on conversion of $321,000.   The Company during the nine months ended December 31, 2013 and at various times has entered into convertible debt instruments with interest rates ranging between 8 and 10% per annum. The total proceeds from the notes aggregated $1,378,713. The notes are convertible into shares of the Company's common stock with varying price ranges. During the nine months ended December 31, 2013, the Company recorded a beneficial conversion feature of $848,014. At December 31, 2013, the Convertible notes were carried at $558,773 net of unamortized discount of $377,589.

On January 28, 2014 (the "Closing Date"),the Company completed its acquisition of Pilus Energy LLC, an Ohio limited liability company (Pilus Energy), pursuant to the terms of an Agreement and Plan of Merger, as amended by Amendment No.1 to the Agreement and Plan of Merger, dated January 28, 2014 (collectively, the Merger Agreement) by and among the Company, Pilus Acquisition, LLC, an Ohio limited liability company (Pilus Acquiror), Bacterial Robotics, LLC, an Ohio limited liability company (BR), Pilus Energy, Daniel J. Hassett, PhD, (Hassett) and Cody Harrison (Harrison), and such other individuals who joined as parties to the Merger Agreement by execution of a joinder agreement prior to the closing of the merger transaction.   Pursuant to the terms of the Merger Agreement, on the Closing Date, Pilus Acquiror merged with and into Pilus Energy, with Pilus Energy being the surviving entity and becoming a wholly owned subsidiary of the Company. The Company will pay BR a total cash consideration of $50,000, payable by February 20, 2014, in connection with the Merger Agreement, and issued Warrants exercisable for up to 100 million shares of Common Stock of the Company (the Warrants) to BR, its members and Pilus Energys members, who each exchanged, on a pro-rata basis, their membership interests in BR and Pilus Energy for the Warrants.   In addition, the parties to the Merger Agreement, dated November 25, 2013, agreed to amend certain covenants and closing conditions thereto prior to the closing of the Merger. The material changes set forth in the Amendment No. 1 to the Merger Agreement included: (i) the elimination of the covenant that the Company complete a reverse stock split as a condition to closing of the Merger, (ii) a replacement of the requirement to raise $2.25 million by the Company within 180 days of execution of the Merger Agreement,  with a requirement that the Company instead agreed to pay BR (a) $75,000 upon the receipt by the Company of the first $1 million of funding for pilot programs or other projects utilizing the intellectual property assigned to the Company by Pilus Energy as part of the Merger and (b) $100,000 upon receipt by the Company of a second $1 million in funding by the Company for the purpose of funding projects that use the intellectual property acquired in the merger, (iii) revise certain Intellectual Property sections of the Merger Agreement to reflect the right to use certain Trademarks and Trade Secrets by Tauriga, (iv) add a covenant that the Company will cover the costs related to Pilus Energys intellectual property following the consummation of the Merger, (v) add a covenant that Tauriga  shall establish a stock option plan for BR, (vi) add a guarantee that key man insurance is in place by the closing of the Merger, (vi) address a plan for management of Pilus Energy following the merger, and (vii) revise the Merger Agreement to reflect the Assignment (and ownership) of certain Pilus Energy intellectual property, rather than the granting of a License to use such intellectual property.   In connection with the closing of the merger, BR, Jason E. Barkeloo, the Chief Executive Officer of BR, Hassett, Harrison and each member of Pilus Energy entered a Release and Covenant Not to Sue in favor of the Company, and a Standstill and Voting Agreement with the Company, agreeing to restrictions on acquisition of additional Company capital stock, transactions involving Company or proxy solicitations.  The BR and Pilus Energy members that were not previously a party to the Merger Agreement (at the time of initial signing on November 25, 2013), also signed a Joinder Agreement binding them to the terms of the Merger Agreement prior to the Closing.   Subsequent to December 31, 2013, the Company issued 54,557,827 shares in connection with the Conversion of Convertible Notes and issued 67,014,000 in connection with consulting agreements.

-5489199

-8207636

-21230874

153000

3101043

2924227

11498376

2665050 3533214 539001 3410 562817

48083

8245

94670

321000 321000

5915

-109900

-1991

19534

-14928

16758

85435

147524

232977

7846

53339

-31600

41191

-4611

96678

86277

-184703 -98832 -96437

90000

-96884

-1505163

-2519916

-4885906

5134

2940

28954

7893 7893 168750 168750 70000 70000 2665050 3533214

-243884

-2675883

-3808811

136425

150000

361425

52364

125503

141350

5191123

7402827

1378713

1553713

643956 643956

1656488

4644803

8548506

7153

2243

34296

-85406

-548753

-85406

57628

143034

619624

70871

169543

-1378354

-179572

-1557926

-65000 -95559 -689000 -689000

-46247

-25000 -25000 -250000 -250000 200000 200000 -106250 -106250

778

876

2788242

1004731

3823522

-848014 -37500 -940405 848014 37500 940405 85435 85435   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 90%; line-height: 115%">Volatility</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 7%; text-align: right; line-height: 115%">168.32</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Expected dividend rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected life of warrant in years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.27</td> <td nowrap="nowrap" style="line-height: 115%">%</td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Number of Warrants Outstanding</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Exercise Date</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Granted - October 29, 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">75,000,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">10.026</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">October 29, 2018</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Cancelled</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance December 31, 2013</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">75,000,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>   Octobe 29, 2018

Common Stock   During the year ended March 31, 2012, the Company sold for cash under private placement agreements 6,624,452 shares of its common stock at $0.05 per share.   During the year ended March 31, 2012, the Company issues to various consultants 14,485,000 shares of its common stock at prices ranging between $0.10 and $0.14 per share. These shares were valued at the market price of the stock on the date of the commitment. These consulting agreements were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions, and other mutually agreed upon services. The aggregate value of the shares has been recorded as stock based compensation.   The Company issues 1,565,000 shares of its common stock in connection with the settlement agreements. The shares were valued at $0.14, the value at the date of settlement   During the year ended March 31, 2012, the Company converted unpaid rent on the corporate office in the amount of $78,000. Accordingly, 709,090 shares of the Companys common stock were issued at $0.1098 per share. The rent was payable to a party related to the former chief executive officer.   On July 11, 2011, the Company converted a $500,000 debenture along with accrued penalties for being in default and accrued unpaid interest into 10,000,000 shares of the Companys common stock and recognized a loss on extinguishment of $336,836.   During the year ended March 31, 2013, the Company sold for cash under private placement agreements, 48,844,286 shares of its common stock at an average price of $0.10 per share.   On May 15, 2012, the former chief executive officers employment contract was amended to award him an additional 2,500,000 shares of the Companys common stock at $0.10 per share, the value at the date of commitment. Additionally, his employment contract was amended to award him an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.   On May 15, 2012, the strategic planning vice president was issued a consulting agreement for 36 months. In connection with the agreement, he was issued 2,500,000 shares of the Companys common stock and an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.    The Company issued 200,000 shares of its common stock at $0.125 per share to obtain the rights to a domain name.   On May 21, 2012, the Company issued 2,720,000 shares of its common stock to convert the Caete Invest & Trade, S.A. debt plus accrued interest. The note principal and accrued interest aggregated $225,819.   During the year ended March 31, 2012, the Company converted $95,575 of accounts payable by issuing 1,592,920 shares of its common stock at an average price of $0.06 per share.   On October 19, 2012, the Company issued 200,000 shares of its common stock to obtain a loan at $0.15 per share.   On August 22, 2012, a signing bonus in the amount of 1,500,000 shares was issued to the chief executive officer in connection with his employment contract. The shares were valued at $0.20 per share, the value at commitment date.   In December 2012, the board approved the issuance of an additional 4,000,000 shares to the Companys chief executive officer. The shares were valued at $0.04 per share, the value at the date of commitment.   In connection with the chief financial officer consulting agreement dated September 1, 2012, and subsequent modification, 2,000,000 shares were awarded at a price ranging from $0.06 to $0.20 per share.   The Company, during the course of the year has issued 2,150,000 shares of its common stock at prices ranging from $0.10 to $0.25 per share for legal services.   Commencing October 2012, the chief executive officer received 360,000 shares (60,000 per month) of the Companys common stock as salary in lieu of cash. These shares were valued between $0.04 and $0.24 per share. His employment agreement was subsequently modified in December 2012 to begin cash compensation in addition to the 60,000 shares award per month.   During the year ended March 31, 2013, the Company issued to various consultants 30,878,983 shares of its common stock at prices ranging between $0.10 and $0.29 per share. These shares were valued at the market price of the common stock on the date of commitment. There consulting agreement were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions and the mutually agreed upon services. The aggregate value of the shares has been recorded as stock-based compensation.   The Company issued 5,335,000 shares of its common stock and 643,956 in cash as commissions related to the private placement agreements.   During the nine months ended December 31, 2013, the Company issued to its chief financial officer 360,000 shares of its common stock at $0.04 to $0.07 per share for services rendered in accordance with his consulting contract.   During the nine months ended December 31, 2013, the Company issued 4,569,848 shares of its common stock in exchange for $141,350.   During the nine months ended December 31, 2013, the Company issued to its chief executive officer a total of 7,790,000 shares of its common stock at prices ranging from $0.02 to $0.08 per share for services in lieu of cash compensation.   During the nine months ended December 31, 2013, the Company issued to its chief operating officer a total of 5,250,000 shares of its common stock at prices ranging from $0.02 to $0.09 per share for services in lieu of cash compensation.   During the nine months ended December 31, 2013, the Company issued collectively 63,635,121 at prices ranging from $0.02 to $0.09 per share for the conversion of a $1,203,354 convertible debt.   During the nine months ended December 31, 2013, the Company issued to various consultants collectively 80,461,224 shares of its common stock at prices ranging from $0.02 to $0.09 per share.   During the nine months ended December 31, 2013, the Company issued 1,500,000 at $0.04 per share in settlement of legal fees.   During the nine months ended December 31, 2013, the Company issued 7,000,000 shares at $0.03 per share for a commitment fee relating to a convertible debt arrangement.   During the nine months ended December 31, 2013, the Company issued 4,387,826 shares of its common stock to Green Hygienics in connection with a license agreement.   During the nine months ended December 31, 2013, the chief executive officer contributed 2,500,000 shares to the Company to fully pay up the Green Hygienics license fee. The shares were valued at $0.04 per share totaling $106,250.   In connection with the consulting agreements and the board advisory agreements, the agreements have as part of the compensation arrangements, the following clauses: a) the consultant will be reimbursed for all reasonable out of pocket, b) to the extent the consultant introduces the Company to any sources of equity or debt arrangements, the Company agrees to pay 8% to 10% in cash and 8% to 10% in common stock of the Company of all cash amounts actually received by the Company and 2% for debt arrangements, and c) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultants performance.   Warrants for Common Stock   The following table summarizes the activity of the warrants for common stock issued in 2010 in connection with consulting agreements outstanding as at December 31, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Number of Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Expiration Date</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">394,465</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">0.75</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">8/2014</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercised</td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Balance December 31, 2013</td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">394,465</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> </table>   The warrants were valued utilizing the following assumption employing the Black-Scholes Pricing Model:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Volatility</td> <td style="text-align: right; line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%">241.65% to 244.92%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Risk-free rate</td> <td style="text-align: right; line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%">1.34% to 0.41%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 115%">Dividend</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 9%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life of warrants</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3</td> <td style="line-height: 115%"> </td></tr> </table>   Stock Options   On February 1, 2012, the Company awarded 5,000,000 options to purchase common shares to its former Chief Executive Officer and 5,000,000 options to purchase common shares to the vice president strategic planning, currently the Chief Executive Officer. These options vested immediately and were for services performed. The Company recorded stock-based compensation expense of $1,400,000 for the issuance of these options. The following weighted average assumptions were used for Black-Scholes option-pricing model to value these stock options:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 88%; line-height: 115%">Volatility</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">220</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected dividend rate</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected life of options in years</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Risk-free rate</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.87</td> <td style="line-height: 115%">%</td></tr> </table>   A summary of option activity as of December 31, 2013, and changes during the period then ended, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Weighted</td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Average</td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Remaining</td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Aggregate</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Number of</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Contractual</td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Intrinsic</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Options</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Term</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">0.10</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">10,000,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">8.92</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">400,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options granted</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options exercised</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options cancelled/forfeited</td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2013</td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">0.10</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">10,000,000</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">8.92</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercisable at December 31, 2013</td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">0.10</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">10,000,000</td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">8.92</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td></tr> </table>     In connection with the strategic alliance with Bacterial Robotics, LLC, the Company isued on October 29, 2013 a warrant to acquire up to 75,000,000 shares of the Companys Common stock. The warrant was valued at $1,139,851 utilizing the Black-Scholes option-pricing model. The assumptions utilized in the claculations are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%; line-height: 115%">Volatility</td> <td style="width: 3%; line-height: 115%"> </td> <td style="width: 3%; line-height: 115%"> </td> <td style="width: 28%; text-align: right; line-height: 115%">168.32</td> <td nowrap="nowrap" style="width: 3%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Expected dividend rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected life of warrant in years</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Risk-free rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.27</td> <td nowrap="nowrap" style="line-height: 115%">%</td></tr> </table>   A summary of Warrant activity as of November 31, 2013 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Number of Warrants Outstanding</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Exercise Date</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">Balance March 31, 2013</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Granted - October 29, 2013</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">75,000,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">10.026</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">October 29, 2018</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Cancelled</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance December 31, 2013</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">75,000,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>

-1139851 -1139851 -70000 -85434

EX-101.SCH 6 taug-20131231.xsd 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - Consoldiated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - Consoldiated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - Consoldiated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0006 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - 1. Nature of Business and Going Concern link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - 3. Equipment link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - 4. Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - 5. License Agreement link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - 6. Convertible Notes and Notes Payable link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - 7. Related Parties link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - 8. Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - 9. Commitments link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - 10. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0017 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0018 - Disclosure - 3. Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 0019 - Disclosure - 4. Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0020 - Disclosure - 8. Stockholders' Equity (Deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 0021 - Disclosure - 1. Nature of Business and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0022 - Disclosure - 3. Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0023 - Disclosure - 4. Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0024 - Disclosure - 4. Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0025 - Disclosure - 8. Stockholders' Equity (Deficit) (Details) link:presentationLink link:calculationLink link:definitionLink 0026 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 1) link:presentationLink link:calculationLink link:definitionLink 0027 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 2) link:presentationLink link:calculationLink link:definitionLink 0028 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 3) link:presentationLink link:calculationLink link:definitionLink 0029 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 4) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 taug-20131231_cal.xml EX-101.LAB 8 taug-20131231_lab.xml Common Stock Equity Components [Axis] Additional Paid-In Capital Deficit accumulated from prior operations Deficit accumulated during the development stage Accumulatedothercomprehensiveincomeloss Caete Invest &amp;amp;amp; Trade [Member] LegalEntity [Axis] Chief Executive Officer [Member] RelatedPartyTransactionsByRelatedParty [Axis] Warrant [Member] AwardType [Axis] StockOptions [Member] PrivatePlacement [Member] SubsidiarySaleOfStock [Axis] Warrants Class of Warrant or Right [Axis] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Other receivables Investments - available for sale securities Prepaid expense Total current assets Equipment, net of depreciation Other assets: Deferred financing costs Advance to acquire Pilus Energy LLC Lincense agreements, net of amortization Total assets CURRENT LIABILITIES Notes payable Convertible notes, net of discounts Accounts payable Accrued interest Accrued expenses Accrued professional fees Total current liabilities Stockholders' equity (deficit) Common stock, par value $0.00001; 1,000,000,000 shares authorized, 401,366,096 and 226,449,077 issued and outstanding at December 31, 2013 and March 31, 2013 Additional paid-in capital Accumulated deficit from prior operations Accumulated deficit during development stage Accumulated other comprehensive loss Total stockholders' deficit Total liabilties and stockholders' equity (deficit) STOCKHOLDERS' DEFICIT Common stock, par value Common stock, Authorized Common stock, Issued Common stock, outstanding Income Statement [Abstract] OPERATING EXPENSES General and Administrative Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense) Interest expense Loss on conversion of debt Gain on settlement of law suit Amortization of debt discount Total other income (expense) Net loss Other comprehensive income (loss) Translation adjustment Impairment on available for sale investments Total other comprehensive income (loss) Comprehensive loss Net loss per share (basic and diluted) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING Basic and diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to cash provided by (used in) operating activities: Stock based compensation Shares issued in Settlement Agreement Impairment of advances to Immunovative Therapies, LTD, for future stock ownership Amortization of debt discount to interest expense Depreciation and amortization Loss on conversion of debt Decrease (increase) in assets Other receivables Prepaid expense Increase (decrease) in liabilities Accounts Payable Accrued salaries and wages Accrued interest Accrued expense Accrued professional fees Related party payables Cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of Equipment Purchase of intangible assets-domain name Purchase of license Advance to acquire Pilus Energy, LLC Advances to Immunovative Therapies LTD, for future stock ownership Cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from notes payable Repayment of note payable to Chief Executive Officer Sale of Common Stock Proceeds from convertible debentures Commisions paid on sale of common stock Cash provided by financing activities Foreign Currency Translation Effect Net increase / (decrease) in cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest and Taxes Paid NON CASH ITEMS Conversion of accounts payable to common stock Conversion of convetible notes payable to common stock Issuance of common stock to settle commissions on private placement offering Conversion of accrued interest on Caete Invest & Trade, S.A. to common stock Purchase of intangible asset-domain with commons stock Investments in available for sale securities Impairment of available for sale securities Comprehensive loss Investment in Green Hygienics, Inc. Issuance of common stock Additional paid-in-capital Beneficial Conversion Feature Additional paid in capital Deferred financing costs Licensing agreement - Warrant Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Sale of common stock under private placement agreements at $0.10 per share, Shares Sale of common stock under private placement agreements at $0.10 per share, Amount Sale of common stock under private placement agreements at $0.05 per share, Shares Sale of common stock under private placement agreements at $0.05 per share, Amount Issuance of shares under consulting agreements between $0.10 and $0.14 per share, Shares Issuance of shares under consulting agreements between $0.10 and $0.14 per share, Amount Issuance of shares in connection with settlement agreements at $0.14 per share, Shares Issuance of shares in connection with settlement agreements at $0.14 per share, Amount Vesting of stock based compensation Conversion of accrued expense to common stock, shares Conversion of convertible debt to common stock, Shares Conversion of convertible debt to common stock, Amount Issuance of stock options Net loss for the period from April 1, 2011 Net loss for the period from December 12, 2011(inception of development) to March 31, 2012 Translation adjustment Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Shares Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Amount Amendment to former chief executive officer's employment agreement at $0.10 per share, Shares Amendment to former chief executive officer's employment agreement at $0.10 per share, Amount Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Shares Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Amount Issuance of shares to purchase domain name at $0.125 per share, Shares Issuance of shares to purchase domain name at $0.125 per share, Amount Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period A net of vesting amortization, Shares Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period, net of vesting amortization, Amount Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Shares Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Amount Conversion of accounts payable at $0.10 per share, Shares Conversion of accounts payable at $0.10 per share, Amount Stock issued for commissions under private placement agreements, Shares Stock issued for commissions under private placement agreements, Amount Commission expense paid with stock issuances under private placements Commission paid under private placement agreements in cash Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, shares Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, amount Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, shares Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, amount Beneficial conversion feature related to JMJ financial Issuance of shares to CEO as signing bonus under employment contract at $0.20 per share, shares EX-101.PRE 9 taug-20131231_pre.xml EX-101.DEF 10 taug-20131231_def.xml EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!F'MSGR0$``(03```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6 MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?>O%D>WN#15U% M<["NU"HC+$E)!"K7LE23C'R,7N(NB9P72HI**\C($AP9]"\O>J.E`1>%W/%#J\@)JX1)M0(4[8VUKX<-7.Z%&Y%,Q`.*TKBK@$'H MWH3FSN\!ZWUOX6AL*2$:"NM?11TPZ**B7]I./[6>)H>'[*'4XW&9@]3YK`XG MD#AC04A7`/BZ2MIK4HM2;;@/Y+>+'6TO[,P@S?]K!Y_(P9%P7"/AN$'"<8N$ MHX.$XPX)1Q<)QST2#I9B`<%B5(9%J0R+4QD6J3(L5F58M,JP>)5A$2O#8E:. MQ:PP"3N'[6- MHR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B M9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%H MT9,9J&74"T\U<%J"`=[!ZH^^CSYLK$SO+ M=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A M`%"KK)4XNI9!KFWZ`L!7;Q):,I#[R]Q4F.`V$[27LQ2`)K\:SZ]F1 MUMN?KDV^M/.--;F`22H2;0I;-J;*Q&PO=V]R:V)O;VLN>&ULE)9M;YLP$,??3]IW0+Q?`9.F3=6DZD.V M59JZ:NG#2\L%)U@%FV+3--]^9Z.0"V2H>Y48_(^<7'T7NO?-*"R6G M?G04^AZ7B4J%7$W]QX?OWTY]3QLF4Y8KR:?^AFO_8O;UR_E:5:\O2KUZ`)!Z MZF?&E&=!H).,%TP?J9)+N+-45<$,'*M5H,N*LU1GG)LB#T@8CH."">DWA+/J M,PRU7(J$WZBD+K@T#:3B.3.0OLY$J?W9^5+D_*FIR&-E><<*R/LC][V<:3-/ MA>'IU#^&HUKSO0M575[5(H>[DSB,_6#6%GE?>2E?LCHW#U#>E@YZD1$A8_M+ M*\63X&N]"[)'[^-9R%2M[4]!VDU[BB&!M;OU+%*3P?TP#-MK/[E8969[$?`! MXCL%X3GNTY.NO*TB%#I%Y]((LZ&WLE%?*&BA5?T6*HM\KSH3\*6Z32.;.*9< M@X@J3P4#B>@5RYE,.%W84$T?H5$MA2`*^1_*/4.4&%&HYA">H>U'/D1.HI"B$<6[&3X=%VS8] MZEDP"J'M+YJ_U=`P.G^WLX"C)SBZ9[UASX!/VLD>8>]%/?,AU]`'!C;`28RP MX:*>XPZXYP`#&S#J.7"P"137@SZ89G$0M"<%%PZ("P(#?<,)%C10BN M!@Z=X$.*'(#LE=+SY0`$%@Z2A.`1@T,GF6%I]R3!,T9Z5AT&@2*MV>#5N?-\ M\Q[%"W,8!*KL0'CF2,^UPR"090?"4TAZ%AX&@2P[$!Y(XGPF MF[,59S08V!UI5EJM]G!-,+;1&&,!FIL9>A:=DG+?7XY;O5__HZ?/%VKF^2R3\[E)=OJ/[-:__3R MZR_/[V7UK3YE6:.!PJ7>ZJ>FN6[6ZSH]9452K\IK=H$SA[(JD@;^K([K^EIE MR;Z]J#BON6$XZR+)+[I4V%1+-,K#(4^SL$S?BNS22)$J.R<-C+\^Y=>Z5RO2 M)7)%4GU[NSZE97$%B=?\G#<_6U%=*]+-E^.EK)+7,\3]@UE)VFNW?]S(%WE: ME75Y:%8@MY8#O8W97_MK4'IYWN<0@;!=J[+#5O_,-C$W]?7+@O&LI9QM3:%29.\/%?ENP:Y!R.OKXG(9+8!Y=X?&& M@5-"Y+-0V>JNKH$7-5Y_AXE).R2X@[@8V?6(F`8A&_8'1EF&+XEZ MHK\DE@?@YS@2;[AF#4$/D<.LJ)'?SX@^0`&+`/O[!/*`>A\^W*8=_.Z6<'R, MA+<($8EN"=?`(O$M,HJ@@,U'`A8P)+OBHTN\#R1B*8B-A[:;)<)9(IHEXBD" M&0!#73[C`M[J8.Z02.[H:SO#@42\-M\9J2>][A%/([5T[[E M*"L6Q0YU6HU].F8!DYC);0.)R)@9@P1EA-BIA&E[/G=)!H4J8=F&YSLT=I7P MN,%@_H>I;;V/58(;W#0L-MX&.2#:.V77FW9`P,0!LHH#B4@'GNY;@)#['B#D MO@D(N>\"0J9M\!^Q0!:7*F3.'[1+BU> M"$PV5VA/)&,+.D;-@9NM8`$3=DSG(]3QFPTC6B`33\I@*T0?M=P*V76I5M"- M.V"2F;9BG@D7Z$0+F+ACI*7P'*KLP-@)T5`M=T*V7\@)VBDRR?23Z;NP<^/: MO>N0*;-"+.,8S/1)(8X6R,1$!KHE-BX@[`0,YP$G!(W+@S<*=^5!,IT3HH&Q M;IQ`R+T"@0#?@YV.E-F((<2^4R$0(!:7Y8RSADT0/=7R=)`=&$J'<1/N3%"[ MM"=F^S[\H_F`&!-"<#RB$XH'>3"\,].V/)_Y1"?"#.R8KF.2I(DQ`]E@&IX[ M3@MV0_18R]V0'1FD_]`8TYXN8)*!"1D8,IV[>22<1Z)Y))Y$L`^BV5KN@VS- M4%:0(`.FMF_P9H0T%SMT_@G>P9!I#!'@,IND2]2=5XVF"R?^6`-'+YHL)7KQ M(#7_^,!D:X9<($$$'=/EM.O"@Q)=&5)E*HP0J[2UGLA$'3(E$T_*8$-$R_6X M(;)10X:0:0^89'I#F$J9'RF&(&=N!@FB1%(PP<[]D8@:>LKGI\@\V M$/Y0D]G2Q`T21=`QT@V2V+ONI-\^8C\9*X/X%,X!T0U`2E7<`6JVC`C.!,CM MQ]<%%U?A9RV?A!ETS/TQM/OL;AX)YY%H'HDG$>S'0[TE?!F@'94_)IEL)CI& MU@?38>CPY>2SUR\?R;'`[:!%^>WQT.V M@;?C<'P]7``?-J[),?LCJ8[YI=;.V0%N9:Q<:*,J^6E$_M&4U_;#P&O9P">- M]M<3?,+*X)6\L0+X4)9-_X>XP?!1[.5_````__\#`%!+`P04``8`"````"$` M%N1[T(T#``#J"P``&0```'AL+W=O,!1ZY>^-*1=AJ),]SYD.9,D+^&4K5&A;J&0VZW(N$/,CGDO#!(HGC&#/C7>U'J$UN>7$.7 M,_5T*&\2F9=`L1&9,*\5J>_ER>++KI"*;3*(^X50EIRXJYLS^EPD2FJY-0'0 MA6CT/.9Y.`^!:;U,!41@T^XIOEWY=V1Q3Z9^N%Y6"?HM^%&WKCV]E\=/2J1? M1<$AVU`G6X&-E$\6^B6U7\'#X=G3CU4%OBLOY5MVR,P/>?S,Q6YOH-QCB,@& MMDA?'[A.(*-`$T1CRY3(#`S`NY<+VQJ0$?92?1Y%:O8K/YX$X^DH)@#W-ER; M1V$I?2\Y:"/S/P@B-1621#4)?-8D9!S0:#R=7<$2HJ,JP`=FV'JIY-&#K@%- M73+;@V0!S*?(T(>+]5*H$*,EN;,L*W_J>Q"%AOH\KVD\6H;/D-.DQMPC!MX= MACA$"&Z<);#1MO1VDD_*%FR5;=*ME7O\HBT3O2T3#Y&QX)4/W,Y\/.X'B)C) MK(J?!)-9?$&9#E&VX+YRPXLQ(\8I1Y-YY_7QIGF@DVEHONLS;<%=(S1N*HA& M$`-V7)HH&;^=_LD0;0ON:SS6HW0`TILY;5]X.HZNS3W!TM4\_C::.&:.N06WY M"_U'[(BZ7AP'6D<\;IAK<02Y%J1D,FZ5OTE5-PN#1B`YGX$TGO2ST!F"44#I MG+1FTO$PDD%CL4+W,]'$5:OC8/S/>1PT%&'7.H^Z:;):%T'M`T'C>:\! M<.7"C23G:L<_\"S37B(/=ITB\%?JOG6KWEU4+6ON!]BT2K;CWYC:B4)[&=_" MHZ-@"EE7N*OAC9%EM>]LI($=J[K2FE.-W8;M#MBM3"M_P(` M`/__`P!02P,$%``&``@````A`/&,LW5W`P``%PP``!D```!X;"]W;W)K&ULG)9=;YLP%(;O)^T_(.[+-_E2DJH!=:NT2=.TCVL' M3+`*&-E.T_[['6.@8-HD72Y"@,>OWW..[9SU[7-9&$^8<4*KC>E:CFG@*J$I MJ0X;\_>O^YN%:7"!JA05M,(;\P5S\W;[^=/Z1-DCSS$6!BA4?&/F0M0KV^9) MCDO$+5KC"MYDE)5(P"T[V+QF&*7-H+*P/<>9V24BE:D45NP:#9IE),$Q38XE MKH028;A``OSSG-2\4RN3:^1*Q!Z/]4U"RQHD]J0@XJ41-8TR63T<*LK0OH"X MG]T`)9UV9L$#.5D:G,2_MI0U*VW5*(`*9=H/A;&/>N:O8=4U[ MNVX2](?@$Q_\-GA.3U\82;^1"D.VH4ZR`GM*'R7ZD,I',-B>C+YO*O"#&2G. MT+$0/^GI*R:'7$"Y0XA(!K9*7V+,$\@HR%A>*)426H`!^#9*(I<&9`0]-]<3 M246^,?V9%]E'=(M1>ZDRL:=H&GK>VGZ"\2..B:@C M9"VE;#QX8(/?WC148VCZ[171>9.P]-:I[M2#H1'-:G21B*>$[_31C+Q"S:_W M*N&-">)]C@+/[W6;I.P4,VNR[#KJ,T:BRTBL$*AX/U/8BXS\`W*]?PGK_H-> M5_E7S'!F_W7J!HFFB$;$YXB1?=CJ0_MR??MP%)U?,G*0'H;F8*>895,&Q]*7 MLGH[#%(;'[\W?N1^]C_NY2#=_4PK@F*&_B9%F")Z".>(41AP,`R+<#[Y$M;M MSS7[BAG:U[Q%%XGX'#%R+QN*P1%YWKV$=??Z#E:,VL'^,@AFNOE+0*R`M^,? M>5]^Q+N$=>_Z[E7,<.;)PIDB6GSQ.6)DWX6M.LS]==NW&:4'HGG8M5"W@>?: M^ZA]/XQ40^+W)<9!R+^QJQ<0M%33*BRT]=]"0W.!MQQ#T1O0)`(UV5#G%5%! MJ/Y,]0PE9@<RIP(:LN9G#@TXAE[`L0#.*!7=C6P=^Y9^^P\``/__ M`P!02P,$%``&``@````A`*Z]A95'`@``2P4``!D```!X;"]W;W)K&ULE)19C]L@%(7?*_4_(-['>$DRB15G-$F4=J16JJHNSP3C M&,48"\CV[WN!K$TU2E^"<0X?YYX+'K_L98.V7!NAV@(G48P1;YDJ1;LJ\,\? MBZE7R0;DL;Q@$@J6AP(N7Z$H:I*,#Y7;"-Y:P-$\X9:\&]J MT9D33;)'<)+J]:9[8DIV@%B*1MB#AV(D6?ZV:I6FRP;JWB<]RDYL/[G#2\&T M,JJR$>!(,'I?\XB,")`FXU)`!2YVI'E5X-(3`>(4D:I<-^TA_\!R4[4F"\4!ZT0D)9/J4YM70R MUFJ'X.2!<=-1=XZ3',`NG@Q"_G<\D(M;\^H6^:6@-M#2[:27C,9D"WU@1\WT M7I/>*F;WBBP^2PCX.YN$W*Y-OF_.B:$(C"[FT@O7%S`-FMZ5IG_>V2MF[REN MO,%&CWMSX@(#^\I;\YZV5\*N"Z.'VQ`F5G6^HTMEX13[QQH^6AS:'4<@KI2RIXF[;^?/ MX.0/````__\#`%!+`P04``8`"````"$`7W8DILD"``#$!P``&0```'AL+W=O M+I;8J0T;3):B88E^)TI_+#Y^&%]$O)%E8QI!`R-2G"I=;MR M7966K*;*$2UK8"<7LJ8:EK)P52L9S;J@NG)]SUNX->4-M@PK.8=#Y#E/V:-( MCS5KM"61K*(:]*N2M^K,5J=SZ&HJ7X[M72KJ%B@.O.+ZO2/%J$Y7ST4C)#U4 MD/<;"6EZYNX6-_0U3Z50(M<.T+E6Z&W.]^Z]"TR;=<8A`V,[DBQ/\):L]C%V M-^O.GU^0;![$_W4%>";1!G+ MZ;'2W\7I,^-%J:':$21D\EIE[X],I6`HT#A^9)A248$`N**:F\X`0^A;=S_Q M3)<)#D*,#DSI)VZH,$J/2HOZM]TD/84-]OM@N/?!)')"/XJ7!`Z;RQ+T+'`_ ML_A.%'O!#!+7IM.Y\T@UW:RE."'H.!"N6FKZEZR`^.]V@`\&NS7@!,<80<8* M2OBZ"R+ZW/] MR;FWB,`;(",E8,1\)08,W7"5<$CB@=>*LQAHF,&4:(S8_PLQT@8D\[49<((A M\>%6(,>"IN:IS%+/I>"_U+ MP3IC]W9_CK3%_T@SX(FT8"K-8GK?@C@(@ZEO%C%'''Q2\WTSX+&XD"S'[;2S MF.NC0W*IF?7N%G-!V*K::6KG1% MF1S#_W?S!P``__\#`%!+`P04``8`"````"$`EKNJI]H"``#'!P``&0```'AL M+W=OO38U>F%1U:%F"WYC"]^O/GU8'(9]5Q9A&P-"J!%=: M=TO755G%&JH3.WH;S%EF$I;^$01<$S M]B"R?<-:;4DDJZD&_:KBG3JQ-=DM=`V5S_ON+A--!Q0[7G/]UI-BU&3+I[(5 MDNYJJ/N5A#0[#*_J&9U(H46@'Z%PK]+KFA;MP@6F]RCE48&Q'DA4)WI!E M.L?N>M7[\X>S@[IX1JH2AR^2Y]]XR\!LB,D$L!/BV4"?V`J`T.!QO$CPY2)&@3`%37>ZRK!P6V@%C/K M=?FQ'TP\34?S))HMAKI&NF8?T67`8UTA"09>J\MBK%_^+(XF\^EH/@[BL^Z1 M+CA%EWZ9OA1`=WO_`)I%4WWA1)_%0&I#YB&99GJ-.2.L2MM0;:MHF"Q9RNI: MH4SL3;,DD,KP=NCC&[]OQ<,$]-&.ENP[E25O%:I9`4L]9P[)2=N)[4"+KF]$ M.Z&A@_:/%?PP&1QKSP%P(80^#4S3&'[!ZW\```#__P,`4$L#!!0`!@`(```` M(0!7]K2K:@,``.4)```9````>&PO=V]R:W-H965T-_>:946:#0R(U]5JI=N:XLSK0FTN$M;>`_1RYJHN!1 MG%S9"DK*+JBN7.QYD5L3UMA&824>T>#'(RMHQHM+31ME1`2MB(+\Y9FULE>K MBT?D:B)>+^U3P>L6)`ZL8NJC$[6MNEA]/S5PD*]9(;CD M1^6`G&L27=:C5SGZ;,DSO_XD M6/D+:RB8#6W2#3AP_JK1[Z5>@F!W$9UW#?A-6"4]DDNE?N?7GRD[G15T.X2" M=%VK\B.CL@!#0<;!H58J>`4)P*M5,ST98`AY[]ZOK%3GC>U'3AA[/@+<.E"I MO';?H#/%C=DMF6B&O/2([H/6S?J%3UTT5=WW1!^2FP5X'5*)DB'&A:J' MTJ$MX]+_?23Z"C6L*^SWV9F%\3YXV*9+_F5)1.D4R9;(3&2_)&)O*I(OD4^1 M2<'^M&#=:Q^^45\7KH.`&_D9>)^&=I7N#!.,F'":X\M=(KM+[.\2^5?$Q`E( M]?'6:WAC@\O#1`7>K)$[PR3=Z*,P3>%OYL"8\,,41XD_);(Q$09)BM*9QGY, M)-B+(S^::N1C`B/L>TD<#,C$`CB,'K=`PS,+T&P,=X:!!`:;YD-PE\@,$74V M/OG(0UXPWCA[Z/T7PD MS/5I[H6:BA-]H54EK8)?]-7H0SN&U>'6?L;Z+)RM[]`*#O'E>H96<%+#NCL$ MP"W;DA/]E8@3:Z15T2-LY3DQN"_,/6T>%&^[6^K`%=ROW<&ULG)?1;J,X%(;O5]IW0+XO8`)I M$X6,FE3=J;0CC58[L]<..`DJ8&0[3?OVE"1>X'OS[V" M9"4R#DL^Q8/M]UE"GUAR*F@IC0FG.9'`+XY9)2YN13+%KB#\]53=):RHP&*7 MY9G\T*;(*9+ERZ%DG.QRF/<[#DER\=87/?LB2S@3;"]=L/,,:'_."V_A@=-Z ME68P`Q5VA]-]C![Q5(9V#'V MJJ0OJ?H)!GN]T<\Z`]^YD](].>7R'W;^2K/#44*Z(YB1FM@R_7BB(H&(@HT; M1,HI83D`P+M39&II0$3(N_X\9ZD\QF@V=Z-[?X9![NRHD,^9LD1.^1`*`0D^6T=AO[*>X/$)+5F8S3P MWFAP5[&]*%0^`:]AA+"U&:^G[H*BQ`I%I5*Q;

>6,T7?"HZF$MMP=N2,9G31&4F;?P!NT853 M1]L,ZLI1%%]ITM:@= MH-[6N*+YM.F"JD.YE>*)H.8H[QXPZI7DNG(2=5'^&89$WOS:]XV.@N[_F#VC=*G*@WP@_9*5P M;D`(``%8&```9````>&PO=V]R:W-H M965T(5?N,%7J\^?EENE'TW'N47`,)@*=]:."T(,Z[BD M)E(C'^!+H[2D%H:Z)6;4G-;3)-F3-(Y+(JD8L&=8Z',X5-,(QF\5VT@^6$^B M>4\MU&\Z,9H]FV3GT$FJ'S?C!5-R!(JUZ(5]F4@QDFQQWPY*TW4/OI^3G+(] M]S1X12\%T\JHQD9`1WRAKSU?DDL"3*ME+<"!BQUIWE3X.EG4DM7 M2ZVV"!8-:)J1NB68+(!Y[\S7$;R^9Q4\.I)KQU+A&4;@PD![GE9Y42[)$V3* M=I@;CX%KP"0!0:":4!*4<5S2VR'OE1W8*;O072DW_L6Q3/JV3/81&0>&KAT5 MGQ>SP.N5/28_PA0!<6(0(.<;=.`*@ZL06U;$@=TPYGY)/HG*>O>,95MOY MR@Y\JIQGAY9Y98\Y]IPG[[@N/Z+MP*?:67'PY+4])KA.R\N3W]>+PP0?O]_? M?OE+KEO^A?>]04QMW-Y-(+WP-APKU^ET,H0/L*U'VO(?5+=B,*CG#4R-HQD$ MH?W!X`=6C=/F6BL+&WIZ[.#\YK!$XPC`C5)V/W!'3_A'6/T'``#__P,`4$L# M!!0`!@`(````(0#\A%\1>@,``$P,```9````>&PO=V]R:W-H965TUL M=M^^8YLD&#:4S44(\/'[]\S83)9W+V7A/!,N**M2%+@^6#9L225-"*<%%B" M?W&@M3BKE=D8N1+SIV/]*6-E#1);6E#YJD614V:+K_N*<;PM8-XO082SL[8^ MZ=@1_X_*I%&!XUDE M=,-9',3)_[UX9EXZ3`]8XM62LY,#M0?.18U5)0<+4#['Q\SF$K%;`8-(*9%[ MI9*B*7(@%@*R_+R*XMG2>X;,9`VS-@Q\7YC`)C9G0B44[%T\0MS:'M_.W=F* M@I45E4OE;6TNM,<-.^,.$981"-!X(PI.$6A?YAO%H:9ZP7ANYTI;&[=M;(*:VI\X!3<\91TBGUMF,'`]9'K MQ"QSZBW9VCR&`Z;@KKE)I^0,,VBNC]PP-W^/.05WS44=C5,8U]_[!!O M&N;M.=@&U:;=,CANT09FJ[1_J=O!R`WJY&N_)=\SWM!).07;PJ.].X=W` M33=H3B2K=2^T91*Z./WS`%T[@0;"=P'>,2;/)ZH]N?P/6/T#``#__P,`4$L# M!!0`!@`(````(0#$>?4=504``&L5```8````>&PO=V]R:W-H965T&ULE%C;;JLX%'T?:?X!\=Z`C9(H]%_/2\_KBD-9 MY]VB.9]VY+?/M\%!]]*COAUZ=5R<7(RS;.3&:W:XJRONF M>*[+4X]!VO*8]\"_.U3G[A*M+N:$J_/VZ?E\5S3U&4(\5L>J?Q^"NDY=+'_L M3TV;/QYAWV^$Y<4E]G`Q"5]71=MTS:Y?0#@/B4[WG'B)!Y$VJVT%.Q"R.VVY M6[O?R3*CB>MM5H-`_U;E:Z=]=[I#\_I;6VW_J$XEJ`UY$AEX;)HG`?VQ%7^" MA[W)TP]#!OYLG6VYRY^/_5_-Z^]EM3_TD&X..Q(;6V[?[\NN`$4AS()R$:EH MCD``?CMU)4H#%,G?AL_7:ML?UFX0+GCD!P3@SF/9]0^5".DZQ7/7-_5_""(R M%`:A,@A\RB"$+FC,"0]OB!+(*/"IHLRDXN&V!I7N\S[?K-KFU8'2`^+=.1>% M3)806,@3@,@?RP.ZB&>^BX>&1P'=04Y?-C19>2^0AD)"T@\@)B*;(@)_A'A` M;^0(LNDBG"&$:A)N([!K"H`;KS*)$DL13/]=I3X MX?BT00H:1BE.'8-;:J7CC@RV@>$G(J`7(#`"EPD7&@6ERN\DBR-0C MF,J)E$YW`,[C*+)2G\DH,O6^0=\D=Y-+D*E-,*ND4HG!I0.?LMB:UYF!H%'D M:Q/;)'>34Y"I53!KZ51BD!PGT+%CSF3)Z681^[ZJ6I/9369!<-`;P\1V"XF1 M&6,P32QA,PL1!]KN#'+T)K<8T*9;<%7)6'`2@^1H$"2AW0T&@I$X#)7T)KF; MS().S8+;9B$Q4KD@#J/)A!*1+/J-GN<7U04+1)6`6C^^)W'8)B;DVYZY" M3/4LDQ!F%L&D^H+FU"RTEI,I1@RJR'QB-P;5[U,:?M(85(QLS6V_((8#7F\, MK@)+8HA!8D&4L"`FEL;9L.IE6`<$1C$-5?N8"EI.,>]U0/S/;;V&&PO=V]R:W-H965T&ULE)5+C]HP%$;WE?H?+.^) M\X!0(L)H8#KM2*U457VLC>,0BSB.;/.8?]_K&!@"[0QE`0DY_G+NM>-,[_:R M1ENNC5!-CJ,@Q(@W3!6B6>7XYX_'P0>,C*5-06O5\!P_6!^B>4TM^)M*M.:8)MDM<9+J]:8=,"5;B%B*6MCG+A0C MR;*G5:,T7=90]SX:4G;,[DZNXJ5@6AE5V@#BB!>]KGE")@229M-"0`6N[4CS M,L?W4;9(,9E-N_[\$GQGSHZ1J=3NDQ;%%]%P:#9,DYN`I5)KASX5[B\83*Y& M/W83\$VC@I=T4]OO:O>9BU5E8;9'4)"K*RN>'[AAT%"(">*12V*J!@'X1E*X ME0$-H?ON=R<*6^4X28/1.$PBP-&2&_LH7"1&;&.LDK\]%!VB?$A\"$G`_G`] M#L91.$G&;X80+]35]T`MG4VUVB%8,W!+TU*W`J,,@EUA";3G[X5!16[,O1O4 M#07:P&1L9VDX)5MH(#L@\VLD[A.+:R)Y"2&@=W*$PL\=7W=S,-2`T8M;U+_S MW"/#,V34)Q:O$3TUN,_M:@[.,62_J%TT9>Z12==3V$[ZG^CCX%+T=KZG#;7? MKNW@"^VDWZ^Y1U*O?9+N0XLWH)X@+.C;!1U$3CLWWON$2\X#*,D3<))VF<6 MYTPVOV!P`` M__\#`%!+`P04``8`"````"$`AF=R(SM,``!L\P``%````'AL+W-H87)E9%-T M&UL[)WK;AQ7MM^_!\@[%`1-+`%-BE==9FP?4!0IG+Z(XG^9#7B)``AAY%#_*/$E^_[7VWE5=54V)MF)1]**:S83GYZL'F^L:#K)CTR\%P>/\AF M\WPRR$?EI/CJP6TQ>_!O7__G__3E;#;/>'?T\LGL>EKD@]E541!UB\7DSG[;N]L M/<@6D^&?%\6^?[3S].F#K[^<#;_^3>08[&5;&YO;S2\/B_/U;/.Y M?;G3_#*!L?=98'S1?#]`_KZX',[FTYSS'.?CHOG4%V=[W[X_>KV7G>X?'1SO M'YSVLJ/C_?7F8V&Q?=`RS4>@8U!\S/Y4W#:?^V)C8V-SW MUVTP-C?6_GWE&^^*Z;`4+0;9JWS>>GD/:@V,8H>C_+*YRA<7^6C6>F=_,9UR MF.QP..MSH/\H\NG*];]86]O87MO>;*Y$)H;>^39]\5HM/;CI+R99*=%/H-[ M!]G1;+8HIO_6?.V+X[+Y47VE[\K18C+/I[?`-NIX/3W[Q2Q[7UR7TSG2DYW. M\_EBEH5CM??\CV+6W#3`;KMD^^#ULIRV"7HZSD>`4=MJOQQ?YY/6DV$YOAV7 M(&%>]G_L9:=7^;2892>+N8DUD#:A2&P1*!%H?8@0MB#^XM];(M1\W0C9_3(2 MV!*R_7(R*T>#(:\_?IJ^SAXR;P;_/I M:NF.+);/9BSW^^:[^_GLJOG9R?P*5$^+?C'\D)^/VC0[FGPH9G/Q^BQ;R_(/ M^7"DYS*T4S;+^6-6]!?3X7S8?O6+GW_Z^:?FAN^FQ74^'&3%1]1H6TK.RCG" MP8HF*WZ0YA('?UX,KP51+YL4\ZR\R`8%"K@/3CNTI9]P!4I>%1<%6PVRB^$$ M2HBO^^5LWN*#O<$'(]2\S/(^VT^+[-UP!/L?3(KIY6WVYLU^$\HW0RC+";/\ MB4O-+F`];.!^*@!,]F"`:H)5DF-HG[_OGJY;G"Q`XG,P+!&_>W#)^ M'^C=M;Z]?STM+XJ9S#3TORC:W+3,&:-A?CX<=;*=*8(K9`RK_T560"W,Z:-! M<3'L#^MG.QF9O^^G3WL:+IV;!M[:>]G9V7O0VGCW+AM+(`_NXK%12EL\S['0Q M/D?XHJVVAY#O_E7ZJ(7,`=K!420A6AM.LGY^/41D6D_V<2D6(],RX>C9Q;0< M9]<8MFF&#S,U[NNB1^O%`0*.9`R*#\6H-,F3SW398B]HG=XM3;'TT=S3X@HY M&'XHLE$Y:^WG9#7T)YH%@)MG\D>=\M(WAK#E-S]-[3NT[SLL!WY5,1]BH%=J MX-.SD_T_?7/RYM7!^],OLE<'AT?[1V=-4%=PU=V/[26>NOLYL_*#NY^I,5O[ MP1H.9,5=.4F/GB2V^!Q;M'VG'[JU>^?7I\4UAFS#/-&M)HAU'[;UY#@Q?W0."S8W.L*Q&$[-D^/XN6OY M68::/QJ/%Y/R`T("XYYA))$SZ4O?OR;NR?@:#V0^,L[2DZ/\)INAB)OK[M4,85PQB[:H^;#+ MORN63QWH&,>@2]TX.I;54EQ+S[%^T)-T.I\Q'-M+VE8 MN5'-=^O'N@=@J)A/J-:(@PRI=KN5/3K/9\.^,>(`_T6>9A.<[P^.7G]S=O`J MV_L..7M]D.V?O'U[8#[OL.!V:5 MEC6/?-/L<%3>?)87O+]W^DUV^.;D^]/L\/W)VZQ2"7O[9T??=3I&>XEX)M_X MBR4.GQRAP"J2^K[`P!7Y,"2RSL[Q&Q8S1Y.)..9]E(*Y'BT7^U1N1`:2 M>4FTQ/!U.GDA2@G>`1)S6HG+7O07F^BK,]EG*JNS5[U[**L[I5'HB4[>*C5Q MI[9K'@Q`U>3%^YFX3OB:`;/N[6(,7A@IDY>:J*GR>-'Q]\=G)K9 M6\WC[Q9XCT(I*C=%2%\NQAVXGI;]HA@$ M`SRY*^PB:9+?1B=#3T8ND4SM7PT+J/61,-I\C9,+`I5BV@3Q5+$V9$7MIVQ' M\YEW2R"YK?9@;U"3G,K0W%=458! M]&HT'Y;38G@Y"3FC_FU6-ZX'%Q=%O^4@R(9%]9`]:4B_M'4+,$Q#+WMY\/KH M^%@$/#G,\!>/3EYU/WAP_&KU(Z??OGOWYN#MP?'9WIOLU='I_IN3TV_?'^B% MQ#$D+P]/WK_%(3TY;IF#Y%;)$SW+/Q*SO`/)35".,:^VX-'9P=O3YK=8S9#` M%OWSJ-:"HC&K=1>AEMXVGJC%_W5&O(O<"CDL`0($]>>TNWMZ]C'VS#@)KB'. MQ'F&TT43Q)#[><%*GHG*_DL^OOZ#.&=0D.U;WUO_ M%`;J:JNI[Z*ZNQG.K\+!9MT,7\^#R4JU7;S5B;"&X;[7J\EOE&U\329IDGUS M>SDL)L,^T0AFL94Y7T6K)E_MM9():RN2"2^)IY0](:2J$>NP(`$\;854C64% M]HIEWY@-,58G4 MN_1H[0@2U[4CL6!GFB7L(JE,F8_/2K-TO1C2+&0@[I5JL8`(H:RB`10FT5Y7 M^&.Q1A.U+RG83":B0\A']S(\09*!2E/5$\ZM4+SCS>#9?NK-:,Z6E,F"(L^T M0W-4&51!1&9NE^P7IA-4!4]"VZEQ_I\VZ3U97*B$%ZM3"HLP6(ZL(\2>UNO[< M:P/\28&'8!,+X-P53GZ/(_Z]=_WLLT+.Z^A;USSD>!1R79\D5\=9[K7J9\.Z MDBXD3)>E9^M%!796TSZ<1=7/O5A>407(U'0M6[.**SN.^5L!E(H5W?!\-H)` M.ZRJ0LBG/`OVDE?\,R7TE8[X&#WW#/[G/N+_EY+2\Q4?Z3?/H+%NJ& MR',A0R^`J%PH7<\_S4-TI+:=Q(1;G!LW)4T=^ZN7[89V/P$7DQL>#YEG:"&0 MU7+D!,\"2[2@7Q%<&=-8/NOM>G4K*(=E5>:JODF"_T?`Y.:4?!XPP?C^4R'H M'P73??`D!.&ACX;%0NQ`Z*\^$+1%+C^L;RD'E4)W@L.UM5.9C%XHAGX>17[= M3OZ`N_U@S=?>@K-N4T]UG^7M`?1HT-V:/CG(Q>A/YIE+9?3I1? ML<]]SB/J,:B8?D!YS&!D.4]J@&AXGK]8_GZ3#;M/B.<3 M*9)L:)>K>4<=\&"BSM)/Q=';38W9?,T]'R&M'GZW7NL6D&!F/.Y,JD/I-\6= MD<6B0M]X]DLEY=?LTTV`CO.(FY3FC6!O!LG8>/J+P/Z\Y3X;.O3SBO`^PKL5 MX7W^B^#]I1O<_P15MT=():L'B_2R_H^B>&]SK!"&:XE6(%MZ@JD*_B?SA7 MNF=$BQS>I8J%ED%(B5XW"!L[3578H0-8*M085H2UO]S:WV?=;AQUP"LE8[XF MMFH\M-Y9=31&E;#]BS3!?1:]%Z0=E8Q:LXKU0?YR77O?Q;LAO]M9AC%K@M_D M)TL7K+4[,K@48DFM]O,Q;TD7^M!J7C=>D;#&T,YNCJ;YWDO9\WHC6\M\-U^K MK/Z=KVVN)Y,L%IE/0L]Q3P^%3BR@W^-RQ8CCY8ZTVF@LAY/">0T8G=G']:_?5B"#CG0\KW83^47_!^;ZZ&=.U2=ADM!@`Q+@9J(545Q[Q@ MH=?6K370<@Y@!`V%W;P83!=J/1]?4W<9S!S&D"P3F?5VW`R0P5ML0U\&3Y)#`2P""H72VZK(0F-AO?_U?1V=O_O;7_TV;+>L>S:9Y,1K& M(S[.;FBX++`N=8!NRL6(0"*TW^?T$Y[/AERD(%\!""RWGIU,NOBIOLB\F-(/ M:@UH\RLP>=LBRRO63''FEUCM/ZQ@[GJ#A[`\,OIBJAST4[9YLV>YG[P$>D?^Q=,O>;F&^"LLBFPOYVX2%!H M!?5[],'3MN],&Q[.+E7$Y9U^B?#PW_E-:8G5Z5#-``A'D-!*9.?T@+FQ9,V^ M-.]4`MD?T;\;I"FUG_/O$8ONC4;EZ7PXSL[>F@[3O[/O\H_ZMWBLA0<1Q=A$ M/._7X%`[=4KTKVB(8NDA?IB:H(3D.B][S5V?GM.R!XC3XF*$MO`74$Y:BXX`6ZD/F2]F.D(6*H+<9P_A_SR4+"X,?: M7CY68C"C(4S0@\2LC'Z2%^<NP869 M&S4JU/&JDVO]*"_Z^]CV%TV`AON7076(MB+!(!^K'6\].P*[*+U*.?WMKW#P M=3FSRQ!\@3.I]<[!#Y@Y9P#M`S\*"VEY2H@Q#["&"LET[3\A..S MO:I;*V0(V<-)`Y^V%*(6";+YS/`"180$VZ-V%E.TTNWD8*5I38BY60J42`E& M^1KNFKE2U6MM"'Q5I(SMX=<*31""17%TTJ9\SR4'"!^1:^PMU;E'PG#1O^JI MWZ8->'W1"YIFI2#HZ59+-_>;2*YR6Q9D8KOKEM`),>52!KZ6)88^T&I9+F3> M?UA,,+'TUI/K5`-<;15[,A"?9IP")QIZ!>4#(SB938RYSSHUIM]TWFMPO3`C M&C>TN'O]UI14I=[J)D>MG/(FKG(`M$=<'$`MUI4N90#Z??9H\_$2MF^&L`!6 M"9]?Z''U("DRBBRF?#KX0*]=8#XN`O-18H>E/2,C8^6JQN!.[@$?,C*#:2Z@ M3`N-$:MRTLL>;3VVTQM)6FS0\GY0FW[C:A/.T87I9:W990S.\L5T M>)EGIWV:L,AQ?KY!6-=]R+,*L>ASFM@&H8(GU,UNQ^?E2.X$EZ1?HQB1X-B; M@USNH9I&6>#T[K/29Z@;!F[4C[$C5[02H"4V3B?_DA#I\@ZX_IRMKFQ\3M9 MM6+M@O_IX:5P_M*C-?Y%$T*!'S'0GKWLJIQ=ZZJ;7`N"04#[=V31),Z^A@SDC"$'2^4CH&<`-3 M[_2V=Y[UGF\]K;&S[#E(\!IQD(']$!BP!]AS=Q8(#9,($BPLL9'6MVC(<7\T M\0M'A&9^S4@NS&NZ6`W[]'5'*.KH?[JUJ[N)=\"C%9:18+7HAYL[V[UGVQOF M8RG#&F#EM#U]%DN"VFS*X`.\,%#R<'/C:6_KF?5?(5JVDIPT%G"&:^2#?OXI MI!-__BF@T/2X7&\*-#.[[:G>/=:&@-;>+)0$;,[+GW\2_F"P6D&FE8;BO3N( MX&,5#(B2'0I^1U<&.P%3N] M;-O,4OI`G(6J&2KVJ+XG!W4-X7Y[+C4(4 MZ*W/'K6_P+E2-$74<\$K'.O"KSQ#;TXF-,!F[]SBP6GK'6OK?ALA`QTSJJ/6 MXH0G!/$N=KH:@M_6GR^04$6V/'PKX\Y!DO&LWR"%:/)U[;+EZ)8(?#"T"'L\ M[$_+-:9JD*V8C;D.]/KMR>RQ":'^R@!AA)_C\EM,\7D(02>6#"$D18?B+[%2 M'X],'@;"))^&S_%N,E9`I8J1\T%Y'2#S[,`UAIU,)U^-2\ZQX"Z\^QPX>//B M1@X9:>_E1>JX=!Q'E!8?N7.HQ5Z6$/YE.<_.JK2!^<`OW]<^(BAI$PYQCXV@ M!K&=Z$-U$>G MHDD-HS@>B0>-B$(D]QMY=UHN+M$6\(V>3!%,GOU`^FE.7LTN&DB%M./<9))Y M>YS_P`UJF$3ZU<0*"NB@=IDRO&PO<&W&]CM>B%33!C8Y_P6>%/BWARZGY0T" M$A3QQ%]13BD0L8JB@CER_2#^!?I@NCJ(P3;N'>68K>Q6XSM:+D>7X!\3`-L] M;Q1UAXOAC:'2,A"4C#DA3?0YS8EAVYCRJ$\<"-(NR=4<`ED(E$]VG<$D-;I! MFESV![\`/H&IAZ2?X-+;Q^98.79XB%T(\7";N+$^)'XTP47G"9TFPPPL.$<5 MN[)V[<7!X-OE5"(<`>XS36LQI^?`SE.BM%`N+TE?$FQ2]#87Z>#E>S/2$6'! MU0,:I&@R"X("BE,N[E:L)B%R?RFPJQ]B'TWZM__Q?Y*_R.J$(I37F>LQ6]*: MQ81T11]:GP=[P*%&LS+SN3"H]_@YD:3LA'3AU%2-=-*,3:0`"'JQ\"'I%#0= M^RE#'M(9*5TDE^35OIVU1E]')4@DYTK:"@J4L`>VBU.2TL1L(%J77$R;+9U) MY1S%O0Q.$BX,(:Y=*K#'Y$?QB3$%:-^@VFWA/DABP($,&GZA3S,00T^03/:] M(+K*KDA,RE3T\RE=,*9H$+"I:%AI^8I["'*R*WP^F:.P;3]A,//`>;*&^;MR M+K`W?_[I9='/I:("#0,B+5=,K#RNU*0I6QZLF'IM7J[YO`EI'*.)SH/MP&;G M'QP.[&DYG)7RO\"!PCQSE:Z_<;3/%C1;P%HHW#S;T8H[N\BX,I09G#0;+D`N MC3^:^+"07Z,$EX%>W7,8W;HAJ*#0:?-)7L`V@9*F/.K_MOB]EZ%-4/5R2@B, MLYRO%MUW;]I/9BY;23XZ9M(:V_;"_!:S+Y?$).8BH+CXP\6R MS*<$L,R6L6)`.45TA`&M8[YDN'&B1UQJ;:F09U-DTQP9PH-W>*DQ=<)X'"_$ M<,8\NV`Z08R:G$]8);]&TCX.E2."4Q]NQ8WLY$>5J^RX#FAQ5UWT[70;$>N7 M[W$@W9!(7Q62(IUV.5A)Y^UE#T/@!-+Z7#:!+R,$6Z##/6:)1T;N MK71BA07.I^DOTN(6J.%.`D=Y`SJ`JN:51,^XUVDW*V(%WI+!B*1JF>F7%K/J M:\>].35?-L:NG1GC:CD"%%F719S6)&"KRTDJ>W.S7(:1:EH8KF&9I',E12&O M,.JI/A3@="`-[@+T[?KI>O;:,L`Z]9YY;3S*'[J/HTW?D;SL#Y$6/&.(YF_L M[;TSE2P,R9$AR5XU#59@:.^JQB=NELYHP'`HAUK#T<@)VE?L&M0#^=-226,G M%S$X-!!2Q27#:EZ=R9UR2NO\8*<6F,T MT*5AT)GI/A@7`RE:$8S5X`:P)F(%Y[RP&7)DE6S5X"EA&:205QP1=TRH M3\YFRJOC#03\F5@&Z:B.DO+10BR(IIO#]'1H?&%70XQU,UUHTH$[GMU/AIW` MFIN=>0)DR,9X/BAE\]D"^N,J`'FNPI&2QKPLAE`X7<5H8@U,@>YW\)V^%_5P MC3332EYM2SC@>VS6?5`_N[)2'8#@(QG=P;DG?*&KF0I99^7;@&XE1T0VLQ7T M0F3-/S'4P)+0MI3@-S$X39/(#-$''T,Z$0T82ZD2F=,#]U\`Y8\+`L-0>-YN M'?S.E)91P3E;4$B4DG;XI$Y8UH^6WIG8X+,!M,8.F<$6,^HB'W($I1_N M]G:>O^AMOGB1*(=70"@%KS,/LJ`,R\#"6%&/@Z76LU-TAD1446$0K7HHCIZZ M),&F(X"K:S%,"YP:$%N;O2TF]SQ_MK-.]C1*J-=DN.L5M#GJ00OJNH$.`?3Q M!D(,(:47B`T\*8B/HC@.T0G5R*;8Z)*9QO&PEJK^K=@+!"GPE:ZQ_>)$'HZ= M*N%.'I7!LT/2"/*&V-5O1)!3_/,"?9W`E!@K0Z%4#!HD?#LCXRV=AM-#50/- MKZ*T2Y]V6L;A!T'"#I!5:0M!V+>1%]7AT+*IDUEJUKRIH>O42(Q!J2WMWL9L MH105F6=LKE])U?JSQ;6\;$N<5WP3YE7(<0E%\T[$":HTOX@S8#YP_$7%-MY, ML-I(B>@P'@*I5&^EAB@S,55B@<.)#@4U.`K&$A%Y,1M0.Q2'"3EFBBC\([!I MU?_!9ZJM$,'B#P(I9W97,4&%6@L.GZD%9SW[!L>%8-1EZW[J MP8M/RRX#*BOGZHZX*FSAX6/TI`2+6OSA6.';]"^-`>;.2`)]QH=A1G-I9A>X M@T$?Q&2!REZ!CX-5A,6G((K78Q-.Q!W;?<+M&33\!76*U^;P>&;)9<3!M78! ML\GQWR$%2_G')%P?]T<<1#F^=#!]6C^!\=I8Z7OCPV3#@V72XU&XX%-LFR8B MPEI"X"IB-OW!+?3J8HSV,G!/==M"("&9\INBNT;HBKBV;H9U/)*M;J[ZUO%_ M0$I17G]KM3/.@\>`7[F$D9]85ZDC64E MC`1(,[)GEFN]4E8DU:*A>D2&B44M7P)7)>5HT^:C`5GDJOJ:__DX&":P.@TF'CS M6^+PO&7#+9FD1PB-)KP890>$S>1)H".\+LT8,^,H.7,X)GVZX@@LY`R6H2`: MG(>M[M6AK3XI*W!Q0UR%'ER93T%/ MO<=YL(6@)/4%.4(]E"QE4P0TZ*C%J4%1K[&J5^??A$[Y$XI9:>N)G9:A=<<#)`RC'UUA1B53=5Y7:ES5 M5RPJT$I2*KEN,<51-<+,]$N3%6K?&S9@X5H"`)\HA!(FQVI"Z.88!43FC`W( M4ZHK#L!04]XAA+R3@`TU(;#O[>8@0F31XXE'JN:"5-!MG6B_[E8=IE1)4G0M MR3UCETX+&&73M)T[)0'W8E-RH\Z\*UI:C.$@UE+>=3^J_"H!VV.T%8),3XQ] M2:O'T:2_GCV2CV%9Q%2-J#=2+CW\6*V<$!I]D9#4M\AP#*KD.14`YR7F63*CS#HQQY^/[MF6-57#U#!,VXP M%@^^%F9YS^`17$S,M,8%3P$G&^.Z?"F5MW>ZGYV1RNIG6T\W,M^/??1_[_B? MX1-^S>$ONE+PU8/G#_A'GPYV4S)C`-C4)]-#/"%_XHRFV5EV3-C[GO%\$WU[ MD=/F-NQ'HU;%WIY:>]'IP\C$-S;4; M!ZJ$]4W-A=FDV<&[4Q7&]3%_2C(#$2BND(R$A0<26[$WK&X3;F4KZ1;X$.?4 M(Z,0T`A?LY.Q"GZ#4W:%S[$6?8')PFJU:'26TULSG_==[V2#KVW+Z!R^\DFJ M$<0EX;]C@[CR\DP_.W\=8E/3T=C6P6@-;,$9VL.W4^8X(I`:')T,'A2`O0FY MVX!UU!=YF7Y(TH1LI;?8XR4J!%ZS15!L0:Q@H-J/D)P*FVO0AH4`]WK5I-.Z M!&$O%!=Y=]BJ!4([G.3GV>9S]:;4EU^SUY9VA+5B_$N3$*(K_Z6F\8*#MJQ/ MD%CG1AP2_!2%0M&QQ.0"HEPJOCOU\*D$<`X7W$Y>4P3/F"->6XO#(ND*$U(Z@-0KB2:+&))<( MH\Q%,A;&W>&_?NN_OD,H4YEMC><.R>(LY[Z3C'X7"I9XVUK\URP,LSH53$H: MA!<-^;;*(T-.;$A@)T]`SNAWP48XI(I":@S$/Y1]HE'8\H;F.\C60!`(A8NH M/B&/_,VJ&K@\;\U-VMG`HK^9Z'"\``&P<^5,M$S$2OXTM[KKXEC8$,4R*2=K M$;>6-1&#U^LYHM'NQNX:A3+SO.>W06+>^3Q0^+2D?6RR=D#2IKRE[D6_CHT; MJK^I0TD&9!23]^$LWL9[N*SF/&HRZC1;0G$X@F$*^<6U*6#BX.2VUXPQI>N1 MQ#M!#;:?[Y`=;_X+:"=7!N,:S,9L:9:\64/EQGJ2? MD*CB`2JQ.'26/`K"&S(&HD[5)Z7`2%I(/*F6#'.JW3EL(Z_KP"%Q*D=?,98NB\WX4>]86B^(7[!QA`%UK6..?5`R ML`VXA#7;1_C'\XND>$G]P.YFO>WL8C77C`EH"ETTN%H'5&SC-XW!F8)=P*.F M$*IUXA5>4(;)!S.X8!A./!`=WTQ:,;VVZ<]@F96=M)U2`'_Z%1464W^^5EC> MN+FFUU5J^P8O2/T23K&H&RHM%TDMIEL2`KX@EB2N\YMZ.`#`(R)WR40[S@S!0$4DR3F:7*BH*I2&6A[W+/F,R);A%X!5FS*E/;;VMQG4=):5')5Y= M;[7,AJ"N3A>6AC*Y*S4^"!MER-T)]O"TNC)Y.'T1]7IJ5>[ M?\'Y_;99A>F*G`IA`=%>=&^A.P4)#!K.G@?#<^M[HM:>,Q;SU6*(@U2+^M48Z M,GD)&3$9+DD-675CB>;FYNW8;=#V;9?E.<1ON'"W]@;)HK_$L-*DO3V@#)<\ M!-5?>L')5>!Y,?R8/C<#2_`>1LGSG*`BS3XL8M\.B:OX0RLZKWD`_(^"`91( MWS*ZAM[^<$I2%/R@8O6!E]A=3)RMIU/KOG$L)'?3Z>HE'Y<*`+!JDGL4=55C M=<>@RI%8C^,4>K+(;!:]9S^S><4UZ(-TY3BD,@)(EO6$UT65`P6XZ1I;1\%Q M"'=BC&(>9#G!N<^BXK(N_2;\U*`(>@$8;9A7*"\-"MV)5T4ECRN%:@E[-&=A%FY:%E8+C2 M)F8/)'0Z^0D_BW810BU,Y_;B6A@-F&=347*)C(<\IYNB7$JN^%(B`]]?%;H? MCL0[J.(6J6FYS0Y14I(-C"MG0,0&5U-X5_!'O^@2D[4AX:#NW^GQ!02>N1^P M5'(6+,'Q<'>]1F7;,^DSP5JIE*32NAA>BU9YZ,KY:JGU]R2Q[-?$],8KA"W\ M=E=3S.N2D:IARH"EE^N](B$ZDVA:M:.M90[5LRC55V1OJWBTE;24C7_.U+D5 MCUL9@X[GFGM)344>T!?L"P&4`3O:^`!E,;!#AI[16 M,D92:*&=#AD19C_"+X,E0^P=`!6B(TDM"=_">M=O'@K#Z=XH6]K/RW`"I),Z MR*WNR\'UE?VJ)QV2DD\>;"T8AN_MQ@`A=.!M*^=CS2IP>RY7'!L-769OQ`BS MS.9H;5<&U1C0>X9YR*6_6D/R7ZF9UL\4X:TWP$"%2%9)B=U!\C6I:Y*JP?N)&D+*H/HAP,=_:+*V M`[9U;\"&$S*]'!FL*-4'H99!#7K9:UKP6$"`:S_9O@I9QIO"KBO2&L1J]O&H MVUN,X=!'PW7HF.NRUV6T$_ M6BSU5?FIP&3X$4VZCU9A0AH\J;D:6H*I(O;)1?G:-[[XXY9D':9*2%T^8B^( MQ)IKD^)NF'NM1;`F/T73JMIF:ZLS:WE4&)M^1<2&AIY5B]S. MT5E)7YN8)^UDKA\+"(4!HR:B^G=T>IT.T@[I-42=W"3OU7V":M?LA\7@TGP8 M!#D8"M5&*F^TEH+H0+P):[@%@:KY(58T48Y=&\?=9C@ZE1=G/E'ZBI!*77*A M5J8.%IMM(&O8Q^^8U`\731OK':$?0V\<]QX@6*W!PJ"$X/(6TKT0W9,@18A` MTB?C#8UH?6%J,;/,8^CR21#HKL@:T!#G.^Q+AXCW6!0I1@]NS(UANV$SP/A` M'`_%:KTO$7[Z&!/%VI7LP_1=)!$B)B=B@0L*IFALXQ0"W65G0<2>[E\&T4&A MI`XSD"B6GLL\^E+-7V*O: MY01"KZL"4UQ#!&T6EFP0B].+-9T[]KE_%KI_^`(K41-P2W'P4;?\U:48`^YV M'?7I/_EEG]BOR22_1H@*,,2LQK5??6TI@6]A.#NIE0&4KU;ZH#-*#M]Y,"RJ M!4@@I70D_J'9D7;`:_Q;>2-FY'P?6^ON6#DTRBI@K5E!68)H'P5*(Q-4V1-OC/4IOHD`)`7.,Y`8)N4KVZQTBLK@.Z-<2GB-% MI0&%M6TB)I=Y!N+K[1`CQM54\H\YGX>BB,&*GVEE*)RA!X_2@1BWX>8`)3@F6%J0A&C=7)A/3=62M=" MJFYG=K+^$=/JQ4%3&,"B+.=HPG<<*8T$^C+YB^KBLZ%:=5H"$7`N?)_R:E>6K3H0V M/=$]A6M`0_4AG@'C[S\/FSPGXFO]N0MP%?Y]V#3)(6$L+5-:9G""_-Y"OBT-5\O M)5#A;>,CX#:!TB+2'AWN-00(E^9:%GE[??6O6IYI>-K+D4I=J_NHSZ!$H(]I M`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`O1@[-"*@C]:Y`H7CAND#0KN/G_8Y`H4AQ/( M-'+E29-!0:AF7$!NA.KE_*KSKE.GS]NAIC7(.E[T7];1M2PQ+\<8VTU*@X,F>64J\\83H$/.V2)L5C90FNY.O] M<\P#%8_)6?>IZ9)HOP=#&HGI_3JM!C@IZ<+M:-J:=$F&\D/_JBQ'_"%-H&!^ MR=VLS0C^IQDIRM1/W65BGB_,5A$HN\_`4/S'ZNI2%SND6K9V()H&:_4\"Q$# M3]AM_'K6.-HJX5(<&+(#,W0`Z64/.\(SK1S`GF7!Z@%YQU`]R:3%(2G8`Q*! MF(*L2B(4A&%P[8XC`/W\DR'+8L*#]*/-)V$P:"TF_/FGKJ!0G,5Q0N^R;QJ/ MRRYW#57=W;#Q264HA&BR#9V-[`$W*R8 M)2F/+29JOS&SUPL'#[N1F$\/BG,PA.W0??IU,]('#T M)I0V/^AN#+9GQ?C3T-ZKL3C4[1Z]V'A,?_5M2IW7T.WK!\3Y-5KP9CGY,348 M5%EZN)Z89V10+`LA["2Q/P83(2YY=`YO@J'`J+Z"2+<@W2/=X%:'5*OZKIE^ M+/-)BA4WP-Q^72]2O133S$OJ3/>>EPOR*E/F7X=B_#4CD@.#*7-@EF(*5&G41ZZ"1J_C?"R:4HZ69.Q%K2YKH!LC`_O*#EECC!ZDQ<: M@U\Q.K%]4)B(RB\*E3Z[>_(KPYV"#+.A;B"+.Q_M/0[=C>;%`)4&B.MOSJZP MW\^N3D@B\V9'AQ<$<@Q()W9C.=7P>3YB/.@XV#)8Q4@GX[5M32>[ M).@F*V'%$-=XFXOTTY1WW0MYQV;-,F;R8 MWB/+K!_C<.&QMA1P)&0F"6*WI3%'^C*R1EK.L]J_07[0LL9Y+;>ZF;*$3:/V MU!ITZ6'UGPT\MGRR4.A_<5%+,MI\ZY5^&/ZSDM_[_LN!0PGZW4MRA3I@+91N MH5SZ?8LM!G'8O#2-1/^$]V.R"<^8=#[_G8B/:19:.;U5N@9!,53%FT#J M->-.+UYBF2YA#(!ZN/UTL[>S10KS#+KYBTJE+LABDS23N0%C^D2]%9O/ M-USGIMR8LG&28J,T(SM\/IQXP-?B?[U2;$Y;**[52O^44<`.^EP+.2\2+@Z0 M)WEZ6L=&]4MGAL/:AXN)K4<&1CV>4NA`*9%C:67Q[/'5_IK2]_KUR%W5TOU& MYGKVJB+39XQ>8TCFUE-+;FL0O@$5T`X,$=9(JLV-WM/P6^PA;@RO!$%I5!EP MY42-<\83JS4*:%M\8=FDAR^>&NV^;,RSK+ESX==3&L->EO@HQV4((P[NX*=* MX$V)/]S9\?R_<=G23V>C%)D`,!JB[OC.2:33BN=@=D%@'E?C?0:@Q^6T^!5J2F2;JSSF:-[XG:DA@&610J"24PND\&-]48^V$6Z-L8DXN%:%7+>:8%P4N86T&\]"<,Q_S2F\,-A`TP'$51G;L,ISDO5G!7 MD,5[6RWVMF[[>LPD#\1TBF%:/Z-I/_23IJAO[OCUKV6+E/+1#S?C4%HI)%(1 MR>JD6A1H?6NM[5O/7*N8@9[=)H.>=&R'X-2G>.EVO^C\\.GSWNXSS,5]M:6.%/DHN`4O>B\^BVN" M5C*VD7#7>^>0GRJ/D>8/)><$P;[&,*:1RCN],*'8E;Y^809M'=J"8NK.P8-W M-+&01E"/SRL>66;0<)AECMSM/?/*9]P'!M&82Q@$'YI"N-]+J3.>D+O-`$Y^ M\J65&I$UB,@;W,M,N?G6L!&*%6@.:2+-7*$?IEY##"@V#3>0!U3KTW1MD5A+ MN@4&5/V5T\1@_[EMM+G14J]>%X<&?3+D!"VQJ.;&,HH34O%PL[?]['GOV>9V MI9?Q52IC:L`!!FHD3.Y82L(T;&AR?^Q*F>LW`:TFPU_#NTJ"N>1]0H&(GL]W MGO7".4Z,)=52J3J/S,WN+FAYMOU)T=Q^ACYZ_J+%/<^8 M5A7N^88HX\N&PW!L#B.8/4R=^*=SZ-S9>81W\=NFIGOV"SMBH)]_BAGJP.W> MV6?3AK+]PY->]G*Z0!Z_R: M:/)K:XSBNV^.6DAZKGESU;BU+\)4A^R10BR&KCUNXNS`QXBL;HZI<9G-CY); M.[AS!A]-4][*:RE+[RV&COW8J MC\ITPTPMYE`UJ.^J)T?,$'KHDT>CST+2UG-<=2,+4P3S'A<.IS!3'A-X89^@ MZ1$3K5D_+A^I1H2#:NP8.`U-'\)\TY2Z1$(75TK#^&^N<)M,./V?XD[M]VHLB,,OTI?,,&1&N,^^*1(D8PA$]!P$':8 MBR@7IFW`&L`6'GN&N[Q#7H!GX5'R)/G^JG7::^W=W8X@N;-[[[T.=:Y:5;5" M."M&15QD)FF:_6/;O<,J'6=E$:;%**_.\R7$(;'93T,AQX4*"KB?C+?=`XK8 M@.T:'&MK%]2>VH:RX=EWOHIDUBS]J#4Z<(;VQ"JH6IN+V,P#UHQZ>]IFP7*K MX=;@9YH`P;K4A(A_2X>1V8MDL",&_1XR:27V46/2XMU8\>[6_G@+_R7S@[XJ MY9R(D4D<)=Y2T@]YG($G6_M[%2-@N2#9E%@0ZB+D)^N"WYX;NG`BB%&2+*X[ M.?T$4:%MWT3;&QXI_^0::M/ET>T5TAE"7-R##6P)7A@.+(>@`4&T?.6K^NT# M22B+"XEBW-(M8F.0-R?*'1:=D]UHKP:@)XO#=#XN-#"U>=:$H(8,1U8*[F>C MBX@P#'G-Y30F3X6QV6QGO#?;::A^#=J913WNZN6V,ASEMS?>F\_'T[WRZL&& MCZ`!%%ML9I:DFPO*Y'`V&PC*>H)E#Q9#&&`Y*7C^K+4M,OB`:YS-A=,9=;FF MQD1GU@?J';<.:&'9">D[/%M*ZI&\,W$OX?-28G<#C\KT]YY-WV;9[-LCK3B( M=G90;`+[UYM8Q<1/8WMY@T:A$':KM]4"OZT7ZT50BM1;&J;%I17\9M`S!74# MST?/(ZJBCLZRH,%LQYU-).OC?CE<>$I((TM1RPV;GDSQ/\&HL=9K'I8 MDB3?1G+T\9=XJ0P)2IAZ*S<3_!:(-(L''Y]FC2!9UX@/L1RN7,%R00ATT2V+Z(&?=K#@A>@`>[?*N/YQ\N/S3Z%CWI8Y'1YL'FY@:N&V7]*9) MK'Q46@RJ+@&D4N/'%%!E&7-Z9$@W8F[3>Q!HBL8HVADUHT/UM10]D MGS.W=PR,FHMS$!&TB!C#8G\ZWJ>%0!;U#72&!>+63I8D?=B)1]W]L='`56N0 M3"8/Z18)03.TRS!>W_0'UV^OL11#W!]8A;8;\J8O/H(_"$NB)AL4P*-+P`6? ML@B]/*#6-1;@[YA?`W)RA?$%,I*6J<1S%LEFC35[1O0DYS%9]3O M0YL0Z"T.)OKHZ)1YK?S#M@-;F)U69CQ^P_`)CV33GL!..J+PQ(TC[-MY5O$1EG'`.URYG75I8] MO[@TW+ZPM,)?-67VGC,K;MX*Y\#-:EDI>G\A^1$9/!/;`&W(/O1LY]E.Q[;< M"/^*Y"UIJH-@0"9*(4B5#8'L]FJX-#2+X=+C+?W]XQ+:8[#N`Q(01@ M6IY%K/,/A`M%#(;*FF45=+O6::\@B8BY5`@Q(],(TSSJ5M!7(F6`C)WUV8'^ MV,WD:B(O"COY^:>0D?'#\!^=[R[WQ'Q`_BHQ$I42UO3H):VBAA, M%T?LNQ3[HM0D9[_[WD,F'OB/=D:Q]^WQ-)R=_E^]$*?_W[TON)5&(45Z M`GT>[]"NEP3./82>IYX8&.):TLT0%FKX'".?CV=[N>&^Z-"+( MRGXDP_CCZ*^?WW)MX/G"/$?(M>/MY:+K9)%\DQ4/6=2F?L[I,X"R:@)`05%' M/<&LWEGX"Z96[COG_4!>FP/PG2YSPL;-&*$DH?)WJQM0DA;1B%?Q[TC%` M#?8B)RAD2+\6@9Y_>"T_S$\,E3==)![K9D.8ZY+#';4'4>ZR&_>IVTMIA,*5 M?NC$B9K66>!'YLX5_IXR;QE0;15(UB.+U\)-!1N$/<1/#1(6+!-N255D?F4' MP/^Q'J/ZM6-H=WPM3:S]^8>A12X!:9(9D?[)A2.`5"Y>GO/T!U-3/6O5TX4# M-RS9LIMESQ'!Q\8GB8=L'TDE8"UN3!##RN`],S"XLW\J" M>E%N+^"BP&K5'B8_,3\3[TLA>X5&&C+^V4ON/1V;+H>058`D$>O+T@B*+!M*O+MZ3%4QAW.=Z/=/Y9'-G^X>O7Y2D M/)W/-_>G/]3OO#R_^N7>&S22]=BJGTXV9W.3`EN;\TGS[4,E)^/CU%^!'U0"K4JNP M(+XE@>FQ`#].YXFD13A+.QPH*Y.6H6EAUVO/O?_XKI0TLTIG0.-SQJ/X^ MMIO^-<3`1]R2S@_8ZSGA,FYXI$H!/<8JC,\O*_(HF.-I\FTW2\82F=>F8B#QD9 M*$E7?UTJ]_'NR1,0L1,8HW4H^/+$`9_33]G#S`TG-`2:"-'2Z*'47B)/;T5R MC3!'4%J;^9HRZ023+YKUE_'O\6LDA1&00+"1%9X4`DDJF:V,RX(O7?[._M0< M#7JV!*E+STT%4*_I$_U;L]6?PT59S=(\^;C^^>693KX`:_W@(%05-#+S,`0D M4-?U-X^Q.\@T/%_4#Y[W,_*1L5[]\C$YH/5OK]2ENOXQC.KW")TUPB8^)HY@ M^F/P!?J0+%3<R]0N:-J68`T3 MQ_6NQ<0_NSU6@YW:O5S;"'`:/584J^ MH?WTM,^L^1%O5LNX]_5+C?^:6+D(TFF_?K"OF;:14&`/.K!! MB*U5;X46;XY.I4\B"0N2'B(5H2("V(+H^CIZI6.OD-&8D6'_!F M`V'%/$`0%AJ\2Y>IAD2>0!'FD[R^,YG9N=SFZ"GU+9I">+:Z#33MF<)60)HE M,L9;3O@5U^Z,(64H"Z\Y0W%,/Q>MCNPP!S1C2 M`%*TD$F]&_G%IS%=BO'O%EADMM!?Y?OHVYZU2A'CFFG-$'3@-LOVUL4+;_Q0 MRE*PJV/GA)+&HSDN<,J8ZI&*J^(0+YVK6*+(I#@;G:"'%MLC#M.<3@8#@K%9 MT(14OJ-<;/3(+C>IR;]Y84FS0B@Y]F":>A.F>:B3/J0P0":+F)1*:>TCDK=H M1#=#`6AYG`L\<0HS54H$F%]P4>75Z!%7?'#QT$\_'F3P46#'B0&$'X?D%UFN9^RJ1G$`T$%K/#<,4/ M\(Q/Y1U3&[DY$;UKM.4CZ&#MM`"^Q.@-PX0 M.LA@"TKP-G"RKS]=?')(#9#/NJ!_\-*'*5$P!O$?SS%6G\"XZ#/Z#+/R=P\I M:&;'X1?;J!!P>''Z6:GPM,"%"OP-_\='UCO6KMT3B,L24"[^M5)DP`W:%*.2 M&`Y(JB&K$F5LHH55[PGC7A?.@51V[15VEWT?LE$"&?.NL$[>*112WC?7\-@+ M0EEX!1S$^@B)[/1]O:#4Y*!DEPZ*09+/BE^C6C>33RH=Z4+;GI4_82.+_33I MU34%YS?\]_4+5&SV./!\3?D'17.J\_++DU4W#A1U$L^5M3K^#YL.E.OGMW M?HG:D>;7W:+H`D&VFL>4AW`:%]B0W^.K@C@^UB&`(X/?S$^][_F(9EYQX4C7=Q!_VBK^(&X`[,=?T2J7H15!.X MPM+A'$W:5W4%5Y<$DTPQ2$7[1L7A!57Q7"+ES9M<8N=@EO!$J]$R?\+VR M;]7R9Y-TS4BJ\$>Y)K$V8$@5ZPS4D6%]QT!%'H MW<4Y7.&=0;HA0?%"TW<"%'0[F$7,L:22(:,RB`P>Q(@(5OU/.$OQ(W3;VO"V M2&C4#1OD>^9=@8NXJPH.VJ2P4?0$B6^F/1H&B/;8BP-;E&H/*1(:[D,P2R`J MJ$H6.)\O_-X'LF@+*+T(W3FT:BN[J;:?C1:1WMD;F?"VD-2:0"N+0UM.KE*) MG-'M7S+[=)I@+;".3\BD>WLB:K^!VD^AHB6L9<<]=MF=S>AW=!5Y+R7V3)SV M`R<'U00:<&-AIV@]9EY@50.+"LL6AZ`4,/F1MR@.BBA8?QE,L_"D4:[$_\:- M6-HV^?;ZQ-Q,(1$!\@M=\U2K!R]=\_M"@4$)+N/]R"M#@B*,BM`'RGE&Q@LW M]`B%)6Q8D"YJC,H]$H=1]DU!(!D4V;*4Q"K1?F#,9+)H0P/(`OATA2*R),%( M!YW9>[$R5@P1H2]X>)C"KFW6&EG]26KAR?0BL'`;84&XL`K\QKL0SUJ913<%KQWGYX1;,< MX)99U<2XL!E$75#,1@!")^[A>>1VY51UW*GBH"]*REB?9Z0.<"#9X@KXFXOW M,A7C9)+2(.=WG9UR@*V[(%&D5ZD+7)^-$HTD8PX+QG^T3E`I=!#KNH!/+Y5N M!*TC)]RS),,^`_*U_`:VQIRT0U[#.N\: M,(=NZ#0D6OC+#-H3Y"YP9T<&9U0';Y.`MJW$B-UHF4(E?91^:$D[,9_'_ZO; M`/D9)C6T)(E@2E-=)IJK1^/_-A^@VZ.;.M2`\HK=SQ%%J)7ZA9=G_1WRZO=FQ:T+HXUC M^0%7S9)4YWPI85=_W7?)P.`HS9JY;DG3U8.N+,,>G.%%_VG/D1FB0^<)&6>_ M57';>F%TH7^6[K)Z$&MY)8M^A&7$^:@P[@>G7IP[8.BR]$P#*D/MCZ.-OQT] M'-UI(!O&>XXLC>,=-.,UP]4+>X;5G[/_X#821^IW#`@])W7U>UV""%,/KC]1 M!NQK>ZZ'2R^,1ZRR?BK)2IJ0`JGHT.J>#&D\4U9-43;3^Z5E6KUZVOPVBK@Y1.*>'BV MY("B?3D>2C0G;?%0\3&TFYAQT7N.?9>< MGM[SZENJ]H^K9.Z^CA@6_WB7X8.E-LQ`R%+C=;CKN*!@>6L M^FQP<:L^O,U24X*!5*I5,NB4[2?E_VQ@GQE9_G&9`+B[YR_1NL`/PW0G,FW2 M5@)IO9F7["6E0"B^X(D-X;KL0G;4RQC^:`!+PQ\,BK;A3Q)*[WM20YO),/SM M$DC<@O=FC7!;A^=F-1AO,>-\D-LSD\5(\6@`"3UO#D*_Y]T$]GH;<9"@YP9F MK]Z*_S8J+3X(HPW.>M=/_4=33_K8RZNZ?W7UZY__(P````#__P,`4$L#!!0` M!@`(````(0#;[_N+^0L``%IL```-````>&POKI-U4J]JC)@$E_\A=IF-[FJ_WMGGK_- MP]A^!IN7MH=N@PUOYC,SGYGWQ0_[^KL7UU&^6$%H^]Y,';SOJXKEK?RU[3W. MU#\_&!<350DCTUN;CN]9,_75"M7O;G[YB^LP>G6LST^6%2D@P@MGZE,4;:]Z MO7#U9+EF^-[?6AY\LO$#UXS@,'CLA=O`,MNOJV?._>@9^!F0`\_!K-]?AS\H7TX$S M`X2W\AT_4"*(,MC'SGBF:\7?6)B.O0QL_-K&=&WG-3ZMX0E&C.1[K@UAPI.] M6,-Y]2P136K3!&%P-@WQ#+7)!9-,/%EMD_G3`9LX7:-Z7:?XC]/%K*BVJS5= M15X4?'B*KBQ61$_PN)RIA@$U9-#OHUMIP#I2-EWT0=_9E%V.SF;9T!@:XU8M MX[A8C!LJ'!IMNK)&H?%A?'LV=[:OK,RZI`R?*P,PX=KUH@VI6Y'?8P-?Y^#) MF3NT3B)6[,M8YN6E\<%VK5"YM[XJ/_BNZ:%?:9_&OLUUR91WW4C?$0*TKR&E M5JWDTT8NE,6UJAH'H5L788B[PL^X%`+);,?)QLW#$8XLX5()`458+@W%%-IU6+NSN#+>(41V:MC8\3 M73B(;ZZ+S1IAGKKT@S5<#$NO\`R&,$>,S]U<.]8F@AEI8#\^X=_(W\*_2S^* MX-+1S?7:-A]]SW3@;2]MD?ZM:`D7U^`ZVDR-GNS5,RCC%NQCW\0JNM*053T= M9Q/Z6.^/]9%V&4_86E+M6FM[YQ:MRW0?Y"6X$7U;;SCQH9B0KQ_V,`I) M^`1;L%"S2`LV`$ZDE!!LT8:-^5JZJ(VDA9B-I(&@C:2%J(V0.H>2*_7DVM_! M==W]`!O&I-^/URU%]50+),`/,.8P"-*FZ,_:)@<\6MNFJ:U07PJY,=?PQ4;' M!RRM:5&TLZ;!`2MK6HC:R/,FC2XG/%NZP/)\`,F>O[FO'P<#%,4-4SQ[13"I M3W@Y);Z@(ESN>',+>O9,:4N/L!G$NX#M4+>8](_0W:XLQ_F,'>!?-UF?"\M8 M-]@J:Z25-E+,[=9YO=^Y2RLPV$85 MIH*=Q37I_&C.!@;Y\0?'?O1NYF.*@`<)+*LA(KJ\20L$.FY2Z`@PH7&-#K MMM/E#?(#^V>89.*/RU:PF&H%*OX8,;)7 M],S7P-P^6"\P%8VO\[QLRM=Z`4FZOK%/1AYA*:9FU5.#9S;S!U5U_L:"VLQL,*D MZJ(#TLA2-P#AAL5\]]<%I6$`VBR&-6ZGK$I'!XURK`P0KG96N6.>+++69ORI M")O3OH'+V`Z-9FE(J])P?Y9=Y3&#K8O7^JLV>J0W;X#E\)B"I[@@0AK1(QQ( M`WJ4`RO*6@.'R#"=@[>_.G(.[I#>E0L#AZ4N]7F:"!>"HXE=`ZXYLX4AM\ET MSHJ:XIIZN(+IY>$3E-UME>3@R:B2A.E#^ M2YC.6?$FV#@H&^74H"L=?]+"\'\V[,+KOU5=E7"64!\>,8S`!$]V0\';)1N. M)GL>>7BE0:Q-4U21KEF\E;GHD.M'.NJJ3PS-V0ONB7CQ>IT8E_A!8SO,:KLV M2:4UC81P861;.PXD6LWLH'EW6!HP"ON(6L2-=K@$K>E@^`%&*;PF(2W'\M9& M.YRCBN":A_=<70]U<77?TT&]*%7>6L?<"V@[S3TQ,#MX;')>2407? ML;]Q[W4T[CB:>5QH.P)W#!4!UZ$1)-^Q%?&^W=+')127[\4"SA<_OJL3+M5' M4^(!!9EFH<#PJV-\^TTD':B63@ MG,K5LP+HJL02@B?L5%"=DK44=,%4L^?`A[BXEH+:<=]T`V9PF)+X56@`[S)]2KQP*"=M. M!QOHR,^1^1\C9]OM%+R1*MSWO?]KY4+YL$*298OLR)[ESG;@)D*X4H=;(5>P M$\)WY_')9/-:E:QL\1$OXU-9$(JFLD!"O%*HX?98@@M&Y4UE@?I8UA"L);+@ ME]J-9<&6Y406;E[.<>FP0:DI+FB2R.)]/Q+TO7XHCFR;?XX+31;!167E<<3^ MF<@"DYO*RN,(@:.RP.2FLO(X`D(B2P2YBGMR17!167D<>:X.!;E*9>5QY+F*)C?%E<<1I!)_Z?!!4UEY'/DZ MH0O6"6IC'D?>]R-!W^]75)[QFB#C8REY[.`=\1'.3D5\%$O)H\:S?"C(\EA* M'B^>W[H@OV,I>:1`'K%(AP_$+%5P MGWDFC@_Z2%#<[WT_\Q$O08-#$4!_@*?DP`-X%/!+["&>P[C'N(F8+!=X]^"5 MB29BH'6,AN[C.3.A&G721W<`PM M`OQ/NXBX$5L1(3@;%A'R8$=P/ZXTB3D1"$M(A`^__*)L/@*/6UL;<.=%#]N%,S=__D=WI M#LB4?.M[^XL?,1$S-7__"6\A"%D,2UQ0;CZ%<%LZ^*OL`GNF_NMN/I[>WAG: MQ:0_GUSH0VMT,1W-;R]&^F)^>VM,^UI_\6]P&3YTZPJ>VG3"0ZW8P[?@MS0# M_2ITX-%706)L`OYS?FZFDH,8/KMO&,"&&VJE1O3"[*%@-_\!``#__P,`4$L# M!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM M;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC M@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C M=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[ M[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYE MEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%T MS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/B MPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[] M_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N# MUO5D"53,+2L?VW9`X8NXS'"LY1 MZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ M2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6 MKZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[- M&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F M<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4. MEJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P M!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_ MS3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A M0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N M'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+ M&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<>U20Q83>*L;4K[[^O.?QL8]]6#V^ MET7P1H5DO(H1'HU10*N,YZS:Q>C;UY>[!Q1(1:J<%+RB,?J@$CVN__QC=>3B M5>XI50$X5#)&>Z7J91C*;$]+(D>\IA4\V7)1$@678A?*6E"2-R^511B-Q_.P M)*Q"QF$IAGCP[99E])EGAY)6RI@(6A`%_'+/:GER*[,A=B41KX?Z+N-E#18; M5C#UT9BBH,R6GW85%V13P+C?\91D)^_FHF=?LDQPR;=J!':A`>V/>1$N0G!: MKW(&(]!I#P3=QN@)+U,\1^%ZU23H.Z-':?T.Y)X?_Q(L_X=5%+(-\Z3(Y@LM M:*9H#C.'`CTC&\Y?]:N?X-88@LA&H(/(_T]AGB(=)>S"V+]/(5^::?M/!#G= MDD.A/O/CWY3M]@HBS2`-.AO+_..9R@RF`6*-HIEVS7@!%O`9E$RO)T@C>3=T M+%?[&$WFH]G]>()!'FRH5"],6Z(@.TC%RQ]&A%LK8Q*U)O!]-,^CVTTFK0E\ MMR8X&D4/,SR;_QXE-,-J,O9,%%FO!#\&L%X!7-9$KWZ\!.?+:8%\:.V3%L?H M'B8N1A+FYFT]7H5OD/VL521&`9^=`KN*]*30$P@,'0CD9CB(%FL0/5^:+#$W M[+B1%[>OF'0*!P2R,!Q$BV%)6..==JZ&S"BFEF+F*M)?*1PR,!E.IL4Q@E%W M,S%WXR9&89/=NXJTKSBS.V10"L/)M-@E>W#C)D9ADRU<1=I77"&;WT*FQ2X9 M]A>XD=AHV%_A?U+SB9.&6`XT^S$ MZ<-F`O=^LZOJMSQ*KQ*3QCE&#J97->D%S35.O0D/GF!LMFQ[*\'>TDI:S:_Y MC(^MN<:G-^OA?&9KM_DBOVRQT=BQ([]N+VBN\>DM>SB?V>`=/K]TM0O^6NP\@KTP0;C9W',T-34&DKF3?;T"R*%I/IPAJ+6S`W M'1RZ;_,!O>A)J[$!([^>+VC.-B[?3<<'-+\]OEXA]T^'J%?(?8W/9WI?T\F5 M5.QH2HM"!AD_Z%X60^Z[NUUSWG;-W0-H@7C+N3I=Z*ZN^U^U_@D``/__`P!02P,$ M%``&``@````A`)9U$``!D```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`0?[G^G8?ID;-9H,Y46,5NH,:ED$Q^D M/LA\D/N@\$'I@\H'M0\:'[0^Z!QP3ZX=_$NQ_3O\JV24?]DS:P;6X3//F6S! M11(?I#[(?)#[H/!!Z8/*![4/&A^T/N@<()Q)O?WO<*:2H4G=Z:QSZ*S&AF:U MH4>'GH,'D\'#0%(@&9`<2`&D!%(!J8$T0%H@G4N$LVDR^#NS`9O`TD!9(!R8$40$H@%9`:2`.D!=*Y1'B;_".\/9ZL\'2K MK'NGLC/6F@1VAHB!))K,*>).*":R5Z>#$4MG()0#*892KK0W(Y6#$4M7(%0# M:892KK2WMK2#$4MWKI#P-'4RX6F]XMVI1./T;??TVWI/WJ'I?"0"W/I6(-FMO?&!KE='*U2M,K0*D>K`JU*M*K0JD;4(&I1JQ-6TG]J.^). M&;_47:=Z4T.Y&T_J:X.\#KOR.BQ;.3W6H,!JI8P6/Y].V,3IL:A=H%6)5A5: MU8@:1"UJ=<)*>E[M7K4A8(SM\EV@BA%E"'*$16(2D05HAI1@ZA%U`DD7:HV+%>X5.]OA$LU MA=ZJ1O!H5NGC4/_=V&M>+I(3-(+YVR-2JGOZ(U>@M`>JR]GFHDUP\_ M"XO9RET_=,&09DX[,D-O@Y.:@F3%=\P,TDF/;(U*N*]HCM9YI)/P'*$&K%%&&*$=4("H158AJ1`VB%E$G MD/2?RC8OGQ+5`N(=,ABDNK@SI/T4PEBYRQ07=)8I1OH(93;S5#*^+N]E-XBR M:2KKNZ)I.DET9WN52%!KO7S"3]C9REFS#'+7+$:T-`QNPA68K7#M4M_-7],: MS/5Z!6J-<-["K?R#L6,R,A6*C9(?AN[\%J36*O!RZB5 M(L8&S>U)6((HQ8(9(YNFYH@*1O:.)2-;L$)4,[(%&X.< MJK:(.E%0^N^Z'8H*G>\_LT,1.7W@C>'8%!29/WPIGK`5?RON=8V4KULW9091 MI^'>DK.5_AI_.M'_R2.Z@HVL5(E2%5OI"JWN'KQIM&8#*],PG1=0[(&IF]R1V%4NO=;$IZ.Q7$D:47PP3"6PB4[:R M/34SB'(]&RA="3I$/:-5H%:)6A5;G=6JVJ7B9<$:J1.486S,EUYJ&=,QGRI( M!Q0V:AJ=?[HE-06=T9BQECNH+M$J4*M$K*S96(64B0VQA5D_8ZJ<+F+F7[>"9*2(& MGK:BWQ"IA\-^MH"!5(E2E:S0V`(&,@V7.=O4EJUT)<<7,%=;!I.FUK\AF$K% M&X(:>4,0LA%M%=+Z'8_&2JO\+)@@5=DC0;U,'TT;E&#BA6YMK-3L M/H3.VX/'UF:881&EB#)$.:("48FH0E0C:A"UB#J!I.^O.T%0FU!OQ!BT6`S+ M48PH090BRA#EB`I$):(*48VH0=0BZ@22_E,[2W=5.7]F&YB-J%W7U@;)Y0.> M7V$K._$GB%)&YCN-Q>IN[J7DF3$):94?^O\\M*<)LG64(EW3.F4NYU-ZE+A? M'$5*$WKG!K&QJ0FV9\Q_[A,]D:M=.$E;*W&N-1C)62^L\ M?11#S>C;[,8*4,I6.E;>%)3QU7Y;*ENA-CU7M$+OD=R$A9XQ'8F)UU%B8R5B MH@LZ*&4K_OIIYIVA9<8@I*5\"-K/^YO:,5S1-KW!$&W3B-)`GKIC6I140])]*.%W_^9G(1;]]HE_5*.\(MVKDC)S86(7N M+*&M%N[&=+[R#D934Y"LN(MG!M%7BXQRE"]L06*F=TX_$7JZM.,87C-9(S-IPNJA,DBIA[$((H9>2&9V3] M,5K.@2(7M*$N$)6,SLI7;&7E:T96OD'4,CHKW[$5KCOJ.=DK8M&;RT%@D-Q; MK?Q#*6/E#)4$46K08M)O<9?AV!EMQC=TA@5*%6Q%2_2P0L'.O.2"9J&;W$UF MWM:B8B%[N]H@9Y`W!BW,OG<>3/PA8BV&(2*DQ1!1#_Q>$Q9,X'L%__PB\-;Q MF*UL)TL0I8S.=K*,K6P?SAE9^0)1:9!SUE&QE=6J#5K8AYP;MK+R+6IU;#72 M^?TT_Y<6!G7XXRT,!GECPC_R,U9B3&@MYQ0P-5;J8,5V9/B-&]_1]M(T9Q,5(ZM5&R1ZO*ZJ4_N6"UJMCE&O);LX]2;1Q7_-^4K%FY`T\A8'/YT/ MC97M.XE!"]OI4H/H^V%UYO:S"(2E:W!2NVLJ@V2'1\J'R+6IW0 MDKY7&Q=W!?9]?]G9#!U%@O,UHF2,9[G86#DH090BRA#EB`I$):(*48VH0=0B M4F]Q4LW6#=)^U6]ETJ^8>=T>OF[C[9I_UV]<:D_FANP>1W4;!D]T@$; MNIY,KSR&$RB1[H[7J$#L$B=!XU=H?=.T4G'V)4%7>D/>/P:!%0# MW3S_2ACP6ZR\*X_36?1(3R6.W(>NJ)^OC5V9TY4^X_74UE.ZCWZB"JX\T)5Q MOY$/:-2/W&=&/J!'M<>N4-WH(62\D@2K2"7E>(4R[DCETWB%DN5(I<(C5$) MU-)RCU?HM6"/8_=?4Y7':TP5'M%9DRO'//D81(_TNTV\\9H\/-:5Z$FA2#T' MA"7H^9I(/3V#5^+YC,J,58N>[J`R8U?H>0HJ,U9E>GR!RHQ=H><>(_6@(]:` MGBF,U$.$>(4>[*,R8QV&GI"C,F-7Z#$UJMM8N.AY+ZK;V)4NC.CE#WC_9!G1 M6QB0%\N(WJJ`O%E&])8$Y,DTC%*]"?*&1#)=T)6Q>Q=A1*\?0:UB$=%;,9!7 M843OQD!>AQ&](0-Y$U*O'N.+B%Z-@?;K,%J/\3B,XC&>4)/']!-J\)A]%D;T MVA"\;QY&]/(0XO>#Z^C5=^^;K]MV<_BZ>SO>O&R_T$2MWKAP>W/0+\_3_SB9 M'RY_WI_HI7>4:=#+PN@EAUMZ^\#DCHR_[/ZP?#:Q$__+P````#__P,` M4$L#!!0`!@`(````(0!('TUUN`0``#\0```9````>&PO=V]R:W-H965TMA??W^O*>$-M5^)F:3H3VS104^!#V9R6 MYA^_Q]]"T^CZO#GD%6[0TOQ`G?E]]?-/BQMN7[LS0KT!"DVW-,]]?XDLJRO. MJ,Z[";Z@!MX<<5OG/?QL3U9W:5%^&(+JRG)M>VK5>=F85"%J/Z.!C\>R0#M< M7&O4]%2D157>P_B[L+2+R45=E_#**F41=1=FIP MF[]4D/>[X^<%UQY^:/)U6;2XP\=^`G(6':B>\]R:6Z"T6AQ*R(#8;K3HN#37 M3I0YMFFM%H-!?Y;HUHW^-[HSOB5M>?A1-@CD M-,"1_'UXWLI#?UZ:KCT)9K;G`-UX05T?ET32-(IKU^/Z+TIRF!05<9D(/+F( M.W'#P`FF_T+%8RKPY"KWD3SYNL_BX,GBPHGCV\.GGX1-61@\69@S"8/`GX8S MR/Q)X(P%PI,%3C_SO3D+@R?_GC.9.?;<(]][[K1%9VTH@EW>YZM%BV\&K"R8 ME^Z2DW7J1"#,9Y^.7M3#/Y4#U`$161.5I0GYP$QW4,-O*]^V%]8;U%W!.!N= MX\B,+6>0(B.R.Q78JT"L`HD*I"J0C0`+3!!.0.U]@1-$A3C!<]APX&Z-JZ3- M&3QDIP)[%8A5(%&!5`6R$2"E#8OE"](F*DL3_HH"<&>>G.>&<6"Y"%(@4[:" M(KS0D+V&Q!J2:$BJ(=D8D1R!-O`%CA`56%2P,D6VOJU4_(:2O&>6"(JP1$/V M&A)K2*(AJ89D8T2R!+(86_)X;^#-@)"'S/F(-PSQQ:K84L2#.1#NN#.E&G:" MQ(7V3,@30K'@C(6F>>-`):7\D&K(E#!E90A'/']JG:SO*\MF)]SR)/=,8N2$XI`7K&HEXSS52 M32-C")SO1E,S$XY*WD#''WOSP`/8OKD)A"R;P)"1"13QZ$%CV`,T9,^B1FEK MG$1#4BTJ8\B<%).4%3G:CO;$YUD1LIP515PXB8T,#(6!0T5L'Y+F,FG'2,Y0 M$D%@A\H*V3.">U\/G]%-)%U_/@^4OI1JNAE#I`4;WK=XR3\X1XS]^T\KAFC( MME+$A1YUMS54!KYEI%'],&1*EU7H>LKVNV>$^Y8=:R*)+`*G4F6F4DTD8TBH M51<:9$QR)-+41G[CK-HF;G3,%!:SYY+C^J,!SV53CB+ M28=>J+B?ZM+DMD/FWAN^1@N+WE[HP;5&[0EM455U1H&OY&;BN#"Y`A;7IO4@ MH.`;X%\%)0HO-GX$^ZB.;X,(-C0=CX,(]B<= MWTXC:/DZ'D\C:.,ZOIU%NZ&&E<3B603=$/B6>`'7MTM^0K_D[:EL.J-"1S#1 M'K:TEEX`Z8\>7\!&PO=V]R:W-H965T M&ULK%C;CJI(%'V?9/Z!\'Y`0!2)>J)R3$>@,4FFYEGOK^$MIV M5YY07706OJ`&[AQP6Q<]_&R/=G=I4;&G0?79=B>3F5T756,RA;!]1@,?#E6) M(ER^U:CIF4B+SD4/X^].U:43:G7YC%Q=M*]OEV\EKB\@\5*=J_Z3BII&78;Y ML<%M\7*&O#^<:5$*;?I#DZ^KLL4=/O06R-ELH'K."WMA@])ZN:\@`V*[T:+# MRMPX8>ZXIKU>4H/^KM"U&WTWNA.^IFVU_U$U"-R&>2(S\(+Q*Z'F>P)!L*U% M)W0&?F^-/3H4;^?^#WS-4'4\]3#=/F1$$@OWGQ'J2G`49"S7)THE/L,`X-.H M*U(:X$CQ0:_7:M^?X-O"FKK^/'"`;[R@KD\JHFD:Y5O7X_H?SN):3,7E*G#E M*JYKN8'O^+/_H>)Q%;@*%]/9\$<,G\0..>!<.6!LV>>M^!A"+%0G!&$Q_6ST0T'\5SU`(1"1#5%9F9`/S'0'1?R^=N?NTGZ' MPBLY9ZMS')FQ$PQ2940V4H%8!1(52%4@4X%\!-A@PN`$U-X7.$%4B!,BAZT` M1M8H:0N&"(E4(%:!1`52%G.>6!D0,LUU!(V/MC6C(EG!D9`E#O"GK?A-'>?M% MPWV11,PU1FX,'-I!-8UTN"\T,DTCYPA<1E,S'QR5O(&&/_;FC@>P^Q(F$+)L M`D=&)C#$8QM%VL(U).91H[0U3JHAF1:5TJ+8W60"*="I83'JZ6/C*ABH3 MC)MT+B!IZ0:38=2RDV2O]+.+QV$;+NB$HFJW''*AW]P,#I31[P3K%A@):,96 M6>!ZRBXS%HS;*S@1T$TG%1#7@6.&8FXF&#>=7$"!7G%D<_73/K$=FN03@UQ: MX[SJ&.0]+(T(3HQDL7JL--Q9X"NOHY@SW%MI)"+HH70J6%PZ\`)E"C)=FIQ@ MZ7CHTUB)L1,I.XO4J#VB'3J?.Z/$;^2TZ9#WZ``/1^$-%5#P+3DBDSE1<3>$ M7>\=W`MA\Z?CFVFX@8'J-[;3$+9&=W`_A)W$'7P60B_6\=T\A*:HX\D\A!ZG MX[L@A+:AXTD00BO0\=TBC&BI*$8DBQ#>J,"WAQMPA+\41_1;T1ZKIC/.Z`"F M3VA;;-F?`.Q'CR\P&7"ZQ#VG7$_Q9@^!T-K&@AQXP[L4/\H#A[Y_UOP`` M`/__`P!02P,$%``&``@````A`!Q++1/J!@``Z28``!@```!X;"]W;W)KRSEYCO<&F0=H`+5`4/5QK M9=H68EF&I,TF;]_AB%+$(<<6;X(L]^?\'([X<=;6X_MO]=G[*MJN:BX[/URM M?4]NBAQ_;8]!=6U'L<5)]#J+U.@OJHKKX M0X1MNR1&JB_?)Z?5?CY>F+5[.D/>W,"G*,3;^8(2OJ[)MNN;0KR!<,"S4S/DA M>`@@TM/COH(,Y+9[K3CL_.=P^V&3^\'3(V[0OY5XZV;_][I3\_9K6^U_KRX" M=AOJ)"OPTC1?I/3S7@[!Y,"8_0DK\&?K[<6A>#WW?S5OOXGJ>.JAW"ED)!/; M[K]_%%T).PIA5E$J(Y7-&18`_WIU)1\-V)'BV\Z/P+C:]Z>='V>K-%_'(^!_X=[.S7IRC*'X.OL!NETGP8-/#OI`DG10"KF98$ MRY@OR;X]H[,42V>Y77(I'X:!N4UDMXE=;*08]GNV^"C:3'$'YT&3S#3II-`2 M!,GR!*48B@,5GO;-W-M!M,`:PBRWEF*TGC97C<"C/UO,@SW+S,5*BG4K-3(\ MO?/'`YZR>0KXQ*ZAZK>?$SE+-U`CVI,2K^VY2`3/3LEM*RG6K=2(F%"TM23GP(A\,/QW0Z*^.07IW8_H"%3DQ`-4E$<<*2"#GSLCK) MHN*8YU]BR"Q.PN3D1(#01,`X9,F)0.#.4V8>_E`-Z<5A>!TZ'7]4D^*P``@) M`?#HA+%L`.X='1,'&,PX.IF].I$3#U"M)S4.F=6)"`]N5P?5)+1B@%Z='PV% M=IM&3@Q`-7%C&1`1!BP^.CB1N"A"Z%S[T4/H.3GA(%)G?P:?<WJX-J$EHQ0#LZ"=,2Q$X,0#5Q8UN"F#``JY,N.3LXD]@H M'NC587J"V(D'J"9N+`]B"P_"[&$%R[M3*'7X9_C$6&"LY\2T![$3#U!-8*$26.^=C$PP8"0C(Z8W2)S`@&H]HW'(!$,BS_+L;X7;B:":A)8!8$@_ M0TQOD#C!`-7$C85!0F`@2[.HK<:)Q,76&R1,;Y`X<0'5Q(WE0F+APK*<%`-F M1PAC@;%^A)@V(7'"`JI)3BP6Y&EQ>.!,%F``<-,>N)3I#1(G%J":),*R(+&Q MX/X''SB->"@\:*5)F28A=6(!JG6W<K$`E23T#86I$QCD#JQ`-7$C65! M:F%!%";WKQZ<2%QL+$B9'B%U8@&JB1O+@I2PX#:H44U"*R;HYX;I"U(G`*": MN+$`2`D`)*BC)7]AXT3BHO"@GQRF+TB=6(!JXL:R("4LN%,SB,F"A5:Y3+FBLV<4(%JXL:B M(K.@0E+@]O'"6<3"QHF,N6$S)TZ@FKBQG,@()Y8?+Q,9&`N,]2(QEVWNA`Q4 MZSF-0R8R,;%R M@6D<-DY<0#5Q8[FP(5RX?8I034(K'&BG*&?:A8T3#E!-W%@H[D%])T/-D^ M#R\Z!=-OX$6C:W$4?Q3ML;ITWED<(.8`A'9X56GXH6^NL'9XW:CIX14C_.\) M7BD3\.K-6OZ]>VB:?OQ!WG+32VI/_P,``/__`P!02P,$%``&``@````A`".< MT8__`P``_`\``!@```!X;"]W;W)KBMQ[I5QDK-S[:!7Z'BT3EF;E:>__^\_3USO?$Y*4*!`7)2M]DV/(Y.=CQF"7TD267@I;2).$T)Q+F+\Y9)>IL13(G M74'XRZ7ZFK"B@A3/69[)=YW4]XID^^-4,DZ><]#]AF*2U+GU0R]]D26<"7:4 M*T@7F(GV-6^"30"9#KLT`P6J[!ZGQ[U_C[8/$?*#PTX7Z+^,7D7KOR?.[/H' MS]*?64FAVM`GU8%GQEX4]$>J0C`XZ(U^TAWXBWLI/9)++O]FU^\T.YTEM'L- MBI2P;?K^2$4"%84T*[Q6F1*6PP3@URLRM32@(N1M[V,@SE)YWOO1S6I]&T8( MX-XS%?(I4RE]+[D(R8K_#4@K"DPN/;5'(LEAQ]G5@WX#6E1$K1ZTA<3#C1:^%JD%0WI8(C*)&AIF!P<0MS+I!.#,`R'RA"@R] M@!DV]>O7V(!F4$.:^=0*K*F;(IM(K%=UNW4W2](JL)O61F`#M33&P\6#Q39? M@0*[5#9B]D!;@C+5UKK7>S&-R?K[7%-BELI&^%@25 M[(K!$4C_G$$/ZPV="`HHXYJ/9$:+VZA14Y06.- MP1BHM@ID0ZZHVQ%1';^88#,F`-NUV3/(A@9$=8S`6-$<38TI?+#8D*OI;D33 M(AM0WM-ME`T-:.I8@=*$4;R:[E/?%I`-N9HV(YH6&0/J.T,=&M`TX`USME/? M')`-P0+\<#HZ&[:.N1T"8]]XP$U MWR*P0G?8;&A`4\)$I:'2G M?-8G!@1U3&%BN?6]`-N0N]Q&3@IXD1=H=$?(Z&$A&O""*-Y,.[8>Z++4(;CKO]Z_U*W4:KF^WK9O^P>_UZO_K/O_6'K/[7'UV^>__N73S_WAV_%INSW=V`BOQ_O5T^GT]O'N[KAY MVKZLC[?[M^VK;7G<'U[6)_O/P]>[X]MANW[H.[T\W\51E-^]K'>O*XCP\;`D MQO[Q<;?9MOO-]Y?MZPF"'+;/ZY,=__%I]W8']9=G>]Z_5+K>#+'[?TS"O^PVA_UQ_WBZM>'N M8*#3+_Z77TT1;2Z^_RI%^B_N^W/X\7?;XY/ M^Y_FL'OX^^YU:]6VU\E=@2_[_3>'_O'@_I?M?#?IK?LK\,_#S-U91&^8VSERDS?[9#L#^O'G9N=2PBJQ_ M]7_^W#V]B__`TAA*`@28Q#[)P91 MZ6U<9BK+WQ$EP2CV3XP2IXN'8,G^//*Q\Q7G46`0^^=P'M%MF65I7A:B&G>@ M;'^AVO5I_?G38?_SQF:_U>[XMG9S27VTD=T52NQU]E\A>VEUC;]8KE.7"Q>O(!)^]1*2Y9X#;2"E)FJHCQA M[[KQ?)]>)ZW2.#\4*&%`BSB+W'TV[!@A[ M16=S2B0ZD=`B84($TX^4D(CF#SER#7*5<)RX26\EK8$()!40HH42B$PDM$B9$$*VJ M:[1RG;A6+"5J8&82"AH#"37TGD\HD=`B8<@P`@FEK.?D&;7`A[I>7":VJM5] MZ/L52N&K44B$4XMYKG;L?3X$2]U.1K2,&#H2EUWC4*E2SJHRI7+Y)@<,+E6* MG6NM``(QDJ@LRJIDA;]!)IA>$":`='(4+2,FB%#1G&5]OVA@=*EHS#_5:G## M[L[1BC9>-4PP:`9-4WM_4Y;,G[5CA$"*#0>91;0EE7**EP[]I]-GDY&M(P8-I3J(9;KQ1*L8"ZK=L\4+11,,$#LSUFGCU$" M2"9S^@@3S./V".WWW$/?L]-DZVF!K*,&&_K."=N,A9A$M(X8- M)9!@'J5H9Z61$RX@)(C2_/$9_@60>HU\P MKU7'@PUW!8Q9VP8;0<^T2*K)`CGTGDV=;CS`+*)EQ+"1I!=;!%0I9Z-9J9=O M(V,PWZ34%TR,&B&L7BZW6'UKD`@FEVSSY2A:1DP0H9)Y;/X"R3PV_^+FJ_>< M=7QI\]ED;;`1]:RJBOF1=NP]FSF=C&@9,60D";FP1"FGRON3J^_%ET8VD6J$ M`JG3(`)Z57%2L:6BE6-T,J)EQ`1&0O7R^'NY;"4>?W_Q]@5D%D(@AG*+S60V M(A*0M)613D:TC)@@0C7S^/L%FGG\?<'F4YT`!)N&BEL);+V8CHQHQ_[S\U%& MM(P8,I1^/IXK+17+8^P7B.4Q]@4W]@E`((==;GP)-GC_63U:C!+(P4Y&M(R8 M($(ULX/A16R!9JX7*V+E^:K@I`0($BQEK4T"K<.4K2K^)*!%PG)SYK^3$2TC MA@Z%^D0JEL?8+Q#+8^SY0YXZ`0CGFS_!1._>8I2@9&(4+4X3C[LOF1^H$0ID3X,( M*/8ACLHXGT[*X29A5I!./I*6$1,>#$FQE#G]\`OC/4T7QXE8R(3$DI%61CI$ M4'*E5)IG$=L>UW(<(\2AZ+L.AKS MAP$M8>;>&6=05J0JYS>TFD$Q?S!O*%"5=A4Z5Q&J&3/Z@E8>@U^RJUJG`)VU M2BO[#CVK^0@%$K&5D4Y&M(R8($+5NLKIISZGSW?`$`H(TLA(*R.=C&@9,8C` M1>[W.,<+3!6S)_1^GY^Z7K24*?YK!S5"%T,XNQLP%D@$-&UEI),1+2,FB%#) MG%-FFX>RL7#$1#)^.XD0WAJ-5PS5@@B@I\K*R3;KV'M^B901+2,&D6$D]C'R M.%2JE,?C+RCX'H]?G8\`-Y'II8M/L]S64+:1T2`2S"[1QG=R%"TC)HA0S3Q6 M?X%F'JO/=_[J%"#,+K:WV&`K7M14)1%;1-NQ?R"_AD/,(EJ.8B9#N?A%'BK6 M51X_]7A\_NY;C1#(413N50F6@PTBP003;7PG1]$R8H((UKH;)8 M?2^V/%9L-M4(@1P9O$@Q#@(J/B(!/5H9Z61$RX@)(B3!,H_-7Z"9Q^97_%ZR M#SV\T#IY(0Q;0=$DM;_SR5QM._:?+4^=C&@9,7PHLS?>&?/W"Q/,X_.Y':C[ MT,-[%'F2)YGB,ZY!)IAA<*P`TLE1M(R8($(S["J;GWEL?L4RI$8(UD@K&I^1 M$`-23,517"AF.]HQ0B#'($I`4BU',8B,8['OE)YK#-7+'HD[5ME39*X7KV+L M;&N$8!!EE.;V]R_/H\`R!H$"I]MBF`#2R8B6$1-$J&@>F[]`-(_-K[C-SP"" M)"LCMHPVV`R:QBI)TX05PG:,$$BRX2"SB):C&#Z6+$[.*4#U\IC]!65_:O;M MKW;065=GHDUO$,')$-FO6K`@K1RDDQ$M(R8T%*K8558_FUK].&).JD8(Y?`^ M^$8D,.5:&>ED1,N("2)4,X_C7S`KIX[?UFZ>98-7=^YU\N`[@U90-+.OH4RF MY-!]=KYU&",@N9810T82>"J9767T^UZTZL>\0M4(@1B%NS7B<[9!)'"NK8QT M,J)EQ`01DE[N=4R^4LI%K._%-6.K8(T0%'W^TFN#K:!H'%55PNO7V'\^OV1$ MRXBA0W%[Y>>A4+$\1E^>B_G4Z,?\\RTU0B!'FMA':#&W8HB$$DQ&.AG1,F*" M"-7,X_<7:#;U^W'$!*GSP:CW[VAR4X&MF&#VZPK\%Y[;L7\@P89#S"):CF+H M4/K%:2S%5"R/SU\@UM3GVX\$C4>`_<-ML[U#I0`*S+,&XV!NY27_TE*+0"!&)R-:1DQ@)%0G M9NX%G::FWI9HGE&BWVYR0$`GI1)K(IAQ:Q$)*B4>2,M13'`L5"N/L5\P"Z?& MWM[)<,UD8Y^+2"LCG8QH1.#BV)<0R+K73P431*AFS-H+^36U]-Q>UCDP@<1H M9*25D4Y&-"(@5:'X1IR9;Z8`^P6.SE.4W=-I@D+I+,=.;?+V4JL4@[LG->FB;^ M3/,C*7Z2K(???NZVLQ_UX;AI]H]S<9?,9_5^W;QL]F^/\__\^^LBG\^.I]7^ M9;5M]O7C_%=]G/_V]->_/'PVAV_'][H^S<#"_O@X?S^=/NZ7R^/ZO=ZMCG?- M1[V'*Z_-8;"OFP_`&)67M(V8<(BJC.")<%9]7B#_#W8C7-+_H+-]2&>$^`I5$/KJ(JZ@KN,^NYL`%X2B M4-2!$B&0PTNT#$54HP@;0Q`2\)B01-QY!WZ<0X`NGN7<>83D;>DLC,X+413, M>P+)99*E*J402R!22)7DF;Y@"`$8O2$!EP5]M2^<*\?=Q++0F6_+H$0(.'+A MRK,PBK`Q!"&14A+Q+#@PS4+!7"L1DK994"(1B69YJD*$+*26,KO$%\=!B!!" M%[G*NC01[Z%=\!2,#P1W$V/1F<<4("1,@6)$JW&(10C&0AB5)-V`)RS<3($U MT/%"H6GM5$8U74- M7S\A8`%=7K*!;ZF)-#,=@#KOQ&YZY%$:(787>069HG$KW?P>&(*+%U`O^J,0 M&[5"*3C)FTX!!3(L'I%T4T5LFR)4T=SHGH`1@-"9D2Q%EB"DDD5VK74ZI9ON M/NHB=;]7_./Z6HE08+-<,Q6W_GJ8Q2`*-`%.YJ8S0%$,&>BN.'W\0^$$W52L MQ58B!"R42/NC-T1H(:Z.7B=QTYU'00R=AUD:'P"A:BYT*M@(J40(*-(T8_PM M`>2IO%8[\B;9;=&T]?`92^DQV'H6(M>PUJ;T*@HI\ERQX6,9(M7J2NW+F[2W M15/_1<):2^E!5^H6VZ?'($EH_+WB(8!%D>9YEV-2^A(J87KUM&A.@`V\TH/. M&8!9I4A[*7"/?9Q[C#1.G)@=2^WH/#=%TF$H"R>&P1B8MB:6**%4#+I$XTCV MH#`=+&/5.,1&(90*/"FD$I_-28?F"6&#L?0@'VPC>FI,`;+0?";!`'EAKI43 M4^.)B4`UI4V)=8KD=*# M_*-%FF>\=U4>$M8:IVBC9BB'FW19#N@R[_NE!YW#UV\\E4?$*83*O#MPQJ%DU238!V^E`B*^5EYC&<[O$"FF.@26=XDU"V:C6S!VFCI06/#J4 MNXO752>K*'H>%*:"-Z+*8WSM&0EL*5=+$?"2P013,4J%Z7=<]!3J-DT%UVT/ M\JG00O6Z+4'`#$3`?B]G@$]"(YE.9!YL5U(&$*LP&2,,')HG@'A1SM/(87U`PYRX,JTL;A5`N-PFX M&A!PR29!I0?Y?*0FA2DIK9>*0'2J8=NO5U+X*+0"*_/<7)O4JIOTNT6SDI)L MW59Z$#X\@UUI[G^HS%+RW7M+[E=:%EV":/29<(^,A@'!EERP%8)\=4#@@K"A MTE$$1#;C_"R%4".4P$U:K5!C24/BO:3T(%\^6B6]:3A!I*)(>WLR!"%2F(9W M&23^:R;3\02T:%X[K)N7'H3^FPSVTEGQ$$`&;\Y8]5D"H!:H\TR8IRTB-`HT M6@+%Q#&5QDSQK M%$V:""[/'A2RZ"4"[40@-FJ%4@`SH3Y/K"EW%Q\8K.Y+C:#0SWY"$..[%[QI MZ^W8>"L>41AC.@VE3/Z42KM7BCTFW1-\:2'(^R!4EJM@H8]=UALZ8[+"9*Q5 M6P8Q)BN"*J9DF$R[M(R__=0#"3B/(1[/UDM5.Y2$QLC9JAG`Q3-.G<6GO8BV, MSSQ*#SIS<:M2SL5#HERB9B@7)O%Q733]M3>?>I<>@Q3@D.0``[029X"802N4 MP$W";@:$G6M$Z4$^"2*!LWV])(QKOXV:H1QNDG6#)!N3P!E_+50 M12[S%%IZ]=JI'P,)#)5\I'0%)]]?JRA$P?8S*R]+$?`:0`=OIR@# MIMLC#(;TFD\^3*C%PP1"Q*#_(2#J/I/J$??[$LW?D)0F5-^A%^X>$'8?-N&U M$1LT^$[]@HV_$>]1*\FX[;N/(']^4@A5P.EB.A.JX)BU&TI1!E$S2`*/6N,9 MXEU]>*NK>KL]SM;-=W>,6D+GN/QZ.>+]1;K#MNSW4MQ7[3GIY>4"G+S^6+W5 M?ZP.;YO]<;:M7\%D'DYM?_T?P```/__`P!02P,$%``&``@````A`"UG@.RJ!```2!`` M`!D```!X;"]W;W)K&ULK%C;CJLV%'VOU']`O)]P MS0TE.4I(($BG4E7U\LP0)T$#.`(RF?G[;E]CXS2:MO,2#XNU%][+V[=9?'^O M*^L-M5V)FZ7MC5S;0DV!#V5S6MI__)Y\F]E6U^?-(:]P@Y;V!^KL[ZN??UK< MJ2E`8XDK_3]E8>^O/2]BUZ7/_%6![78BH^5X%6J/@C+W3_C4;`-:`5&D^_&7(^M)P_&TT]=QY, MH=]/^CKA<=#RN%!)^$G@E`="RP.#3WUPSN.@Y7&>=P]\[K##AHN._C;O\]6B MQ3<+IA2,1W?)R03U(A`6P\ZZ+POAG^H`"H"(K(G*TH:$8(0[*-ZW5>CZ"^<- M"J[@G(W)\71&+!BDNHCL=@CLAD`R!-(AL!\"F0(X8()T`FKN"YP@*L0)D<-& M`'=K!L;$@B%"MD-@-P22(9`.@?T0R!1`2QNFR1>D3526-OPJ!1#HP[OA')@O MDC36*;&D2"\,9&<@B8&D!K(WD$Q%-$=@(?@"1X@*3"I80V2VP7RFY[MAI."9 M)9(B+3&0G8$D!I(:R-Y`,A71+($L5$L>;PIB,2!DFKGH\88CH9P5,4,"&`/I MCC\=5,-6DH30C@L%4BB1'%5HHMN<2I(0VAM"&4=H'[7<87#4W-D*.2*;0W\N MB]<-A@Q@37G@20`K(5L?B89N"4<42Q@2A'3Y]%UO,'VV\KU(8LPXJO>//``-G]A`B'K)G!$,8$A`3MAT#W` M0'8\2DG;X*0&LC>B,H[,23%I69$SK;(G/L^*D/6L&.+#$>QNX&Q0V_$CTG0N M76;['R=YM"2\T`OA/*53=ISBWV?$9Y133M+FWVPP;?:&=O8PS)5=TER$TX3J MXG^:-T1#-YT(QJJK.*O"57%$\'X99 MPO+^M*8"`WQ#[E5D9(:X'\&1Z0$>1'!R,/%U&*VAH^:+31C!OFKB\3B"#<[$ MDW$$^Y6)QY,(M@`33R81+.LF'D^C+:WF06+)-(+5$?B.?`'WN$M^0K_D[:EL M.JM"1S#1I5M->/)`/R/\! MK/X&``#__P,`4$L#!!0`!@`(````(0!:"T1GO`4``,05```9````>&PO=V]R M:W-H965TRMK^3QOZZ^?FGU8W6+\V)D-:" M")=F;9_:]AHX3E.<2)4W(WHE%WASH'65M_"Q/CK-M2;YGCM59\<;CV=.E9<7 M6T0(ZH_$H(=#69"0%J\5N;0B2$W.>0OC;T[EM5'1JN(CX:J\?GF]?BEH=840 MS^6Y;+_SH+95%4%VO-`Z?SY#WN_N)"]4;/X!A:_*HJ8-/;0C".>(@>*'_/7<_DYO*2F/IQ:F>PH9L<2"_?>0-`4H M"F%&'A]&0<\P`/AK524K#5`D?^?/6[EO3VO;GXVF\['O@KGU3)HV+EE(VRI> MFY96?PDCEPVJ"^+)(/"\$^2!HR\=X2D=9Z.)-YTO^+<_<)Q(1WA*1V\^\A93 M=SICXW[@"6]YPO!48W5'\].>/'6?2$9Z?&^M<.L)3.DX_EB2L43Y4>'YN MJ$OI"$_EJ$TJ%L<11<%K+,S;?+.JZ-M["6SEO4-:%M-EB&]>TV"D+5G@L;#@$T1#$0Y`, M03H$F08<$*%3`DK[?U""16%*J!RV"FC2#-)6%LHE'()H".(A2(8@'8),`T;: ML#"':?NP1]W?7=1\,R?81XSY]LVTMM(&%E-7%%/39->9=*DC$B$2(Y(@DB*2 MZ<00`#:8H0!L>_WD"F!18`V!8YN1KQ5A!(4Y$=(B$B$2(Q(@DB*2*93HRL0'8]*[;5^?ZH/Q,^ MO-NQ0&;&@OCF!C@95'MGI&0)$8D0B1%)$$D1R71BB`!#U$5X/+7,V$Q4$$A4 MY;!#)$0D0B1&)$$D1233B9$5ZW6U4^QQ5LS8S$J229^5(#YL&OURG@^VK[`S M4F)$,I#?!8H[&SW0S*R,I#-2@5(4*).$C]'('4YM/7=Q@O.R;D]E\;*ED`&< M>7&D%NPWX?=>Y5$)&-H:G0VO$5`,9+NO8J1 MHAB9)*"'-C7S3E%#&Q=.,EV<.R)`,ZE4X-:F#`II.DCDBUY;]"GL:V`WZ5&D M'+7DL6."48H=,X66K*S,_%@S\^'"=T7K(WZL\(G?2N1!`KV:BT&A[^Y:S9>= MYK);$^$]EU>(.W$GT*V;-I&*Y/4K1"%C",/@B;(R5N1BL)!29=6'SQ0R'DZ?FO%I,K6BU#9H$\.'$UF?NBY0+NI"-4I"K_4*$9UQ0D]?J11R#=6#99/#K./E:E8"UQ[K*/ZSUJQ((,E)Y#'JUT*(Q#K2WOY MAB42NM)*UI\_]R<^JC\9O"^06+D]#)XH*]A]^B%@`5'X3#GR;S2+C?5?#P3\ M1J\_VKGU34MT<4:UR<:NG\:=BU"(4811C%&"48I19B`S;]:A:7G_PZ8L^CDC M/]GBZ?DA%(('WY1[JPBC&*,$HQ0C=N73AQ?YB2L<\?.Z(O61[,CYW%@%?677 M,^XN(E,^!;=MO$UN*0>P'\Q+O#_0!^^F#^-`F> M(`7\8CL)X(?!'0XCO6L_"Z#;O&,_#Z!?N\-=^`(H#OQFMPB@I<(\7@30(6&^ M6P;0=&`>+P-H)##?N>,@A+,4OXGA#3N+X8W3Z0IW:-?\2'[-ZV-Y::PS.<`D MCGEC58M;./&AE\97[`EN2PE<8(Q'4"0'2EOU@7U!=_^Z^1L``/__ M`P!02P,$%``&``@````A`"H`:<_;`@``10@``!D```!X;"]W;W)K&ULE%;;;J,P$'U?:?_!\GNY)6D*"JG2K;I;:5=:K?;R[(`! MJX"1[33MW^^,G2!H4H6^1#`J&$FU8F[-:MCREKUS3V_7G3ZN]5$^ZXMP08&AU2BMCNL3W=5;QAFE/ M=KR%+X54#3/PJDI?=XJSW"YJ:C\*@FN_8:*ECB%14SAD48B,W\MLU_#6.!+% M:V8@?UV)3A_9FFP*7\2/?4<^[$/3.M5+L`!EITH7J1T$R9W843]]SUX)KJ2^Z]*Y-]%RZ':L$^X`ULIGQ#ZF&,(%OLGJQ_L#OQ4).<%V]7FE]Q_ MXZ*L#&SW`ARAL21_O>=`H4W*<=G4[IEAZY62>P+[#6C=,>R>,`'B M\[E`$HC=(#BE2TI`1D,!G]=1O%SYSV`Z.V#N'`9^>TS8(WP0[95!;;HR@E$9 MJX*IW+G`4"8Z+S/[B`R"H:R#Y*/XIN=UR@XS'V`6/6)D$"#3#2(8]@`VLJ_; M:6T=:((TT$R71K"5[HOK(G/H\$$R\7F7UQ^10O!8ZA!Q33IL#^BRH05W6&[P M9%QH4EPXUCA$ALTR"X+S=G#83CX/"!Y+NRP!*`VMY/1-IT;VFXR-ER5_`NO:TTRN<.!',&LZZ/]9;&Q=\7; M^#S9N$O$[[_`$.]8R7\P58I6DYH7P!G82BEW#;@7(SO("D:Y-#"^[6,%US6' M>1=@IQ12FN,+7C3]'X#U?P```/__`P!02P,$%``&``@````A`**9F87]!P`` MDBD``!D```!X;"]W;W)K&ULG)K;CMLV$(;O"_0= M!-W'MD0=;&.]P:9!V@`M4!0]7&MM>2W$M@Q)FTW>OL,A*6I(RJ)RLXE'PQG^ M'/(C=7AX_^UR#KZ635O5UUT8+59A4%[W]:&ZONS"?_[^]&X=!FU77`_%N;Z6 MN_![V8;O'W_^Z>&M;KZTI[+L`HAP;7?AJ>MNV^6RW9_*2]$NZEMYA2O'NKD4 M'?QL7I;MK2F+`S:ZG)?Q:I4M+T5U#46$;>,3HSX>JWWYL=Z_7LIK)X(TY;GH MH/_MJ;JU*MIE[Q/N4C1?7F_O]O7E!B&>JW/5?<>@87#9;S^_7.NF>#Z#[F]1 M4NQ5;/QAA;]4^Z9NZV.W@'!+T5%;\V:Y64*DQX=#!0KXL`=->=R%3]'VPYJ% MR\<''*!_J_*M'?P_:$_UVZ]-=?B]NI8PVE`G7H'GNO["73\?N`D:+ZW6G[`" M?S;!H3P6K^?NK_KMM[)Z.750[A04<6';P_>/9;N'$84PBSCED?;U&3H`?X-+ MQ:<&C$CQ;1?&D+@Z=*==R+)%FJ]8!.[!<]EVGRH>,@SVKVU77_X33A%V2L3" MKGTLNN+QH:G?`J@W>+>W@L^>:`N!59]$A+Z78YV$WO$@3SS*+LS#`/*W,+)? M']DF>UA^A='82Y\/P@?^]CY1[[&$WO1=@FX,N^0>'I69._/,?+AX5SX(PS!- M[$[#YJ3ASC#>@\['\;J/*S(+GV3@D_8>1""X^`ODSE`-_7PEO1!-)"M>A%06;$AN:\GXH[TU328FN)`%*F&!:E MBQP*>3\)MJ19E(DJRONI2!1%X#7,/)&->QO9I,DAR@`$GVV)ER;)!@%7I$4D M35237ME4TRQD1(('L'+[Y:-,#DT&$[@F6.:+Z3KU?-!9I(EJVHS4B2_IP72? MJ),``-$D30Y-#BIXK*3(QH(R0;$T!./5B*)98(AL,BB30Y&##3XR; MC8?(Q8=X9$N,9@$"O8W5-(J(V$#$?2'HC:%U)=A&,T#NP3PF+,I!N48@'O-5 M/IA^N'.L5QZ`PI94I#*1B1\S]S2)#8I,Z+;1@0&@`_8TB0U.<%'IY`Z"K0Q! M$B%4D-[\"9UB`R$3@FQN8`"WH%F0X*=1`^;*Y!@K`Q(3O>[9H*=?'.NY):>? M\/*9?@8K>*58LIG&;FQC0YEHL48V_-@@R81L&Q\8`(IEG\7B6:Q`;YQUPQ'5 MFX4<48$/CQ%E!DYP04\?!;$9G?S*1,:3C4"?@=>0(_?'$[U-T4RS5XB67CZB M#9:@:.9S)&$V5Y2)ZAZ[B3%0,Z&[/Y(,BLTT(*5NX>6C&WR&H\YU>YW$&&]H ME%N:J.P1UK%90$)OJ]PF-:27CVR#65CNB/&[]HES`.OYU9_6E(GJ'L$&OP\9 M#OA$N7M(Z7*SC3[H>@5HR M"VKH;>DVH2:]?'2#SW#4<76G7O7F+8UZ2Q/5/4*U9!;5T-O()D]>]C$K<2$K M\SCH8$,CBX08U:1Q2I9N,HM8Z&UDDQ!S:'+@*.(1[E,QL6&D3%31"(.363!" M;U2D&1PGY@V3]/*8G:D#1EY;+C:D0ZM,5/8(@U/P&BZ+^X.,WD8V'@!,=B%3 M!VG\--F@P5B893C>&OYDJ&D0.M7L%MNI]/(I)6>#>>\[?51.)5(& MSY64B10RU>BGHF=1)I5(@7_THY=4@UN*%EX^HAT@\GK0E=I')V6BLC7YJ>Q9 M(.*WZP+E6C;;Z&DD90LO']D.5L4^)\;4II4R4=DC_$UGT0J]K2FN02AE>]\- M9C]**VR('>D/RLI$96N2DFIGX#5<6_=IA=Y&-AX`3#3;"!NS'P48-C022Z;1 MQ'KF49FS`):)&[OATUMELJ&<.>C$/!Y(8SM#DB06D91I<%))L_"4]7C2\T2: M')(<[)E^+I?9X%$F*FB$M]DL\*"W,7R210Y!#JIX;9R9315EHIHTZ&F19E$E M$[P@\TZ:;$VY`QE>I,2&=.24B6H:V2!R\/)'!GH;V7@`,#DT.?@0>3T?RNT3 MCC)142.W%/DL0*"W(4HRPR'*`8AH^OB22Q@,CB_*1!6-;&C\U>6,,ME\P`#N M,AE\N+]IY#T7]!$ASLR]4GJ!Z/[X-";,X`3>=WJ]"LDE((9#VC-#YXVSD^:O^4(W#NZY MQ[TTMC.2\%`XSV:P,C$Y)Z=`Q"YWK7%6V,K0 MW"-EV#%S]Q2?48EOE2YE\U+^4I[/;;"O7_DG4O"*\_&A-\OOM];Q]DE\P&5> M23;;)[@SA#.">25E<`5?HEA74KB2.=OD<&7MO`)Y@"^./'D&?<.I9.9AT`-X M'NYHPZ`'\'C8=05Z`$]075>@!_"0T7$EB>"*&ULE%;;;J,P$'U?:?_!\GOC$$B;1"%5NE5W*^U* MJ]5>GATPP2I@9#M-^_<[8Q,:H:9[L.ALDPFXEXE MFU)4UI-H47`+^9MH'5X&?FJ0B MXYO"_E+;;T*NAF,+X9A@'`R4H8^R"1DI)D8ZPJ_WE0@$FU)*.&!'X;DO"Z+PGS"3E_ M]]SRQ5RK+8&F`4E3X:=2QK, MGTD#37QK!3KK=7!^)1NZ;V*_9=9?7 M?0:3X>`&%ESN'%S8U6@B^Q4,IV=:!3JNOQT$=Z6:B/N:.A7"\;S7_,Y.!.C+ M7G!55Z")=+VAX(]+ M?YR40J_%%U$4AB1J@T?A"`Z(-MH>TTLW5`[CT6SI-X^U;^#XK/E:_.!Z+2M# M"I$!IQ\UVA_`_L&J&A*%0U19.#C=;0Y_E`0<$D-L_DPINWN`K6/M7Z_%?P`` M`/__`P!02P,$%``&``@````A`,+^^JYK`P``X`L``!D```!X;"]W;W)K&ULE%9;;YLP&'V?M/^`_-Z`R:4A"JG25=TJ;=(T[?+L M@`E6`2/;:=I_O\\VH=R2DI+)$C%2EBDO&"ANB-2G2W^?QI?>3B6::4*@<8"AFB5*ERY;HR2FE. MY(27M(!?$BYRHN!1[%U9"DIB\U*>N;[G+=R'G!;* MD@B:$07GERDKY8DMC\;0Y40\'\J;B.]@479)>![U<\ M(]&)VSSTZ',6"2YYHB9`Y]J#]CT';N`"TV8=,W"@T^X(FH1HBU?W/D;N9FT2 M])?1HVQ\=V3*CU\%B[^S@D*VH4ZZ`CO.GS7T*=8A>-GMO?UH*O!3.#%-R"%3 MO_CQ&V7[5$&YY^!(&UO%;P]41I!1H)GX<\T4\0P.`)].SG1K0$;(:XA\$&:Q M2D,T74SFM]X4`]S94:D>F:9$3G20BN?_+,@XO@'CX+'`(C=UJ<(AND0,R$A+XLO&7R[7[`J:C"G-O,?!98W"-<$&T5@:U M\,/RTS;,CKI4RC=9:/Z)<`U3/C+:6H.-=)UD&YF9KFZ6;G$-K0:W:6UD!E5H M>`R&DP?--MZ!!K>EJHB=@:8%O50;?6]F<3J?W(+ERZVA7VQK5)%6+P;>L)V@ M+7M92H/;4E6D;P=#,KM^ICZXOZQ@7FM+G$)M.V=F&`.J*?N!FD9WU*K0@*.K M]@.N]H'=FV9#5*%VFP5GM@3NK(D/C-C9ARFM1\40@+MW6P&*Z.K\>YL58OI]"@.VK5/FC\Y]C[E+VTY%3LZ1>:9=*)^$'?E7RX MAM31^AZW]?5D=N.SU18DX0>W_@7N5R79TQ]$[%DAG8PFP&G[6-@;FGU0O(2# MPBV+*[A9F:\IW*0I7$6\"0Q.PKDZ/6B!^FZ^^0\``/__`P!02P,$%``&``@` M```A`,@$^-;4'0``C+@``!D```!X;"]W;W)K&UL MK)U9;]U(DD;?!YC_(.B];=U%*VPWRO=R7S`8],P\JV39%LJV#$E5U?WOY\N; M23(C#ZT6C>J'ENMD9)#\(C,9P>V^^?L_OWXY^N/VX?'N_MO;X]6KD^.CVV\W M]Q_NOGUZ>_P__\C_=G%\]/AT_>W#]9?[;[=OC_]U^WC\]W?_^1]O_KQ_^.WQ M\^WMTY$\?'M\>_SYZ>G[U>O7CS>?;[]>/[ZZ_W[[32T?[Q^^7C_I/Q\^O7[\ M_G![_>'0Z>N7U^N3D[/77Z_OOAU[#UXN[K]<-OOW__V\W]U^]R\>O=E[NG?QV<'A]]O;FJ M/GV[?[C^]8N.^Y^K[?7-X/OP'W#_]>[FX?[Q_N/3*[E[[7>4QWSY^O*U/+U[ M\^%.1^!D/WJX_?CV^)?55;]:GQ^_?O?FH-#_WMW^^1C]^^CQ\_V?QF_[_\L;^\^?7Y2 MO$]U2.[(KC[\:W_[>"-)Y>;5^M1YNKG_HAW0_Q]]O7-C0Y)<__/P]\^[#T^? MWQZO+U^M+TY7IV>R/_KU]O$IOW,^CX]N?G]\NO_Z?]YJ%7QY+^O@17^#E\W9 MJ]/SD\W*.7FFXR9TU-_0\?Q9^VVPU]]@O]J\.E^=7&[.G]^06@_'J;_#'LK' M,WMV%CKH;^AP\6J[/CV_^'>'I`,X;$E_QRV]K*SXMQ&>SU-]BO M-R]2?:5AYJ/NQIL/Z`L#MAH'C/XQ=#U]V?&MAF'B_O&B(UP-X\/]8SC&EVYM M&"NK:;!LGN_[VD^.PUS;7S]=OWOSOC]VNW'JZNG+MAEOGQ,\Z[ M'TT[S3?GY1?GYNVQ@JH)]:C%XH]WFY.S-Z__T/R^"3;O:;.R%KO!PDUFYW:? M@BP%>0J*%)0IJ%)0IZ!)09N"+@5]!%Y+VE%?C8>_0E_GQND[*/-^`)/@ZT3, MP6+HLD]!EH(\!44*RA14*:A3T*2@34&7@CX"1DQ-E;]"3.?F[;'^/QJLYU:] M]\%&:^1H=&I-=J/)J#!(!I*#%"`E2`52@S0@+4@'TL?$B*W%X*\0V[G1XJ*S MTR@DEP9OM'E.[=%D5!LD`\E!"I`2I`*I01J0%J0#Z6-BU)8^1NWY+&=8;IWU M0=1!C/>>G,4RK[;IDC`:#=WV(!E(#E*`E"`52`W2@+0@'4@?$Z.AAL\"#9VU MU="3S;3*[D#V(!E(#E*`E"`52`W2@+0@'4@?$R.8SM<+!'/65C!/)%@\MR^2 M97(T&@<=2`:2@Q0@)4@%4H,T("U(!]+'Q&CHZLTX@7I^XCIKJZ$G\:`#V8-D M(#E(`5*"5"`U2`/2@G0@?4R,8,KIC6`NXURO7VE6+\PYG2.KI2?)>+Q,QN-H M-(Y'D`PD!RE`2I`*I`9I0%J0#J2/B9'754!&W^<'Y,'2\`7Z^9S=Z.=1LDJF%8MZ0%*@C%8Y44%4$E5$-5%#U!)U M1+U!5E*7IB^0U&?U\C=,UO>K.-$_7$#;$>V),J*KY"8]<8]6@_#[%5!&E!,51"511503-40M44?4&V0E M=4G\`DE]SF\DCR]`7Z^:3> MZ#?F^?&0W*9#Z*,*"K<4@2940Y M44%4$E5$-5%#U!)U1+U!5E*7N+]\EJ]]GA_/\H",I.O3]$+:9#5)&M<,A^4U MHU5.5!"51!513=00M40=46^0E=25'0LD]56*D70L7.*%,[DEN5N/5I.D0!FM M-2N>@,S"R8J'5AE13E00E40544W4$+5$ M'5%OD-7/E1T+AJ2O4LR0'`N7>$@F-QYW[K&2I(@DRHARHH*H)*J(:J*&J"7J MB'J#K*3+*IXU*YZ`S)!$$;2G54:4$Q5$)5%%5!,U1"U11]0;9/5S9<>"(>FK M%#,DQ\(E'I(X\8Q6TRH)E.E9L&3@YD0%44E4$=5$#5%+U!'U!EE)726R0%)? MN!A)4LXMFPX@G(I.>;=7I#9[(:AR111I03%40E4454 M$S5$+5%'U!MD)5U6\6Q8\01DAB1JF3VM,J*;%C>!*1-#/-W1[0GRHARHH*H)*J(:J*&J"7J MB'J#K'ZNQE@P)'U)8H;D6*7$0S*]H;,9K0:5]T0944Y4$)5$%5%-U!"U1!U1 M;Y"1=+NLO#F8VU4RH'A($NV),J*FYHG=[KF:S&T4J4$>5$!5%)5!'51`U12]01]099M9=5/EM6/@&9 MTL\MFR\@DH&9+IC9W):AJ2*(8R6N5$!5%) M5!'51`U12]01]08924^753X'R&HTRHARHH*H)*J(:J*&J"7JB'J#K'[+RIM3ECJ(>H.LI,O*FU.6-P&9(V)FLIB')\H96.5%!5!)5 M1#510]02=42]04;2LV7ES<'5$!5%)5!'51`U12]01]099 M_9:5-VTRHARHH*H)*J(:J*&J"7JB'J#K'[+RILSECJ(>H.LI,O*FS.6-P&=G4U/9!#MB3*BG*@@*HDJHIJH M(6J).J+>(*M?6M[\].UO]^VTY/FK@)+1FM[8F:RFTJ(>H.L?LLJ MGS-6/@&Y/],3&9OTQLYD-0U)[TLM`\IHE1,51"511503-40M44?4&V0E75;Y MG+'R"2@:?SNB/5%&E!,51"511503-40M44?4&V3U6U;YG+'R"2A9)=,;.Y/5 M,/[V1!E13E00E40544W4$+5$'5%OD)'T?%GE]\66%3^LC_S7P5^X+]$^? M[VY^>W\OH23WS)VVC;[Z??@"P2_G+)L",O'P5A':!ROWDD(4C^3>1S99#4>4 MTWU!5$X=8_?)1<-JLAK^;#R6U5OGK+<&M(TF M0K":T#Y8Z>[_L%,944Y?!5')CA51S8X-4K>*?6Y\D)MQJL MW,3\X]V))K']:E`]&$P;:XA:HBX@/9+H/&]7%Z?)HM:;3C8D<_7:ZG3I$L-: MS:U1*M_;#2DX5#U(O!U^2^ MI%5%JYI6#5%+U-%7;ZRL^,O*MW.6;P'I;>7AF'KHJS=65K^T?/NY\R.KNG./DL&;5G6#U32Z]@'I4S#Y+@='T_BNN`73*B]5_A_WWW^4F>@#)&-J MPNKOW".3:@/M:941Y40%44E4$=5$#5%+U!'U!EE=EU5_YZS^`K+5WS8Y&>TF MJV&<[HDRHIRH("J)*J*:J"%JB3JBWB`CZ<6RZN]@;JN_@.(A2;0GRHARHH*H M)*J(:J*&J"7JB'J#K'[+JK\+5G\!V:3M-*GK=L$J/F\%Y!XY',_[F].T`)FL MAK&<#UL\G!;MT:0EU4SI%"U0%ZR=`K+GAC3CV@U6T_J]#\@][1<=35+O9)/5 M=#2A-#LL_/9HEA4D%RQ(`DIBDU2MNV!E8N-]Q3G%X$LMXP$R31NL9F*SK#RX M8'D04!*;)-'>#59Q;+ROZ`R/W5P(RIT!O%:$] MK3*BG*@@*HDJHIJH(6J).J+>(*O?7+;[4[^1J(>H.LVLMRX`OFP`%%0W-'M"?*B'*B@J@DJHAJHH:H M)>J(>H.,?I?+$MZ#N4UX`TJ2@C1A"U9Q4C!TG"Y'9`/R%Z?6Z6>Z\J'=YGA3 MJ6T/;5DN>LE<-*`D0TC+H\$JRA`"BC.$`6D`CN<9YCN#%3.%RV6YZ,$\"93/ M#&V@SA`H;V4"%3K&@0K(!RK]?9P\;-WG>S8HRY+02R:A`25!22YB[@:K."C> MEPE*0#YM6[VZ2%;2?'!C+DQ&'W>VQ[8L);UD2AI0O!81[8DRHIRH("J)*J*: MJ"%JB3JBWB"KW[)D^)+)<$#V]'B6U("[R6H\/1)E1#E10502540U44/4$G5$ MO4%6TF7Y\27SXX#,D/16$=K3*B/*B0JBDJ@BJHD:HI:H(^H-LOHM2X8OF0P/ M:+H0NPLHOGM*E+%C3E00E40543T@[?%X/MJ<)]\&%.U]1]2;CE;2 M-#]^ON2]9!(\H&FG=@'9IP'2H]E/5L/$S^@K)RJ(2J**J!Z053FYC-,,5M,! MM0$9E;T2$>I-1ZORLKSXDGGQ@*:=V@64J)PB'K1(S*K M$U8*`W,?GXJ6TZDR"3^?%+HF3\FD,VCP)K/AN!3$L-6)*8A@"F)@6BVB/4F* M%@41715$,`5QSMUY4C4HB.BJ('IF#_8\R<84Q-%L.%@%,7:7!-&5'B^_/K4Z M\:5*?(%J9).6FE_>3I\$'79#DPE,<0C^IKZ*0V!3A:0X@$ET])7HL)/H8%(8 M?:6P9]$^2TXPR1GW3>1<5I"M3EB1#6Y.F'I.3!;5Y\G!ZD@^JY1 M%:V(!?;LM0W%#5T5-\_THP3#K%/<7N).@8,[!0[N%+B7N-/\@CM%#TRA>HD[ M12ONFD1K69V[.F&A.S`SES;GR8E$T?)=HQMOBE9@&D[3D$P?D%*TT%71\LS. MLI>X4[3@3M&".T7K)>X4+;A3M,`4K9>X4[3BKDFTTA+Z)Y,&EM:K$\^2*9?D MK0IB,#-G)L^>?\I-0?1FT6Q5$(,[,^5>XDY!A#L%$>X4Q)>X4Q#A3D$,[J:# M51!?XDY!C-TE051*:Y*&GPRB[DC_\.0';PHHO"F@P=LS)S]X4BQ#KV>/6>$-9GY7 M?W#RB]TGL4TO*/QD;'FA877B63)!F=AX,_?1D6=C&\S\PWTGKYC8>`,[6\,N MF-D:[+RC'\86WA1;>%-L/=,G/]RS"[.)#3PIMJ'7L\>LV(:NWOD/8AN[3V*; M7L9(8_NR1P=7)[R^,;#H,J9FJ;>+F*8DF-95,,U",*4R8%I$P107,,4%3"LF MF"(!)MG!M#S&S,J\ETB9ZAVIW/>^]4J5,5:]\8U97.>7`&1PJ/9H+H4 M!I/"8%(83`J#26$P*0PFA<&D,)@4!I/"8%(X9HG"KJ!=HG`H@(W"GMD!"R8Y MP20GF.0$DYQ@DA-,#!S=5@-N4O4CATG9@4#LQG'*NSBU>;I!:5XM[&?5EIFB,_NCN[TN7/90?I M*SA[D)[9A.`TN;BF61D7?X=+?SI(,!UD8%J9QP/@0P&#F7[Y4),\B9PK7)9$ MSA8%BXP+5Q@6KC`M'"!:>$"T\(%IH4K M9LF(<:GC$CE]JFGE]$QR1@%,*S,I/)H-@TT*@TEA,"D,)H7!I#"8%`:3PF!2 M&$P*@TEA,"D8Y`23G&"2 M$TQR@DE.,,D9,RNG6V2-G&E!\[);4`6%0][E:!Z4-OTZ`-S'W6:%JP M+I([.MG0569#UWQ@_D1T6#6+@46;*`>6;"*I=ZO(;-A$/;!H$\W`HDVT`TLV MD:SS760V;*(?V-SI=.U2S@6C_6"?QL&GK4[F25_>#0E=S:59,L4AN(O#-9,C M#&;3:\P*3>@Z15^A`5,<7K()A2:839M0:.!.H0%3'%ZR"84FWD0R3"+9M)^1:;0A(SZY'#EY/QT[@:3)DW8Z/2&AB+C6;0% M169FYW"K2,$*74-&<0*-)-(%B M]TF47$J^)$H^A;=1\BR90$GBI;4MF$VC6U$"4Y0"TY]Q/LY-H&`VC6Z%">X4 M)C#%Q+/H`JQB`'^*@6?ZR.$@IF8+_&FVP)^F1NPO$=V5$;'H/WE2\=6(C85G MR8S!+0K7K@OCT7A6+$+7*3M7+#Q[_K:%IDSH:J8,-J%8@"D6H>]TP52Q@#_% MPC,['^!/L8`_Q2+VE\3"E3=_02Q\E61C$2HG>V)!G:8W$E&G!::O0PX#3['P M=OJE:#?Y?[AZ!6]33TT+;$&A`%,HPA:FO@H%_"D4GMEI`7\*!?PI%+&_)!2N M,GLN%"^\>+SV%9Z-A6>F!@MV$=,D@)V$!].(!Y/,8)(93#*#268PR0RFU0=, M,H-)YI@E,KOR+);Y^0_/U]N'3[>[VRY?'HYO[W[_I MM.4"$/&CA]N/;X]UM>/\ZE`?:U:/?<:V"]=V6`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`DGIT!A]/O MG,+*PDZNE';-M2FC.KE2"C77INSHY$KIT`_:UJYM+CJ_K*Y^F>/O7=#F%'-A MGN-N0LWP7[97O_P@IW&+VDP//2=RF?FO7;^ZHU,\I-]NF-\VN]GH3BZ-*;W%=N=>VV*)7J=1G;J3HG23UF6O1 MBT'J,S>*](:-^LRUZ$NF&JAS1Z0O6EZY3UARW_1]RBOW04JVZ&N35^[SDFS9 M7ZRN,GWB9ZYEK9:Y/7A_KLFB[VZQS_MS31=]/FJFY4(KDCZ,Q!9]2U9[/;<' M^JJI6N;V0)^1O7*?+J4W?4WVRGW!E"WZJ*PTF-N./F^JEKD^[]7G_6R+OKE[ MM9MMT:=W%9^Y[>@CL&J9VXZ^NGOEOO3*O=;'=Z_FV MNW[X=/?M\>C+[4>50.XKF,='#W>?W-4M_Q]/X<-QO]X_/=U_595T?/3Y]OK# M[8,SD/''^_NGX3_7&4"``"[!0``&0```'AL+W=O"CVT48RP@E_[['4QB94FU92_8 MP'>^[UR9/>Q52[9@K-1=09,HI@0ZH4O9U07]\?WIY@,EUO&NY*WNH*"O8.G# M_/V[V4Z;M6T`'$&&SA:T<:[/&;.B`<5MI'OH\*;21G&'6U,SVQO@Y6"D6I;& M\2U37'8T,.3F&@Y=55+`HQ8;!9T+)`9:[M!_V\C>'MF4N(9.<;/>]#="JQXI M5K*5[G4@I42)_+GNM.&K%N/>)Q,NCMS#YH)>26&TU96+D(X%1R]COF?W#)GF MLU)B!#[MQ$!5T$62+Z>4S6=#?GY*V-F3?V(;O?MD9/E%=H#)QC+Y`JRT7GOH M<^F/T)A=6#\-!?AJ2`D5W[3NF]Y]!EDW#JL]Q8!\7'GY^@A68$*1)DH'-X1N MT0%*=&8W3@S%^#\;9 M;32]B[,$M?Y!PH(C0UR/W/'YS.@=P5Y!2=MSWWE)CL1O!X).>.S"@PMZ1PGZ M:C'YVWD69S.VQ8R)`V89,+B.F&1$,!0=E5'M>F4/]LH^']Z593@XE4G?ELG^ M1\:#"XKKZ'P63T;>H!PPDQ/,=$3\$2!"K@_0@[$&6,@3Z?/&PO=V]R:W-H965T9[PRM4SILW3T>O?QP_9D M[(,KI?0$&&J7TM+[)F',B5)J[B:FD35\R8W5W,/2%LPU5O*LW:0K-IM.ETQS M5=/`D-@Q'";/E9"W1ARUK'T@L;+B'O)WI6K<"YL68^@TMP_'YDH8W0#%057* M/[>DE&B1W!>UL?Q00=U/T9R+%^YV<4&OE;#&F=Q/@(Z%1"]KWK`-`Z;=-E-0 M`=I.K,Q3NH^2FPUENVWKSV\E3Z[W3EQI3I^MRKZJ6H+9T"9LP,&8!X3>9QB" MS>QB]UW;@.^69#+GQ\K_,*;Z438"C03&8+9!*F@@3@ M2;3"DP&&\*>4SD!89;Y,:;R<+%;3.`(X.4CG[Q124B*.SAO])X"B-JG`U:9V MRSW?;:TY$6@WH%W#\?!$"1"_G@LD@=@]@E.ZH@1D'/CWN(O7BRU[A*+%&7,3 M,/#L,%&'8"#:*8/:>&4$HS*Z@JG(FP/6*B-?+ MCC]D$##S'N:?%8-"`3*^4`1#+Z"AG7^7'@?0"&F@&2^-X%:Z,SE$YNT!ZK=N M.:1M#W(4XZE]QU?<.)0X1_J-C->KSNJ!D7#PQE>#X*'4.1+N0[\ MD?GDW6)PVU#A'!D6LWZ]F,U0].WSB."AU#G2ZTV8.^%R:VD+^4E6E2/"''&F MS."Z=M%NW.UGV-O_X_-DWXY!UGV`,=3P0G[CME"U(Y7,@7(Z68%'-@RRL/"F M@31A&!D/`ZA]+>%_(^'&3M'0W!C_L@!AUOW!=G\!``#__P,`4$L#!!0`!@`( M````(0`IVZK$,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**`` M`0`````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````"& M>TOIU$S2LD3-3BXQ<4;C#>';2BR4`-KNW\NZKL[HR2-Y7QZ>[Z-<]+I)/L%Y MU9H*D2Q'"1C12F6V%7I:+],Y2GS@1O*F-5"A'7BT8.=GI;!4M`X>7&O!!04^ MB23CJ;`5JD.P%&,O:M#<9[%A8KAIG>8A'MT66R[>^19PD>=76$/@D@>.]\#4 M3D0T(J68D/;#-0-`"@P-:##!8Y(1_-T-X+3_\\*0G#2U"CL;9QIU3]E2',*I MW7LU%;NNR[K9H!']"7Y9W3\.HZ;*['W=^LE8D5.+M*\2,GUNB#TQ&S`@`` M0P@``!``"`%D;V-0&UL(*($`2B@``$````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````G%913]LP$'Z?M/\0Y1V2EL(`N4'0=F,2@VHI M[-$RSJ6U<.Q@.U6[7[]+HI:4667KF^.[^_S==W=VR-6JD,$2C!5:#<1P& MH+C.A)H/P\?9UZ/S,+".J8Q)K6`8KL&&5\GG3V1J=`G&";`!0B@[#!?.E9=1 M9/D""F:/T:S0DFM3,(>?9A[I/!</X+(*5`Y5!=E1N`<,6\7+I M#@7--*_YV:?9ND3"";DN2RDX.!JUW/&J%E M@H9=CC/A)-B'?,J,\U&^Z')N6+2,6T*;*E+L#3I1#O6BWU5;;:&[S+>TJ/WS%4&:J>;R@H%UC;J?=/8.-Z0/DVKHF!FW0"+ MN1(X0-@Z])IS77E#3NCDM1)EG;/7/L`JX3S/Q;,$>FWMNS;;)GA*[W!6E46G MN8%&0R_>&47U\`)Q#>"]=M`FU:Z\(5_H3Y"-UG7KX0WB]3IOE'Q98,?@]=1D MA2TV!E1`^%.[0"I%(5Q3;R]F+T9!GRV\5B@/G2SKQO`Z[A>^YXWI*$]G#.7U M0WL*L,]]KPS42V1_HWU,?@R."?GO[`_TQW'PTM^?L9_^_IC^`>><'!`S."#F MM!NSB=Y>_^0/````__\#`%!+`0(M`!0`!@`( M````(0!F'MSGR0$``(03```3``````````````````````!;0V]N=&5N=%]4 M>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````` M`````````@0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`%"KK&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*Z]A95'`@``2P4``!D````````````` M````FQL``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`%?VM*MJ`P``Y0D``!D`````````````````*B0``'AL+W=O M&PO=V]R:W-H965T;D`(``%8&```9`````````````````/@K M``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`/R$ M7Q%Z`P``3`P``!D`````````````````ORX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`&-.S$^)`@``_`8``!@`````````````````^S<``'AL+W=O'``!X;"]S='EL97,N M>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,````````````````` M2Y,``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`B&J6R+T# M``"<#0``&``````````````````0F@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)9U$``!D````````````````` M`YX``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`".&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`"UG@.RJ!```2!```!D`````````````````@MP` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`**9F87]!P``DBD``!D`````````````````:.H``'AL+W=O7&4"``"[!0``&0````````````````"= M%P$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"G;JL0R`0``0`(``!$````````` M````````%1T!`&1O8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A`'NZ M>Q&S`@``0P@``!``````````````````?A\!`&1O8U!R;W!S+V%P<"YX;6Q0 52P4&`````"8`)@`\"@``9R,!```` ` end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Details) (USD $)
9 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Number of Options Outstanding 10,000,000 10,000,000

Number of Options Exercised

Weighted Average Exercise Price Outstanding $ 0.1 $ 0.1

Weighted Average Exercise Price Exercised

Warrant [Member]

Number of Options Outstanding 394,465 394,465

Number of Options Exercised

Weighted Average Exercise Price Outstanding $ 0.75 $ 0.75

Outstanding options expiration date August 2014

8. Stockholders' Equity (Deficit) (Details) (USD $)	9 Months Ended
Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013
Number of Options Outstanding	10,000,000	10,000,000
Number of Options Exercised
Weighted Average Exercise Price Outstanding	$ 0.1		$ 0.1
Weighted Average Exercise Price Exercised
Warrant [Member]
Number of Options Outstanding	394,465	394,465
Number of Options Exercised
Weighted Average Exercise Price Outstanding	$ 0.75		$ 0.75
Outstanding options expiration date	August 2014

XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Equipment
9 Months Ended

Dec. 31, 2013

Text Block [Abstract]

3. Equipment
The Company’s equipment is as follows:

December 31, March 31,

2013 2013 Estimated Life

Computer and office equipment $ 55,085 $ 49,951 5 years

Less: accumulated depreciation 28,232 21,569

$ 26,853 $ 28,382

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 15 0001354488-14-000819-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-14-000819-xbrl.zip M4$L#!!0````(`/.&4T1;_C0Y/Y````+=!``1`!P`=&%U9RTR,#$S,3(S,2YX M;6Q55`D``UHH!5-:*`53=7@+``$$)0X```0Y`0``[%WK<]LVMO]^9^[_@.M- M.\F,WK*3V$ZZ8SN/>IO8;NQT=S]U(!*2T)"$"I"2=?_Z/><`($&)_TMIC((A7+;/)RZ^-Y^^#\Z/AX MB_W]A__]'P9_7OQ?N\W>2)'$>^R5BMK'V5CMLQ.>BCWV5F1"\USI??8+3PJX M\O._CK,%CD0YH4S3(E-SCO/]VA\,^X-> M?_AKO_?[L',Y!KJO>`Y/P<7M;F_0[>]>#/I[_:=[O>$UJ>4\+TQ)K7?YO-<; M]'K#73O\Q>5()W(/_V4@MLSL71KYQ6'06PX[2DRZ,Z7?_]?[= M>305*6_+S.0\B\26'Y7([%/3N/[N[FZ7[OI'UYY$XI[&L(NW1]Q4,R.#5SR_ MQ@GK#TJ&Q]]:A^5_M%8K#QG1-29J'D7;G118^U>OSWL^\>U M&&]D^6D7[OH'I5';@_ZSJ]9GG_`#"M.><#XK!XRY&='#[D8#,W!'JT28QC%T MIV%0IK*L2)OYBG/=S93++2/3 M60(VU?5363^)%#C_9Y`/_1 M.8:9'ZKE^)FJ>VO#1!97@VC=%?FX-L1?KS'@+SJ1;I;S@3D=WUK9VNB4-PC) MW_F3A=0;WG(AT0*^JI`&MUU(@YL3TJ\G13H2^G1\/N5:F/<"/_UEDJM"EIBD M(EAR>2L&9BYGB8QD;GEEL80G+11T*7(/,9'`\:]_+X#O(Y7.5`8?S<&E-%L_ M8'+9:UKWBVXCB9"];C-_MT+EPP>5?TLJOXE0Z'+2@\J_%95_?8C@`_M!',L< M!,:3,R[CX^R(SV3.DWNA>__8E3*X)]'^P0Z^73NXR13P8`??LAW<7%YX)<:X M.!Y%15HD(+9XK$%<,+-6,VR&@GSN$4+X`G'$'G)RM+@=WY926 M6\Z7R?FKGM)JL.>'\P1__>;R?^^=*Z#KIJSF-GOG;9+SP[[?M[;O=SM,J>'8 M\T.@_U8"_;=WB/L*JWD(0-]R`/KV3&FEF_=/KC6497?#7`X67,<7RYFHFT=M MC7>U`7=%B'C0\?UV^2M,XSQ7T:?3&0;/.VT>:^M\,)&KVO..=-ROJ%P? M3@;\?=@2O$U;@M]XOBKMK-^[4]\>I^5\>W*&0/.LVF?K[;:'O=LL M9[><+]UGHW5_5?P%7C9H]Y_?,MD&8,8MX"L?'[``)BI,KM(''',K<LX2K@!/W&K.M4?Y&2:!Y:QLMP'7'%5=_3!1/[JVOA/#@U% M)JVB/YZ_6E-C*K@IM/C!O3-J#Y[QD_E;=1(XVX;Y[6;61A).7O30'Z8!_)UM MH!/+.=C/NFQQ[`F^00K?RK9N/E\@@U4>FV8-B+X2F4IE]CFRGY?+*MVFB?W] MFA2N(=`S*,+`5C^CM1G\>'V=Q4+NO2;[_R`FTN3H6?AN.>;L\P.^3NNJEV&! M2WXX?GO`SH^.7Y\.3H\Z+[J:)UPD?P9HT3XZS6%S^));7IAS&I(VS MA>1>*8`;F`B7/SW;^<'C3M&?DYJ]MP+_V_&'*V#A;2.X`[L;XQ)N$ M3ZY-9LP3(RR%V@3AS$>%UGA9FH@G_Q97C7;N@'\4R3)3YE:9.=@ MKH`5XV-C"L@-UR5[HD(#V##;.ME?5%)DD-.7;V0BM/F#Y%9F:3!O*X;8,6:A-W>0( M5N76@-_`M>LO]N=AW0G69MI,#BWLRXAA/=A$KIS)$RN!B4I3E=%>S1G7IYHJ MG9C>O0DL4JJK$5]YMQW#N$LW@LS(8A%)D+IYN75\\@:"6J>'<>U%]PN(_FE\ MVK-Y?P6?ELI!D4^5EO\OXNO)<0-O_9[_T\C>*JW_FJU5L7T=MD[`T;4X'9^6 M7RN^MJ5_G^3[,V;R90(0/^5Z(K,]UIOE6]]/\OWO>3K;_UO_:6\?'^O.Z-K? M^D/W3SAT#/3VV/-9WLV4AI6Q"T#OAIV(!?N@4IZU[(46.P>/'>^SDI0E!%.- M_`\%_F"7Q-28'19&9L(88J'P#W7+Q[\.6_L,Q=>6&=8R\+FS([.;EI"II8LZQ,RVF,IK"#%%2Q,!(*F()01:<8RXC M^,RSV,Y=]7UP=N`3Q"$PL;)8%Q.:3A59;"R?J33&,8*C'3%B`U@'&?+H]P+8 MK;/),*V-52(5#O2LA(+JW&5K.\[8>[YT%I4'VI[R&*P@%YJ,"Z4'5G$)&L.] M'I!3J@"^QT5*#('D0`\@4BAV\;7;;"'S*3L.WG2-&M)\)I&1=WG<88_=$K>? M[1]?O/,?GN\_88^!TK'17"32*_$)F`QP,EK66%RH(HDKK1(GIA@9&4NT$6`* M9NZPTZS)>\*)8)54D`FT.VF"U;&UE:%QUN7"WH'59D:P@XD6U.8D3AXCA6J1 MZP\%2[;BNG@'#E]H4T!=A/9JW21D%'Q-2'1W$)%,T5@1BU=J0>862B?Q`JI( MEEB2Q`U,![*$@C>2/(%GNY#:K$XDXB, M"PK3,R"?Y=9CN?L$4FDG?E)\\P61^9A9E\N7WF`.(*6IC%O?=0/8!&M"2JIS MDG"^4!C#P')19&#<,\^ECUZY%CSW(2+"%X-KC$U1(C,?5,H@$B&4C=E!DJCS M7%K3O7A/W.,U]@N_9/#Y\9K6*ND$6B/+0N=Y3C8UJ-M4-.79!&T$>,VP>@8- MA`X!17$6=?#J2.1@3L2,%N,$PJD=!`X<1-=L+20BVZ%.>1Y$OPS[@Q/[-GMW MV;YX/B<_7%9RN]OQ#53T#YX5&`^LFH:M9H\B2R47Y)#FUO1`BJS&!FL3Y5T(&7CJQK%16UR*V>*)\ ME$6;1D.+>'%'X:J&E>XWUGWF564@`-%93 M%":(Q*,-F`W#6@J2U^`2H%PS$Q@L2%#-7#BP`9ZGM*A-/X)E@[N9DC`F&?B; M*2]K\FE,,0>&F2*:6MTT+B"<>"PQ"G&6$4I)+`PX=@GMM97PT96*5K\7@BX MCR%OSD'(!0KNMR*CWTD!MX'/L9^%6$#AX].>3Y.+-$7]N7@,]F'53C'LC1AI MR^YN$[O>.E>RGH&PE3@95CJU:=JF',267.>(-:< M]Y_4$[L$+4(F3U$X+*'XZ(<=J4+#U7@NC3=(>ZDT#T>3>""ZWL#K/#=9E+2F M$FN^((P+II,J=)<6>SQX0E(@WF:\CD0>#7HM*.+@J6'PE,0ND\^^P>.MUXB3D4& M2/'MC\PS_M&`\Z%RU";'#)ZEB`0@Z1KHM-E7&!A2$,!C9R@@2+H+ MF`[_3U@0UI_*A.L26=>+?NPGX2\_HKA-/&#L>S38H8!7HO"DE)W&K5E;$;B` MM=T:;C]K/1\\#4)51$TNT*Z*/OGX5EJV8B!,FTJ`RT"P!&"X]HJ)?#BURCG. M++;&-MAJB?GVY/@D5,\4L8=E+R3]=+!#R]K,*$Y4DY"3B8S9H_[VL/5LV*/R M@YNI7PBA&K@&6;KP:]4BA6R-\GK4[SUM#9[U;%!@-).;P-II-,7L+BY%5&"Z MKYQ&C<<@=5U=L`LBABC/8YJ'TLG@U\S`&A),%[2HTO1I5:#7<@K++Z17__4T M-FCM]'J?$4H@0BL;^ZAKO9"47>F^LACFU@`FJ5$HD=(8U$`YO$R'9(%R5*Q$ MQ7/(3X`O@:'M%MNQ"/'Y78UBCCA4>1/X^%MA^M!V&N4**XQ!(WISJ,WA M8XO[Q^XPD$&B``&&#L M$IK0VJ(\;JN0R@O/'#(K';%#;*U/RM0">]E"Y^`E89>A"_'&ABU8"X0Q2):% M[0J`H>=8SB4\KS#F2@<1Z^$VS3H##%Q0=S95L)8BP;8LN*[-.QQ@^P)KF=;J1*&4K?2]L,6E-#3AH0*S M.%0YNZCZKU1?'GX(+CWI-.@:8;"3G(<+'.N27,SXS")Q5Q*R.K"E=,"C2,SH M-[1UV,<99KSR`JLW\*RA.J.PB)(D&UHH*10%.I4S5U5H54RFKH0`+ZJ:S[\I M,`HV!V5C;PIDLMY`*V$K]HOY;TK+?.D:*1!E0!LH.C`^#$DTF`84QHXX*5!M M&J1J6T>59$$.8RA"I@Z+3;1:@!OY7HP=QBJ%!ETKF^9MV$2;SJAZ1T$V*`;( M4#R%Q?9[Q,,2)UZ#YWCJ5"H0.Y2G0@`@ZD@G:4104S-Q[$#")QIF` M*C/;"2?7QPT&M\MB$028.9JS807!J'"S@R+4"`W!J*2P`(=*LPBM"`0G,`YJ M/.A&W:J$]G)-017_IA`36N/C"[=U%%R3F(,!G`"J!*\`%P.-0][1$#*:2A,K M0TD;D!`8)D@PEA-A*'Q!M$HI$4$DBW0Q&N%/5,B2R\!BY]@2"S9=:OD*(C9! MZ=>T3C5!",X.I<+"/@=/"=3U^O!#B/.\6#>44]@GTSPS+I#,!0MVJUP3S6)T M-2Y[&G:I1XC)[50[P_V-Y1KP`V!3XWX<"#Y,0"*;8DP$:.3\'"22&,4^X4$5 M#.>CTO\U^C^F%!L4,*R;BG;+<08&`;#2[0FXO`&DY]@ZLG5EV<(/!/;J*)17 M8$E60;8J@+P">E6I8UVFV`;%78H)5!YFT^*)+Q0`9`!JTYDI==-(L#:*5VM, MP=:A?H44W"K3*1&+0-`%%BC8S9-5.SN#R)=@RBDTFT(9C.DPXGI$-5;,P.G) M4HB)TO0WVVY58P!NGDP1(3B.HI)+U_[+VH!(IM8,&R>L?CH4$V<]6>XWF)2N\H!DCQD/;YW/((\$=)`/G@<8'!RNJ.(F'X.;);'P+=G9!FHA;L\/15]^CT52.]4ZM`WU`=V";^ MMB5-`=SUL[&;3%8FJ!>U,4110K?O81>VT%A`:90LVYCU45KA_F%8V#1*PSAT M!-YAY>)'!:RU6$!Y`B4](4.(W'Y39Z2XCG&@]5*EC6]XNTH*:S<\C@:/!%.Y MK0M``K;Y"'_M%NAUZC3?:-9B!@^+S&;+,9?:-QZLW6'NFD$0N)3854^P]/?$ M&B5R7!6/K3)B^KQ,Q>W&VJ**28E.X[CUPS^'+M6R,VN3%!7OX_D?FS#!(A%& M%1DO8FEWQ3-`@-+N+((Y@641*O1?KPKV/$;8$0/71E^AAA).J6.JPBCP?NR< M=]RO.T?;/:`B#3?'X;DB(\!XIL'BY0P18^"<=N#!P5F(&]#JL7K1,JT8L]'( M,\=F@5)M?W"=JS=8_^'YZ@XQHK%EY1+-DL4*=V;]WAAM]?FMD:PJ!>EX@E)Y MALTAMZM..-\2S#)L�)K\..;3S&LM=Y(6B+3ZROTJTOT`4%!RXSMU^;0%S$ MQHV]]QB'NTI=90D%,6Z<#X`6AO2\Q M*3.E(T\CX>R:VUZQY?3#HR/%.51U7J.^ZSIKX-)VL+)J**%:@]AM0U:,!N^A,(BX$<[K>WGNZW^ M[FX97:!.@D(,EC,U$&GB\(R.WR`$:Y>8DO"?F0=D02_9)[:)6#TSN<)2P,B@ MWQH,>ZWGS[8[['V956H[6PG/2K>TL93;0PYTLLWNAOC"6=`WJ6UQ2WC=V!YD M=39O-=I#5)9S7AX%7NL9&D;-6TR591,4NZZH+W\LUFH,S\2R-QP`*IZ8L;N" MR"I,%@-?]/4@QRY2=J?0@KN&(Z;06`46A*(QJ-G$X:VC$BF=-L:.>8&[`0ER M&0ENP@7:;81Z:4HEIJSO+,8*R1*GIL"=)VE/!3K1*K@ZP\X&;<=7YH1)#$2% M59GK*T.9879,<[KT8"K;K,MP@'"^6ECMR%/$,,VF&^RE0RR-6JHXD54)T MG6UW"+9<7+4/+7/;N"JP)7C5[KCB6^2IFL$W$0`?, MIC-`8;!H$Q@%EM38+$*'CE4QRAD?J:)V\"9T`]]-I1.K"$0+5Z=/E(L4&$$[ M[$`].6*%'N*PCCIUPY>@H*$$Y2! MBV;,*2G[$Z^^4XRZ=V;N@BEX@+9=(J\7+\[/8X)55(P-Z`!IV@T4MXWCMFMP MHQ5$MZPP6[GQ2@MPD3+";UU3'R[L;(2K(#-,<<>?3+1$J0ZGU$_3(=(!0ZR. M(V]6[A>DHWY_YSMV!&H8:=EB/XID3AU62$003=NKV0C^ZU_S6R[-A->^*E,. MK;[!L_ZUG-4O[IS+24:"S?*JWCK#7B-(]0*2]6&"+9L_]&6>/QNX?+2&^1J* M%6P!W?#W<6Z^]K;1H&;R&_`SZ@?K3I^(@[H:RF/FRDX3%)'V7,\G*'&\-&V+ M%`)[.@LV=OAXC.UZZYONR#%/T4[,2IP)O+%L)L728/O+?8_*^MF$SCPVCF,N ME6",N7+%MJ1<9Z?,0?``,>$3)K.O<`G603M25/!A@4][][Y@M"@@EK!T[<^I M*A.(ZIX5#%"/_:>]-VUN&TD61;^_B/V_*S MU3-Q/TU`1%%"-PAPL$A6__J;2U6A0((+2'`1Q3AQIBV)K,K*RLI]$<`F+"[O M'3Y:UQBI"IZE3PP-3,"!KBQ"@@)M*<9`)>OP9%J"?CU;B2%3Q<+$)Q^Z-FB] M*,"H$OLI4+]1N1LHCR7.S]$'QCGMG/XI+83I6@^YNLHF@_?N^:"VZ2VXE&#! M-A?E+Y/2HE)Y[RKUVH">WB[Z2I1[,K%S(=,;AGK%TPV9WC9QN%GG.>8*V+%7TA*5L>=YR&4T)B.":,=E'0; M%7H.6ICSCNH*`M&@!&_BW>Q,IQY3>'8*@,@@BA'G\[CEU#/C*Y>HPG_0.>;/ MKKX6^"H7\DC+/!=,N7'3X'_GF?C:+I=Y"1A4'W.Q6Y+&&5,OK`H/,%&N,Q=72I)R2C7B.0KAEZE!P)I%]7]8\;X+`TB^>5%;.\Q!@GLX#E*MAP3?L*Z MED?ARRA)90XUL"F)G@)[QA@C&EX$4$`^+0$*$[#)>YF$IA0G_)8898&%*7N) MX:='USS%(TGXG`.XF"B$)CPEHG'<$K5A/];*7^`.6:0@A!SRE]H>JWZF!XS@ M'U-R#S\0TFT!X4)&/#5<(ZUX*A4UKX?!Q@?GUK^!X]-[S)$%_-Q2Z:`/Z&@` MO1=?M2?M;9D^K3"I4D--D>(9E,=GP:PNK@36I:LN6VA25:>:027J3/&#,*$A M#9;=7WD]FNFD.F(RGGWBG\(4=!$?/4^DW#RWAVV3W'&C]GL>>:(E MJH_I3/NH3=SO>?S\F1'I]7SG1AZ%*/(_%!FYNP%(2]:Y65,U;L3\4:4WLZNT M992G637T`O1'5U56Z8P?G0]9:"8`4_.]S/5&(0V2#L@C7=O0:/ M9Q^.I`FJ+SGBRYY]#U]$:GU&T?455`;N.V11SZ'G^`YR8WX\R=`SAZG;7)FK MC.79A!4./'V_M*ZCB3^TG&[30K!\4NW<.*1D3%PH1RO]K9"R_/5[H1>(S,N3 MSL-"U@P&"-P$\\K(S1=0DCM\'ZLX\-?P3Y`CTN-!QZ#**^HJJ11'[M-OO4:= MY0U8^:[/R=4@410)&.:R*MEX$*AL"N],N05"FH%G9AG*M,.\-%EEMW+2GO3Z MO<^A1I%7$%<+-LF3&DT@"0^%7Y@FVS0HAA.#H0&=]X+Z#SQJ9`[=8)BQDXT; M'J5&!DQ"46$SR^5!YF-8&-\ZHT6`.STS-D*8/WM'-XFO"+2,9VG+F5Q$"TVD M_WD(DM7;P#\(E)[=-XKES`^>,7$7D*M9AHI.NIX7LF> MT4U*7D0,J4:/0N@EE?%$CYZKF['E`D=0C$7/$746H.W,;AKA%NYPJWL"H1J- MK="F=\E[O_AA[CNE$C;@\SB"2:DX):@H\"WJ6G1&\1/*H-:ITW01N)+UFK/= M9,(O/&7IZD+W. MK16.HMII@?8L?%V=.+NF"F#PE_6[D#F;Y=\I>11B1#'Y&<7X\59Y?=ANN62U.KW?"N3CDH<&JJYO%RB@D1W*N#"QB!UU6-6_9`44^=4 ML&OI^--MXA)1E$9(0%).>`K3%9[%G,_//@F69-6>!0(_!891QN,G,X!C(9S/ M:K+JI$0,WTUY2Q8A8.C'8UK+Y]`%HD86LYO%V<0I18R=@"@)"U8/YS]XW5P) MRS"=DLUGUC1RO11!:Q#\O(:KV(8DEUF*`HS$/%EP"^P`G=H1MT7R4:IBFF`I M%SA37$!ZA552DL(QL9Z1H>4<]8,K\Y294=9/9#(^9W4>7;"J>P-*;\>VSYH= M2U">#J)(=WSC_`#.!RI:\J3U^MPUCH..4\%L:9FC1'*[F#P<6\M.?VB@D!`3?:)@0TI',+2QY'_H\\ M4Y[+6%6D5U8IL75Z[PM5#^[GZ$6*)1,`.-PI&^?$P&R?4<=:HQM3K&"/8FF17:H&"?+ML>.Y$P!DX#*[I9B*H"`ZMQ$QAG_)9J"[9'U$4=QK866BT\P,_GH6H5Y'1 M5Z@90GBD]9J[N*;W+?A*1",I3YK2ZO&#Q MF3%PD]?I8H381$YA+`"GLN69:\^,:C[B>SDV4E]M.O[3M.:@P[N MX(+=TS1W:1C:J.H$-(K=L7B(XC]);C*SH]!-[BT$J7*K&V^XJO&&$;";Z,8; MW`@(2!C^4S!6N8326-2(>NW;6;73["7519Z:R/D>52%A%ZK@4?:2R6V<:;^L M-@*T0]4(K6&K1>S7PQTY4$IR8"4MW#]):568\1EY2F+9^-W6E!CC?EMZJ`NN M03!(BD@,!>;M,3\RPI%EG\TC7;H/+OP"BS>?S/'?+%)N6G@=J!V_SD*N!C5ED2S MKL:1;DEY@;D%;6C>*M='*[':6=%0\4=N<09\[[5_#AJLF\A]WC`4;#@4/E*` M6'[X9RHU//IGTJI\H_<%UPDUL_1Q>$C!ZRGO?<%UY;=+_D[%R6:-+,]-77R) MQE]X\3='K4-]+),INEZ>`^[JH9P5'Y3*;9GB5^IJT%@Z:M0M;&M@8K,@F*GN MA?VCI;U3;K#)J3(`2>H;0IK[6G#N(Q$^26L6RVI^B73:&\]-QFT*-KZQ.<+R M1^;=JK)NN3DF$><.3,.8+7DC=$39;!0TCS]4.0X5J\QNKG9+SJU+,U, M_K.LI);E`7H8$IK90^HY:1PR+ZZVS,Z-,M/1J%*/J4\#U2WH9N<3[+>M8(!/ M"MFG#3^<9`FE.,G,4@T%=FT]0Z0KMY<^#/F-99?9O)\F5L\_F29L]#-@FBAIH'1=+#'3_AKEE2,05(/_.0P@[SM*Y6)P7N-R M+2\3JOU\_A_(**2_$6A#Y.U),?#+#>L0DA\KMB=I5-C=L MQ^KN:#I-UPP3+H[ZR2Y?&-XJ1.1"SZRA-*+4NKMBD5WFRZ!,)N.70FTI#UU1 M;[XL>DBZHPRHZ;X@TI5>$EF<=MKJOI3S@HNA>O8&(]%1R7/K8P[ZO!5F5`@= MKL34GKPO5<"Q5_7'_!9D2-.,$F+^WR-''G/EF1.A*'2HTL/R*^.IR"\6G^8KJ.F23S3R0Q#M'PV$6YZB<@J*< MCB3/E;$2M2)+?:,1!F5F!/Z?@EJ4@EF)EL0S"K)29GJ[:8[S-+EC/I<-K(88 MC8;IM'U^GL1$"DRVD$E0O'-.K1QM*"A>NHN6* MKAN MV#'A*GA4F<>@>!$@^.E'H+4\S[00)3+1V.AT:LV!29A5XC;B(#3!G!IV\P'WTOOWN*`D5W.J[(SIE[9"L,(SQ?^_86C#V/. M11R2\O.S-6<'6`.//HN&A1=4C)F;O'PJ*H[KZ1_*X0^CA]B=_/T%__?%46!$ M]\4[!'2LL0+],SY0ZK[!"K?XC+>%[0,7>*0-%T0\NS@5=`=WC1SX$*[YA*F* M#^+`L/-!9^I]]D=B!3P=]",UD4?3K^?B;I4-=BXC#A'D>L!<@VI^QEE_?V)6 M3^B=`>*B^*WUM\O+#Q\^?EQ$4%)1ZO9?;>/=7'(KEY@G9M+$[%P]796W%"&U MMP+HR_6`&;PJL?UDE)QM7?MY9Y+28*!`'((47`'(W9!GM]'OM/9.GJ<[J\;`6_W] M,_#Z6^H"R#][JT9<-@P,R`IGTU M?$Y4P^>\C0_]^RTUZ5'MGP4V?^;8.H8T?XDQL>;7QUL?A\NK7KJO$R&L+SC/ M%ON+=/(CH4'8?U.L[<4N%33'FNHNHU'^Z9=VN]7H=9IZN/CPSABEW>PV'-B1NNI9 M-'';/'A>I/O24;.[`;;7#I<#7%BSD[3SYM48D.=."C)?@/M[<*?AF\>20>.Z M4T<@W%!-5@PS_!$;;R6I>,#@LX6=@U2"E.R*I/NX<^:.^M(D>H#/X^3&E&]! MI1B8-X"'TV>3$3Y7-?KB/+$)'J;74:/584!MEI&,1NM'JM1KNUJ99RNK:=7MLQ,I0\ M<'48E1HEF^.A5MX:_L]>,;15ON],?$Q_-8_L58O334?YOG$GA*\X[.':&+I1 M6XAOL]C#56C]YC[J8KQB:U2.A5%\IF1,Q-E[QN0P8_L*S[>ZP-2J-M+%^^?+I"T,[<6,% MC8HWX=]__51:K%7A/J:O\E)/"TF`%BXCJO,2(59Y/?V`+1#"17:+I<".PU,; MIF@!O8:JMQ]6T='XH;Q'NHY#$D5\%_`_OYWCH,>'!O?,+8^N,E'DW]9]"WGR M6)A-CP'#`*+=&[]%O,6!,($*V>C+`D`V$`W*(!U;B../19G0E%?(9IA M8W47A'--0BW$&G$-GEL/&^(<2MG;^=?H`5M:-S"`2+%2;!PL>UC"8>2YYI^]+0]V1'`?=/(1O[SH"=6`\B"-0T=-70((ZP=;2*D-(@-"IHQ++C M_*:>R:CCXL0DZA$1Y*/L\NDW*A#-SC$V.*!B51TWML9A+E M)>PV@0Z0XY,>+LUM:#LU0[BMEC?TD,?H% M#(U>!SZ/GAAR2[<"F!9VS1D!H43X106*B:BCYEN?6!=CBDH+24S>K/S]H<;\ MC,4X`D7&R\8$$&".&BVI8;_,I@KCPN&&P%+Q$9#/J7=NCE_^=/W9'+_\&G;Z ME,2N"'QUB6^X@Z#,!"ITT<]OE2#)QYKC=<+*YQ9H&26OQUQ(M2"D%A34K$2= MSIHY&76#+N#%^BS3J2X*6NIKW"$_Y.R'S(G3A*[KS_#@LSC)7$ZMRJ>W&4/8 M>``>#0M`8L5FB_FU('`/41R`[>`)E>;%"4P1:1(BQN8"-&X`!#HN+>'RL#<$ ML@&C8:)Q+Z2)8&=VV>E?=D6:N*G0<^GE3X"5LT`M2BU1<9O?0WYRFO,,F/$46K?I.55PD[C^%,O`7WUA4'*JDS-4 M<.B('/L,-(V$YKECE[IY?DJU#3MK3N0]EK#7#NYPH^9'EA\#A]<+G&ZB)[<; M8!$H(347Y==35\8J@>P.9(HH&E:I MM`WL4`2+Z?Y%LFM=8FG=>A8*J6S`RXMD*RJUO&P2D^B-4@!SX9$?L'_#?4@R'RTD',*=,O45=".^%.P+AMUUS6FK?OA'%G)# M&AQA"F:N7(5`0.3CIQ6<22I`MU;CJTG&\;43#_LH;F(&=U`&KJ+.*:G'/?6* M)IX2TSIG5O;BE'UP\&.Z?9V>&_!6STPM#$<"23Y&Y%@!\4?UMW.06-9&7#EGS M\*F6\2E*-%;2U_AX8UJRDA-`CT7&PN)[-Y#YU8-7NL.7S%O&$N0LU0I)[D$@ M^GG=+L$E"R-^(TH>49IWAS],>*&.1O*^7!Z6H/"CQ+-IAW)#N5QU.G8QPDFI M^#AFGTB9L+]VL]B_9:WT.QBQV+AS6NA;=DT#],:2V,7^4/>WS1Y'-]$ M@2$^KB]^_\7H&9 M)B+@5LF8-8^:FS@;P?\TX/MPYQ&/GX>?_`BGG+@>]TJ^BQ)F*/@K;-@WH6DV MRIF7R,YGB3_V`RRDD!INT>BG(A0Y7Y+GP"/OT[4B(]UJ5>&.@D:)66C1;K3: MO4;?Z1JLJNC5+#;X@[.CT->SJ>0=6OL53AM8J+GWKP> M+-%1X^V-K;O2.SQ<4]+?;MH1-5'H2T&O@=2.E,G3468Y#6 MB"\NT.DU96=66DDNT"@K$XX8_*ETOW$_O<5&]$Y"D;'$;>SR[P=7B4)=!%;GB M=QWZP;@/:XC]8^5BQ?`SCMSQ1X^*M5T-TP@M#*=4>Y-:F]2/67-;U\%LO9[] MPYN&['3OCJ1`DU-?(Q6,R%_A5ZF9Z8?(T8N2,K'H`1ZQ:DYO>!E^`G[#;`O. M`FP,A&7&7@$JA-0]X/5TB8('$>UA-;Z`XA7H_QO[PS@ZB^);-_23,1/MZU]^ MNTK>$$WAORP`(XCDJ=30SBBDLCEJP:L',HQ(*0<.U*"_TU@(6`%>-OF.Y/QR M=,:0FW4".G!&WMEQ!&?)`G3+PM-EN:/+X1K3"YE85G,&$MD4VD]HP7<1D,6[ M*+6N<_\KV9?OOAF_>G->6J27*,PI=<'E!,").V%-7)J$5E&QY7@'C5-#JCJW M?L=NPODOK*(#CPE5$@5KE'(<:DZA=*&(T#M_(JT*'G+))H2>=XK.YS]P&H:% M4UVYE7:)`TVKK>@O=O^(8NP.+IO0IC'PVCA[2.^V+F:UOS+U6+.:9;2)-<[M+1&3)Q>!(-.2G<%B; M&^AB\N>L>GZL?%"QO"_1/7M50%XOSB&@D8$^-VXM:'5&/."K#^J8]8%"'I+/ M&3P+_VCZ7V#1JSL_`J2#>2KR=O=Y>(.]H?(%`9!(G`%<9<'KZ&&"041;6 M((#,D9P3V27?#'80A[JAIK!1D!DC?+E*-N'0,RB."`20;Q&),: M7U_+T)'Q.^RYBLH):)7P*B+L>NZ!W(F!9929)HQ#GTJN@3'?RL28E_` MK<8DB("3#>/LYH9BU6C(TI/!`#RZQ(R@2T%>`<N=':-BG M\%*,Z_KP[INIYRFTSC>$^&^1B2D=P7RIBE$XUU=*,.F(]ZB3HY+]5I_3S7 M7`-X0-F,,1X'B#<%D`COD"?B?'A^YPT>LO-G"/P'V?F-?O\QOO^$)AXC4T"V MGN1[-R1D+DX#5C$!*3=@ZWMT';%=J5WX!L+>7YKX,BB)+XBM`J'G`A'H_AC= MH!BEN*5!$',.3W`A`KC?,0_I9.^3XN+Y&<=`ZV"_@@AN:'%*FV'%<88&"GKS M_-R=C7.,J(4F9P@27\^[>8VAAH(I2`::BBE M^R\\`XWDCLFP=,'\7^_$T$7I(26!O!T/3;61'[")G[T)9!(.5W#AE5L(>N0&8E9T0A)S1_'G+H`T>O MLZ891`_6NZOW/UU>O2_=[XHO4#E4'7;BMQNRCS8P<#7AP$W8&2S(%S6719%` MYUX"@@V-!S"-@L8:8ZIY#(9MW-MBYPGO?L&ORC(7$[7"QZ- MY#LM;A56&M9+U<$"_AA$*$?GP"@U`'@[1<6!`<3=0?2Q+T![Y.5PJH3-5BR; M2[1W)"/JCA[DD)]9`ZM1JH@T5`!%)RP`]4HBHB,=H!ZW?G[/_`R=F5P>%+E7 MHZG&]H_\OWMO55_HWI^%;N;Y'+)>TL<_#TC_>''QU13J/-8*']UX:O1:/AE*P.*".9!HL1`[P#CD3BI9%?Y_CKXRHF@.+Y%:Y:ZO0W[3LF! M.,).,'J2G_RT97S2X-UR4JP"QDC++\P_I%.)7A/HJ MO]?0T:/=42;7OQW),M\(MF''T;`C](J.3/.8!3?/Q3T M?HQ99Z"6R/RHXPX''HIB/F$PSFS";7NY>GD M8M:99=YQ.G>F(>_DR3G'II-L^(ODP"$6C"*7 M7-V*A?.(81X*J=(Z,`-ZHD24 MPV<"L7S#1B>"/R M:S%1Y@E&>=Z3U#^F%11EB)])12N/-#L`%#_P9Q?1G1.72*I":DLI=(-V0N/ M#]T'F$5!V,?J6SERV(KNQ=0$80Q-C3+LZ'F?5Y$9PWI9A)T#N!@#P)@7Q9C8 M)8&2VX^UH`KV9&D@.TT1:9H,:KI$6 MDFX^S%;&]FD$K?5O'.1;&/:6X.A&%>E]\!,L,TF0A-709ID9H3"IHK[S>MWS M63!@PTG^.BM=#Q@GM8+2@14C,YE+<;:O2C7-F6HI/:]*FA5:]$[_O$E]4[VM M=AN6:3./"L6[(\Q4TD^`24-O0#]T579<=IKJV-:A9(@^6'.6(8OO,$J#'8]G`WS-$== M+FWESC/C,;-AD5])N7!9<&G3%_S!C3&6DGP5\7=TI1_('>?Z)LTBHM0NF3FL M]+E9GQWA%@?N7D<3?V@YW2;U>_!)/LESTD)T4L(<_:T04OWZO5"K).,&TEHK M.`Z!E#!<.I25Q@$%X>'[F&6"OX9_`B?0R7OT9RPP`'+TE/23T[5?(^-]`XJH MZW/P%WC")<:#^%,([4YIKF%&"@!$%D6&1/'5:1=\XJ"#-K/\86:O\J?B8H: MN9X7<^C?X,+2+"KR-IVNQ"/D47M6)EVB$_>1>F@&?:Z&XT*W(--(N4Y$3"6T M#:F38TG.&#W3HVB8)43&2_:,;E(R[KB`7PB]I-)ZB-`YXQC+(-A-8RQZSO.] M[?Z9W31\.L9@<'J2W)1_9I>\'LL/8(M,SC@=T$.Y7>8+!AR-!.MX(@W9AUF)@K4$B91%F(53J8T$6) MA4/IH4==Z(&FH'-^I`:-_4=C;'YQ(PSM\J@]KW-?(QGIDJJ*O2<8>=*+@KD7 MBF9*!](C[76:G;-.LV%](`J13_PKDRJ%/K[`*A_4*N?6[^K!ZV^:[AVME=(3 M9I$Q0T]RD@"_P25'426NH`T)7V<,SJZI_$K\9?TN9*BF_#LECX+SKR4_PB8A M*#8H:17KQD"R/LK'B4(6'J]."X^DAS6*\^.IE/FRVW#-#&YZO1-.2B33"C.] M0:>FM.`\N1SC[6>4[H(-'5`YQL&*2N M>LRJ1E$Q=<[ROI86NR[=3D11&B$!23GA*4Q7>!9S/C_[)(RRA)6?!0(_!8:1 M6N,G,X!C$&IE@;B9,$Z<4,5;G4909 M5@_G/WA=$BID4[)YC-K&@4VBJ`U"'Z>5U4L#D:'EE*JQ:^BE)3VW<[-(<0^E*&80< M'\OH?9LAAK)O'35'O"Q#$V5-$QO)D\5RYXQVOG-2*CEU9?T`ND]U0YQB1-+, MGZ'/W?GP)&*94HE$@%8@N46,)ZD&+1GV(B7-IK-W4VC!M!+E3[\8_NBU^^/` M7DA!QY17E+H_8#$>6Z7,;9W#;UP,J>[:8%-J8N'3TB]/R7VR'H<61TEF>#.U MHL'16O*PZ3X0):Z[/"O0_4%?7A#%1IXN0EF@"1^GZ!^I7QP3AW]1?_#80V0Y!C#&T@,J_B]Q0[<(.KT>%RCSU];GI8DBQ MP70#-DVD.X%&$;=5ZQ@CV*I M9UZJ5&Q)8NP"8PKU4U*#0G,7`Q*=O$A%X63%HZ$NAA2$D^!$-ZA_D*TQDRD= MRFB(U.[,5:0K0RY"D;(4P0<2";EED7;%T!HH2C(JZZ;!?>92KD>O5"UIG+)P MC]HZ*KE+O0MZC\!`FABW(-V*A2O]2)&P*5J5#_9.!!P09'`+Y78(E4R'DY)I M"OL47J,D2W_$/3NG@)V%1IMT^/$L1&%)JJR9-$GP2)T\-]RG]RU8@#E?+/3H MF8:'^G_I\&MN;Y2SJS78T&PSWT1@^@DHK^_S0Y_3)77K4F90EP"\**_%;[F$\&&4=E?*^T[002!*IPC+`3+@F`.OQ M-!4U#.&J:DM&L3L6#U'$_%')FIR/.:V+G"/6YTM[JIL<Q6T3J/=`89C M&(MWL0*$T\B1&[);,"WWU&5]!8MGXW=84N^(*+MTF$-<@&"1%)(:@ MVN(PT?W;880CRSZ;1[IT'YP;"0I\WNOMOUFDG`SP.E`+>IV%7`:@TL_(B&8A M+Y43/"6U%902$,5BKHR_V7KF\FZ1ZE1&JA].,OD6(NG;AL?#J+8DFG6*G_0I MR`O,#0)#PU+16:VL:-NKH;SG7#0'?.^U?PZ:"LY>IGUX@+%4$`L?*4`L/_PS M9>,>_3-I5;[1^X(E2.71/K:C*[@LY+TON*[\=LE9H3C9K#+MN:F++]'X"R_^ MYJB]21_+9(HU#`"3W*8$Z%H]E+/B@U*1V2E^I:X&E>*C1AU7ZLRISS&Q61#, ME&[)[AY=;V#VF;K!LGFEZ)/4-X0T]::2V2I$^"2M62RKCGC2XV8\-^ET+=AR MQN8(RQ^9=ZLJ'^3FF-*4^V,,HZ7DC=`19?DZ:!Y_J"Q0RI&?:O!6V9!)9=(!D*6(,6I/D.QRL+,L+F/[-$D'Q)WK#/* M25 M[)2E#._A_*2TL=/H?;G MBD/PQGXR(P3$H(;*M82:338W`J"2DJ82O,R(P^(`@NRGCI[R@G,_],RT>2.\ MH\MQBZPJ7P;E(1F>Y+5/N86>>F]E@0C2VZ1O7I>M27=E29!BVC&F"YGGQ2E" M]>2,1ZP#'.?6QQST>2O,B&\=^<"@,!C:F(+@(S/GLCKYQ_P69'3$##A@YL@C M!S%RQ95#Z!2%4(D%^95Q#V&/&9*,LI`4RSV\O",KS'I7%).9[$RF`9ISV85Z M@WQ%/7J'J[)S9SWO'`V'69RC<@J*44[YR3 M,D4,6GXB3-6TO#\"=;.B?&+,;=0!?E?W2:&V?3(H*5,!!!?[ISKY9>:*R6HC M4M7-"U0//5#(\!Q*$Q`_7*WW&@H"%VJ@U3BD+D^QGZJ:#?:]R&5!790]D@". M,X;C#.$X8SC@+)@5QKDV:<,X%^502L;`VYG0FJ!P+6(ENK7'.*:4X;M)& M&N%\<=VQ`]-]QF96?VH2UVR%K0SP40\ACD=2X@)&"I6:;EY*:>IFP2>:1V]( MUJB=$S/VC,E1\EWJB#FP+-TX7S+'`C5,M1KV(LI-%NDJE#=/,S55HRH:SG0H M`^[+Z``0@]V"O&*<5T$>@(;T6ZZH$^XX\X3F)%AY]Q#,R@O1WZ::_V:I3!C% M@N74R%`JA"C,$S.TKA35ACA^<*_OW#T8-;.<0KOF$J8H/XL"P M\T&GSGSV1V(%/!WT(]UP6OJ^9<0A@KRU.?3+J.9G;//[)Z9?A-X9("Z*WUI_ MN[S\\.'CQT4$)16E;O_5-M[-)5=)\^AF'I:1M\I8E;<4(;6W`NC+]8`9O"IR MH,57O0%\G4ZCV>]LR(V78[`"A3_KZV@/&H..?8C7T=P917)B?IV"KXR%T=R. M-23B!B?[+)+D[=QF/!4I&WQ6+!M-SK=P=ZQ_624 MG&U=^WEG@H[$["80AR`%5P!R-^39;?0[K;V3Y^G.JC'P5G__#+Q^EO(3>9CQ M5ROTMEO/X3W36RA?Q6CUQ/T\<.;?OV4_AJOX&TV;/'G.ZW6,;NIS*YY$K53W M&$3V5A7=2U]40ZXIS])D;Q`I6BT%:)NW]JSN_<,/$0\Q3>)0KOTKIF:?[GR[ M=Z[&@1W,K;\':W?[E[Z&WO^49,M>X3F=Z`!/M#M#5WGS>UOQRKYS`\IW*HP3 M6-G.F_5ZUAO+V:)7M;\KIVIKT&ZTNRO[^;?LU]_3_>S0^M[U_3;/>X=RN8>Y MV,YNHO\3SN'W>Z/3.P#F&%O:-F M=RKM$2#K!-;1@G4(*^P=-4]7OU$6[4Q5S.'J.ZO$+^O=Y(`MWR-X/$\*K$-8 M8>^H*6%W94'FM:/`"\+)NCFXG`=Q@3,9:'GN$)[H1BL7>1>+:X1M[SV-]1`" MFI-)+2N\J3;&>>LZ5T-/*.8I#>IC[Y!'G0%6(IP>CY$J_,MOD2>"+7:**R.( MDHT.+2I?K]:]`8/_5X1MO*E)]3YEZT8E!1LRQV%/@9U.LQW5O)0U2WY#'WELBV/&AK\8*9.[=F6W*7:O8D5N%OF MEJOM-2J*^V^)@DOI#!Z:A\JS'J6-0+O[&B=EB4>[UYM/"OIZ`G0[=9MK*^O[ MSQXX8!'J.,W:A>@&X,S7)(]`"'M2!=R_U?"T)/`VH\^[,R]VH-VI^9IJ0M6) MQE:W9ZNRP>=A0!R0I^.)T=-YOUU*FBZ)%]3@YE\EB&!.9O\#F=J#[ M;1`X.#0M>TL9)GM/+3^ML"KWV4%SJ'_3JC)9,C>K=Q+.WCLEKB%W=_#%#"]7PLKA-\4N:X?RM)C$@2&4G)!KD,H)H_,P>BWB\8'PXP/##,WX M.R)>O?54U0.-$.U[T0,%Z]#.>HBDM\;#W"POJ^,\B0X\]4.X9@>6W?4M;YY7 M3C]XDOUU=H90N]EH-NG_3VBM$:W]\\'*[7BWC-!GR"7:NZ3HFJ33'E*6I,EO MW6*A0^4N04\DO>A(&O*<UQ6[%F5[;3]9]XR`E7)W[[!/GM M'G7;(7I<@D!X@*%X)/SJ>NZI<>7>7\<)ER=<[@Z7IP=_*')C+WJZ\M*[Z<:- M!=>DI`V`KV>`V8XI<0VG_HEC;L&E?T)JK0[]O4FBY\8_UG/W/P\[2"864T'G MUB3::2KGLY1KN\?H\Q!MN\?K`4FW$R\Y'!FW:J.#:JT(IIL;7"2)2)/++(X% MX,;L4W"17(V,W@16%OK\A]^_OW]A>6+HC]T@P68$_[";@ZX]R,$L++K&CLW6 MTAU[S7:OO>*.7V,Q<7T/^]"$B:A^UA^)_S;T`V!#<29>6#]ML/X*)QMT6FUS MWG+)VM,`_.;&?PHBE^]BF,5^ZHM-K[0#]-[,P5BPP\;`E.)D&;@ M+$>(TV_UG?7`^12F;GCK`^+JX66M7JO=,FABSOH;@;$6R?.Z:Y^KV^VT6KUI MEEEEDU685[_?Z2[;X[/OWF"'Q,VYE-WJ=WOF9[F*QS6[K?:@WZ5S2^& M0[A;#\A[))($I+0;?!0;8\%IM0;=CH'UA;O4`=-RY+3M?K?;WQ"F&@FE#<^Z M-P/.RC=6(]6T@6IF$;,W2W=P_5P7&<;GL; MX!!)5@>G#=_=WF5=>)Z?D@;S%2SS3^&E._%3-U@%34UD]LW.]FYN?=A:-C!B MI[L%(E?7N`%LO4&[U;>W]_C_\UZ,_"%`,QQFXRQP4^&-XF@\B?V(+%%RKJU" M>6=VUVFWG=96T/B$0.4;?Q*@SL.JE\5^>)O>"4_*4?T,0'[I\( M20?&^N^)#J:_L;:A,L/--H=E5Z=;P2"<$2[UG>[ZXO=?S'N7W\>FY5]1;E]I MN;V^G:UD^>I[U07="KC=`#K];,H577@]8QFB7=MA-:,(+]^K+NB6XV[6A*@. MG?$G:CZT+J:*)N#TJNOMNHH[R[2#*^S*INVG),'1OBL=F;]A[O_IRT<^=[?5 M''1+P3"WV0B::53,@0;QT1XT3=?)NM!<9:@7A#@`8>L(,O;:'*X:4;4`+I#! MN4!>==[$0E6@T^X/[(&1U5'8HO+^CK&_L\K^?:?9Z[:Z=>UOG]&VJY]_5H?8 M#("2"ZA3@Z_YN@#"9B5RL3N#`?Q_C>32R\FE.3AK-1?OW^H,G&Z_M>+^V?.W\GQ4R%_*%%^CV[P5<_]`GM0+^'0@:5!-Z%^,H3OV_ MZ/=S=UA;6>X[+:=4Z=\(G-T>Z@^T?<^X'?XFG2;U*N+;3['=6H#+: MI`Z05HCP#\#X7A>DBR'\.1;>1Q\V$)^!VWG3"31J$HB"-#\K,_1*D> MWGX4:]LT-N"CCV]N9L6*6ZUU[>49QQOXD: MCZ9F,46U=OCVA(`5[84C1\!__LTCX&=4WSGH:`W:;3,'[EB0P7;",T+&E!!6 MLSFHC?S*C//K',0TS^VM8&41T`>%JQ+.?\+5(ES-?7H+,=?;SN-[,JA;S+5. MJ%M*=3)>*C&8V%5PV.ML43-8!8^DA1K?D:M\^#'Q.6+R'K3LU0GG'Q?9+:`# M*Z;;4O==MGAIL)H=S1S^^BIB/_(8@6;1G#J/5]V%JFYCJ1Z]+5B6:@E;T_`_ MNGY,$0XPI=1,937U_5\1V%28KOKX#2[F-S#`QMEXTQ,!RG#ZQ:P3_;QMUZ+X M5#[1/G#I_M@R+ML#9[>XY!/M`9?5G_L\M-GGW7YKMV@[7'S]Q^!G%0C/J4-V M'0C^OOG)GQ]C(51]2[W4=MZTG=Z6D%4&^:&B:BU":P+V^D>-O2V+6T!@LUV' ME5CQ/+O'XW9%+1*B6?2_J_/L1'"\]^]]3X1>E=>\#B%N6628QSA8O*W)!?>. MNYOE&]Y4V1`G^MGKQ0FW!\_!G7S:SO[:>J9XF'TV__AJ-_>'C`U<-;^0O^A3 MR$Z%V0!_O:Z,O0&[W$&V,^=8R2'JQM-'[IZ>Q53QF[NZ]*Z'>\5&"\2#C/K. MP%<9`4DE^EC9(;QJVN;7VFYRYP?9R,MM@][B="L00GW'JQVS:O6G0"6;LJJG M>S2#53R=(/6*0->FDRV-&'T38Q>L^/#V$M`4N\,T
L**I7\UC[``>.R14RAX\5D].F`/ST?C'6#E7(Y:K(=92Z00TG M.#S5XRE=RQP2-_CPT^1VRP\P6X`74L]_--CJ:X+6Z?1[O4+!Z*)=ZH!IA5+D M9K$SVVHP47[,I_'$]6.\@ZO1Q;WK!_A!>!_?7;,K;RUE@HXDE`K[U@3J"A6% M"U/RU]^Y>BWAWI"TY:K##0Y6X"P+BHU7[)$VSTU@=[O=7M_L\FAN6!68%3ND MS0&FI,9W,V!6ZH\V!YB20N@R8.AF\0:O1D8]\N^A)V*P'.^!B+X&[I!$P`4P MS#H[8`B4+7`^9Z*4(D/@5V39$%J^`Q19X1_I.+6 M'V(].?H3Y;;[YAS;.<%6D;0K3K(=N`\'-:MSEF/'1%V<9@]XNHZ^9O'PSDW$ M^P@C%5_=-N<8?WSU7.3-3_O)W6<#=]H?ZN'G?/0 M#::=8W#([:#7G$=5V M#G*XN%OLNNDTN[9VWSQW5&W`Q@"1G7[?/AQ$7D_G M%^?OQ4VJ8(+/X(@L;5?M1"/I.0M5DHU`WPY:MJV^].I&QC9II$9=Q^GT[7G\ MY^F??1/%R.GT!O.UVOHPDW_J:C0U$&SW#A"[,W`&CN(,%4%;[UA;?MEVM^IA M-KFC^E[FH-/1MO/A@;[!PX*#=08U',SHK?$QPG$%8Y^&329+`AZ[>$:=5LLP M(C>#M)9#;_F1=5H;'K7&^ZWO"7;[@\TO<5\GV^"%=OO]0;M7_[GS+\L1YPC8 MO_WT3N^!,K9\X54?[)+1?N:-;@3.S@^VP7UN_]BXQ!)Z0("3NWINL=T:=+HS MQUD9B!T=8J,;J_.()=JKB&B9/*YG^-\OAG>^N$<[F>']YOJ)^"5R@ZN1K*A$ MV;QC'_K"P-Q6#K1+%.XK;+>58QPLXA8+O<5N_^>$ITU4!Z<]/^2W#RS*K(8Z M]]TOI]O"@7:/POWQNZT=YL"1N`GO>ZXXVQX?W!=&8<=/X6=?9/`K-W#CQXN4 M2H*O1LWS9IL"(>WEJ*I:-]+J+I&L%6':R2'K2@N,\PJ@KOD_/\,KRJ@+?[DR[)4]G\"O=UL$V"FX-%65]K'_N="&EP+DY]58&=C\+%,NUO M@FH0]?U/7A[J8ES\.?;X%GCL.?NSDX_BJ:2=0L%A\TN68R[K0E<]I[7 M`;E>-&S;\JOM\-N@@1J38=O=3GT7O?>S;E05U&WW=XP)8!QN^'B1IE$.'GM1P>>&H&\'+=OF"(L2HS<`^`"0L?C<_=Y" M#O'$S[X)Q^CWVKWY+J7Z,#-;QE-6H./]D27I>+HAV[H)9TZS[W3[1E9\%0AV M`/TFF6;UG>TZ=L,D6.$$5>.'/5OG%Y?NL1X4E:G`MFU4$'H[`>4_[\G=E[IY M_S:/*M/2.^&)>Q%$$TKW2]U;LL[:I6YHV_;].WN+M]WN],=]-OS5*&EP*U[M!H?;=MN=>:]VJ40[`3^-5[B/`H\ MD`-M\+S@NIKS&,UFIP.]O:P=&*WFT&K]7;ZL7F^PV`ZO!FQ=1Z_OY;6[BS/E MJD&TE_-5?YF]!>7G3^'`&V2.=3L#9U[/BJV<_FHBL$]^H:667&VPRY?<6=A" MK3*P=1V]QI37MK/0450-HKV<;X,JX"=ZX/5?,EQWN[V@A4B]IY>M)_(1`=AQ M8E]/N=OJMCKV(C96$=S:3E^C1NPT6ZW.@F3NBC#MYXC5'S3<[5,_\P9ZM=-T M>O8BEW;="$#/JRM;;[:[M.`OI?#F,FYVSOD?K@!7KM!;>WW)`=GB8 MZL^SWUP@<`_M=!N$ENQ6N]U:D%A6^:@4V_!OLI0:S\B*2U[NW6.IVGT=H7,J M\/\2G^'',)D)>;=KE#9-K,?+`S);`O6P,+()H]X#OF:I\+M(TT"4-#%:)?NP M/AZ^+$5Y93`W/VY]+V)QQ&1E4'9\I%KSJ0_VD!O,+5F8+ES/@3]&,5:N4`<5 MBA=^%+Q(:Z>.RX4IA*O"N.%!Z]2L-CI-+=>V;:?DDSK>!KI5-M0KO!C6Q^%BJ7G!G5+C/P:N$/ MW7ZKT-AQWF:U@[4)I5<%6HVX_`7N(':#B]"[\,9^Z"-V+]O="JK@AWU)-Z+20P+DMBH10#TF_UV_N+,Y:MN796B^TZ[4\_.58ET MT.[V['JVKLJ&6TYAI/:&^*Y$>YW^BAOK2+_DLZO:M,LFW/0'78/49G99"XSJ M1->T>W;M8%2E0*?IM)IMNU4W'-6U`M"M[,X6;J42:;8Z_8'36PL;GZ@:XW.4 MU$*E9_/)--]H35BJDNK9?%K=&):J]'JV@&`W!J8JT9[-I]HZ+JD2Y9[-)]WY ML'R";6.P^6HTY#J]?FN0`S&UPQH`5#;3!EA46]_^52FTUW;:M2*@*E7V.NUF MS1=0C8>V[2K[>]D0G1#Y_)JI1*`::;-%`1<3MA4WKQ7J%0AZGHE0R_Z5+:F# MP-H&AE5=M[;L%2S;_Q=J_Y-5#KVGM75V8+ MA+K2OC5>TL8$NLDE;4J<9EWZU0@?PWL_H9R!K[$8^]FXGOP3FWK\KKQI+5#6 M0,)K[5N5?+M.Q[&=76.GLN-@T&LWVWNXPTTI_$L41D65N$;5XFS0!\/$L`3F M[K816)5-MZ(VO!V@*MMPJ$^TN_:VX:ILSJ%?N]W>P1U6M.P*"O7*0%UAPXA+ MLV%$;@A^C&+AWX:761R+LWN?A!R?>>&UV(\B6(W?OPTGKA^ MC%_"K41B9.[HI!Y8+'$#\5T,LQB4[7I"#&J@0W6PY.[K4JM'00;_5'ZP%VP\O[D7LWHI"Q8XYUK\D.;=UZ`[ZɧWGD@42L9N*6_A[ M$/A8$O1O-X[=,/V7&V2U);W:=FO0[]BZ)F/)EEL!<).&`>N!KV[IL__?S(>] M'S'^$T1)%HMK@/==$`W_7!6[__A?0?KSQ$K2QT#\_<4(OO36ZD_2G\(H!C"M M:W\,]N47\6!]B\9NV.!?-*SO(O9'/UMC-[[UP[=6\\7_NDU_OD@L'^ABB+%7 M^)<%>K3E#H?<<5U6Z"11X'OT@9&>7P?DE%)H-FG\K[_9K9_Q>[)/NW7GXJ)# M]&]Y5BA22_ONK8`L9"L:62\[C79_T+`'`PN,8]H7Y("PQG"]5X, MZ4:LEMVP$`/GUG=86>#R8D(7#DL9+:T)%NIKW;`6@F0`XM@-I]5L]'OM<^LW M-X3OTDKN>/+SW^QV]^?$F@1N2-\/,D_0NK'K8Z\'_/Z020=^'4?9[9TEX(+3 M1P($4/VG2!,KC:Q1%@+Z*,=\1/"K07420*N0362`#!C MN!18-Z8]=4X\W-=8X.7A/$$\J"^2<^NC"T\;MDDC`@)!A<4\@`NN3(.+.]]2 MB4=J_!6=%(D5`T+#C)P46>#!C]@B15%'CE(<,(UG`[2FL"=".11N8A[PG$#( M7UOPV+!P<^M0VU@T(,KB*ASM_>,><A0'+*80`_^R-DV_*`^%OS%$2&8]0(B$2!CR:) M"^LF=_2DS;<'?\^($!4@BRX71<]/$Y0<]&G^GW)Q9-N=5]8E7,--[#>L7T5P M+U*`&`01<-.S:6D$_V;/^7:YHK-(A$Z+V^_#.^%E@;C"_N!^ M*CZ#(0SB'HC^%O/?+@BKUWCX]:1P2@]X*((@F;A#0!3J"/3SQ/4\]?,T:I9B MY<'WTKNW@)#FJQ-SWA;V#YP@3'8<$'$\G^V=GS7R'8.X9I/F*KX(`X,.Q^2%"Q95%@^ M^R.Q`IX.^I&:R(MQS;FX6V6#GKV7VWCW>B>CM9(B%5Y21$R>RN`O5P/F,&K(L=9?+4; MP&_8&S+@Y4BL0-3/^D;.#O$FFKLZ?<=Z%&Z-SP2;&_*>9Z1-K.M M&S_OP$VA@S<0AR#[5@!R1UI*J]=JM%N;:BFG:]OIM1TC0_F)',GXJ]S/O8;O MNJ330>'3M06=M=M^@<=^:8!@G7@U+N7C/SZ-QUD8W5-+.DLW\VI8V,Z+8/`U MKK<"C21V/_0$KM`\[_CA;E%Q%>;Q<=NA^+A=C'J30XGB^A1+_"SCHA>%N.AK M_(8*\_5^GOV0_%/_YS?6@Y_>68LPW[#&!9" MAW\ID@6?CC$NY_\%'PL"#)EZV1!#RZ%'L;O$*D<`QR>_\L<3$PG4010CDL9! M,#Q*V05P##>/]$]@@U#&'5WY$]S&F031XU`M[O][Z%.#AI1"?Q>Q_U<4NA1J M5.&XQN83RB/#35OH040P\]O&F7'V\1.=4I+%P>?HVI2I@$`\CG$/@5Q3S M-G(GX,]!`&M?!$'T/?7'UO5O!#C^;/W+_0M^9H*9Q955@J`N0WP:8P"BWCLATC?N-[, M:[0XWJP?_H#?O74CT@>,F)M`X.7A^E,$CK_ZPJ`8SY#`&OA>U8W9/;XR0I#.U\CS6CS* M!`E\R0-@,>0/,<(?BV0BABFCJ1P&R@_!FKVI0#NL>6_DB,#?W9@22"26 M\91PPG/K(K&2;'B'8!,,TZ`7J6WDX[MUK#%'V1Q8.B:?'".?(7(5S->#3"LXD%>,Q.4:9@0%E\(6? M6_`T/HJ;F,$=E(&KZ')*/"5YNP\WOTW$$A`+?)^`F+@QY3=0C@A]S%.D,8J` M43T`4&^MU_:;PHZ4-I-D-V-$CA4(3(117[N,LAA^Z]US1E?^*TT9YIZ.LU&L]F$3[6,3_E) MDNF\+N/CC6E1EITZ?PHRT>S>024>#5RI?A);S"/`H3Q#E+U-J'-'/ZW8) M+H=WH%;L/\SA5M2IA=8E"/]*H\7)@^"*N"=I#>!9B]<\Q222O'O\2(K%\? M;WT!8AX^_BD8)DA<_9=?/UFO$R!8$#6P MM4VTW7_#^E@>%3*$COH6D;',ZRN\4,Q@"PV=E=+7B`-_0=JT+D!1Q3P@E83% MN:.%?Q=T%3?FEE+R9G[Y\NE+0S%#5.5*SB],7Z=3XNL*U&PE%$)X/D>+!36HC"I-*`$O]O05VE\*J-SCCI',.#1 M(OX3I^O>%&3'47.X"\+O3%KX;++WQ/4]ZZ7=;C5ZG29\1XM,37R!&=PEFP@S M:!')^C"T*([]L_3\RTI:7G.W!V5Q@R`DW<`2`0`11Z`6DMG8T*)$@@<0`:,+ M_+^4,52.)IDECW\*525,R)]$"SP5#V@N6T-T/^5V-'Y%%R907K[^TB1Z@,]C MI4UJ.BQ:[9__K4^I?_5&F;4EB`+.&P0*!;F1IU@EH)M-:JPV2A^MUX/F&S!K M'[7@-JZB@%1X&ER4E$T`]G&6HO@V*)J\@O2W+$2?W)#]=.-)('Y(+8DLI)LW MFNM^+1I'D95178%2P`+T([E)Q-JD&`%Q<\'*;11YH'Z1_R$B8]='?@&O%14( M\DX@-4[\("*E`[3`,6P/_\(K9O4JHGH:+'3SI6ZCM+'R"U=_53!C38YZX00J M+OI'!(\?_DT/1+"-2ZQ!V?CT`>L>?I?%\'5R0#6,]"1/D.N0'P[:]@JI[A0K M+920E2[)23[`?:@"DT#*)HCF'FTUI9892_SOI*BDL?]3NAZP0M!NV*T!IK/M MK_S%V*Y\XYF(G/YJH2_YLG#@3+UJ%-Y>`X%@R]*]%JIJ[_3Z M&6WT/M,>1KNTTRB$JU,X@.'/U-V;3_5=XP1K)P&#&\,@B M6#XD?-/[R/W&G@]&+7`BE&/P:&^Y-/-EJXMI5ATVC?F+Z);+P@2;8"G=!`-C MZ*R#EV;WFRR(=5`,8QUX/'KBY];WO':-U\/JNAM4],C:TW676@".<60B2@Y< MB`\4.DLW2VFY
X5WZ;,"HY M.N4&K*^GLR!1?.7EH$MWNX^'%LA:AJD7=[/=AS]M!LG(AK,PX`X&`\LDXSEQ M%*/XI`PU$J76RW:;A2,]M'_^]D_KHRHOQ3`BRA3X6.B[4NG$*(V?9BP>25>` MBXWSAX=1B#`*SQ3Y\AT#7.0@B)1O(`;"'L@G2-I1=I-@H"B4-HN;-C3ET0/" M:+QZ$;%\JB#SD.+=,,S&.00-]3COHL!3>CQYX]BK-N&0B)\4&`\_(MMX0_P* MF9KA:0Z%^2?>(87[8[>+FGB`R]Z2'8(G!:"G%F6>B/Y9[IR1*Y2QN"<>!\\8 M]!IR?B)V&`W&!G1XMCLX+@7?>&5YLL-W(X\4XAS%<3:6L*-JH4#)HQA%SRES M-K"5@$MA6(24+4'?=68>.6IS!:Z$2CIQ6^9]D1M2?.X+*J%$Q6V#B@L*N`Y@ MO[2EOXQ8-2!)*V):AXO0Y8Z&MM-371KP""8.E"$(J+G1PVU-%(YXO"T+A50B M6(T.9T%0E"X]=+4AZTTR M1EB0+?UY+"?UP9!FNOU&I]>9)T_FMSH'`L=A7`3B`6=XY1Q(A(;CDV?NFHO>DFH_$J$5.NO*5:$TQI M:Q0,!3%HG)8N,E,FTIZ$0 MGJ$Z2H53L@SB8XU6K]_H*>Z4:Z0F@`3QZD8B'/U1>0V8IR/PF"VSR=O,N75OOOF`48FF\.I;.TI_^LE<$BDY??PC@P/ MK$&Q4CR@JY.L$'2O83^>1, M\J@"LV;*J/GU>;FC6G)K601;Y+%7Y"%?`Y>@^0W60<\A2N\Q/\F;1XS`AQY] M]DMT;BO_W.(5.!MO&H&<)CF,R$<'6I1R6>4'XN^7)]G>L)H!KT^G(\E(-:/A M(D=M8PDN]<64XI,6BJ.X@-$Y$9B*%_;N6V%1\_Y8W7Z/C98"ZY_GUJ\N^J)` M1?AZ][YAKB'_8*(&\7(9>8_P)>!;23&O6/VNL#,;,J"`*4=J[JUXN(O(99J' M22:Y;QOQ/GU)>#.<0:*C%_A]U(%<(\9O9"L.Y=.1HF3,"Z9YQ_\MJA>[92-? MBP^QJ!!.(U('G21KD12!=F*1,AECGO3(AE*C*%`3_ZW`7UCGYZ!6?.]CF[(< M#Y30PB_L!N3LF`T'H(4@X.>"404V?GW/=_-63"J]HF">Z>2]=]]@%59&*(^@ MZ!ZG?G+#*2@/4'N:+A+7??6MP8B/I'>P[*&/8F'LC M/].@QX=9E)@11;F$G*+KHBIW!EAS57\O`,%GZUA^=Z9]&Z)^:DMMPBN0C^:= M?R.8>$'H[.G^;;9[P/L'6^*3``6MJ8(MNR"%[N4(ZNTYK?6:Y\S3P7* MI[#0%TT=9C8]5^DL+`"H91]V>V,-/YD$F"Z,T7-]<'(3EYT2)):4886<&03\"PT(O&^4C7KM@ M_]ZZ"-S]&^18](CF/4-.*==I:L,H4>T1^6+G2!.5;52"+UT+H%RU238>N[-/ M!P"<`Y\\0=F#8D\OB!\0LC[F##+#,%S9E,="=X_"\?6]K_:X!7&/%5PR%?Y/ M\0B<$>E']@]%9Z!/7Q\*14KS^(U<-<9>H:[>D46E;F,[8WP5,:-HB!["O4%' MJU#'!;T]^LMKRE50[57?Z%Q928T%".9D+X#0OU,>>ER=2MWDN?/:14F+I-*7 M+G1,DKY,"RPU*1I$9__$7"'K`[N"WF'Z2Q!%TOTS)XL55L%O:AM,VU5XGZ2? ML=8U0T;*Q>=:WT1`37_9-I-/Z$N4*B'R/:/LVI%['\532F9#%D9^Q]*3)*4T M5OC%OZ*T)+N^^#W\FVP_C(I@["O&%IJN!\VSP%OVR.(:>;L.TR?`%WD`@B2P6E%+5^:Q!,N/5[+BBKJ?-.6. MYOE]+T0_5XJFY+!UVHU.!RL6>GE9M-;C&((O4&WATY?4EE* M5B5YQR&.O(GX(?AKY[IBIWVV7ZD.`JDMVIU68TE@)@)E`AYR?(SSD2Z`N51F)L7C^N=VTFVUC-%SY5NL# M5/5=.0.G[9@3:.L&J/)%VNU!O]7KK@H130_))T=>C2Z\>QX@4._KJK1/Y5OH M=CO-3E/.0BG;92TPJN*^U6FU'+N]*A@71H.\JQ&&#M_+\&9R'7V2GL6%(]:K M/9Y.:]!LJH$Q53:O%>JJ=\L#V/<+X(T#4F'0_L>L'\RHG]-8IB>]!IM1]8"9-7+ MMMN]CK.0(+K%".KLMG6!6I4"!MUN;Z$0W!ZH50F@WW66 M\N\YH+)+9=X7T*,LDH0B:Q]%321@]]N]9DMY;BUG^_.WK!GV-.^_W M%RJ:J\,.XN'23>Z^]/HE@=YH=NVMXR5;?OU[( M*_,%IX,V<7?_D%>FEG:_WQDT:X$<=`H*/U]'G-0M?G.'=WXHXL>+T/L`OY&] MIVO0'FW3ME]MW_J@K1[!:C?W!VUE$[`_Z*R-7!(T7[-X>`>Z^U8W^`9*9UEERUI@K'J+]<"H4O'J\,=U^ST=/YS9H?K^F[K! M5]JDNK=LY4/*>*5^5I1`QOECGX-A'1CO-7-O_.+=-@1LTZNHOF/EU[`1*C"( M:`S"N%9S,#ZGWLOI.$`S.286;;ZWM7X7V'GQ+%![9N+!N'=?N=KKM?G^IOE6R?;V`5R6"=K?= M[C>7J[A;![QR"+'3[G=6\`BO`/B'T4@,TZO1!]GYX1M(ZJL0%[L(/?S/!SVO MJA9BZ=D=`^%5=J\;\LH&MM,^$,@K:]!M9]"M!W2B,NIT/!VTJL5:!L(VR7K^ M;IO!5=D8AO?6,^EV6X!5MG4W0E@!@@M0U%>-[?2Z9E(D+K7Z\LW6'(*5A M*X5,*^ZSJ?-YU7UJR*U##=A(B)>M4_&W%V/,J;3K":*#<=(R(WA+MZT%SNK) MS[U!I^?L&LSJN>Z=3F_@=->`4VK7>0'$5.KL=;1U6V?]O2M?9[>3AUA6W;@V M:*OGR'0ZG<$FT):Z(:ZC[S0DEDTJLJFNPJ\QJ#NI^*I:15V!@A3+%ENU,\VM M0%6=%OJ#G!@VAVD'1ZQ,0%LZ8CF3N513'S[I?LJ;28QJDJK:]I6II0WZ4F\> M?YV_=YTP5\^:V@SFQ7D9G);Q;S^]8W)*MB8A:@!AC52Y_.%4W+]NV*LWVJ@) M=@X.4@#C4WAQ[_H!2AOL^P"&\7< ML/=#+.YP6MR]J*N?C=-LFGK5U`[5]]_T1E;:I'+*X>J'S"_F4TBCS_7DPZG5E"*-MO0]#J>QZK[EC=_*F.#.TZ,/1J;G%#0O`3];>JQ=;MF54Y MB[?;'+C*711V"%ME%[_9O:8:3@M6*<&ZV1ZZ33Z%E]QIC^J_:^%^O7[? M:1M.@I5WKQ7LRHDNS6:[U[+W#79E3W[?:76<3;!-7.*='F224U8]_OMVOZE3 M]LIV60N,ZN6@O8X65K5!4=V#T6ZVFYU5P9AS>;5PX<*US-MH;6@J-S,R;J=V M8*KWIS$N:25HWHN1B&/AZ>#J)75(KN.:N$O"@EW6!&2-^'(50+YC.^?X\6HD MV^/)://CJC@YS)$^*2'%%#/T^P@ZW\>1KHI8TZ'WPOO7N+,R!> M_6S=N,,_;V.0Y=[9,`JB^"U/D7^10X.`Q&H72M09NH$ZXTV4IM&X;)F_75Y^ M^/#Q8[X0WA8MYJG%)"`#A"/P0W%V)[#!.(!F=U[IZ9YXL#DM21?>"RWPKRAP M4YY]@TC&[^O!H*FW'#9[/FC%Z]OY8KU716JCWNQ;PZ/=[9^WG%5Q&$8/L3OY M^PO^[XO5T;`IF*_F0DC_C"M1]2+2W1+\V"%GF-*$-4RC"3V:@5>1=#YW#)K4]T-,W M/_GS;!0+<>)32R7HN=/;#OWL5&C^1$IIX5?',/IVZV-]GYU-L`8W6O/=*IQN ML"H<$]`9_OV%HW%W@S-WXS,^#!PJ`*18-J`21WYXY;>ZI0>*"]S@/[YD:OB* MGN]WE:4)CDO!T5AXOAM-S;N14Z?KR:_G`\]:%-97G/U\NHY#N8[W2C?9]6WL MSEZ0_+O;VYYM_'B\[3W53% MP-,PRG^AD9*>=98?XFJ81C0#;K`6UWY>ECJ/ML7_W[OBMK45-L71RXH4M$,_ M2_.\Z73W?G/;5[EWJ%)/L8_^4:K06W.YLQ7BG7CN@41QC@'?JRSZ5'C;\:+O M:>B+EVC6!\$>.-0RK]'V=SAQN&?^1$\<[GFK9\JK^7YZHO>!,,/S#C`K+\IN M`K$]?EC8Y&1HGQ[WB3=NAS>NECU!SV=9Q%XG&,#_V($JR6%P#-.^""J7/-:5Z%T.-7,1K$;"$Y3S2N,VDDCTFS+S/ MJ$U">BH))$#[5&A#F$RK?=E/K9?.\V;$FL"Y] M[OQT!^8=^%BOEUAI1*#?'0/CBZ_JH],4,"OW23QD[2(KM#R MQ+T(H@D=,4N`^R<)`(39CK<^7HS\%GQRR*4Z\,\TCKQLB&4\^`%`1435=^,L MS=P@>&30/"N;(#Y%?(^(/"!#1EDFV5DZR1./\Q/BR)!DK*LT7/.:;J,Z'AJK["8&2A3@=V*+A9O*9`VU/ MHIBQ.$)>X//O72H[1M2^[/7QIL\M;,<48_Y;\-BP>LU!HSDP[]_85B*DW?UY MBB0T,Y),0MYL<]"?XE\,XP,\N8EL+X^,`WZ(TT?X&S495RP&1-T8:V[O?#&R MQ`\QS'!>A#Q/?-1/\RJT_ID!H[/Y\NTYEP^8>]EA`Q#X[`U`F\E[<(,("(K> MI@1AZ`6&"!2''$GT%;ERI;3J-3[6D5]'7SDAJLCTCD:17`'B(HP1*2AR@L($@D6.=(E%<1OJ1Y/?+_5M8!\TCO0RCY1CX09'4Y_'FA" MT/7+55;FSFON98_+;3(7`T&\&G'MVD MKM0:R1V8L*[&G=>L$)C"@+`.;\X1WT.S/@@2[16IM0Q5J3#*"51'0[]"1S-5-_4!UD35-:P M9[UTG$ZC;P^.^MHVM:5>#CJ-3J^#-^G*/K7:5KGAB\?UP5(>.(V!L^QQS=&K MFMWGHU>IY#=[L.@E3;,JEF?3&,W9$IH0B%SF7\_%8PGHO,AN,^`:CJ.PZ5J) M?TM:P4T4`K^8L?1M)2C9()..F%RP*Y=>N9I+KKDI/6&.LKC$T^.0GIH#,>7W MR7534E>/^AY!]](!\_Q-W$2H7+N321S=X[W5XNO(CTP%BB!J3YOD\BK+ M[(8Y;I3%5]8T'-!SW'0$2-&T./*;*].:&;TC[K!$"BH_GEP1E])8*>,>B>3O M8I(R%6C1A)(\R6X2\=\,/S>./!^6(G6:`&"CK;=F.W9E:GT6HMSS<(F:%VVZW&H-.U%*MQ^7-R=,9T!&Y1;.&HT6SP&#"LA'292E8S MD^E:X#:F'Q;02#)20!>M!@)& M6VP&D]`6V^D6E]YBN]'I#AK]=G]Q4@3H,CR,D2[FI=VV&ZU.\X3@BL]D5B,T M?/Z]1F^PRIN9HY4W'?6.^D5/1/$M3:F(ST>Z;.,^(T"T2SRGY#X[#:=3RWT. M3O>YO?L<1D&`_@[0"!^M;JO1!7W#=NS5+\806%()54W:T:L%O++A-%O`+=O* M%X]C?B@"E9Y;F4U3N+5^L]'N`IK!=*WCI3T#UU%-EZ-][R4.561,1L8D MW`@[AT;BR!U#->&V-^T,E2AN3?$F8G[:&43^MOT%:G;@$P@@1.-)R_Y5%Z$I!)X\:_#-^87&@@),LHD0LGC)\-8<)1O#*<8NW^*Z7`O MP01'U"3S$^Q%7-C,K,NY\#0'GKH,]IWJ7+O\+V88!5XTIL&B-^FH6;$N1<1_ M^/@/W2(8;W2F0-'7!8I'7ZIX76`;W$`[HXG/90*[AD@QK%*`MGEKS^K>5;']P5Q[6;/TTYW7?.<3/R:- M^F!NO:0G^Q8N/=A)`[:]T=LAM%TYG>B03K0&P>]^XL!B-E)HRU77L(%ZFP/- MKG]@?=17P'!KT&ZTNRN/--OBD?=X/QO@KVH'[%W?;_.\=RB7>YB+[>PF^C\! M[VKOYBYJXO]3\[Y6EDD;8&G=/ME;X1S'T)AV!9ROW)/V0)OT'3M8A[#"WE&S M.Y7V")!U`NMHP3J$%?:.FJ>KW]35:'J'^LY3[#V]-[;S* M84RC_-].NWT^<%YM46@]7=7JFY_\>3:*,3-:116?&^W8YZTV90@VS]OV$Z"2 MU0-,_>96W/?O_7OL/5C5V[BCD,6@3D?W8%>.[JKNQ&?HXYZ((2:W!_Z(F@0\ MF"E/>[8!#V%@=;3MJ-ML2% MJL(U.\NE)G1>%]9AL&KG1*X=Z`2]K>B$JYM?NX_C^6`E4+'67FZWR[2=N;;1D>@5GK2 MJ-F_'?RT=,IMYD'LSF#>@;VB%``_I.9U)[NE@H>F*AM\'B;Q`?GNGA@]G?=[ M]5#4KJ3I5DSIW5J%%[)P]#%GAGGMJ$M%RR5M#U3W0NZOEIB=?,%`\B,JG0^Y M;4(##!NRX+!F!INX@A5SLBE686A;RNS:>TG':86:IE%OP.>T(^S?TIDPY?#: M21K)WBEQ#2UC=X_R&1'":85]LH`+Z48\<8#GS0'V2`>G%?;)`+X)G""'(U$. M@P7LFNY5K_N='/_$<7+,SVG=\;18SHYQ-J_-S0EI"Y!V&7%[_/^X1] M*,/$'QX1CZL#+V;B1R6L5&Z64]X3]$#!>O0SGJ(I+?&P]PL"ZWC/(G.5_5# MN&;G([NYN]9'E9,MGF1?JYTAU&ZJ5.036FM$:_]\X!P(0I\AEVCODJ)KDDY[ M2-"2)K]UBX5*E;MS/9%DJB-IA'7"U;/'U0DQ.[0$ML=MQ9K=$$_7?^(A)UR= M^.T3Y+=[U&V'Z'$)`N$!AN*1\*OKN:>&L7M_'2='ORAR(V]Z.G* M2U\VPVTWHF,#X*NZY@Z"$M=PZI\XYA9<^B>DUNK0WYLD>F[\8SUW__.P@V1B M,15T;DVBK=)->N]$N?MNU,GK^Z[ M0_JGV3'CV$$B;^KG!H%/1BG][9T[!+!]V.5;!(3I#Y,&0?3Y\V6QD:%/P\QA MR:MA&J'4=P8L]2U7]2?%CG?N\+^9CXWR)OA3+V].*#L0RLGI=2>:OR^O"T?]_USD[RQ'Z_`D]IQ MC2&LD6&/-]6E$0#'KAW<*W`'K?OJHJCMM]Y803'=HK]&S19M'62?OP5054^^ MJG4Q9VUN_[RULC801@^Q._G["_[OB]51L`&$M3;ZV[4Y5D,_OU-H#W;VPAJ\;#M=%(ZC+%8WOU"DGEA7 M69JD;NBMU;ZF!@%WNID;5L8XO]=:L^W`Z29JOXGW:[4T>E)&A?*K])YRY>J> M!R?LS,6RJ5U[\)@\7U=*]O: M"AN@IVJ0?$>Y'^=-I[OW^]J^%KT;+7F*5?2/4BO>6C[='JHWGPAKW67,YAA0 MOOFB$\@80(/M32HK_>&_[.;DW3N=O_S4Y:?O:! MQ!(_O+VXC848PP%5/L80((:O?!.CO[_X&$=C9-=GS?99TTXC^K?MG+7L%U86 M^ORAW[^_?V%Y8N@#;A/,9?C'F6VW!OV._3\_+=YK?8ALA,)VM@O1A7>/TNLZ MNN#L^Z]^D"4?0A'?/GX.AG8!KHOD:K0J+#U@S$T)R9(]-H>GV2J!YT?BOPW] M`-YVG(D7UD^%;=Z+D8ACX7WT0]@.D'09)6FR_G'[G7:K+8\[9^WU]U_U>/_S MTX^;./#?XO_"C_\74$L#!!0````(`/.&4T2=-JR@<`T``):>```5`!P`=&%U M9RTR,#$S,3(S,5]C86PN>&UL550)``-:*`536B@%4W5X"P`!!"4.```$.0$` M`-5=6W>C.!)^WW/V/["9A^UY\`4[?4FFLW/G8&[MWYZV/`K*M'1!N M"9QX?OU*&!,,"(0!2^F'CN.HBJKZI*I2Z<+GWU]] M;70Z$CQG7D`L&#-$KAM@;P,XOQ_F8&@.^N;PA]G_.>R^+-AS;X#/6K$OSWO] M0<^\F`_,2_/#97\H^30?^`&-G]9_^=3O#_K]X<6._+.#\)^7_+\G0*'!#(GI MY0M%5V(S-[?WR[GUDKZ((.PMR@%CS;4W$N>73F MQ<5%+_SKOFFFY\]B)N7]H?0QAK`% M_ZVS;];A7W7,06=H=E^H?;8W?FA!XCGP$2X,_O/[XSA^*F+@=BW/[?$_]!@X M@0NQ/\+V+?:1O^5($3<4E`D?P'L$?]PO,K3^=LWZ-D7N MVF'&Z!TAX;6'J>?8B'4Z^PMPN%5G*PA]6B9>*6&+LDT!889901]9P#E:T%PN MS4K-!R/D(-+)8K+FGH6!5\FTQ1R:DA;9Z6==`[JZ<[QG26$E&+0DZV0Q\SWK MSQ4S&'/--W"!+.0?)70AI_K2/S"_3.!D\26@"$-*V;C^ZK&(Q62Q("EU!Y+D M]>6X$6"SP)7IU?NL&QES"\?`.ZF\E'5DI81-( MNB[R0Z_.4&#`\`',TFT)&#U" MNCNFVC??'R4%*B%K32YI:&7I6QP[DJ:4I6]?4K.NJ.;I9!W4E75P.EF'=64= MGD[6\[JRGLO(:@''"IQPUG_/?C^@@"\^Q#:T]WRXV#4*4>QK3M_O]TVC8^PI MDA\!MHT=N7%`WXK(Y06F6-X!$S*>QK//25(CHC5VQ,:[[Q@$-F)_^75?T=L+ M[GC6@;`.+REZY!#G2-:P;K@`]"DL'@:TLP1@W>/X]Z#CT_TW88_H],VHAOA+ M]/6/G:N]#@A)S+H<\`2=\+$_HG:I9CUU`O-RCEC.W5_3XB4ZPHA8AD?82+@Z M,_O]/2-`K(,.D"W(1BUZE"?#G%&'(>?NZ1?$FN'U93`-4#V[OO)\`,L'`U%5+I$%>%H*%=9.YS24^Y2 MAR4DT"6D"-`I4;1!8++3K_GH^]61O^`QK[HTL-OH(G"(GH+<8DN7VWK%$QBZEDC/Z>R5& MEU2Y2>,WXWKN$7A"CEPRF]=6H>C)!(I5U@ZA<`LCI+XL0J+VZM,-:82*5=8.(=:A2`#M*NZY@$1]OE)E M)!4KKBM4;.:Q@)1O!@;.'93'2TBG/M^I"EJ)";1#+KVK2-8=EM')(?=!!^3D M3*`=6V5=CK7]7`H5+@GOZB;I5NJ3UC%AL]TK'PUM>M*(]M&?NBR MI@#98WP-UL@'3D+^`A22[ M[SU=2I"C59^]EB-301U=2PPW<`,=+RS"SGRPA+<\$U\31&&D35*_@""\3%.( M!V`3O-4GQ](#M#E3ZM=-$J*':\+,ZZP)7$%,T0:.L>6Y\-ZC]`'ZD\4U2X-:=\RJMCU51M*!AH:*? M>VD][]GO)]ULEG](,-YY-JRR\^R`UZ\GV#97TBC*B_VV\="2=6HY10O4,4@I)R#)(V MT"Z50J"8`VS/!PJ[EUC;`<6M'>+"WP]:+)( M+#33=.$ZNHUMPY\ZN4UF4LB MXS6I][EK4CL6J34ISL4(V6BR)L5@X#)-B;=!S$!?MM\IM,CB6^,T@VR()T0JX=@-R"(5>1C09E MM[HX'V6X]E2RLEMVQ!3JS_S4]ME5C%3^T.5)U03G%PB MX[U/,"A%C>50^:@E*D5Z:3K0V,R30,!WH^]^,CVE+S"3H96#\Y.6<%90\\V@ M>WCW5!5LTY1RR%Z\+63SS?,&<$U=9U`%V`RI]`S_34$KL-`;P/;673O>%L)H M@T)B"W\5F(NX2"*N=5'G&+N]`?!3MV`4W@,G1RT)MM8UH2IV>@,@9Z_0J.C` M,]22(.M=$*I@IQ/4@432I._0$!6'Y.DEP=.X9%355F]@C-X$<.X=OCY(XA:F M*EPD8=>S]'24QIJ"+[#";F]!O=6_7!XJ5__`-ER%C>]!_`:L%<*0;)-7L1:L M#$K2:[MJ6`!J>M6PDJE.<&OG-"#6BHVQR2)]2ZOMN0!A_CI903"2(]5V\5`" M-'DM%>`5O;6O%)RXG;;+>Y612*FN_');T9I1"9&VBWJ2@,@9Y73H\+6IQ&NU MDT;TK]]D,*#!+?E%TC$\OEH78?E@6A3?E-47EO2LW= ME26@T#;;*@`NNT>KT!S:31J2`K]N99&ZE$Z"5-M4[#A$"PW4?BTG?*TMKT)0 M?FW>!,^`4XH5)Y2@TS93DP!*4D5=@\4C7$=3M,DB47#8"G8A1&3%5-KF>?+C M3L8L^H&9]!:ID]9RCC1#I&UZ=YP+%1A%N[@8:@P)\NQT;5",8Q&-^MRF7*/L M>9:J555=#[LTI'K1C*:&ZFV&U:94+QKMNHW=V\4"6OYDPD<6/":8 M:S7"-O_!RYX;EB'@HC?$5>.B/N)61OH8,VE]L"O:@A]=^!C=5!M+'I_P^B!U MPHL?\$JR^Z>QNT'2>!;A<3>_B46=I*.H]8C4]I-09=(^(5 M8O'*S7AE9[SR:T69[`))+.]%6MYAU\A9.FI4G/2"0$8JLY^6ZKQKO%(9Z==> M-BI=5"0?+0F$N38SS;1T[[M&1&4DR-JZH/3@#11L7.56:&)A!VEA/W2-!!,C MI`Z'U>Y3IH[5J/B':]%9:8=I:3]VC8C&B(G:&?"B]\UGA3Q/"_FIJ\;)AO6" MZ,`]YO=C<6<"<:YG,M^GI;[@'2%FT)H??:+P9\"><+LY",&Q7!\RCK_/7>:> MS-C3*73S0G=O9J)6)7=OO-M_:JN'Q*Y\?KA9/E8@$Z^2_M]XMR-K2[IT(!`) MF0E2>>&@;6&%#D(@]2`3Q$K=1-LJE"1E-]`'R*$/_.0G7[W*JI2)?)))&E`U5Z#+-Z9")M!3V&JO0X MS^J1"<85]#B/](A*+/R_)T`A^^;_4$L#!!0````(`/.&4T2B&L(J,!0``($D M`0`5`!P`=&%U9RTR,#$S,3(S,5]D968N>&UL550)``-:*`536B@%4W5X"P`! M!"4.```$.0$``.U=2W/;.!*^;]7^!Z[WL)F#'I3L)/9,=DI^I;R56%Y;F=F; M"R8A"3,4X1"D8\^O7P!\B!()$B0!B9*=0VQ+0.-K?(T&T&B"O_SZO'",)^@1 MA-U/!V:W?V!`U\(V?#K[==49W9U=7!P;Q@6L#![OPTX&+#W[]]]__9M!_ MO_RCTS$N$73L$^,<6YTK=XI_-J[!`IX8GZ$+/>!C[V?C-^`$])/__N_*]>EG MEH^>(/TT;/7$&':/;*/3D9!YAP//@HE`M%@$+GX"3-Z].1B:@[XYO#?[WX?= MYREM]QSXM!3]\+#7'_3,X\G`/#'?G_2'DJWYP`](TEK_^6._/^CWA\=A]5\< MY/YYPOY[``0:M"-=#N>\_GO1Z/W[\Z/X8=K$WZ]%J9N]_7[_<67.X M`!WDL@ZUX$%'Q_W^+=QT4S)YP?/B=L8]F(XB63ZK>TG%=*%CWKA ME^FBJ$!T"C1!)X1K\@5;M/>9Z90B,H0EV%^=N%B'?=0Q!YVAV7TF]D',$^]L M#SOP%DX-]O/;[572*J)VT+7PHL>^Z%$>@P5T_9%K7[@^\E\8J=Z"`Z7@N:2Y M!Z>?#GP0S#K,:)CQL.;^*5/7?WFDPX"@Q:-#.Z-7`^$9=@EV;$3MTSX%#NO5 MNSF$/BF#5UI1([8;X-&.F4,?6<"I#317BEK4;-Q"1B(93\>/S`E1\BIU;;$$ M56B1O=[6&2#S2P?_D`0K(4`3UO'TSL?6GW/:8=2+G\,ILI!?"W2AI.;HKZD+ M]^!X>AH0Y$)"Z+C^C.GD1K%8T"MU!Y+5F^.\"Q8+X+W0WD`S%]%.`-0'618. MJ!-R9S>TVRP$2\VBFI3FJ"^^!^B1L5@&+%.P>=MT+0'<&7IPX(@0"=F-#2`2I3O3G.6^@P M)T#G`E_"JO-+*QAS*U4Y.,6U-(Y4.7B2 MU;6O-LZA#Y!#KH'G\3UKP]6'2)Q":XR:D#;'M?+J[5$24$DU;;BDJ96MKW'L M2':E;'W]2,VF4,W-81TTQ3K8'-9A4ZS#S6$];(KU4`8K\*P8;E[A-`)!5"L. MKK%PUA$'-J$`I:BC='XD4Y/H]6K07E>GE"M"/.VFL8^,% M0!5!9VMO`#%OJ;.`BP?H582[6E4_5N`XU1#R"OIQN=@?5846U]FH3<(I"!R_ MME'&U5@W/VT8=WZT.5%B M6$6)%5D;4*0D")TH<5BDQ%*(@:?&4LRF.)$)42>:'.5J$HI8TX1),;B8+6E2 M'+=.5'HOI1+3*"WN7T:X=#'>18)_BL_!8LT<;*VHX["#..SE^E/N!Z>`/'!G M&)#.#(#''ELU]:#CD_@3OH[J],WHY.V?T65[+8`^2<` MIQY>E/9GU'>X4(-T!U,@!P;VJ&%].C#[2RP.)M"F:V@OR%%Y&RR%1G^&%X_8 MY>'+9R1C:_G5E'*8N_8NXVR5"@%?13KGT+=5HM:PGDA%!@N)*BQP+*.`B)Q!?^?9N3=S=%!%4+S6;NH+FS+(E121.*Q+8C84,1E]^WQ_';"M M)%TMS.GRD7R--I894EC9O*+WROE8W>$*^KK8\G$YYG8ZL)%M\WX#S@U`]I5[ M!AZ1#QPA*U&]PFH:AHPZBJ05$/)5ES#!<(C6L\"BN]N`'^LRQ1X]A#V<;$X* M1TD%"?=Y'KDMU-3113CS:&?)#CSDSNCNUX9/T,'\L(?X8`8KU)U\NVGX5\R,*I1JW' MN@,.'$]9RA)V.9)O+FWFQD-/%/Z-`RRN0Y(J1T9^OVOV;Z#'C2>T(($C4R&Z MO>PIU5`X/[6)[-&"96%I(3L4O<]DIS043G#;)[M_I&UDKXO>/[)S-121?=0F MLI6/['71^TRVQ,A^KY9LMF)C)Z-QU(?#90=;@<.29)=`3Z'_`T*7^:&1:],? MAU+#6YG\=M.N5DT1]Q]:QWWA:%CBS+"Z!]\'CV'#WX]ILJ%[`Y5DKH(N5(IQ0)#,'Y< MR?T5KY]2A=O=]P68A7VL.&9U#?TOF)!+[(4SWB759/3H(8==(V0*^KJX4KO[ M7`*[L.\5AY#RH)Q#BVMI#AB<*VH$%JGXLA6 MO;.U":;_ZSNQRF^@O5:B04\A_XH#7"I@:SB>SFM@__F76&[7SK07Y;H[@].(96@&[C&$\G2*+I<;O%=#6UA&0JCAO60%EI3$O+VSLR94;F9G/98N>2VJ@,CF.XY_S) MGS`"QR,:OT'"LW<6+*SQ%X]YJ)CQ&S:^6V:BL0^$-K79'+G&*JE8(31L_'7; ME(R?TIQ[QPXH^8GE&8`^O**_$G_B`1O>=4===H(9ZQR=<"9[JHKKBD:M[):5 MJ%!6:`Z:,_)J8Z^X,FG4RBLQ!PGOH/J2B;4$(=9^?&E[A0!$12GMIK..,D*Z M]*:WB;%)I^)(2-D3NF1&E^IG5-E!1OB8\B7V^/7ZA"$E)8<;Q2>"C82VFTP% MN@FY5?U(:DVHQ:=]C83N)[]I_+KB-XUHZBIH9!M MQ>'#9H"KKV@JBMYGMF7&MN8BN,5Q9-R&WFG,'9:%6',-5A.XGMS+C5G'T\12Z_*Y@X"S/-BXA?Z-G]$)C M!OZ/!+R`S:IBVLU?+6V$C&E/[*-3PXCP-P&[LU/L!D2P2N0+P'I9WLT::3?; M&G05VL(FXI0UH%=?;=5NY'78@HPGWT2(<426E^RD;]/AES,VV%I5D;N3C%=4 M3TBR_@0[6;1UQKB\W+TE668DZT^;FV+1W8L<[7N^_ZL]M=>1OG.$UU921/N1 M_O!8-^6).])C^3*&G$2 M;A4I[::SCC)"NK0_0INZ3"")%Z4>^`U#]_T/-9UX+>GMIE>EDD+:M3?J>TR[CG#6'WUBJ,2!SCL[DZ-[7&M>ECG;`T7ZLNRVJ)G>W2*VGGI!D_7$O6;15-SO5Y.XMR3)O M9=(?Y6)HQX_\1<(KE^%$:(^;C&1YN3M)9\:P]=A5%VD#\ M-L?&@[AT:CS&A4'%OBL6UVW3R_;&(0/L(1 MPCU]R5W@3S`+DSGH+_B%_NF2S%GG8=E%'9H:;+/WT;2Y%"ODMB=8[:Z=D*&-4>JY,%6';.5Q.XKPS)C6'&,JN")K96W9@J8 ME*W>;L8J:2%D1G%4B5_+E7F;S\DGIM)T`&OI`$U1E"BT>`/`9Z/%WWGG?0"CS:9>(5A%3E M=M-100A10D%NVW3TNABSLX+IQ"S5O4;V&?OB&3O:RV!P>HG(K MQ=I+@1"ML/=3(89?>FN*T&;^C+_+^6I%*'SV6>ZZ'3>UHC=:!&Z7XNEQ9:^C M1<%I0*@>A(Q<^S,.$ZHMZ"4S@X]\)J+?[W\P.L8Y(I:#":U(_S"[1BC$P%,C M%F,`US:X(".1U-,`_RY8+(#W0E>F[+E$>K\,==HU4<1UHKEP?N#.V2!P1 M`OUL'YK]=5"'76-9RXBKZ0`71MMA$FO/@C/7P1UUC:B6D:JF`UQJ?7V-?_8 M$;#C)>I%H)OKDLRC==#'S`H2`;K\YP.!WP/:P,53^A;I):SW&7_?9ZXRKF;$ M];;GW85>WLS,596\O/$N_DV3>20>?,*&Y+&,:VJ<#`F?IU7_]/7J^IMD=NME?8J%V".U/![X7Y*B\099&/X!G3V@K MHV=48%MKQ91R-*=B/2MX@!WZ*4N#6H:4Q9RL=C4N`BND8[O#@YUPG:X'^$3.EL+5[4WD8=FE-<`H"QZ\]#6S+W'B?B"RN]BL5U5A< M=!;V=27(G365E6+W6XJTZ_0$N%C='9UY1!TR?F0%R3CP"5WYVW0?>!T4&X#R MIN[SWB70IO,:/1J+#&G+\\[RY7CI]TB':3[\RTBIBV>ZP$-DN;7+VP54E=5^ M4ZBGTMX[C=\AFLU]:(^>H`=F,-:>OX5@(ZZD"$#[K6J#_2!<[[;;%(4S^MIX M(U=N."0U6:12'+MOF.J[0[@Z5IOHDQHR"=1'Y'']SFGO"')^RJJUEU%I]"(" M4KF?FTI%*0L)F]F8<.9P4CXF;)AO4>&WJ/!;5/@M*MR6M4U;0GEO4>&WJ/!; M5/A51H53,8VRR'"FZ/Y'AW-5;N4%!8MDVPVZ+BQ`\&:- M,FO"NO>7M-`:XR7).7I"-G3M+:P(TTV_+OL3]H#(\.K>V:+0\#(W_F1U?ZBB M^P1Z"[/$XK2TN1NFID]UD8U]:%]FQ"";&9%Y]+E"9L1@2\_\#;-J9)Z`KJ#& M<$MJ'&;5R#PD74&-P[<\E;<\E;W-4SES`"'C:70P,_9N6<)@<]X":):GBRBFJLVIVXHY%-/-H8@#3D"0$SAN3PK MME9J2WD5,F,`%X)NIT]K^O3%9ZYFG.#^V2N\J5!#8_=Y?J9UVS(-.K?4G+;[ M!%WKC:&>2GMVVA?I>(F]*43L3B9VO]/R88S$V/4YDM*FVV])&^F!/3OMV[5' M-_?="*OTPXX>]94]([@ZO6_IN4UY$+MODHK[8D?/_/;SB>*]-\[JW='BHT&= MJY?MS.N-8.V^]6KO'8DS2!5QJ;CA@D?ATT7:2UPN4E$G?BP_R(T^9_^Q4V3Z MR?\!4$L#!!0````(`/.&4T3]OV:-T4D```Q$!``5`!P`=&%U9RTR,#$S,3(S M,5]L86(N>&UL550)``-:*`536B@%4W5X"P`!!"4.```$.0$``.U]>W/D-I+G M_Q=QWP'GG5C;$5*WI/9CVC.S&]5Z]-2L6J63JNV]<$QT4"1*X@R++),L=6L^ M_>%!LO@`0(`/,*N\$S&V+&4F,L%?)EZ)Q)__\\LZ0,\X3OPH_,M7IZ].OD(X M="//#Q__\M7'^^/9_?E\_A5*4B?TG"`*\5^^"J.O_O,__O?_0N1_?_X_Q\?H MRL>!]Q.ZB-SC>;B*_H1NG#7^";W'(8Z=-(K_A'YV@BWYS?_][WF8DM^YJ?^, MR6]YJS^A-Z^^]]#QL8;,^V@;N[@0Z*_7VS!Z=JB\3Z=G;T[/3D[??#H]^>W- MJR\KTNZ%DQ(J\LOO7I^GTAY].WFBVECKI-BE:._GRQY.3LY.3 M-V\Y^Y\#/_SG3_0?#TZ"$>G(,/GI2^+_Y:NG--W\]/KUY\^?7WU^\RJ*'U\3 MMM/7__WA^MY]PFOGV`]IA[KXJYR+2A'QG;Y]^_8U^VM.VJ#\\A`'>1MO7N?J M%)+)7WT%?4F3Q/\I8>I=1R[I4HJ'UF:0E(+^UW%.=DQ_=7QZ=OSF]-67Q/LJ M[WS6@W$4X#N\0LS,G]*7#<%8XJ\W`56*_>XIQBNQ,D$W_'9[VDR!N!N/5WBK*H=T%]>DY\J MBN,O*0X][.6J4UF*`,>:8G$WDUU(C]R*W(`&RRBN]DCJ;!^/Z6!$!R5F[W+V M\?VGF^WZ`<>+U?V3$^/D`Z;_E3,RK?_RE8+N=5T3RC&+>?7^\D=?GFF;9,TY63/#!UM\GQH^-L M7E,LO,9!FN2_8>@X/CG-1L1_RW[]B5O6S]](0INR*0K3)/9%S^I M6:O)8P,W1NI3#&DQ3(XG$RWKV.*D:$>+?J74?X>!LYGG^72.YP2WCN_-PW-G MXY.A2QB3-'ELXDQ+_3+.E`Q@<*:C91UG.QY$F<@*!F5L?9$F&<4N\,IWB7S7 MW:ZW`1V+Z;?9D%E;'&WHDH\HHQCR9'64>$ZZ#()J"0" M41F("4$[*=8PZ&UC/WQ,G["'GW$0;6BT)DO;1VR"Q%8A$^)1TT`%*ELD0,6F MGMHZ".62$!&%2K(0$S824&>[YB/2;NQ2/\-/.$S\9^R'Y#^)&HDB7!H*L`;0 M3H85X#3BA@',+BHWQFH]&2-A\=S!*9Z'SSA)9Z&WC!U/$1P5Q-8PUJIP@2L09T+\[Z\V?ZO]'3`CZE8L9=%&18/?58_3\VL,^7T^0'^K+ M"/*K3]?XT0DNPY2L<@2+4R&%#>0H5*-P$?QY47 M[&[I6'"L7DTH.FTM)#=7+"TD%^>0XTM>Q$7`H!RI84,8S2GSICK([ MS(;.6R=.7TC\"Q-ZE$@6&>]>RG]1[)29"+")07/#RI#4YP:#4&.5ZX#5$P`J M1O[BQ$315!D5:S0V,2A4KPRS"@$8)(FTJH,EHP$6S6:?G=A;DE84`:M&8W6+ M5:1>94NU3``&#R*M&LNPG`94?&"G4(L-#6/*&"&@LWO$(U&S>JQ3(P*##YEF M=8R4Z!)@@>,V]I_)$'<;."X[E%*B149L$S)JA#"PS\M/GN'L`9F[,Y=-9@FQY.IIHW3U8P5$5Z4[4>7 MN*IC2'7[#/+B:S=3"A4C(_G1#13`Z8%L4:R6\<$CM:=J5B M.EB<$ZS&3C`//?SEO_"+U+@&G5U@2-2L(J-&!`@:8LTDV,B($:-&A'P*=.1Q MC&X&"L` MJ!"!0H)(,RDD.#&90GCLMMX4Z)@113RJS%7@/`KLJOW=%AJ$:N4HJ/P1Q-<7 M:=38=\]I$"6:XEN?;^.8ZN@GKA/\/^S$\F`@)[6%@#9EUT@+C=/@2^>Q5$3GTS7D)C%PP"]:I0*!$``D)3*PD,."%BE!.. M,>P*/#M&YA?F%]N45?LAL4L>%I5,EL<;#0-JHXZ"`Q"0--24;:V6RAH<(O6AA6V5S,X4@8HI;)87?FA$[H^\8`H\15) M"&:LDQ16T3!&6%]%P3GV#`YMQ)GB2V\3]93;,L*5/)J"2_!_/)2\HT+]PG3S`^ZX+6A;C# M+O:?G8<`R])KFV0V/[=,R?*GK].`@8%$L3HD&!F*=W0P\/'!B?^)4ZK0/7:W M,9G=X#R*2>Q5./XWN67#0X3K(::A-;N73.%NM6K9@)",,!2:=>\:,9H$>;$ M,&!3F5_IS,$FG,6VSEZMPB(MU9!N[S8))E@A:N16)JXP@''+:@RF+[=$7W;U MX+>MS^JPW6!Y6%&QV(TN[E22D8$8FM7Z-"HL^Z1NRBD+. M8XS9B5)2S'&<-@.0ZW2+E.F&)=)5]005Q)*9=0D)9.U[[SX`=L;XA, MTUEZSU,4>#A.^&,3+=-[N\N;);J>S][- MK^?+^260,\R;*,7)K?-"MS+5HYN0TB;>%*J6H24@`X,BN6YUP#!*M.&D,*!R M'H7/F`RC1"%]U+0Q63WKU#*@<@JJY``#*RTUFT]H%4PHI%R['2$_<:,MF`)& M,Y=KHX4W&;'5J912X#*M2G._UN`CH[<M_"@%?I8N3/3K"M%^^1D]G=)1`K6=T7J-*`@8U$,G1FQ]^.#IY M^P-R0@^=G?UP]-UW;X].?OP1^;1"B\=^'>TNKR(G11?89963T9O3(T11PH@^ MD-YZ*GX%`ZN2%WU+'2R;3F@P`GAQ66"(QK/+)2XPF-=65?$`,TW#//9#Y([Z M`'/I%$QNQ[C%&^(MALB>CM4S@4KO<%`8\63H2@; MAL=Y:7F8>'>Q>U?WGCZK>TEW8HBJ"XZWSB%QSR$$VXR7PW5$.9[V MEPK%,0:W2,=QL@>@!W_\>;"]G5QCEB-Y7GX=>,Y>![Z.DN0&IXO5TODBWX
+B;7M(!,1<.87G?16H9H](8TJ;TBC(9Z/'FL30'N-.O6B7V^Q#VOO M2*J?>.\HJ:SSL_@(`SAM.3(=4VM@935UR6:"!3A-;<7PXUN6E)>MW)/.NT[[ ML!EX9O7#/>/X(4JP6:QHZ-K8%UPNSO_KKXOKB\N[^Z_1Q>75_'R^A!$O2BOT M6R=>Q*P4C,?VK6YQS*J?M6]SR3DGVC1L,T6RCRAC`S,-TM=5<[<1'`AYO;U9 ML MJZLHOMJFVQBS$7SQF>B2//D;T1&P'I^UDW<3,XJ#=QVFR?%DJFEC4%QO'#_. M*PD[O,1`0FL,S-?K;1@],W2AHH4C1-M@Y=M6K!4^-4-1W@Z,X'=1*L\C/8DM MD]@]*V\J5SWUWOU]360'Z15+W< M:U!-<6E7L9RKD4#+YA.KU]QXXE2PID#ST-NZV.,%#>A5O,6J5-S@`C^T0D>; MWRZH#,VJPDV3&1X0S107CJ!DDNX6`GB1TP<@25+O'3^D.MYAE@NXC*[]U']D M(_T]3M.`;>C*MEKT>*UN;)F84]G>TF$$,ZZ::-O8ZB*\%)%)04@1&3B?4;*% MDKHW*ZUO%ROJ91=9$9C;&*_][5K2+QI\5K.4=]PRO"([\%-UIK4'QJ@"[3=;0>3>V%]_6WKS&)V3$AI^`"Y(?+ M)R=Z5,U4_#R'=NI\-UR4-O^HO M&MK:<5BS5#D8H>B-/'\G')!3=;NO#>^2=M>;V>"N8[>?J':_B%U>IX*?>PE, M;$&EDL-RWG^;ZK6T?QDY+.BU*RK(_`=YT?_2B4,_?$SRZWOOG,1WR&-E6U#WSQ03I;&YG%>(,'M%S)Y M?R+JS)YQ[#SBFRVM#+=8-2[4M&RXF(NQB="N1I8A:RH##(8[*EX']2^7\_=_ M75Y>H-G/EW>S]Y?H?/'AP^(&W?]U=G=YCQ8?E_?+VMR&@>[BVMEB=>XD3U=!]+GM?I>:Q6[-H';E MJ]5!Y/1@4*>A9+-<<'YW,%HARH08%[B;A&0^0[6[C:-GW\/>NY>/"?;F89%1 M.W-3_YG7LFG)0^T@R/+I7T=#:T>$AE+`@+BSZHWEUNS^K^CJ>O'+/;JZ6WQ` MNVN-L_/E_&=`CZ_1)P?\5'$:72:P_%IZ3;':V^C97\&`IZ$2[,/GW8%$LHSN M,/TB?H`KA^C+:)BX-TY3=@M8C]=9U9+7P[<#QD%&-*Y95KMHBMZ^C//&V/-R M;&^"_-:E4XY-UA9Z>$'?;!/V_M.WI8M33M%D[^?F!YKZ9ALQ-#]Y35.;5-*#7;XL_)88"(5A:B=Y/)LI#J29:!OSAQ M[!!WN8KB>QP_^RY.%O%YX/AKV<3`4(;5:PM=S*M<73`1``:@7;1NX)8_LY$] MG^&':)=;CF;YJ^8CU4?8'=TN5K/L\GS-5`6=M?H'*C6+>@XF<4$9I+>BI52W"FYAL7EY7B2X+1M\\>`WW+A1C.S:J4< M]9@GQV-7C9M!B_.A;_Q,TK=T<>`P7K!`I0EV=]C%_C--`94N9#48)X:FQ)`6 M3-:XH+TDH*VQ^-)*O*.#"L#;&--7_=I*/[2Q30L^L1%JZ%5YX`-/J&\==AD1 MK*6#(K"7'UGI/$8+A0`9J!4&:H[6`@G[,&3+U1:4:<[&;0^7QFUPKWXWC9VY M?.E_Z[S0&*_=20V^:<$J,4.-SQH38$B*-14\/,>H4$8&%7.7ZTT0O6"!/.J4ZRS"9;UY#16*F9Y>P*6*=?."6&-,Z=M?X`(=' MJ;(R"`ZT]I$=`,L4I+EU.*&;HTYPA26GPOK,]HZ*30W:G1_K>&=>_;6._&O02:\IIEN0J37$'# MEI<%&>#&C5(0`!AK&*H!9X44,/&WL^IM-V[F-S]?WL.\<>.\9#GP,_>WK1_C M#X[[Y(Z,HOZS+;/6FCI%!E5L\6IS0ZA<9:=TX1"(*/=$-^6B% M"MJ1EE-Y6XO5/$R)$K1Z.3_M]Z*UXX.8LZ.0\(^.LVO?E>78"H@F0%!-00%<,@J@V*AJIP)"P"G'RKCF MN>!%"+SU@VUR26+@X\MUX(IL:..PEU6MI?HNCUI)#@HF6JHVK\HQ)IH<[7`V MQ/@09SQ"U]?GXX*(9G>7KA.4WU\T>"2SAS#;T.MNR"NIZM]\Z=R^V;>1Z*[=M_)QM7[9MKOR0>.4`VS9*00!@K&&H M!IP54J!OV[2KWK9MBAS$D-=&T>`F8L=.E-L99#C4Y%SY]\O$*77["[9;/1Q6I%%N>G>5!$*RN.Z]+)'L&U$P^S0YB,P` M?&\14I"K0I8ND[5](&T#BOV>5@XH8ZB1MH(J]1D?8C>MZ(NE60!S>0!+X`0P M_350[T44U-5MOU7M7FS2R/46;M*4R\FM!Z9`DNZRTR$U?<8.AA7>9S!@!_,^-U!Z3I^LY?,4/Z4 M&2H_1,;EPT`O2SE$Q6'V.IE7QRFLT4FI8@;-53U$=W+R*!'I=NYE* MBW*J8#;RYY%]B$]G5CM]P_KS/G7BM*WK"\U$6ZM'Z-WE^_G-#=U075RAV\N[ M^>("8O>^F:![+T/E+E!%+W'G7MYL+"5JL M5DO'&AA3*22KP0=FZ#90MK&[\_'V]OKRP^7-+^X]WEQ23Q<$* MFM]<+>X^S);SQ4WO$L;2>UO\8B)]\M3Y@MFJ3[0N%--9O(TE5[-T\:I)-#E6 MVC1KEGW(RAS2V\N,&%%J&"$J!_D-^5SDQ]TQ>.@)5ENT!F00)=NX[='S_F)M MSP6'Z(3Z2-I'YN0P']B0QL1S<Y1ZO): MW*HT,Z>T8ZG'.#GHNFC;W+@L%V]T\G(GI3-`>/N7=&^_9';L/Q+7"NAO9VNJ M_JG$.37X[):;U32C6FNVA6ER5)IJJD8D.Y[AIS.51(BAD2F;'XI.+)<1+RW/ M-_W9KO\BO(W]9R?%MX'C9J^)KUH MS((SP?7S(XKZA$EGO\[$T].F#6\`;?(6""MO`F+,S@YJZ3$%F?=LJ;XFH5O% M/ET$;S=*'LCEO),CO:/"K1.-2F$@"N%S!Q,`\RDS^G=GO?D3WSIX=/Z!3(OI4CA/@>^QN8]'IO1FKQ;TM(V-*VUU:?#!` M:*9LB[)$ZZK]2A5,PQP<"E4ETP7HG(8EAYCP\=S9^Z@3L.1!)EQCP3_:>M(Y9TD>B5?\["\L*/ M_?#8Y5PCC:?O<(A7ONL[P3&=M[%2I68R8(J+)D=&F61T!.U)4V@*[ MP@Z]9S):>1(A4.M#7`NMQ>(B:G5+M4/$A#!`T:)=2VC@*:1CAH8+O,)QC'>) M".=1TLB25U):0X1:U0(/8C(8:%#JUGRDCA.7;EZXE'RL1S59A2V:BI*_BYT] MMRTR1$%L[VG--H5WKVO**&&@HDV]QAN;.3UR<@9TC#(>&!/=^]1)F6)+15&) M.I'57%RA@I6LVPK%Y$A1JM7(I,V)T*^,[._`4''MAWA.?I1=QQ(13H*.AJ)" MA!14\%!25TV!%$J*&"T4N#PYI%_X>E]F9X7$*D0$RE7`4?H[Q,LV`OV:JY1' M/PSI.//.">BFRA'B7!-=N6&;0$]1X)'U$KT`F+Z(O;).!?.VDT)/C0_!]\)& MF@HV+KA_#(F6]72E8K:2S-*35ZFG'P_SIC2E`O:4V3=T,M3ZD+WUU,DE@SK*2?? M@QY3=GTP[)C2E+LGGC+@F%(7>@B>,N*84O644<>4W54+[I"L"\ZC,-D&:7D[ M-7F'T\\8AW3`FX4>^==W[0/+@,(GN)8S4(<(;N?TE`S#>X8V1Y6&PCPAR1S( M+=HH>\X#;R6;DM%;[O2G[ZP-.0-TAWS<&5#X/CF29`0:3/+!.))R+!K>D:R. M2'-Z)RK$+CW3IY=*^"U`P6JOPX#47?9D;M2W.Z1>U%4P3"?J:8V&#]&\DJ() M?D@Q9%)^=H*M+/EC_&:A94`/ MT8FFB=-]VIS^13 M14,!4Y5?TC-,5H-)S3TY>CNKK%$5G@KJXW#&C3T5"\@HB:'`14M'46E_VD9!%8%(WW"B*=^ M\C>D&#4./. M=+NC@^!)$=FY(Y3`-98*%]]=33%R@[P1='K&7>$;/V^(1EIOU]2W="QFK:$W MW&W.8.R0L;O(GI*^B-F,E?F&$/S#AL/Y#6--\]-[/;OR`]M5@MG2^W M45W>6S(O;LQ))]+!YM[9)-U;WDBSJH#5<$"FN@]1@E77$*8P MOAY`RD\S.84\0.EUIR?+B/QSI'14F730J7;J+NF9Q"T2#6,<'=R>P1.ZR2!* M?X"=KUKODJ%O0HBE[Y5##7HK0B3Z+!]>S]]:3R_4FB%XJO:-[$6_H%NQ5A1FE:W:U9`85#\/!1K&I4;&ZACYV#5T"WOG9I(Q;%CQA^5F MRK%L)#>;\I(&^8D]_8 M#`PW'-6V+LGI;M8BKY2=MTFGG+RB0^:N]H>_H7NJ\P60SBWMK5]VNQK2L9G# M],O>ET;Z^*75\7(9Y<^,7+`716Z<-69]<::Q'=E#V&3>96RPU(&T)<'T$5/U M-=R`3!LW^:,UV0,U(9&:H_S,WJYA!V/U1Q@#89!AKCE.:$O:6YB;1GLCF$-8 M_92V-<_>YE9?;.E3??R\GAVN91GI1.$X]?_%SLMZKX9ZMPQM%C905YK.RGHV M"],U1[6USZRML3U_]G;GTLACJI13468HQ.SEHNSI;>24M(*QT.K2V*NF]$U3FMV>=WJ6 MN%YL%9LL]'HV,>&\>)#.4\F'Z:7#&*4WL\ZN4+0]SFU_!*`XB MK"\O.W:0R:*S9Q/[YW+:"]1>\@_,Y3HL9H=RN5%'N=I=5]I2G^9R4$;+LC^P9>V57J71+5$P,.IQC51#?X] MPZG!15$MG(Y;,9EF*O('&JXBFJ*_]A.J7=*2(2D/KWTEVLN?'<3T7]!%J&E.TT,:#/`/84)S MOI/++(H)L3='>2V[PC&88)DOC#='SW6CAK9X."T"ECRIN\U`S`0H-S92@&UM M&=`0;:JX`L<,OQIW>]BSNLF3O;U''#$+=]G?I82W&B1Z4%E_^/&(Z')$E,F6[-5LG\3RJ<.0_6ET%C%&PX?B M^?KG%L.W^KOP_`YG'*-[OF/WB#^[!39DK^I]R%$:GM#S1^Q(A>>/T"I4SQ_/ M5#W/SRXR'MK0/T*WFDP`1FS^L(*!]F1@M+9_1X&AP\3`5GBP/#\@W3H/KWV\ M);]R`B=^F:6WL4\I3EZ=?,<2*SL\"M1-[K3S^H[=H)ZV&PJ%ZH*=+=&?=/LA M"D@#[`^L">H=#MU`X]3T3%2V5CNGGB,R4+74.@A>$S' M96IWC[$\QOQMG5[Y(?F=[P3+:/&0.GYX'3DARXKIM*%L)G%"+^EBNL(_3,1! M]8P.-NCYQ-\^_`T5DNDO(B8;!41XGC`=#O'*IZKL$ANOL)-N8WR'`R?%'NV*?Q0*BSK/7(8UJ'!@>,HI-^FL#)T$);PH]T+84>U;9)M3)M$OJ#EUC MN+CNT<+>.9K)@KNS^,-RM(Z+\)Z.9G^W=Y;LWBXM/U)*>^.DZU:OF="IWN7UVLPO3B;>T]6SWGC,,1&Z#WYA-K+H2]Q[O^@^ M?ICXA>WQ8A75*J]4ZD6?_,`VLKLM?;J)GM)'^G2&RE.ZR`7K+SV,T?2:JT6S M'$^]LOC)#_G!QZ3K&K/.,!I'_?1'VBZR#T0]^DRZ/1P']NC#QD-G?!E MEA(1(7ZAST;>X_C9=W%RAZD)V"O5_^IV,Z5?$Y/6RAF@`QBE M6RN'M43\*6N*5_C.&D-QUEJC>MRDMT2Z]8Y9;:I>3>R?OQG4INHA_\#\K5-M MJ@'\;=3QK5F]4E27LGAW5-3!QB)L%OSI8ERYX(\)/PR\=U-:4/"G\1J$J#KH M^&_22E.OZ=M.Q5ENZ2$,GLAV\F.7F5='T=,G_7?KC/:$?C.Y,#Q@6&.,$O'Y M@V-%4D#MI90B\?'DQ^GOWNAV1H=[-::B]\=]3._#F,D]$/?I?H^ED_M87?_3 M\DI.\L3,/F5F_V`^SF@(F\8?I]P9U;7?:"_45.@^>(;^?J>9Q+WW MC"Y[FET\8XHQ8T':=]+J(ZF9_6\[CQDF0J?V#/,.:/,,?8F@/>T7G,,/0,ZWD=_,4:_B__(<#TH9K> M@X:Q5``O'9EV@<;C1KHBP7I'-SO,GC!R=]+Y>T6@1@[M'NCR+)B^U+WP#^/' MOW1%[K]_]'CBR\P_[(\?],3<"?G[GST'#1U1TWJ"OK%J^+?+`8QY;>6U@9Y+ MA!;[598:!GP=47"Q;1+:V^7L*;:[!7$];(^=[Y;&_L,V90^BG?$RC-SH=R_" M;;-E1,^\`_]?^)K\9Y@TLM^_D\-_S-9L9M&-W&7EA+N1FH+A9Z/;)TCC*QJD M[GA65/G,'//A1;JA2],RLK91D#?>O)3QG;51Z!ZG:8`%CQAVNR%N(&["T`=K6%;Y%>;6ONF49J\U4)E9;T"UD MHA4N`/YFRD2\%E.-\O$T90$&N'YVGI:@?05XEUP]78#;CN"S9\U[PI&O"M*',*0'?R7P5\(T$@G6`+E9H.H*3B^;W*XEPY.^D3Y]Z MK6FZ4>0WE+D'#J$_$A@)W'>'Z#(RF#K$5-66%ZO2B:&HV_1Y(517%IJC4U6Y MP@@#L(;:FE51)F@M'>:.A#OV_O>#DV"O7"`MNPTM,KF%P1K"M!0O8*6DAH$E M'17K`&(\QXRI6H$NNX8^&FAB)\6/OCL+`I]&UE^<.';"]&<]:1P+0DK22!1@T-":$UT"@5+8`B MI+(*#C)B/$0)OI9A1*5A'1Z8_8X'<2?HL`C\[_+W[9^^B+L]P;5IS<`>U^N9=LW MF`VRO,IL8/JOG.2!&9%I]YH./J]QD";Y;]AP='QR>IP-2+D9B_C1";/J/33+ M)PI\CP?,T+LEG4=BH,/S$XI:#_?D-^S,/YD])*P6D*2+!I)M8]@;I3O*H!Y$ M\.0SKS&LJ7M+6?81JDA'3NBALGRZ;1,_Q$G"$/8^HN'ZG'96W'LM M,`Q^LA-_HMLXVS&@G`-<>&(OT:Q\ MEZR"F_8M\9?T'6G\G[*9D":S3=B9&529?6IQ@H&CD;IU:)Z]0O?;]9H^RTMB M8$D4$H`6!E(+DUKBGX#.)OZD:I:AUB`"@RJ99HU-$T*'&"&XD'8;TPO&ZO;@JJI$'"H5@9;,PG[A>NV(/S=JR:<80"W.UK!0;0C M+O<)C-T1^/TKQ&_#$?CEU]%@()`6/=`>]V7$-G&F5K@,+3$E�IU:L#B!)# M'H&OH_!QB>,UU;,M=$EH;8)(J6X90T)",!!2:5='T`^O4"D'#MU$*>9;R?RG M[)[62&DEK`U^,UCO?$Z;RUK"B;X)1?9).\OD2#+3LY$=P:"31L(#+AB!Z0X' M1"'OUB&K=Y8_0ZRA)R[Z,RTC"3:#6`?3RJ'-@'URF';7N0[9'U^A3`BB4L!L M&O/\C);Y5YW()MK$"I8!5:4`@QFA6HW\%T8$;EK5S."A(5<_=AGP6SWZ,C5+ MG7LE80:#0%.-Z^#\XRM4%O$URM#ZS06[L)!^"P.LN[NBR2ST:"$7/WS$(3V8 MTUYA&LJP"=I.YI6!:R0`#'B[:-TLZE/(8$N.BA3(RUHMX]N"L*D0<*!6AF,S M"?L%Z[;`_):NJ0LY,"![OWU(\&];HM#ELT8"K)SG*^"^A!0.M%@4; MMWT*"' M/`66Y7"]2&Q7,=B$5+OB94S)J<&`JE7%QI9?(Q\9"*2.F=.4"!B*O?;)*]\@Z77^EH&:Q>D"F MH7SEG$Q!#P9I&DHVL8!DM50HP^!"J M54<$(:+QIB"#`8JK*,;^8WB^C6.RB#4(.3J,-L&C;T@94.U<8$"FK6H=>!DC MRCE1J1P`#!"R5WU#C_Z+[E`_.P%=Z-F9A3V1+3800#2!-M&QN[ M].WE$A<,'$JS]?6@J,\.XHZ%!B!U><%@TE!AT6GNAI?\#SUT@ MGJ+26K3V%B)L[!@U"GGI)QB08ZJ\JU>`7&RR$C)S\L%#^OH0G:*H1^E.DJP> ME'4WM5&,S$P,&`AWUUUNH@O_&03)4ZP6-%;4M<$[5YYK=4*KTZBK$*OA[$5 M6':0`P>RW95OP+D01<]WJ(AC)@/4HOL.)YAT-=VPO<#/.(C8-M?E%SK-P,I9 MJ!:GW>M+VJ94KRVULH%!I[ZN=3#FG&P#T]OQPD#A%7$46L0N]^X2];4#?`2L7 M\B1_3GR6+TQG-]G4N_5JP."M@#B"[]=%6B?UW9H`XTKCV"4]]Q_KH<3:L>V2 MEDQ1EC!IX[#WR*&6ZKLG#)7DD\-*7\?6PW3$V6`$X9TW7/FAGV*V`2&TL_4. M5A=)5@^=NIM:.70R%P/M):+N)NQ)ID@IQ@LK(63/HB6+^,Y_?-*X7]A=WC0( M[VBV&.>&PN"BO9LA=W:_X[ MP]@^3",3.<6`'23QE`%:F'RJ,ZI9=6>ZC7V7+E#7D4?,22/VWB3FU6=0)ARN MHY73+T]Y=NB[NX%7PGAY*C1T:Y9P:-XH"9_I]?).,:JIYJ]();? MP9^%'KNIFEU4O<"IXP?)#56&9JTIBZQV%66O\FH_8W?E6+O)@0')?LI+JC@L M2J_*S>JORJ%,)BJ$[L=+PY8>8GW+/UB('VGNO&K%(U9/E`X=\0@;PY/ M]P:N<)P43A.$E+9>(M;_!"UZBG-X'U@.KZN9PSM6]%L^$4QL?)Q,WW%F%6FGJ_7VS!Z9O$+%6T< M(=H*6D4Q6K%V4,(FTDCC=G%`D<56U<`LI[4V\K:I6^!-1@AC[&S13GY[ M-*.'L>*5'J&]CTOCHNZY6\8$XOBT8H#6:2CCF!Q<1FJ*$O&W*8Y9AE^T6ODN M1AC64W$SU]VNMZQ8>OD.-?DYP-G%F-DZBM/L)6QI-TBZ;3CQEE\+'K13:F\+ M#R(;C&<,;%#=AZ[)PN4GLM8N&D&>YEW_*<($;!3E";VN.IG]\HZ6M=$0] M0H0,1G"3&O(QP:MM<.VOL&D7E#E!#*Q-4[2`MV,#$TCT=34:9]&6L:.`\%O* M&=*8^;>R3)8UU+8.:*&?'$X&2K8G#@VT.I#@AK\7Z(>/5[@>B`1_MX8(D5K% MYR__$<:W%FC4F$3D)&B%@5R%5>0!E694Y9F3)&QV$63UQDUG0RM7;XRE3`[. MWJJW3X6=$A-X6)?FQOH]Q)B`P%4RN5=S[`,,=VJVC8@P0,9RQV/L*4SZ!=/, M,N)69+WC/.+6"7\_D78W)_H;7]V0Z"X/#+@',*(-^D4Y8`]=6U]*:!WSZ_-. MO;AH/\C799P<@5VTU5YW3'XN7S>,%R86#H,24GC;6VV*MG^=8^1%:\BH M*^N,.0S0A-`EZ:?9%U]XL%(A@/<5Q.K5^YY1(4J&?J6$4%Y+$N8:S&A>V".[ M\/GN19S!FV42+K9I0D#ED17IS7;]@&-))XW0SO1%YP;HIO;\E!Z-6/64#8[] MR+M/G3@U3V[I;V0C0XG]D2989(RHQ`G$]V@6QSQ)MMB[V,;TUC;O0FI^4D[T MO?R"8]G2X=:412-3W!.'49=DC!',OPQBW!C`5E/(63(\8%<"1KZZZD MI;]R`Y-YR$/C&,X_L!*@8L`H'6P4"@;5`,[(/879IO%@L#F`9"NO%&\*JS9^ MS+.CG%1XXMO.8VWK3E?]8LNNC6%R=)IH60=3B0U%V202%XR(/JZP)X.*S/.* M4H&E"\6TC*5+7.CGB+Y!%OCIRQTQ](,?^NOM>NA)0`<%0`TF@W?L('-*X]8G M=]/)3*[[_([V"&64OQ\?=[Y,[..Y`H?FX]6.M>WCO/7?E8]73%;Z.*?\W?CX M=-_DX+QZ(G?^/?EQJP,?H-_>^I@HN44=!UK(3>AE: MI"QTDC(Y@GNK+JR%F/$C+@!E$HJ;2&>`QH\>*8;OV4,">5:1JJS:*"WMQ:2N MO:N&S'85-#.YAXUO6WN*.N,]E`3UJRA>89]6X:15C7<95T7?C/0!--K=)Y?4 M[L8A';2U42@U9FT;W.[#F:1#\>(L8Y8^G##JM45!._ODI=)N&M(K&XTX4-Y!,-``UC@S?M8/>/=)O M?G\6;(/;;!H`?E_+N@EN(_?4"52`L-']5I>*AQ%$+/2":5@YW)7F!"%$N_5] M"A:&73K26A5,`+"]@AWO`G/;*G.'Z`4[R'AT\:ZB/)OL4/WIT]9#QHX,:!Q,_NML^4/R`.?_H,5W[&2>T$]F:C:=S M1?17I3@Y>WR,V0'DG'2+'R:^RS+!1IH^]M!GGU8FO;M]R+5*9V4.\32D;VZ%QDP-0?\E\7MN*&9MO[%".,NG/,]#1AP[#F%):LU7?N@SKS M:)2F6T:I$UCQ:[VF]\FM33ISA!U)9;L'X]0&QNK[](%54#8]L['B[WV5VJ=( M,,P'F/(P\T"CQR#=H!]7BH/,UZY#0!<<2H"1+*5*>R@@]A9T]-FGL-*[VRWL M+;0KGR#?!+EPU#.UVZ?+._ER[KJG>Y=/EF M3[/7)[PZ".ZALS&-E-^$^(4^'$CX=/9>Q@325&\8P8-!=QLTOK+6:AQPP`!Z ML=$2BJI7&Y=D0!@UHNC;K8$\K<33_[ED,<2%`W@Q;0+CFU553*]70`;COCTX M='B0[&9_"RH/?GC>KXLF^X=:*]W1`N+!KIA(ME'RYF1O8U7_;FW30Z16L9=1 M_B.,+0J!1M+O>M%2%G"L+IVY[G:]#>AD-]OQN")_)"B+XL4&9]!M]+46URIY/37>"6\?WYN&YL_%3)SAM?D()(;"OI=:R M\6$*,R+"[QO'YDX]7)'"[VY0`9;$B`8'N.Z\W M0<1G`X\Q9C.%67KRZO2$C/ILPC!;1]NPN04_K'A@WWT,VQIHR1M!:816K!GD MTG80SAM"$6_IZP3AHBWDY(TA)T5_H.TA$LQ10EL\0KS-?08+6`C(H+U\14:UC_ACA3M:-$5=NBZ M#(,Z-^=]>9/ M^?\18T:_PKZ6I;N.K MM?%-][6H5C2!*4PPU>T7/WTJSGEI]F+R,?1P3-;LSR0(W`:.R[>@)5^RHS2( M7[F?*6($L+B*N5"^1OM,Q**$RD5^+AAMJ62TX:+1II`]+4IH+PAM+B:#"5VB M)D\*;&C+@(H(4P,4.&#?7_*I=W/>A"_CDZ=I/GX^&UBL9JY+5W8D@KVPW$:= M1;HA/[2/WD7YY@RE5NA^\]W0I6 M8?(R4L_;]!CWY@N+M#;\M&1]Y#(9?#P'\#WC+?:R*4S%/CWO57.#_K):JK=^ M7BJEF*W5ONX1=][)O9;_G/H$@!?X(:U8JS$HM[/#_<[:NJL_M+L3@SPBI_FE M88S'*G,U'+J=?3^_M(%+MW_IZ4;B['SBS%.GW"'G[&0;1ABX'4>91M M>!E+@/6]NZK?>#`RNW]2$H2X)$1$H9(LQ(3!^-CTCQN:%Q$5>1':GUG*"_T# MMRFN\VFI#,2$H&C2E)*+S'Z:O!:F?OHR#^D9%\^"D]XCTV`"]A7U-6Y\OHP5 M$5[$F5&)>XJ/1N^LL5B0W5:3?B@9(:R/TZ)E(XDN)\\OZTWQ">;KC>/'5`LR M<_>>V09HH_M%1+"Z7J%AO=MWI&R=D1'3R/[Q='GD,QMGOS-))\M=&/L)&0^QO\]#[-EUVT(T#6H'0VP7^;N6(Y.A!`/[ MR,-:U0!&)IX.J'Q?CIV:%4UDQZQ%(^7CM6Q'_CL8)S#].TJR%S24X$/#E7+_ M:&A<3;>_5.^H972.(W:0O4OJS`ME7T7QC"9F/M/RVSR!_,[Q$_P^?6\8S$9I%38BQS19`ZYD57%^NS5_1`A'V(W5G'+CE?.RKWD0\>J0,8IX?)[(`)B9-T>8(N MF020AOGY$\=O*>6ZF#Y`FH)V[D']\-E'_H'"KT-('!)^D&:JV96D(0<<#5". MT"ITJ(YGLAZ`LTMAOZNA?80^UQ[V1VO[=PCT#M,%6W"'M#[[VSHM;J,MH\5# MZOCA=>2$;%/&',$FXJ"#LH,M>CBCM_8*R?07$9.-`B(\WZ;:<\!H3S5-Q!T& M8#I,)(T!`VE`O24]_T0/:B/Z`."-L^;9^QV&1TU)T&%B9H8>0C:93.0QH2@D M4G-D5`&AV"ASXTX*PQ\T5XL@U2]B)@?HKS#J>?,0[I MC9U9Z'4XONTL&39T^IJE`:5B=R)KHWRV]L!;R:Y2T6P`P$>X'?I*,PYUEGQP MX#*-4SW!!39RE1:P]^2'%#_Z[BWI#/H0YMW6?EA MBQN<+E;T22\Y](J9/9O=2\0.8W,?!"<[C)(U"MTB?;L#:_F" M&'\Z[`B%F*7G/W.=Z)98H=0>1-O.'=XO^O9L]O>%[<&BLR&VT4P-;A"!N_2: MD`J,)3*PX&GJJ/S8_&[/9K*+C#>LZM]B]6Z;^"%.:#7^]Q''.QGJ0^VK(AWE MP/J,_8QHO#W$"RHN5BB7Q^Y",HDH$PGC;@F)6==10A]EX#&,UFV?;6(_.#T[ M.6V6TU:3`_ND.KHVOAP)F+2H.9L(ET(INW[,N-'I$:("H'RM"^RRN]2G9U2K M.1/`BBE<[&[`+Z,/I(FG-]3R,ZV/:BP5_K?O:I(11/)&T.D9A\DW?MX0#?JE MJ@3?TC&<$B=30*I*&6)$ODIX#WIU.SZA#3@M[(``X.NOHTO31GI9]J= MD>YX)_E8[$V[?)XJ*1PA(@+V0>0:BLHH$M>9K';J8DM+D80>W7G)']W*7RP2 MOK+3Q@#K2VAJ6_\J);9\!DOK9V6,R)OHK9[\E'.QJE\$]HISS\8'TV&"]=$, M-*Y_.!W6*;YSAL31=!M473JH]:QU"*'[CR/-<]1^.()R9MJO M@P:,1[#/0P>T:$P<[5L\HD<5K;GVPXD^!$PI[!H<6?P,YW2/IT[U_AHT8(E$ M'Q[$Q@U>(HA-&,7R9U6P=Q7%NQ&Z&%E"- M8H:C3*X&C":-1AW[0Q:!>HD[#*BH(TU?J$P758KZF=>I]XKTR!6KG`BL?8V*WME74.O5J/G*J(Y01C=1J7E,&O>RHTJ:N9*D23.#0T('H,NUU!.4 MBA?13_,F/8NKRVCF_K;U8WSK!]ODDD3,QY?KP!4]3:^DA_)%=-5L/E*OY)LT M$,DC$(!>ER@DCCD3=>.U[SSX@9^2R8(BJ#>I`'6O0KEZ5Y=()XWQL]U[&-D3 M&32OZ98^BK$HWL1HQAD=KD]O)O\P'905U%YOYY[(94I99O?T/9I+6N.:K*EH MI7FF:EEYELI=YQ"Y6'^I@%QR0&.:\X3=## M%GI/44!6X@E]SR-]$<&A2?7I.S"?5Z&<<#LB(_T:<6(T2]/8?]BF^2.,M\X$ M@5@P?,Q"3^_KM/$`LA#>N$G[!'HVQBO_>U:N'_0Q@3H.^KKVEAAE3CIEV-?*V=&WV3L4P6_ MFRB,JI%;X8!28D`?JEW'YIV5'42$2[S>1+$3O^S.`ZFZ]#$=>D&($^!Z[9!U, M9_/"2=PPH@$YW-`6-2:+5#Y*20.H:`&5SF=Y&T>HU,H1*MHY)@T=TY;0KJDI M475.W_7%3R2V^,]XYRFL$,+2^2*%3`L?-#SHJBO^V!7N:J`X0C>\0`.1,M%W M%-BF^GP*`IU-3]@L6V3B6!Q]5`?M09RH&JNL.QCMDJ8;G5Y[B1/ M1)MGW\/>NY>/"?;(()&O@F=NZC]+ES#ZW("CA!7U#Y1!/ M_1;M-K5WLB;ZOB18L'50D4GT@3Z3$N+X919Z]'B)')Z#O:JAPXW9_ MQDYGI9D`5$@H3N.8C,,JSP`DUAKINB^E&79Z7?MN?58JI@#@42V*R3L_HX27 M0-KH=C4YE&^@J:59]NB$7X?$YO*EB?*M#-V[)YTE`?NF/0R0?&YSB;#FG'S7 MMNN<4\`-X(OW4-IPSEF(FG[.>81UB. M$&="@@W0J?+&V;UL?EU<]#G*?P<0`I5J-;+$&=$1XF3`#L+)A!7[CR&_+N2^ M+&,G3!R7O741>NR_`O[RA?>/+3_ISX\H;VF*%?E#Z9QQ&?%31I,3]5$4`.2C MT]C=X8P_4PCE&J&22FQ7KJ04VFE5/77.=(-Q^LP+$HBZLC'O$E(!0)&&*JR[3]C;TOD=F0CX*;XFN//J&X=+AF!1980>8@!\NR&T;XPEF2SJ<%S: M,1.'=O(0%XA^92(1E8F8T+]/#H+F!1U:N_P7^K($7>S%=_[C$^D*/2@8"@,) MB*XVJ&`AO)1&Q1ZA7#"*8L1%`T()G26](U-0CXY29(CB$8PJ_,BJ][Q[V9%D M1TBSST[L917!2\6^>>%VZ31RR$8@H6HTVX03VN,'*@>5VT*EQN@RL$R7-8A8 MBTL]V]_A",@_Y5L(8J&YM](#PK&_K MF$@N:<'S,'9ZL,Q&ILF>0CCS0Y83.-K\H-'(`SQ,<:/3HKG81K[8>*[ M/SO!=A2T=U;F@/#?OP_&]`BN73[%8/K136+ZZ]ITNM`2%6HBIN=A.4HI1$SO M*.W*'+ZC&/3!9(Y2&5=,'*7\JVOR$_EU_BOR#ZH1^PFB8H``!1J`(`%0`<`'1A=6`L``00E#@``!#D!``#M7=UWV[:2?]]S]G_09A^V]\$?LM,V MR6UWCQ+;6>]U+:^MM'>?>F@2DG%+D2H_'.O^]0N`E$21!#$@`0)4W(?&<0!P M,+\98#"8&?ST7R]+?_2,HAB'P<]OQL>G;T8H<$,/!XN?WWQY.)H\?+J^?C.* M$R?P'#\,T,]O@O#-?_WGO_[+B/SWT[\='8VN,/*]#Z.+T#VZ#N;A7T>WSA)] M&'U&`8J<)(S^.OK5\5/RF__]^W60D-^Y"7Y&Y+?95S^,SH^_]T9'1X`Q'\(T M'X?1XH1T&Y_\_9>;!_<)+9TC'%"&NNC-IA<= MI:[?^/W[]R?L7S=-*RU?'B-_\XWSDPTYVY')O^*&]@5*8OPA9N3=A"YA*94' MX6=&W!;T;T>;9D?T5T?CLZ/S\?%+[+W9,)]Q,`I]=(_F(_KGE_OK[5Y@(G??1\2E7'YX02F(1><*.&FF[48-?Q6Q-:.XI:JJDR(@IB/)U/5W1E(>!)L;9Y!%748J_\K4]._'3EAU^! MQ`(&T$3K=/Z0A.X?3X1A9&F^0'/LXJ05T8TC=:?^EJS+$9K./Z8Q#E`<$[W^ M')(=B]#BHDBX'`"[=Z?S(5TNG6A-N($7`29,<,@:Y+IA2A:A8'%'V.9B)!0+ MN5&Z4WWY9XI7%$41896&W;]-#`0G6.!''TWB&+!T\MIWI^0&NRB(T601(01A M!J^]$ETE!EI")WD;)HB**_OSSED[CW10H8)"NG>G\Q[Y=!$@>T$"D.KZU@IT MKK#P4`%-UL"%3-A1!9++)4[8JDY0(,!0!2;F-H!=@*XJUJO'&/V9DH]F^O9]K9QJ5U"-*^F,:IJ03$YS]:LJC)SF7AHU%48>L+MV:^,")0[VXULG MBMA!M*/UP1M.H33FGP"+8ZF]>GD$$B3HIHTN,+30_AIU!\A*:'_]E(Z[DCKN MC]:SKK2>]4?K>5=:S_NC]6U76M]":%U%*":K&3OVWY!?['5!+PD*/.1M!J)T M=_!$D5_3_J>GI^/1T6C3H_BC$WBCK/NHV#^G>$.S'[I[9/K4-1=&(G[-)E\^ M_]Y$Y^0Q3J@C=C.0[SPBGPW_.^T+ZWK2AMB!$^GW@(GU#ZZ0]L M(D>GX]Q5^._D5[]G--RC!::?#A+JGJVAG#2M;UDFM"@)D\@=A1$1+(+69DPG M MO4YJ9GJI*9#[YS9ROW;6)F"8$&H\2M&5[RSJV5]J`F3[6YO87CM+$^S^E$9T MBE9_MZC M51A1SVX6P-%HI7)Z`$%Y9Q\HS3PPAPV3D4]D,5V$4>/!H=00B,1[^Y"HG;$Y M`.[21Q^[5W[HU)WZMU3O-0.?V>SC?LUT#2Y,X7(9!LR+]?!$YAU/TX2%U!$% M;5R>&OM!T;'Q2`U@B,DS7V8"9F>@*_([SB;2T!P*CI5';^[TS6-"S7(P(H7& M4#RL/(QSIEZ#QD\GE=G=D%]H<82+XQ:W7O"ST=%H&QU&?BYV'>5]1UGGT7=? M`B?U,/F7O[1RAQ=E;.[$CPRO-#Y:.,XJ$S3D)_'F-V6)RW_]>R&6[0H'A#Y, M%"*,L']>ZL0NVGEUU0BB=2;F?*E2[%UWT]XLQ$_8+6%8W<=(>"4FEN MS,.N"AP.`^S`B$;A\B')_M68NQW$QK"&8ILX/$V>4'2/7(2?]T)XJMRNMC3F M:F_!>=X\[4#A%R?Z`R64L`?DIA&FX9GYO/B`-'8RYH]O@0U@]G;`=!>AE8.] MRY<5#3L6`L1I;LQ+WP*:QAG;`=(#[MT&'?`L0:F=88#ZA?8[(/WHWV:RY M%#+RDC!Q?-;2L"Z%*Q0EZSO?R8YHF\C'6]2H4DV]C+GU6VF6>/YV*!C;.J%G ME]K&QOS)W8WDALEW18<70I8K_R@!+V,N=9E@,, M.'V3P*E9]\J1Y4(3@]O!G%\:#JUH#C;M2/MYASQ;#\YW;:<@.-_K4BF':]S= M8.<1^^P@1TR;:B2YV(Z`CP`%69LIW\&ZD.63'>I73&45+HJUC:&8:;/4I1D? MBB=E$T3E!&0H6J)^4.#4!^FH`0[&%SLPS+-EP=CQVD,QTW;\ZHA9,Q_LP(H5 M64)Q`L6*UQY\F6$I5LU\L`,K(D]12NRIW4PAJL7K`D5,V[&MNW8U<\,JT.ZB M<(YB6L+,\:\0'#EN/RA\VHYF:N`3\,4.#&4TKHNJ:;MP[(@52,<&>=YK<\)3 M<*8[TW9'UN%,-Y137"$ M=?#)66&BV`6B&W8X0%\H7MK.V_+[&I@CFJYAR,::+E-6+RNO>W!%)G47X3"J M%C(L^_IA?:&H:#M,PU&1F-6AN/\OT#/R0W8E2W:#!;JD1YM5A&.4S[[(CS3" MP:+<@Z^S*L:&2H_&6U5)G5;'T>%+5V&J[)*`+&QD)D\HB/$SN@[<<(ENPCB^ M1<0"F3DOC0<I6Y-K4E][>)MZ[(WUFGQS:"Z*H3LHY#3V&46/ M88S,K]2%]L/O&GO0=$Q!([+*=*OO(D39[" M"/]SMW@W8E?M9#I5J`MF/!98BA6K$B.#TZ:#Z:2B[ACM3]U2?)J+(?"FUJ84 M@K;@NNY(P0H@F#(Y!6^G;,W-MTWFYFZ043@?[8:Q).,[.[UOB12;9-P.)A,D M,JX&BSQ-"I(FP>]BV+`4(%).CQ!-W8[E+WL7S2?'U(FWQ`&K[TJ+@^=4\W$2 M=C1M!HH!".4FI/529?9$/K["*+Y)O..K,+I*:5U^MB)/OQ+"XB>\XMRIP+J: MMO#`<,"G9),>72#"4'+4+);=KKO=*+8R;=#):DC='.W@?F4F$ON+>7--%@?N M;(?N1=Y.;'=U`0"RV-AT\G)K**LS'CJ8MV$0[L\NYXG8!@1T-582LY4Q".:% M'`CCJ=7M\9=DT_`EX[.#`[K?Y$\?SL(;G.`%@^H!)8F_]VYDS?D/UMUX[G9; MB9!BCQW+]F1)BRS_D]$XG5.AO<`QRQ"ZB]`2I\N&6!EQ5^.IVFV1!+-E^#K- M95$+6\N")/&VB`O9,'C;&B60(U*IF?%\\-9XUDUWZ!A"`O:RFL?D]Q%R:"QH M]B>PUE#'L8TG-$OZVY6QTX[-O&D^5V&$\"+(4J7<]2QR@IA,@`(3>.QO?@:3 M]X\T9L\T?T1STJ1$Z^OERL$1 M)9E.%,77Y*`4YZ^!/SO8I_G-9"JQ4RQ;*1`\%1\PGB*N5]#483!\0[=;9H#2 M=`!]^>M&UJV&7(%!FEDUTQ0+2&,GX\G6VN0"P*NAB\.E$P7D]!%O`CL_.C%V MR8Y\@?TT:0K+$W8TGIFM32R`/+/#7/F-6%U/A*K),SEH+M!MNGQ$T71>"6L3 M'Z+D1S*>3"QW9&K+*ON!+A`/5O"VXQG/56X-(UP:Q/RT(CH4>^7H4/JLQ)4? M?JT)#OV^-C@T&Z(4'$I'&;%A+`D.+>2X;&%SYC@_7'] M)49DD]H&1TS(N?DY2Z<3QPZT&,N>C"4NFE6/:$N.V;%XTZI,.&GV7A?;F`XF M[<#O2G'[TL3M`&3GAHIGX3URP\#%/MISO,]"94JJYVNF0UQ;Z+%.MMLA6)L3 M`PVN6-++'D&(+*^]Z6!9K4B%(!;8!"M-Y:+9VL1`I%'9Q"#\S8DBAW#G*HP> M4/2,76)\1I]\!R\;UGC)84Q'ZO8H!*T8K"DY8>=LGL[S1PYX!9[JFQI_V*D' MW/BSUXH-/[J%3$DF0^;X4MYE9=JAHV0-?G"3P/3&) M(4Q'Y;O M7A#JF7.(8K#E5+%07)<%OW81@;;2%8JF-@=82VA$ M^')X9"NDE\N5'ZX1RM.""C.70;=I%.-9%YJ`%G/.5LQ+3_?2!(H:-OD>=P2I?'FD="^3D@GAL;WM_XBXW=,).< M[>%J\T6*J%N*;4YW3@1ZBTEN%!LRJG1HMYAS=NSL\"`.%>%%%B0^*<%;GFM# MCQ'GS#A+L5$3CM8XEO'$$W4!:0">V;$V$(LUOYF8N'^F.$*_.(1'`8K6D\"C M-517S>4PH/V-OZK8`:BPU8S;K@GJ4LXX-N)=&KE/9%6Y2K> M=AC/^/N<2D6A/4>'GP(.9Z0*Z]R"Y#YEEIL\YP[T1)>_#Z3D1-LR[-?'%^H;+0CH!\4GKZ=*!+P M`&=Z*"LOG&$JK&2XA/3MGI%78'G.#?UD=3F?(Y><*BY?W"`1>S:I"T_W],$XC0,'][B-# M8==V,=E"W53Q4YM38Y<"7DHSFH40WP:T.Q0[;0<294"$;:9ODXI37UF!\@@O MR/Q]^MO)DDYAS-=A0%>A=E#6YGGC;G>IL%=1,[# M";KS'3=?K(@%5WBEOKS%*A@8"KJVRUL=VJV.XS;J?>X\I\<%PH*4U4*64_^F M$<#5K(8B$-(5>'FK?DI;:ST?:1 MDNM@^TP)K6BHF.U\`>T.1U':WJV7!EN-='Y4`I0$$=H;BI\WSH`4_*<[I MN^;=O0[!J;Z<7W:6VT%!T>:6T'/&X?!#^P)X'7R.$`K^>[W`*,`NT6GW6+CN MU7>"(J/M^E3OJ%0B.#-0MEEFZ"Z\Y%)!!.6=$W-$$RD5^&[JE^U,8 MUT;MT-:\QN#RT$,"I)DSNHK^LF1-2NV"&$!T\)Y"GW`\OF#K[H[@[>-4/X`>IZ)O4Q6'^X\1C1=+UJ/O\H$M>:.J2&-& MH=1C54W=309A;"B<-:<5E=N)E+$BO+JO>\7PE,,L2C,J5AVV`1"BM>B:_-@0 M<5K7UC)@]L2*AT"!_.+SUC:@D(D2=;&$`8L=><$00.J[#1&;^ID4GBHS&;>] M3]L%NP[@H\-I;ADJ31)7CKRNGU#A\1*5IMS^FYR_(/HWCA57W]3T^W=2+.9/ MPR[/3NTABPO.UI71V,V:-^@D=`'$"7UG3FJH.JZ;+E.6RDJGM(IP&(59A3EB M^38JC-0(IE^1D]:C%OSI#2DOI7$@R1/RT#/R0U;O*TZ6P5O<:9FERAY&'4SUW-QV/JFVML36$$'(G:AI(SGI92>[^$A#:RY&0 M6[]C/$E.C\>G=RABPII)+&<953.T-78,%WIU<]6Z,W8C,;NXUH+T9FAK;!^- M2.^ST2*D3[_7IM/5H:VQF)0CS6.CE4@KU^GJT.`[T@$CW8M.%Q[)9H+%**1W M9:F?%"\&XX\H^8I00!>=2>"1/]Z"%%OA^$#,M47VP#!7SE![@6_4&O`UN^HG00(Y6=CVAY,_HW/T-G:^T2YDSG,^?E+HS8 M/R1)A!_3)*N7=.3/HE#+#F(ZWT@J>-U9Z3SD+R?_UW6'Q/@`5 M+\/.+_4\M>A"JTRHAJOJ^@^`HU*&#WXOAOF$?-[+=E&RZ"W):OB$T?SR!;DI M??-M.I]CE\;5+%=^N-ZC62(J1?5'H$)@T%VE8]J#$(3&E4#U1Z""8-BWI8>W M9BX_R4\L>8\6%R(_)&B!7;*@!0'YMWPB$BN#KH]!!<.P,TTOKPGG=DX"0`U!>*/!B^Z0W(^L,=GCH,!X49GMA,F)W M&)QB+`8J4"JL@LX?APJ4W>%UBK'H;:_);RT_.2A!64V?6>1XZ.%XS MS&\YMV@(F)9*)XB[MHN"Y+62,>O@/.F#D06>ED7&EX*D7`T2(\" MQ=*PC[$E=TQC!0[(`8T"QU(9: M_%W&A,)JV+^FA'/:4:5$">3L.N`\K[H_2XF1H`@:]JMUX%)_9Q04,L)V]W@% M__R$<`$]T]-XEJ1P[^`8?0X=?SK_\?M3^A^U`5I[Q+5\&RH;EOG3M"(Q3&F2 M/0?K^#94FBQSIFE%HC=IRN,.5,X$+$U:O@V5)NO\;AJ1&+(T2:Y0&BD`U\3Y M!B3+E.3/<3C^+)P^)@X.;D(G8,[/M@Q';\J?/O702/^`%#?_\&`9IS#$$F8W7+D"[ZT>@4%L7QJ>"MY8+@KQYU>$C M4$&PT;?8F;?]"L*N3$ZQ'@XKJ-CA%"4W+A1N&YU_;3AH'\)MM%MF7"C"UCGD M6G*P/X3G(:]>(J/O!W:X:[V=MQL=7$[8.K2[<--6S&5UN]WH4,SM&.WU?C-+T_JT; MJ)"(FSGB3W]LN7:W'!V*K75)L)VX:2OF[2ZZ94>'8FZ=GZT3-WO"G(8&._$3 MHV?,Z/FAE48#QH'B:)F;#,PA\XA)Z2-@'"ABEGFZP!SJSP:N*Y+#Z#MC]+UK M>P*2'1>*J'V>K78R5I=]%AF7&A M"-OGNVK'0?L0;J/#,N-"$;;/,]6.@[VGWN_7D%>AQ-(#0S&VT./4CH<6@MRR MI`)\8"C(UH5RM>5AGR!3[YFS>4ZQL_I"1H/":9WW28I;MF`HKYV0T:`86N=- MDN*6/H]^5@R>%7XXR](L,@(_KFL-^%E(75\^_B>Z(7\-XLJ%Y5M1_0QM'X1* M@F%_E'Z>]Z;PV6MY-?5"6@=O28P(A=LR9U8+KMF$I^0B+C$B%$_K7%G27.O/ ML4RC]5EY`G;E>(4RLL[;W@@`AP._^&P7DK+\L@9&V6L"X'!0&"WS2\GRJS\8 M)\\.]NGB0(,Z'#\O9\?*@G2YIY,<%@JK9\-F`.Z=IOERL$1)7,Z+R^3#\A-(YQ@ MOLD`[`S%PG0\CQ0O-`%2^]`BA_^[/%"?K!OPJ;650-'B`;:1?$Y8_G52X0>C[8_.OM?^X1PMZ M26B&R7;>>RS#RS0X)NM(1L-M;OE_3&/"@CB>!-[G,,M\<%&TLX9P0H98.,POEH,\S(";P1&VBT&?D[RS?%?@XW06#;P4CGCS&+`6$+]N*AC>Y=>9"D,<'D3DT[)\U;8%ZK$N+ ME>);WG6YK*FQ1_M4W(=TN72B]73.JD20$STYQ.0W%_2I'<(#MV@\;_7W75E_ MSXY'^5A4@0NCC7;#C;;CF1/2ZN3$JMG4Q^3.V039C`C!1_+Q/QIV4V!_PWHI M1JR\RTKQQ;`"4C-@M7>$VNK8^[*.G1^/=LW-R=V6A6+-J6EJ4&'NHI"LO\F: M/CN:D%5]RTR`LD#Z&E84+BXE_8"SP;!N7),Q@@5U(T_B&"75;6A\6E:1M\>C M7:]1WLVL, MJV@6@(:VX6=5%1V75?3[XU'>:[3K9KG$'I**=M++;T49AZ.!A596R!^.1X5!1JPW\[QD/VT&,B>Q-#5!1A=Y[0TJW4T8+&8H6E+2 M`&K&:6Y8L9IQ*&E0XXP-ZTQ>`O?.B9(Z[\;XO*PB/QZ/\CZC32>%EX=,S[*@ M;KC;D/:$=#0H]`4VK]FU(2&(^KZD=ARI04PI"!2,6DUIP2;37L/*/<8%BP:J M,?_>EE7IW?&HV/T_1MD`H^_R(?YB<*/)2!%O,.5V5EV?43F4TC")(0QO0/7X M""_9!!PQ;L!M`I.I[4:S@7"P0$&MWWW\?5F=WE/C;3N`0=UIF(:,[28YC$'- M`U$*4#_9<0SK8"N<2RK:CG6F-[WT,49_IF2HRV<4U'DC?ZA<:I_26[%-MU'> MS^!F49J"6!WY/4SN>26B('L1.&3%?B0'&W8N800V1&DU]1G:7;)X_ET#BA7AY,0XGLY+ M\UMG_P>LC]#^0/RT!4S*`RC%&#O`O,'DV.+14[6,'=G<"PB`@3+`# MKB\QFLXOXP0OG:0VZ2)O6&X'?1;8&DCJ)VH'"%=AA(AM\"F-R,Q=.79\:MZ"-S!@=_!;,+;`*,46.Y#DQA>!P82/ M`*Z&:@N>LLRQ`]*&*_7RWT6G@Q9#@>N'V`)R:W;9@?9>]#M\!6[L!4W2L09# M"!/L@.O2B>@#C_&F(`(8,6%'(&C:LAJE00.RP@[<&(4?RRG\TU6>:-6^9Y1EXDJZ:N`C0.&UQULCRQT[ M,,T(G3DO8`SY/:"8V>.H$$HQV52(BA3%]JX<&J=T04?.*QA@$OU:C M0;&UQ^/3A6MVX'Y/6$QHH&?H"_2,_)`=MBY?Z-Z!1)LJJ#,457M<0Q(\L0/$ M*R*$M+0.^@4YU(6U.R^#-59B""B@]CB)I/FCJ0K.%YJCGS@X2-;7P79?0(!U ME78']X8"9('71VI>-JG<+?I:F&44!N1'-PMGE=0\^9&@^-KC\&G++5N2CV+G(#^X3\E(?E2)HR#_'F(4?T%T[-\4@D4_* M/S3T+.=N#+8L)9JGN)7:`76)T=T4F%>:L)9"02*+J)-)+]U67*YP@!/$#CZU M]$+"$-L,9C*I!89FV4G7GF6**]%9D13#T=&S2O$"86J,%H4]U.RSPCI?FQ&2 MEVR-I]$]7CS!HHC;#SG(S+3.+#R`PI([%FRO'NZ<-7MJYZL3>8PQV?U#O*W^ M2U:X=)G]3GYG4/,=8X&:J@1.(;?M.%'7S:UXB56C8V*/MX&I-.KF)B>R\MJ,=:AEO/1K6#3,]9;[?9XH2H`6M M4&"!-5:[QLM&Q9BVCI0BWU:@P> M#HG;Y^VO$.]ES?TF-EV5"F2Z2KQ-VTO#Q6UA/RWNFPVAERW&,FI@2"+989H# M@;S1IA#U,VI5*(>RWKPP>FP@NR`Q;!IH_@W1VUDB>\2N<18(8CMT&]6H4=$. M/]=B)%J@BE>GT2 M,+]2UWA_`L7D;!OX?U-^_+0!@T);PSAPF-N,0('\K?5J%@46'34C7YF\X`8` M2LT&Q/L2Y87SGW77T1.JU8LL.N;CNCZ0;3>=P*/NK%MGB2["I8.E+[.[?LT. M&:B57]!-=]?Y[PPF@X*4[P2_H.4CBO@24&IFNABG3O$O85_+(#L.X$(N\)B0 M1R5.TR0FAK&'@\5MVHR_AD^9KGX-?CI=%Y=;'SNR=]?)!*+$_$41.SMLR\#:.$Z(Y5#2SO@ZR!18DS`KIL-TR6=U,JT% M($TI&`4%VU*WPE$6!D08PO%VB;N9+@HMAA,V#RNN+T1.U''5BUIY<`?N11V- M=?I1QW*.U/&K)U6I)[7"_E=7JF7NO%=7ZJLK]=65^NI*U>0)R>PMS&KRZQ+LXJ;:%+`LU'6A=4I<<''\-?3*,3\SY>[+) M_8(#3$OCQL:C.]B-@GD/C#?C$`:E40+-F*+ M1/"`9>\>QW]<10A=!PDB""<]2E[]IP_'PZX*AF]$ZOHU"!LIL/]:H'>6?%NB MV*LMV$B!Z?H>_H^+=L7`B@@O^EF.9 M7A1>PYA;!!]TDIO7,.<^A?0SBQ+9A*0)ZJ!I^9C1PA8V26H#%)982<,(J==3 M-T.II'SC(?=7831'F-;NI-5`=[&76^'7MP0!/FVT5H=-"Q(8ID,MHPQG5:ZH M-,9,MZU7\REC[E7;))8+PS>1(O*M)3JI]]':)L_])D(-Y4@CRK39-Z0-Y4') M$&',+=R[O*N';B`6\;>=OJ?>T6R=Y!I)[[/#L!">$\R8&QW)`HKVN^&+=A_P M'H:D%\X79F0:3`!0>M\?O/1*0G8P!\4VEZK"4\<]HND7V>,]#+34\>EMZYE` MXOLF!GRG,`SQ-X.E14MV!P;P]9_'`!TQ&UV(@0KS0&[(S&!ID3!WV,Q^13&= M,[/"LE"7D/ZJH.23Q2)B3O5KP@<P`7>J9Q_48\?Y(W MZ.1O%SVJ`O#S4+$__`M&*;P.8P6ON(EF8>+X?4DH[.M0`?UF[A-!:!V&?,HZ M>_J2W*YT067Z\.\4U2!\&-+.L;L*YPQ;[&D(25`9/X![1-VX*G<#VI1S<%[- M.7C7(>?@W%C.P;G"G(/S8><<'%H9!.-+5$6V7JLD:)CPT#(SS?M8CU^B MOPU%K8=755P:H-7@(+Z$@HJ'E-_+;]@<0%;%>45ABHDKZ49!EW+MN_2"S-R MDCL`L3VXW/8!E\)]S5U_S5T?8CU=K;GIAVI.?-MY[0,HU*L[;_U0!?LUYYTO M]I;4#38-GTDMX+@+-W0V/.*\W\18E0,PXE6:6URTYO]"_T<##LAO_A]02P,$ M%`````@`\X931)4Z'?D<$````K(``!$`'`!T875G+3(P,3,Q,C,Q+GAS9%54 M"0`#6B@%4UHH!5-U>`L``00E#@``!#D!``#M75MWVS82?MX]9_\#UR^;?=#= M<6PW;H\2VZGV.)8;*9?3EQR8A"0T%*@0I"/UU^\,>!%%BB0HR354N0^-3,P, MYIL97`87\O4O\ZEM/%!7,(=?'+7JS2.#D?'+S__Z MIP'_O?YWK69<,VI;Y\:E8]9Z?.3\9-R2*3TWWE%.7>(Y[D_&)V+[\.2W+SWN MP3/38P\4G@;5G!N=^DO+J-449`X-YKM1NMLV&Z=MT[.FQW%VCSB^2*NK3D_;3;;S6;G3(W] M/1-FS'SZW?Y=O)I_8%_&E)_Z-^3+M?F9?.Z3^SMO\?N\\_GW;W,Q/3O^U>0G MC47SFW_:\GYCYDBJU&E_>WPPDW5%`>#ZW&?^VCKQU=G;6D*41:89R?N_:D>A.`XOOB:"Q M9"AE!?2,"X]P\F*&)/'+1E"X0LK6DIX$I"PB]45M3,@LIAT1<2]IPX(& MQD6MV:IU6@D6U[&I6,LC2]8P<8=S?[H>KN6Y#6\QHPT@J@$5=9D9\Y4SK3*` M#OAXO7:R9(UVP^['=S$#@Y91-YVII,.F`0W9IE/*O6O'G5[2$?%M\,-WG]AL MQ*AU9'C$'5,/0U?,B$D+)$6Q3SAWH(E`&PZ?X+/9C$$;@`?_>(W!%%%@?U"YKM.B(<2;5 M:D)S,&I&Q)K\2;AE!'*,A*#7C;2(A&!?4*O/?Y:_9RX5($8RW<"#D#$DR6$R MB6WZ=C6>I2IK6<('D94KV_VMPX4#30EZ2NL-L;&M#B:4>B(P>GYQOL7;8&;L M.FEH\J0,(Q1B!%*,%Q\Y\2T&)?]]-GUDVSOB`KX)]1AH7>*'5=I\IW2J.&5% MZ&$[)K:9Z(_Z,YS00*UK&D<.7;Y#CHL^YO=C,2IO[+1&3:]OY ML>*5(K)\I[QX^N[C>/\BK.'PO'4+"8U+^Z,WOF"<"@%SJ7<.Y'9@0).Z MX42KC"C?+Z]P@@59C^T(D`!_M.I&(`U]$,[B&63T;`_4Z3-]\IIVBOMNA$*E4UD*=98RC4BP0?G M&^PD9MA_!.9?_IEOX;.TA3MU(^8[.`/V``,?LWN;=H6(,XG,TUQSMIIII9OY$[:R*_J1LALA-P'9]#DS#>8]Z[,P_.+\\U\G#;S:?UY@IWN3:93 MYLDD$?H(:.@XEZ)\.9LK(LBW_,NTY<^P%XDE'9R9!_Z]H-]]@'+U@`:(9LJI MI_D&/J15.= M3BE5O@,RJ6RA`PZY2\D==%>:0"E5OBLRN:W"V'RP#:/,SBTU=[0*_)%)C=7] M8;2>/9(V=5O-(^T"CV02XPH>:3][)&WJCII'.@4>R63,%3S2>?9(VM3':AXY M+O!()K^NX)'COY%'\']X0/L#'1GR8/^.!)L.L/=K.#9Q*6CBR./^.-: M=*KW*T"KSZ=V1(*B"PYV2[^FK1%6'(D@KIF1DCEX#D*<&95[-(U(^4B`QSQD MOTM48V`],.EH[`*R3>ZK0@86:C\BUAN4OU.0$'U50:8"]I&@OEW6LE/`T'2J M`EYM;8^$]S*N)`DW/#??6!Z<#_].'ZY_#<`=US-XYH1^T;6+X,+(C6-*404L M^%NTZG-A+36MHL32#-64B/@V4$)*$]2LCYT'<"I;N261H\5: M'OQ16S*KUE]X\:2H_K6,#6I[(GJRI3;92R.;JR-E;:"/PGT9E4A)O#J'+H MR4?2=Z[CSRZ.`ED,2(IT#B=.Q#3]J2\/5XQ<9SH#!637%YQ07X52C45#A%`C MXV-O0BWZ0&U'+H-"%SFF93C+&9\<;7>IK0.*NB9ZADXH%^R!,@Y_@N(BY=&J M3$^.\BVA'NWQ!RKPYMC0)5;*=T4$3Z[]9UQXA,AIK>J'ADEO<">04ERH>S+N\ MJ.@^N(]U<62".#RQE80S=3CDK>YB%SV`]8#U#)VN"//'8X_RF,,#>X.10&9^S%G#)=H72G,#UE M?\JJ^Z-+>N_A*A8>;A)#1[XN`<:EJ_D,3VG'@5J-1U?H-S!/Z//@,+2(H40@ M>[Y@1T[X_2 MF['!Q`)?)Q#A5:3='.HC#R9+_<-;$UE@RP)M410/YFI#_A[@PYXP\7:8Y(!7 M,C9N(T!;J\C#XMBCB#O"K#X?$!O"%9\Z7**(LR$%0FU11F,?YG%D3B6$96^[ MMDQ;+,F1+SSN'%TW&CIK':=,KRWFGA`^5K02<$-G0#W/ID%DRM#LQ>2M+53[D@:#*2?F3<)8(N5$*G.IJT%@O4:N:@&TZ8' MPJ2>T#%C?S6@IN^RX!Y9U/A5R?5%G,QKR@&K4FN+]VUR81&3@<0(E2G0%L4R M\'K`2"G_=3%FE#,3XM"L9\,SATI;?&\HETLEQ%Z./Q&JG#)ML70M2^[.$AOG M!CW^%N9['K$3RV"YY=IB6K\F6;QBJ3.>(,$"3>,+Z^%2>+QL4$"@+:K,)/LC MMZB;GIG$B$37:]9;S3OJRBW"8)\P,L".9&VZUB[YG]PDW2G.?W=CDEC6WRI\ MFB]W%SYK9.UC^"QA;!\^:V1I&S[+7"EPGX2'K]3R;2_9D8HWU/L!DQ-L')!% MPS_'ZV-HEP*?.I!V@&4UFG8I<&]"JH<+^9R:*`C3S"`/7]/K*D;4%O)T"ZCJ M4(KC:0MYVH93:FT+]TC"[:V5I:W5F*G*]-2!D=0W\88@W/521*G$M2\P5Z.\ M,I>VL9QHKW+W8+9R!B&W5%L\M]3#19AKQ[V3VN"9B>[,93:^C#_.G4NI]@K? M)37EN:M6&[7O@1JS:"\^/NPW=-X3UYS(;Q*TB\RPB3!MK;59JC5TX/\[3$AR M)3YUY[<+,+O(;7,D:AM67?C3"AH"?KX`)LP31D=7#0W<;JO)!=.+31L*^6I`V%3 M`*D%A6VE:!LF2RSA/@`>XY%;)!%D>>Y[+<[DZ;.MA.R!=1!1B;/Q\).89&U2 MA55;2ZP9)*DC42V7.!)99]><,/J`\[?@/-@'P@1]YQ"[/WKULHG_87^JGJH] M3F5/W3D],L[2:4>A3,8H,=O M&/7A$2CA+KH>##E(T:PWCV7JK'B49$-9^@5C%1@*W65U67L4/O^;>N&99V(/ MG?Z]1QB_<0B7F8_R2%U1BGXAHP:@+%@J2M$V3-;=5[BF\M7SX<>D$.L?,=:B M>PXE?-K:8&U7T!7RVRM\_,;AOL@9>.28HKCSM;54_9K29H`4^N%MI.Y;F"UO MV.`E+\BN@V5M/$]=932O*$C38%+!H!0_E03M4\B,G+S#TQ+@/J/L",5WR@B)U:B4TY]:6<+<5J M&%J;(2K?A=I.K+:AEMW=7;=O:_WA!]=_$YLS%=FTM4#N$@8>(HOGQ(F3.D%^ MV7REVL@V%:=?XZJ(1'&IJ+*XO0DEW)\B8B+!M"28$[6@46'4+3P*="X.!!7& MO7$Y#!7K#I]*<&T)[E1Y<*XL2+>0J("A=`"N+&C?0B9\A>?*H=`0W%FED*DD M2-.04<&@%#*5!.U3R(3'HE:OFFT4,]4E:1@TRB!4SYM5D+1?88/S=A*]!:!Z MK"BQ:QD@19HK1(42N[:A(-,T=N\'-_?:P39K@.[-8NW@"O-SF)3;[$^:?65- M,#W/G-=[O!JTM6LV5(+[[&M.+*HO$5<1H5]34]"^K+E5$;$WH0%Y#NXZRL-H M(MD)76"JK*T3`\%"&4ADE5 M.=J&2\&F_.?]=0*0QNO#V9]>V&=88 MOOCO$[']4*$(83FAMBB'H*FP<[8-\@JU17/K>'*E.EJ>'GC@F>`Z0>J302J4 MVGTPZ"/8T,7C4/B%HY[\.%;P[G''9N9B2.?>&SOQ?F9U\DV_]N1%,G8QRJ0^ MXC!$C3)^*Z/2SF<#?SJ%X.Z/PEZA:T)*Q;Q%W'ODE^O@E=MP2'KC0[Y'A>AR MZYT3["-"WJ#NFBIEFMBF[=G[$SSW+=^>$.J>1YI=K!R7=AG(0E9)I M!RQ>EX!\(T*1>J;KE\5RC)W;L-3IM?-2]+'!G+#++=8.2-_'3W!R"[K M7YQ\2Q+7R=$/3/ MWB+\$%^(HYWYD.1FS'MMA,XV1NAH;(0RW8_3P"LP:`?V:DY=DPF:['=2S_XZ M%5\W@L]=P\__`U!+`0(>`Q0````(`/.&4T1;_C0Y/Y````+=!``1`!@````` M``$```"D@0````!T875G+3(P,3,Q,C,Q+GAM;%54!0`#6B@%4W5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`/.&4T2=-JR@<`T``):>```5`!@```````$` M``"D@8J0``!T875G+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``UHH!5-U>`L``00E M#@``!#D!``!02P$"'@,4````"`#SAE-$HAK"*C`4``"!)`$`%0`8```````! M````I(%)G@``=&%U9RTR,#$S,3(S,5]D968N>&UL550%``-:*`53=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`\X931/V_9HW120``#$0$`!4`&``````` M`0```*2!R+(``'1A=6`Q0````(`/.&4T2%)[":)B@``%&H`@`5`!@````` M``$```"D@>C\``!T875G+3(P,3,Q,C,Q7W!R92YX;6Q55`4``UHH!5-U>`L` M`00E#@``!#D!``!02P$"'@,4````"`#SAE-$E3H=^1P0```"L@``$0`8```` M```!````I(%=)0$`=&%U9RTR,#$S,3(S,2YX`L``00E >#@``!#D!``!02P4&``````8`!@`:`@``Q#4!```` ` end EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P,#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C9?0V]N=F5R=&EB;&5?3F]T97-?86YD7TYO=&5S7SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C=?4F5L871E9%]087)T M:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/C1?26YT86YG:6)L95]!#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/C1?26YT86YG:6)L95]!#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/CA?4W1O8VMH;VQD97)S7T5Q=6ET M>5]$969I8VET7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/CA?4W1O8VMH;VQD97)S7T5Q=6ET>5]$969I8VET7S0\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T* M("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!# M96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$Q-#(W.3`\'0^1&5C(#,Q+`T* M"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M3QS<&%N/CPO2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0^)S(P,30\3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\P,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^)SQS<&%N/CPO'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO2`H9&5F:6-I M="D\+W-T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^ M)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#`P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPOF%T:6]N(&]F(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPOF%T:6]N(&]F M(&1E8G0@9&ES8V]U;G0@=&\@:6YT97)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG)FYB'0^)SQS<&%N/CPO M2P@3$Q#/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@W,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA&5C=71I=F4@3V9F:6-E'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO2!4'0^)SQS<&%N/CPO&5S(%!A:60\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@=&\@8V]M;6]N('-T;V-K/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5C=71I=F4@;V9F:6-E6UE;G0@ M86=R965M96YT(&%T("0P+C$P('!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5C=71I=F4@;V9F:6-E6UE;G0@86=R965M96YT(&%T("0P+C$P('!E'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@870@)#`N,3`@<&5R('-H87)E M+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B;&4@870@ M)#`N,3`@<&5R('-H87)E+"!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6UE M;G0@8V]N=')A8W0@9F]R(&%C:&EE=FEN9R!C87!I=&%L(')A:7-E(&=O86P@ M;V8@)#'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A="!A('!R:6-E(&]F("0P+C`T('1O("0P+C(T('!E'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A='1O7,@9F]R('-E'0^)SQS<&%N M/CPOF%T:6]N M(&%D:G5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@870@)#`N,#0@<&5R M('-H87)E+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B;&4@870@)#`N,#0@<&5R('-H87)E+"!A;6]U;G0\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`Q.2P@,C`Q,RP@=&AE($-O;7!A;GD@86YD($E4 M3"!E;G1E2P@251,)B,Q-#8[6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6UB;VP@)B,Q-#<[5$%51R8C,30X.R!B96=I;FYI;F<- M"F]N($%P'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2`S,2P@,C`Q,RP@=&AE($-O M;7!A;GD@6=I96YI8W,L($EN8RX@*"8C,30W.T=(228C,30X.RD@=&\@96YA8FQE M('1H92!#;VUP86YY(&]N(&%N(&5X8VQU2!C;VYT2X@5&AE('-H M87)E&5C=71I=F4@;V9F:6-E2!E;G1E2`H M=&AE($)2(%1E8VAN;VQO9WDI+B!"86-T97)I86P@4F]B;W1I8W,@:7,@9&5V M96QO<&EN9PT*82!W:&ET97!A<&5R('1O(&1E;&EV97(@=&\@=&AE($-O;7!A M;GD@9F]R(&%C8V5P=&%N8V4N(%5P;VX@86-C97!T86YC92!B>2!T:&4@0V]M M<&%N>2P@=&AE(%!A2!A;F0@8V]N=')O;&QI;F<@;W=N97(@=VAI8V@@=VEL;"!U'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!E>&5C=71E9"!A(&1E9FEN:71I=F4@86=R M965M96YT#0IT;R!A8W%U:7)E(%!I;'5S($5N97)G>2P@3$Q#("@F(S$T-SM0 M:6QU2!C;VUP86YY M(&%N9"!A(&1E=F5L;W!E2DN)B,Q-C`[ M)B,Q-C`[4&EL=7,@:7,@8V]N=F5R9VEN9R!D:6=E2!E;FAA;F-E9"!B86-T97)I82P@86QS;R!K;F]W;B!A2!C96QL=6QA2!M971A;"!P M;VES;VYI;F2!O9B!T M:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M!2`D,BPP,#`L,#`P M+B8C,38P.R8C,38P.TEN(&%D9&ET:6]N+`T*=&AE($-O;7!A;GD@<&%I9"!" M86-T97)I86P@4F]B;W1I8W,L($Q,0R`H)B,Q-#<[0E),3$,F(S$T.#LI+"!F M;W)M97)L>2!T:&4@<&%R96YT(&-O;7!A;GD@;V8@4&EL=7,L("0U,"PP,#`@ M870@8VQO6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6EN9R!U;F%U9&ET960@8V]N2!O9B!N;W)M M86P@'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2P@979E;B!I9B!T:&4@0V]M M<&%N>2!D;V5S(')A:7-E('-U9F9I8VEE;G0@8V%P:71A;"!T;R!S=7!P;W)T M(&ET6EN9R!C;VYS;VQI9&%T960-"F9I M;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P2!B92!U;F%B;&4-"G1O(&-O;G1I;G5E(&%S M(&$@9V]I;F<@8V]N8V5R;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP M="\Q,34E($-A;&EB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO M6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!C;VYS:61E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF5D M+B!7:&5N(&5Q=6EP;65N="!I6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E65A6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!K;F]W;B!A'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!C;VUP=71E2!A8V-O=6YT2!E>&-H86YG97,-"FET2!F;V-U M6UE;G0@=')A M;G-A8W1I;VYS+B!!4T,@-S$X+3$P(')E<75I&-E<'1I;VYS*2X@26YC'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!T;R!E87)N('1H M92!E<75I='D@:6YS=')U;65N=',@:7,@28C,30V.W,-"G!E2!R96-O9VYI>F5D(&-O;G-U M;'1I;F<@97AP96YS92!A;F0@82!C;W)R97-P;VYD:6YG(&EN8W)E87-E('1O M(&%D9&ET:6]N86P@<&%I9"UI;BUC87!I=&%L(')E;&%T960-"G1O('-T;V-K M(&ES'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`Q+"`R,#$R#0IW:&EC:"!R97%U M:7)E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A8V-O=6YT&5S('5T:6QI>FEN9R!T:&4@;&EA8FEL:71Y#0IM971H;V0@;V8@86-C;W5N M=&EN9RX@56YD97(@=&AE(&QI86)I;&ET>2!M971H;V0L(&1E9F5R&5S(&%R92!D971E"!B87-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5D(&%S6EN9R!A;6]U M;G0@;V8@=&AE(&%S2!W:6QL('!E'1E;G0@;W(@;6%N;F5R(&EN('=H:6-H(&%N(&%S M2!W;W5L9`T*6EN9R!A;6]U;G0@:7,@;F]T(')E M8V]V97)A8FQE('1H6EN9R!A;6]U;G0@86YD M(&5S=&EM871E9"!F86ER('9A;'5E+CPO<#X-"@T*/'`@2!E>'!E;G-E'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE7-I'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`H:2YE+B!D97)I=F5D M(&9R;VT@<')I8V5S*3L@86YD/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2!A;'-O(&1R86UA=&EC86QL>2!A9F9E8W0@=&AE(&5S=&EM871E M9`T*9F%I'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5S(&%R92!A8V-O=6YT960@ M9F]R('5N9&5R('1H92!L:6%B:6QI='D@;65T:&]D#0IO9B!A8V-O=6YT:6YG M(&9O0T*96YA8W1E9"!I;F-O;64@=&%X(')A=&5S(&5X M<&5C=&5D('1O(&%P<&QY('=H96X@=&AE(&%SF5D(&]R M('1H92!L:6%B:6QI='D@"!R871E"!L M:6%B:6QI=&EE2!A2!T:&%N M(&YO="!T;R!B92!R96%L:7IE9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE&5S(')E8V]G;FEZ960@:6X@86X@96YT M97)P2!!4T,@-S0P#0IA;F0@8V]N8VQU M9&5D('1H870@=&AE('1A>"!P;W-I=&EO;B!O9B!T:&4@0V]M<&%N>2!D;V5S M(&UE970@=&AE(&UO6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6EN9R!C M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/CQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Y)3L@=&5X M="UA;&EG;CH@65A M6QE/3-$)W9E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO2!T:&4@;W!E2=S(&-O;6UO;B!S=&]C:R!V86QU960@870@)#$L,3,Y+#@U,2X@ M5&AE($-O;7!A;GDF(S$T-CMS(&EN=&%N9VEB;&4@87-S971S)B,Q-C`[87)E M(&%S(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE65A6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4 M:6UEF%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[(&QI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&-L=7-I=F4@ M86YD('=OF4@86QL('!R M;V1U8W0@8V%N9&ED871E2!O9B!!B!430T**"8C,30W.TQI8V5N6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2`X+"`R,#$S+"!T:&4@ M0V]M<&%N>2!R96-E:79E9"!F2`Q-RP@ M,C`Q,RP@=&AE($-O;7!A;GD@9FEL960@82!L87=S=6ET(&%G86EN2!T:&4-"G!A2!W:6QL(&-H M86YG90T*:71S(&YA;64@86YD("@U*2!T:&4@6=I96YI8W,L($EN8RX\+VD^/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2`S,2P@ M,C`Q,RP@=&AE($-O;7!A;GD@97AE8W5T960@82!L:6-E;G-I;F<@86=R965M M96YT#0IW:71H($=(22`H2`V,C4L,#`P('-H87)E6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M&5C=71I=F4@3V9F:6-E2!I;B!L:65U M(&]F('1H92!R96UA:6YI;F<@)#$P-BPR-3`N)B,Q-C`[)B,Q-C`[5&AE($-O M;7!A;GD@=VEL;"!A;6]R=&EZ92!T:&4@;&EC96YS:6YG(&9E92!O=F5R('1H M92!F:79E('EE87(@;&EF92!O9B!T:&4-"FQI8V5N'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!E;G1EFEN9R!T:&4@3G5C;&5A2!W:71H M:6X-"FYI;F5T>2`H.3`I(&1A>7,@;V8@=&AE(&%G&ET:65S+"!A;F0@*&(I('1H90T*4&%R M=&EE2!P2P@:F]I;G1L>2!D M979E;&]P960@8GD@=&AE(%!A2P@=&AE($-O M;7!A;GD@:7-S=65D(&$@-2!Y96%R('=A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE&EM871E;'D@-"PQ M,C4L,#`P('-H87)E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2=S(&-O;6UO;B!S=&]C:R!W:71H('9A6QE/3-$)V9O;G0Z(#AP="\Q,34E M($-A;&EB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS M<&%N/CPO28C,30V.W,@9F]R;65R($-&3RP@0G)U8V4@2&%R;6]N+"!I M3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\P,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!;06)S M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2`H1&5F:6-I="D\+W1D/@T* M("`@("`@("`\=&0@8VQA6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!S;VQD(&9O<@T* M8V%S:"!U;F1E6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I2!I M;B!D979E;&]P:6YG(&)U2!A9W)E M960@=7!O;B!S97)V:6-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2P@-S`Y+#`Y,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS M(&-O;6UO;B!S=&]C:R!W97)E#0II2!C;VYV97)T960@82`D-3`P+#`P M,"!D96)E;G1U'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2`Q-2P@,C`Q,BP@ M=&AE(&9O&5C=71I=F4@;V9F:6-E6UE;G0@8V]N=')A8W0@=V%S(&%M96YD960@=&\@87=A28C M,30V.W,@8V]M;6]N('-T;V-K(&%T("0P+C$P('!E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2`Q M-2P@,C`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`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE&5C=71I=F4@;V9F:6-E2!U<"!T:&4@1W)E96X@2'EG M:65N:6-S(&QI8V5N'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A9W)E97,@=&\@<&%Y(#@E('1O(#$P)2!I;B!C87-H(&%N9"`X M)2!T;R`Q,"4@:6X@8V]M;6]N('-T;V-K(&]F('1H92!#;VUP86YY(&]F(&%L M;"!C87-H(&%M;W5N=',-"F%C='5A;&QY(')E8V5I=F5D(&)Y('1H92!#;VUP M86YY(&%N9"`R)2!F;W(@9&5B="!A2P@:6X@:71S('-O;&4@9&ES8W)E=&EO;BP@;6%Y(&UA:V4@861D M:71I;VYA;`T*8V%S:"!P87EM96YT6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UEF5S('1H92!A8W1I=FET>2!O M9B!T:&4@=V%R6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L M(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E)SX-"CQT6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI M9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE&5R8VES93PO8CX\+W`^#0H@("`@("`@(#QP M('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI M9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W9E M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Y M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5C=71I=F4@3V9F:6-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!# M86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E)SX- M"CQT6QE/3-$)V9O;G0Z M(#AP="!4:6UE3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE'!E8W1E9"!D:79I M9&5N9"!R871E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!O<'1I;VX@86-T:79I='D@87,@;V8@1&5C96UB97(@ M,S$L(#(P,3,L(&%N9`T*8VAA;F=E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S M='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E M6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE M/3-$)V)O6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I M9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U M)2<^/&9O;G0@6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z M(#AP="!4:6UE&5R8VES960\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z M(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V)O'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE3PO9F]N M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,R4[(&QI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,C@E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)W9E'!E8W1E9"!D:79I9&5N9"!R871E/"]F;VYT/CPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@'0M:6YD96YT.B`P M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B!787)R86YT(&%C=&EV:71Y(&%S(&]F($YO=F5M8F5R M(#,Q+"`R,#$S(&ES('!R97-E;G1E9`T*8F5L;W'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!#86QI M8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B86-K M9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`V-R4[(&QI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E&5R8VES M960\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#AP="\Q,34E($-A;&EB7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO6UE;G0-"F%G2!E;&5C=&5D('1O(&9O2!P6EN9R!H:7,@96UP;&]Y;65N="!A9W)E96UE;G0N/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="\Q,34E($-A;&EB'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E0T*8V]M<&QE=&5D(&ET28C,30X.RDL('!U2!!;65N9&UE;G0@3F\N,2!T;R!T:&4@06=R965M96YT M(&%N9"!0;&%N(&]F($UE2`R."P@,C`Q-`T* M*&-O;&QE8W1I=F5L>2P@=&AE("8C,30W.TUE2P@4&EL=7,@06-Q=6ES:71I M;VXL($Q,0RP@86X@3VAI;R!L:6UI=&5D(&QI86)I;&ET>0T*8V]M<&%N>2`H M)B,Q-#<[4&EL=7,@06-Q=6ER;W(F(S$T.#LI+"!"86-T97)I86P@4F]B;W1I M8W,L($Q,0RP@86X@3VAI;R!L:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY("@F M(S$T-SM"4B8C,30X.RDL(%!I;'5S($5N97)G>2P-"D1A;FEE;"!*+B!(87-S M971T+"!0:$0L("@F(S$T-SM(87-S971T)B,Q-#@[*2!A;F0@0V]D>2!(87)R M:7-O;B`H)B,Q-#<[2&%R2!W:6QL('!A>2!"4B!A('1O=&%L(&-A28C,30V.W,@;65M8F5R2!F;W(@=&AE(%=A6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!I;G-T96%D(&%G2!A2!T:&4@0V]M<&%N>2!F;W(@ M=&AE('!U2!M86X@:6YS=7)A;F-E(&ES(&EN('!L M86-E(&)Y('1H92!C;&]S:6YG(&]F('1H92!-97)G97(L("AV:2D@861D2!F;VQL M;W=I;F<@=&AE(&UE2X\+W`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`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2`R,#$Q+"!T:&4@0V]M M<&%N>2!H860@96YT97)E9"!I;G1O(&%N(&5X8VQU2!O9B!)5$PN($]N($1E8V5M8F5R(#$R+"`R,#$Q+"!T:&4@0V]M<&%N M>2!T97)M:6YA=&5D('1H:7,@;65M;W)A;F1U;2!O9B!U;F1E&-L=7-I=F4@86YD('=O'!E2`X+"`R,#$R+"!T:&4@0V]M<&%N>2!C:&%N9V5D(&ET6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`X+"`R,#$S+"!T:&4@0V]M M<&%N>2!R96-E:79E9"!F2!H860@8V]M<&QI960-"FEN(&%L;"!M M871E2`Q M-RP@,C`Q,RP@=&AE($-O;7!A;GD@9FEL960@82!L87=S=6ET(&%G86EN2!I2!W:6QL M(&-H86YG90T*:71S(&YA;64@86YD("@U*2!T:&4@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!C M:&%N9V5D(&ET2!O;B!A;B!E>&-L=7-I M=F4@8F%S:7,@9F]R($YO0T*<&%I9"`D,30S+#&5C=71I M=F4F(S$V,#MO9F9I8V5R)B,Q-C`[:7-S=65D#0IF2!T:&4@8VAI968@ M97AE8W5T:79E(&]F9FEC97(@=V5R92!R96-O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3VX@3V-T;V)E2!R96QA=&5D('1O('1H92!D979E;&]P;65N="!O9B!G96YE=&EC M86QL>2!M;V1I9FEE9"!M:6-R;RUO2!A8W1I M=F4L(&5V96X@=VET:"!L;W<@0D]$+T-/1"XF(S$V,#LF(S$V,#M/;@T*2F%N M=6%R>2`R."P@,C`Q-"P@=&AE(&%C<75I&EM871E;'D@)#(L,#`P+#`P,"XF(S$V,#LF(S$V,#M);B!A9&1I=&EO;BP- M"G1H92!#;VUP86YY('!A:60@0F%C=&5R:6%L(%)O8F]T:6-S+"!,3$,@*"8C M,30W.T)23$Q#)B,Q-#@[*2P@9F]R;65R;'D@=&AE('!A2!P86ED($)23$Q#("0Q,C4L,#`P+"!W:&EC M:"!I'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H-"@T*/'`@'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6EN M9R!U;F%U9&ET960@8V]N2!O9B!N;W)M86P@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/CQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE0T*;6%R:V5T2!O M9B!T:&4@'!E;G-E2!C;VYS:61E'!E;G-E9`T*87,@:6YC M=7)R960@86YD(&EM<')O=F5M96YTF5D#0II;B!O<&5R871I;VYS M+CPO<#X\2P@5&%U2!T2!C;VUP=71E M'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O8G1A:6YS(&5M<&QO>65E('-E65E M('-EF5D+CPO<#X-"@T* M/'`@2!A8V-O=6YT65E6UE;G1S('1O($YO;BU%;7!L M;WEE97,N(%5N9&5R($%30R`U,#4M-3`L('1H92!#;VUP86YY(&1E=&5R;6EN M97,@=&AE#0IF86ER('9A;'5E(&]F('1H92!W87)R86YT'!E;G-E(&%N9"!A;B!O9F9S M970@=&\@861D:71I;VYA;"!P86ED+6EN(&-A<&ET86P@:6X@2\H9&5F:6-I="D@;W9E<@T*=&AE(&%P<&QI8V%B M;&4@'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!H87,@861O<'1E9"!!4T,@,C$Q+3`U(&5F9F5C=&EV92!* M86YU87)Y(#$L(#(P,3(-"G=H:6-H(')E<75I6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2!T:&%T(&EN8VQU9&5S(&1I&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'`@2!A8V-O=6YT&5S('5T:6QI>FEN9R!T:&4@;&EA M8FEL:71Y#0IM971H;V0@;V8@86-C;W5N=&EN9RX@56YD97(@=&AE(&QI86)I M;&ET>2!M971H;V0L(&1E9F5R&5S(&%R92!D971E"!B87-E'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2!F:7AE9"!A'0^)SQP('-T>6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE7-I'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2`H:2YE+B!D97)I=F5D(&9R;VT@<')I8V5S*3L@86YD/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;'-O(&1R86UA=&EC86QL>2!A M9F9E8W0@=&AE(&5S=&EM871E9`T*9F%I'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6%B;&4L(&%C8W)U M960@97AP96YS97,@86YD(&1U92!T;R!R96QA=&5D('!A'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/CQS<&%N/CPO2!M971H;V0-"F]F(&%C8V]U;G1I;F<@9F]R(&EN M8V]M92!T87AE2!M971H;V0L(&9U='5R M92!T87@@;&EA8FEL:71I97,@86YD(&%S"!C;VYS97%U96YC97,@871T M2!S971T;&5D+B!4:&4@969F96-T(&]F(&$@8VAA;F=E(&EN(&EN M8V]M90T*=&%X(')A=&5S(&]N(&9U='5R92!I;F-O;64@=&%X(&QI86)I;&ET M:65S(&%N9"!AF5D('1O('1H92!E>'1E;G0@=&AA M="!T:&5Y(&%R92!C;VYS:61EF5D+CPO<#X-"@T*/'`@2!I;B!I;F-O;64@=&%X97,@&%M:6YA=&EO;B!B87-E9"!U<&]N('1H M92!T96-H;FEC86P@;65R:71S(&]F('1H90T*<&]S:71I;VXN($EF('1H92!M M;W)E+6QI:V5L>2UT:&%N+6YO="!T:')E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E0T*<&5R9F]R;65D(&$@ M'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[ M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R M/@T*/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)W9E6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE65A6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UEF%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2`H1&5F:6-I="D@*%1A M8FQE'0^)SQS<&%N/CPO6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@8V]L6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`X)3L@=&5X M="UA;&EG;CH@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO6QE/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)W=I9'1H M.B`X,"4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)W=I9'1H.B`Q M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`X."4[(&QI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA M;&EG;CH@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'!E8W1E9"!L:69E(&]F(&]P=&EO;G,@ M:6X@>65A6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)W9E&5R8VES93PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H M.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE M/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@&5R8VES86)L92!A="!$96-E;6)E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE M/CQS<&%N/CPO2!O9B!W87)R86YT(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'`@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[ M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS M+5-E6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E8W1E9"!D:79I9&5N M9"!R871E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="\Q,34E M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E8W1E9"!L:69E M(&]F('=A65A6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="\Q,34E M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!3 M86YS+5-E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="\Q,34E M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X M<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#AP="\Q M,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z M(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5R M8VES960\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0O M,3$U)2!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="\Q,34E M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[(&QI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M:6YD96YT.B`P+C5I M;B<^)B,Q-C`[/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)S4@>65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,#'0O M:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5F:6-I="D@*$1E=&%I;',I M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5R M8VES92!0&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES M960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS M<&%N/CPO'!I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,#'0O:'1M;#L@8VAA'0^)S4@>65A'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S$P('EE87)S/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,#'0O M:'1M;#L@8VAA&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA M&5R8VES86)L93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!0'0^)S@@>65A'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P,#'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5F:6-I="D@*$1E=&%I;',@ M-"D@*%531"`D*3QB'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)T]C=&]B92`R M.2P@,C`Q.#QS<&%N/CPO&UL/@T*+2TM+2TM/5].97AT4&%R=%\P,# XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Details 4) (USD $)
9 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Number of Warrants Granted

Number of Warrants Exercised

Number of Warrants Forfeited

Weighted Average Exercise Price Outstanding $ 0.1 $ 0.1

Exercise Price Granted

Exercise Price Exercised

Exercise Price Forfeited

Warrants

Number of Warrants Granted 75,000,000

Weighted Average Exercise Price Outstanding $ 75,000,000

Exercise Price Granted $ 10.026

Exercise Date Octobe 29, 2018

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ExerciseDate

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Details 3)
9 Months Ended

Dec. 31, 2013

Stockholders Equity Deficit Details 3

Volatility 168.32%

Expected life 5 years

Risk-free rate 1.27%

X

- Details

Name: TAUG_Disclosure8.StockholdersEquityDeficitDetails3Abstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

2. Summary of Significant Accounting Policies
9 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

2. Summary of Significant Accounting Policies
Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders’ deficit.

Cash Equivalents

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.

Equipment and Depreciation

Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Asset

Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.

Consolidated Financial Statements

The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.

Net Loss Per Common Share

The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.

Stock-Based Compensation

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders’ equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterparty’s performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.

Comprehensive Income

The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income.

Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

Income Taxes

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

Impairment of Long-Lived Assets

Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Research and Development

The Company expenses research and development costs as incurred.

Fair Value Measurements

ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements.



The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments classified as Level 1 - quoted prices in active markets include cash.

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.

Uncertainty in Income Taxes

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.

Recent Accounting Pronouncements

Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consoldiated Balance Sheets (Unaudited) (USD $)

Dec. 31, 2013

Mar. 31, 2013

Current assets:

Cash $ 57,628 $ 143,034

Other receivables 1,991 7,906

Investments - available for sale securities 50,000

Prepaid expense 19,534

Total current assets 109,619 170,474

Equipment, net of depreciation 26,853 28,382

Other assets:

Deferred financing costs 85,434

Advance to acquire Pilus Energy LLC 70,000

Lincense agreements, net of amortization 1,373,431

Total assets 1,665,337 198,856

CURRENT LIABILITIES

Notes payable 96,425 225,000

Convertible notes, net of discounts 558,773 106,425

Accounts payable 302,488 277,053

Accrued interest 51,343 8,004

Accrued expenses 143,737 148,348

Accrued professional fees 233,965 418,668

Total current liabilities 1,386,731 1,183,498

Stockholders' equity (deficit)

Common stock, par value $0.00001; 1,000,000,000 shares authorized, 401,366,096 and 226,449,077 issued and outstanding at December 31, 2013 and March 31, 2013 4,013 2,264

Additional paid-in capital 37,943,812 31,000,267

Accumulated deficit from prior operations (16,244,237) (16,244,237)

Accumulated deficit during development stage (21,230,874) (15,741,675)

Accumulated other comprehensive loss (194,108) (1,261)

Total stockholders' deficit 278,606 (984,642)

Total liabilties and stockholders' equity (deficit) $ 1,665,337 $ 198,856

X

- Definition

AccumulatedDeficitFromPriorOperations

+ References

No definition available.

+ Details

Name: TAUG_AccumulatedDeficitFromPriorOperations

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_AdvanceToAcquirePilusEnergyLlc1

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_DeferredFinancingCosts1

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_IntangibleAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statement of Stockholders' Equity (Deficit) (USD $)

Common Stock

Additional Paid-In Capital

Deficit accumulated from prior operations

Deficit accumulated during the development stage

Accumulatedothercomprehensiveincomeloss

Total

Beginning Balance, Amount at Mar. 31, 2012 $ 1,166 $ 20,770,505 $ (16,244,237) $ (4,595,168) $ (2,243) $ (69,977)

Beginning Balance, Shares at Mar. 31, 2012 116,667,888

Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Shares 48,844,286

Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Amount 489 5,190,633 5,191,122

Amendment to former chief executive officer's employment agreement at $0.10 per share, Shares 2,500,000

Amendment to former chief executive officer's employment agreement at $0.10 per share, Amount 25 249,975 250,000

Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Shares 2,500,000

Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Amount 25 249,975 250,000

Issuance of shares to purchase domain name at $0.125 per share, Shares 200,000

Issuance of shares to purchase domain name at $0.125 per share, Amount 2 24,998 25,000

Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period A net of vesting amortization, Shares 30,878,983

Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period, net of vesting amortization, Amount 308 4,505,881 4,506,189

Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Shares 2,720,000

Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Amount 27 225,792 225,819

Conversion of accounts payable at $0.10 per share, Shares 1,592,920

Conversion of accounts payable at $0.10 per share, Amount 16 95,559 95,575

Stock issued for commissions under private placement agreements, Shares 5,335,000

Stock issued for commissions under private placement agreements, Amount 53 688,947 689,000

Commission expense paid with stock issuances under private placements (689,000) (689,000)

Commission paid under private placement agreements in cash (643,956) (643,956)

Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares 2,500,000

Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount 25 624,975 625,000

Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares 2,500,000

Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount 25 624,975 625,000

Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, shares 360,000

Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, amount 4 47,396 47,400

Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, shares 200,000

Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, amount 2 29,998 30,000

Beneficial conversion feature related to JMJ financial 92,391 92,391

Issuance of shares to CEO as signing bonus under employment contract at $0.20 per share, shares 1,500,000

Issuance of shares to CEO as signing bonus under employment contract at $0.20 per share, amount 15 299,985 300,000

Issuance of shares to CEO as additional compensation at $0.04 per share, shares 4,000,000

Issuance of shares to CEO as additional compensation at $0.04 per share, amount 40 159,960 160,000

Issuance of shares to CFO under consulting agreement at $0.06 to $0.20 per share, shares 2,000,000

Issuance of shares to CFO under consulting agreement at $0.06 to $0.20 per share, amount 20 246,480 246,500

Issuance of shares to company attorneys for services rendered at $0.10 to $0.25 per share, shares 2,150,000

Issuance of shares to company attorneys for services rendered at $0.10 to $0.25 per share, amount 22 287,478 287,500

Consulting contract vesting amortization adjustment (2,082,680) (2,082,680)

Translation adjustment (11,146,507) (11,146,507)

Ending Balance, Amount at Mar. 31, 2013 2,264 31,000,267 (16,244,237) (15,741,675) (1,261) (984,642)

Ending Balance, Shares at Mar. 31, 2013 226,449,077

Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, amount 36,000

Issuance of shares to former chief financial officer at $0.04 to $0.07 per share, shares 360,000

Issuance of shares to former chief financial officer at $0.04 to $0.07 per share, amount 4 15,896 15,900

Issuance of shares for cash at $0.01 to $0.06 per share, shares 4,569,848

Issuance of shares for cash at $0.01 to $0.06 per share, amount 46 141,304 141,350

Issuance of shares to chief executive officer at $0.02 to $0.08 per share, shares 7,790,000

Issuance of shares to chief executive officer at $0.02 to $0.08 per share, amount 79 465,921 466,000

Issuance of shares to chief operating officer at $0.02 to $0.09 per share, shares 5,250,000

Issuance of shares to chief operating officer at $0.02 to $0.09 per share, amount 53 342,447 342,500

Issuance of shares to convert convertible debt at $0.02 to $0.09 per share, shares 63,635,121

Issuance of shares to convert convertible debt at $0.02 to $0.09 per share, amount 636 1,202,718 1,203,354

Issuance of shares to consultants at $0.02 to $0.09 per share, shares 80,461,224

Issuance of shares to consultants at $0.02 to $0.09 per share, amount 803 2,134,435 2,135,238

Contribution of 2,500,000 shares by chief executive officer to finalize licensing agreement at $0.04 106,250 106,250

Issuance of shares to settle accounts payable at $0.04 per share, shares 1,500,000

Issuance of shares to settle accounts payable at $0.04 per share, amount 15 59,985 60,000

Issuance of shares for loan commitment fee at $0.03 per share, shares 7,000,000

Issuance of shares for loan commitment fee at $0.03 per share, amount 70 209,930 210,000

Issuance of shares for available for sale investments $0.06 per share, shares 4,347,826

Issuance of shares for available for sale investments $0.06 per share, amount 43 249,957 250,000

Beneficial conversion feature of convertible 848,014 848,014

Stock-based compensation vesting 26,837 26,837

Strategic alliance warrant valuation 1,139,851 1,139,851

Impairment of available for sale securities (200,000) (200,000)

Translation adjustment 7,153 7,153

Net loss (5,489,199) (5,489,199)

Ending Balance, Amount at Dec. 31, 2013 $ 4,013 $ 37,943,812 $ (16,244,237) $ (21,230,874) $ (194,108) $ 278,606

Ending Balance, Shares at Dec. 31, 2013 401,363,096

X

- Definition

Amendment to former chief executive officer's employment agreement at $0.10 per share, Amount

+ References

No definition available.

+ Details

Name: TAUG_AmendmentToFormerChiefExecutiveOfficersEmploymentAgreementAt0.10PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amendment to former chief executive officer's employment agreement at $0.10 per share, Shares

+ References

No definition available.

+ Details

Name: TAUG_AmendmentToFormerChiefExecutiveOfficersEmploymentAgreementAt0.10PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_BeneficialConversionFeatureOfConvertible

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Beneficial conversion feature related to JMJ financial

+ References

No definition available.

+ Details

Name: TAUG_BeneficialConversionFeatureRelatedToJmjFinancial

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Commission expense paid with stock issuances under private placements

+ References

No definition available.

+ Details

Name: TAUG_CommissionExpensePaidWithStockIssuancesUnderPrivatePlacements

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Commission paid under private placement agreements in cash

+ References

No definition available.

+ Details

Name: TAUG_CommissionPaidUnderPrivatePlacementAgreementsInCash

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ConsultingContractVestingAmortizationAdjustment

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ContributionOf2500000SharesByChiefExecutiveOfficerToFinalizeLicensingAgreementAt0.04Amount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Conversion of accounts payable at $0.10 per share, Amount

+ References

No definition available.

+ Details

Name: TAUG_ConversionOfAccountsPayableAt0.10PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Conversion of accounts payable at $0.10 per share, Shares

+ References

No definition available.

+ Details

Name: TAUG_ConversionOfAccountsPayableAt0.10PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ImpairmentOfAvailableForSaleSecurities

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForAvailableForSaleInvestments0.06PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForAvailableForSaleInvestments0.06PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForCashAt0.01To0.06PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForCashAt0.01To0.06PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForLoanCommitmentFeeAt0.03PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesForLoanCommitmentFeeAt0.03PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoAsAdditionalCompensationAt0.04PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoAsAdditionalCompensationAt0.04PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoAsSigningBonusUnderEmploymentContractAt0.20PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoAsSigningBonusUnderEmploymentContractAt0.20PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoInLieuOfSalaryAtPriceOf0.04To0.24PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoInLieuOfSalaryAtPriceOf0.04To0.24PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoUnderEmploymentContractForAchievingCapitalRaiseGoalOf7500000At0.25PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCeoUnderEmploymentContractForAchievingCapitalRaiseGoalOf7500000At0.25PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCfoUnderConsultingAgreementAt0.06To0.20PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCfoUnderConsultingAgreementAt0.06To0.20PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToChiefExecutiveOfficerAt0.02To0.08PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToChiefExecutiveOfficerAt0.02To0.08PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToChiefOperatingOfficerAt0.02To0.09PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToChiefOperatingOfficerAt0.02To0.09PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCompanyAttorneysForServicesRenderedAt0.10To0.25PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToCompanyAttorneysForServicesRenderedAt0.10To0.25PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConsultantsAt0.02To0.09PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConsultantsAt0.02To0.09PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConvertCaeteInvestTradeS.A.DebtUnderConversionAgreementAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConvertCaeteInvestTradeS.A.DebtUnderConversionAgreementShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConvertConvertibleDebtAt0.02To0.09PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToConvertConvertibleDebtAt0.02To0.09PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToFormerCeoUnderEmploymentContractForAchievingCapitalRaiseGoalOf7500000At0.25PerShare

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToFormerCeoUnderEmploymentContractForAchievingCapitalRaiseGoalOf7500000At0.25PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToFormerChiefFinancialOfficerAt0.04To0.07PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToFormerChiefFinancialOfficerAt0.04To0.07PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToJmtFinancialToObtainLoanAt0.15PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToJmtFinancialToObtainLoanAt0.15PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares to purchase domain name at $0.125 per share, Amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToPurchaseDomainNameAt0.125PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares to purchase domain name at $0.125 per share, Shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToPurchaseDomainNameAt0.125PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToSettleAccountsPayableAt0.04PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesToSettleAccountsPayableAt0.04PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesUnderConsultingContractForStrategicPlanningOfficerAt0.10PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesUnderConsultingContractForStrategicPlanningOfficerAt0.10PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period, net of vesting amortization, Amount

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesUnderConsultingContractsAt0.10To0.29PerShareDuringPeriodNetOfVestingAmortizationAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period A net of vesting amortization, Shares

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfSharesUnderConsultingContractsAt0.10To0.29PerShareDuringPeriodNetOfVestingAmortizationShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Amount

+ References

No definition available.

+ Details

Name: TAUG_SaleOfCommonStockUnderPrivatePlacementAgreementsAt0.10To0.15PerShareAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Shares

+ References

No definition available.

+ Details

Name: TAUG_SaleOfCommonStockUnderPrivatePlacementAgreementsAt0.10To0.15PerShareShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_StockbasedCompensationVesting

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for commissions under private placement agreements, Amount

+ References

No definition available.

+ Details

Name: TAUG_StockIssuedForCommissionsUnderPrivatePlacementAgreementsAmount

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for commissions under private placement agreements, Shares

+ References

No definition available.

+ Details

Name: TAUG_StockIssuedForCommissionsUnderPrivatePlacementAgreementsShares

Namespace Prefix: TAUG_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_StrategicAllianceWarrantValuation

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_TranslationAdjustment

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Equipment (Details) (USD $)
9 Months Ended

Dec. 31, 2013

Mar. 31, 2013

Equipment Details

Computer and office equipment $ 55,085 $ 49,951

Less: accumulated depreciation 28,232 21,569

Equipment, Net $ 26,853 $ 28,382

Computer and office equipment useful life 5 years

X

- Details

Name: TAUG_EquipmentDetailsAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Intangible Assets (Details Narrative) (USD $)

Dec. 31, 2013

Mar. 31, 2013

Intangible Assets Details Narrative

Intangible Assets - domain name $ 1,373,431

X

- Details

Name: TAUG_IntangibleAssetsDetailsNarrativeAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_IntangibleAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

1. Nature of Business and Going Concern
9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

1. Nature of Business and Going Concern

Nature of Business

The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies.

In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (“ITL”) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the “License Agreement”) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (“Licensed Products”). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments.

On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.

On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction. The Company traded under the symbol “TAUG” beginning on April 9, 2013.

On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (“GHI”) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, Green Innovations Ltd. (“GNIN”) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8.

On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the “Parties”. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.

On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (“Pilus”), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry). Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (“EBR”) platform. This transformative technology is the basis of the Pilus Cell™. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current (“DC”) electricity, and produce economically important gases. The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules. Pilus’ highly metabolic bacteria are non-pathogenic. Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range. Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD. On January 28, 2014, the acquisition was completed. Pilus will operate as a wholly-owned subsidiary of the Company. As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000. In addition, the Company paid Bacterial Robotics, LLC (“BRLLC”), formerly the parent company of Pilus, $50,000 at closing. In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on June 12, 2013.

Going Concern

As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Management’s plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consoldiated Balance Sheets (Parenthetical) (USD $)

Dec. 31, 2013

Mar. 31, 2013

STOCKHOLDERS' DEFICIT

Common stock, par value $ 0.00001 $ 0.00001

Common stock, Authorized 1,000,000,000 1,000,000,000

Common stock, Issued 401,363,096 226,449,077

Common stock, outstanding 401,363,096 226,449,077

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

2. Summary of Significant Accounting Policies (Policies)
9 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Nature of Business

The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies.

In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (“ITL”) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the “License Agreement”) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (“Licensed Products”). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments.

On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated.

On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction. The Company traded under the symbol “TAUG” beginning on April 9, 2013.

On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (“GHI”) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, Green Innovations Ltd. (“GNIN”) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8.

On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the “Parties”. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement.

On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (“Pilus”), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry). Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (“EBR”) platform. This transformative technology is the basis of the Pilus Cell™. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current (“DC”) electricity, and produce economically important gases. The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules. Pilus’ highly metabolic bacteria are non-pathogenic. Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range. Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD. On January 28, 2014, the acquisition was completed. Pilus will operate as a wholly-owned subsidiary of the Company. As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000. In addition, the Company paid Bacterial Robotics, LLC (“BRLLC”), formerly the parent company of Pilus, $50,000 at closing. In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.

Basis of presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on June 12, 2013.

Going Concern
As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Management’s plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation
Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders’ deficit.

Cash Equivalents
For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.

Equipment and Depreciation
Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets
Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.

Consolidated Financial Statements
The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.

Net Loss Per Common Share
The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.

Stock-Based Compensation
The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders’ equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterparty’s performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.

Comprehensive Income
The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income.

Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

Income Taxes
The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

Impairment of Long-Lived Assets
Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Research and development
The Company expenses research and development costs as incurred.

Fair Value Measurements
ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements.



The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments classified as Level 1 - quoted prices in active markets include cash.

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.

Uncertainty in Income Taxes
Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.

Recent Accounting Pronouncements
Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

X

- Definition

Uncertainty in Income Taxes

+ References

No definition available.

+ Details

Name: TAUG_UncertaintyInIncomeTaxesPolicyTextBlock

Namespace Prefix: TAUG_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2303973

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 05

-Paragraph 4

-Subparagraph (a)-(d)

-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 40

-Section 45

-URI http://asc.fasb.org/section&trid=2197723

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2197087

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33801-111570

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30857-110895

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901

+ Details

Name: us-gaap_ForeignCurrencyDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144471

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155824

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155824

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Dec. 31, 2013

Feb. 18, 2014

Document And Entity Information

Entity Registrant Name TAURIGA SCIENCES, INC.

Entity Central Index Key 0001142790

Document Type 10-Q

Document Period End Date Dec. 31, 2013

Amendment Flag false

Current Fiscal Year End Date --03-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 522,934,923

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2014

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: TAUG_DocumentAndEntityInformationAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Equipment (Tables)
9 Months Ended

Dec. 31, 2013

Text Block [Abstract]

Equipment

December 31, March 31,

2013 2013 Estimated Life

Computer and office equipment $ 55,085 $ 49,951 5 years

Less: accumulated depreciation 28,232 21,569

$ 26,853 $ 28,382

X

- Definition

Tabular disclosure of all information related to any significant acquisition and disposal. Disclosure may include methodology and assumptions, type of asset, asset classification, useful life, useful purpose, acquisition cost, method of acquisition or disposal, depreciation method, gain (loss) on disposal pretax and net of tax, date of acquisition or disposal and restrictions on amount of proceeds from donated assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_PropertyPlantAndEquipmentScheduleOfSignificantAcquisitionsAndDisposalsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consoldiated Statements of Operations (Unaudited) (USD $)
3 Months Ended 9 Months Ended 25 Months Ended

Dec. 31, 2013

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

OPERATING EXPENSES

General and Administrative $ 1,162,138 $ 2,703,686 $ 4,460,880 $ 5,479,420 $ 16,602,528

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership 885,000 2,714,049 3,533,214

Depreciation and amortization expense 32,077 587 48,084 8,245 94,671

Total operating expenses 1,194,215 3,589,273 4,508,964 8,201,714 20,230,413

Loss from operations (1,194,215) (3,589,273) (4,508,964) (8,201,714) (20,230,413)

Other income (expense)

Interest expense (7,540) (3,410) (57,839) (5,922) (74,249)

Loss on conversion of debt (321,000) (321,000)

Gain on settlement of law suit 20,000

Amortization of debt discount (397,404) (601,396) (625,212)

Total other income (expense) (404,944) (3,410) (980,235) (5,922) (1,000,461)

Net loss (1,599,159) (3,592,683) (5,489,199) (8,207,636) (21,230,874)

Other comprehensive income (loss)

Translation adjustment 5,627 (5,706) 7,153 7,153

Impairment on available for sale investments (77,500) (200,000) (200,000)

Total other comprehensive income (loss) (71,873) (5,706) (192,847) (192,847)

Comprehensive loss $ (1,671,032) $ (3,598,389) $ (5,682,046) $ (8,207,636) $ (21,423,721)

Net loss per share (basic and diluted) $ 0.00 $ (0.02) $ (0.02) $ (0.05)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

Basic and diluted 347,748,207 196,957,424 258,387,696 156,677,929

X

- Definition

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership

+ References

No definition available.

+ Details

Name: TAUG_TherapiesLtd.ForFutureStockOwnership

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7656879&loc=d3e7290-112610

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 40

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6928171&loc=d3e6835-112609

+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 35

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6939497&loc=d3e30304-110892

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,d)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

6. Convertible Notes and Notes Payable
9 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

6. Convertible Notes and Notes Payable
Convertible Notes Payable

During the period of February 22, 2013 to December 31, 2013, the Company entered into 8% convertible promissory notes with various individuals aggregating $361,425. The notes are unsecured and are due 180 days from the date of issue. Should the notes not be repaid at the respective maturity date, the lender has the right to convert the unpaid principal and interest into common stock of the Company at $0.025 per share. During the nine months ended December 31, 2013, $265,000 of the notes were converted into 10,600,000 shares of the Company's common stock. The balance at December 31, 2013 was $96,425.

On October 19, 2012, the Company entered into a one year convertible promissory note agreement for $445,000 with JMJ Financial, a California based institutional investor. The note is non-interest bearing for the first 90 days and subsequent to that, the note has an interest rate of 5% per annum. The note, at the holder’s option, is convertible at $0.15 per share and if the price per share at the time of conversion is greater than $0.15 per share, on average for the previous 25 trading days, the conversion rate shall have a 25% discount, with the minimum price of $0.15 per share. The Company paid an origination fee of 200,000 shares of its common stock to secure the loan. On November 14, 2012, the Company received $150,000 and an additional $25,000 on March 27, 2013. The 25% discount created a beneficial conversion feature at the commitment date aggregating $37,500 representing a discount which is being accreted monthly from the issuance date of the note through maturity and is recorded as additional interest expense. At March 31, 2013, the loan balance is $106.425, net of unamortized discount of $68,575. During the nine months ended December 31, 2013, the Company issued 9,900,000 shares of its common stock to convert the note. Under the terms of the original agreement, approximately 4,125,000 shares were required to be issued. To entice the conversion, the Company issued an additional 5,775,000 shares resulting in a loss on conversion of $321,000.

The Company during the nine months ended December 31, 2013 and at various times has entered into convertible debt instruments with interest rates ranging between 8 and 10% per annum. The total proceeds from the notes aggregated $1,378,713. The notes are convertible into shares of the Company's common stock with varying price ranges. During the nine months ended December 31, 2013, the Company recorded a beneficial conversion feature of $848,014. At December 31, 2013, the Convertible notes were carried at $558,773 net of unamortized discount of $377,589.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

5. License Agreement
9 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

5. License Agreement

Immunovative Therapies, Ltd.

On December 12, 2011, the Company entered into a License Agreement (the “License Agreement”) with Immunovative Therapies, Ltd., an Israeli Corporation (“ITL”), pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all product candidates (the “Licensed Products”) based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covers two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vaz TM (“Licensed Products”).

On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013 and that the Company had complied in all material respect with the License Agreement therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated. No value has been assigned to the ITL shares as they are deemed to be worthless.

Green Hygienics, Inc.

On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1 and 8). The Licensing Agreement with GHI will enable the Company, on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products to commercial entities including medical facilities, schools, and more. The Company agreed to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, GNIN, issued the Company 625,000 shares of common stock of GNIN. The terms of the Licensing Agreement provides the equal recognition of profits between the Company and GHI on the sales by the Company.

As of December 31, 2013, the Company has paid $143,750 of the $250,000 licensing fee in cash and the Chief Executive Officer contributed 2,500,000 shares of common stock of the Company in lieu of the remaining $106,250. The Company will amortize the licensing fee over the five year life of the licensing agreement.

Bacterial Robotics, LLC

On October 29, 2013, the Company entered into a strategic alliance agreement between the Company and Bacterial Robotics, LLC (the Parties) to develop a relationship for the research and development of the NuclearBot Technology that will be marketed and monetized pursuant to a Definitive Agreement. Accordingly, subject to the terms of this agreement, (a) Bacterial Robotics agrees to develop a whitepaper which may be delivered as a readable electronic file, on the subject of utilizing the NuclearBot Technology in the cleansing of nuclear wastewater created in the operation of a nuclear power plant (the "Whitepaper"), which Bacterial Robotics shall deliver to the Company within ninety (90) days of the agreement, which may be extended upon mutual agreement based upon unexpected complexities, and (b) the Parties agree to use commercially reasonable efforts in good faith to (1) identify prospective pilot programs, projects and opportunities for the NuclearBot Technology for the Parties to strategically and jointly pursue, (2) enter into a joint venture, in which the Company will be the majority and controlling owner, for the purpose of (A) marketing and selling products and services utilizing the NuclearBot Technology, (B) sublicensing the NuclearBot Technology and (C) owning all improvements to the NuclearBot Technolgoy, and other inventions and intellectual property, jointly developed by the Parties and (3) negotiate its terms and conditions of Definitive Agreements. As consideration for the Strategic Alliance, the Company issued a $25,000 deposit upon signing the agreement. Additionally, the Company issued a 5 year warrant for up to 75,000,000 shares of the Company's common stock with a value of $1,139,851.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Intangible Assets (Details) (USD $)
9 Months Ended

Dec. 31, 2013

Mar. 31, 2013

Intangible Assets Details

Licensing fee $ 1,414,851

Less: accumulated amortization 41,420

Intangible Asset $ 1,373,431

Intangible Asset Estimated Life 5 years

X

- Details

Name: TAUG_IntangibleAssetsDetailsAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_LicensingFee

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Intangible Assets (Tables)
9 Months Ended

Dec. 31, 2013

Intangible Assets Tables

Intangible Assets

December 31, March 31,

2013 2013 Estimated Life

Licensing fee $ 1,414,851 $ - 5 years

Less: accumulated amortization 41,420 -

$ 1,373,431 $ -

X

- Details

Name: TAUG_IntangibleAssetsTablesAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

9. Commitments
9 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

9. Commitments

On August 22, 2012, the Company entered into an employment agreement with Seth M. Shaw, its chief executive officer. The agreement provides for annual compensation of $132,000. Mr. Shaw previously elected to forgo cash compensation and receive 60,000 shares of the Company’s common stock on a monthly basis. However, as the only principal officer and director, he decided to take the cash compensation as well and is in the process of modifying his employment agreement.

The Company is liable for an additional $25,000 in connection with the strategic alliance agreement with Bacterial Robotics, LLC.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

7. Related Parties
9 Months Ended

Dec. 31, 2013

Notes to Financial Statements

7. Related Parties
On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1, 4, 5 and 8). The Company’s former CFO, Bruce Harmon, is the CFO and Chairman of GNIN, the parent company of GHI.

X

- Details

Name: TAUG_NotesToFinancialStatementsAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit)
9 Months Ended

Dec. 31, 2013

Equity [Abstract]

8. Stockholders' Equity (Deficit)
Common Stock

During the year ended March 31, 2012, the Company sold for cash under private placement agreements 6,624,452 shares of its common stock at $0.05 per share.

During the year ended March 31, 2012, the Company issues to various consultants 14,485,000 shares of its common stock at prices ranging between $0.10 and $0.14 per share. These shares were valued at the market price of the stock on the date of the commitment. These consulting agreements were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions, and other mutually agreed upon services. The aggregate value of the shares has been recorded as stock based compensation.

The Company issues 1,565,000 shares of its common stock in connection with the settlement agreements. The shares were valued at $0.14, the value at the date of settlement

During the year ended March 31, 2012, the Company converted unpaid rent on the corporate office in the amount of $78,000. Accordingly, 709,090 shares of the Company’s common stock were issued at $0.1098 per share. The rent was payable to a party related to the former chief executive officer.

On July 11, 2011, the Company converted a $500,000 debenture along with accrued penalties for being in default and accrued unpaid interest into 10,000,000 shares of the Company’s common stock and recognized a loss on extinguishment of $336,836.

During the year ended March 31, 2013, the Company sold for cash under private placement agreements, 48,844,286 shares of its common stock at an average price of $0.10 per share.

On May 15, 2012, the former chief executive officer’s employment contract was amended to award him an additional 2,500,000 shares of the Company’s common stock at $0.10 per share, the value at the date of commitment. Additionally, his employment contract was amended to award him an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.

On May 15, 2012, the strategic planning vice president was issued a consulting agreement for 36 months. In connection with the agreement, he was issued 2,500,000 shares of the Company’s common stock and an additional 2,500,000 shares conditional upon the Company raising a total of $7,500,000 in private placement funds.



The Company issued 200,000 shares of its common stock at $0.125 per share to obtain the rights to a domain name.

On May 21, 2012, the Company issued 2,720,000 shares of its common stock to convert the Caete Invest & Trade, S.A. debt plus accrued interest. The note principal and accrued interest aggregated $225,819.

During the year ended March 31, 2012, the Company converted $95,575 of accounts payable by issuing 1,592,920 shares of its common stock at an average price of $0.06 per share.

On October 19, 2012, the Company issued 200,000 shares of its common stock to obtain a loan at $0.15 per share.

On August 22, 2012, a signing bonus in the amount of 1,500,000 shares was issued to the chief executive officer in connection with his employment contract. The shares were valued at $0.20 per share, the value at commitment date.

In December 2012, the board approved the issuance of an additional 4,000,000 shares to the Company’s chief executive officer. The shares were valued at $0.04 per share, the value at the date of commitment.

In connection with the chief financial officer consulting agreement dated September 1, 2012, and subsequent modification, 2,000,000 shares were awarded at a price ranging from $0.06 to $0.20 per share.

The Company, during the course of the year has issued 2,150,000 shares of its common stock at prices ranging from $0.10 to $0.25 per share for legal services.

Commencing October 2012, the chief executive officer received 360,000 shares (60,000 per month) of the Company’s common stock as salary in lieu of cash. These shares were valued between $0.04 and $0.24 per share. His employment agreement was subsequently modified in December 2012 to begin cash compensation in addition to the 60,000 shares award per month.

During the year ended March 31, 2013, the Company issued to various consultants 30,878,983 shares of its common stock at prices ranging between $0.10 and $0.29 per share. These shares were valued at the market price of the common stock on the date of commitment. There consulting agreement were issued to the consultants to assist the Company in developing business strategies, assist in capital introductions and the mutually agreed upon services. The aggregate value of the shares has been recorded as stock-based compensation.

The Company issued 5,335,000 shares of its common stock and 643,956 in cash as commissions related to the private placement agreements.

During the nine months ended December 31, 2013, the Company issued to its chief financial officer 360,000 shares of its common stock at $0.04 to $0.07 per share for services rendered in accordance with his consulting contract.

During the nine months ended December 31, 2013, the Company issued 4,569,848 shares of its common stock in exchange for $141,350.

During the nine months ended December 31, 2013, the Company issued to its chief executive officer a total of 7,790,000 shares of its common stock at prices ranging from $0.02 to $0.08 per share for services in lieu of cash compensation.

During the nine months ended December 31, 2013, the Company issued to its chief operating officer a total of 5,250,000 shares of its common stock at prices ranging from $0.02 to $0.09 per share for services in lieu of cash compensation.

During the nine months ended December 31, 2013, the Company issued collectively 63,635,121 at prices ranging from $0.02 to $0.09 per share for the conversion of a $1,203,354 convertible debt.

During the nine months ended December 31, 2013, the Company issued to various consultants collectively 80,461,224 shares of its common stock at prices ranging from $0.02 to $0.09 per share.

During the nine months ended December 31, 2013, the Company issued 1,500,000 at $0.04 per share in settlement of legal fees.

During the nine months ended December 31, 2013, the Company issued 7,000,000 shares at $0.03 per share for a commitment fee relating to a convertible debt arrangement.

During the nine months ended December 31, 2013, the Company issued 4,387,826 shares of its common stock to Green Hygienics in connection with a license agreement.

During the nine months ended December 31, 2013, the chief executive officer contributed 2,500,000 shares to the Company to fully pay up the Green Hygienics license fee. The shares were valued at $0.04 per share totaling $106,250.

In connection with the consulting agreements and the board advisory agreements, the agreements have as part of the compensation arrangements, the following clauses: a) the consultant will be reimbursed for all reasonable out of pocket, b) to the extent the consultant introduces the Company to any sources of equity or debt arrangements, the Company agrees to pay 8% to 10% in cash and 8% to 10% in common stock of the Company of all cash amounts actually received by the Company and 2% for debt arrangements, and c) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant’s performance.

Warrants for Common Stock

The following table summarizes the activity of the warrants for common stock issued in 2010 in connection with consulting agreements outstanding as at December 31, 2013:

Number of

Warrants

Exercise

Price

Expiration

Date

Balance March 31, 2013 394,465 $ 0.75 8/2014

Exercised -

Balance December 31, 2013 394,465

The warrants were valued utilizing the following assumption employing the Black-Scholes Pricing Model:

Volatility 241.65% to 244.92%

Risk-free rate 1.34% to 0.41%

Dividend -

Expected life of warrants 3

Stock Options

On February 1, 2012, the Company awarded 5,000,000 options to purchase common shares to its former Chief Executive Officer and 5,000,000 options to purchase common shares to the vice president – strategic planning, currently the Chief Executive Officer. These options vested immediately and were for services performed. The Company recorded stock-based compensation expense of $1,400,000 for the issuance of these options. The following weighted average assumptions were used for Black-Scholes option-pricing model to value these stock options:

Volatility 220 %

Expected dividend rate -

Expected life of options in years 10

Risk-free rate 1.87 %

A summary of option activity as of December 31, 2013, and changes during the period then ended, is presented below:

Weighted

Weighted Average

Average Remaining Aggregate

Exercise Number of Contractual Intrinsic

Options Price Shares Term Value

Balance March 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

Options granted - - - -

Options exercised - - - -

Options cancelled/forfeited - - - -

Balance at December 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

Exercisable at December 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

In connection with the strategic alliance with Bacterial Robotics, LLC, the Company isued on October 29, 2013 a warrant to acquire up to 75,000,000 shares of the Company’s Common stock. The warrant was valued at $1,139,851 utilizing the Black-Scholes option-pricing model. The assumptions utilized in the claculations are as follows:

Volatility 168.32 %

Expected dividend rate -

Expected life of warrant in years 5

Risk-free rate 1.27 %

A summary of Warrant activity as of November 31, 2013 is presented below:

Number of Warrants Outstanding Exercise Price Exercise Date

Balance March 31, 2013 - - -

Granted - October 29, 2013 75,000,000 $ 10.026 October 29, 2018

Exercised -

Cancelled -

Balance December 31, 2013 75,000,000

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

10. Subsequent Events
9 Months Ended

Dec. 31, 2013

Subsequent Events [Abstract]

10. Subsequent Events

On January 28, 2014 (the "Closing Date"),the Company completed its acquisition of Pilus Energy LLC, an Ohio limited liability company (“Pilus Energy”), pursuant to the terms of an Agreement and Plan of Merger, as amended by Amendment No.1 to the Agreement and Plan of Merger, dated January 28, 2014 (collectively, the “Merger Agreement”) by and among the Company, Pilus Acquisition, LLC, an Ohio limited liability company (“Pilus Acquiror”), Bacterial Robotics, LLC, an Ohio limited liability company (“BR”), Pilus Energy, Daniel J. Hassett, PhD, (“Hassett”) and Cody Harrison (“Harrison”), and such other individuals who joined as parties to the Merger Agreement by execution of a joinder agreement prior to the closing of the merger transaction.

Pursuant to the terms of the Merger Agreement, on the Closing Date, Pilus Acquiror merged with and into Pilus Energy, with Pilus Energy being the surviving entity and becoming a wholly owned subsidiary of the Company. The Company will pay BR a total cash consideration of $50,000, payable by February 20, 2014, in connection with the Merger Agreement, and issued Warrants exercisable for up to 100 million shares of Common Stock of the Company (the “Warrants”) to BR, its members and Pilus Energy’s members, who each exchanged, on a pro-rata basis, their membership interests in BR and Pilus Energy for the Warrants.

In addition, the parties to the Merger Agreement, dated November 25, 2013, agreed to amend certain covenants and closing conditions thereto prior to the closing of the Merger. The material changes set forth in the Amendment No. 1 to the Merger Agreement included: (i) the elimination of the covenant that the Company complete a reverse stock split as a condition to closing of the Merger, (ii) a replacement of the requirement to raise $2.25 million by the Company within 180 days of execution of the Merger Agreement, with a requirement that the Company instead agreed to pay BR (a) $75,000 upon the receipt by the Company of the first $1 million of funding for pilot programs or other projects utilizing the intellectual property assigned to the Company by Pilus Energy as part of the Merger and (b) $100,000 upon receipt by the Company of a second $1 million in funding by the Company for the purpose of funding projects that use the intellectual property acquired in the merger, (iii) revise certain Intellectual Property sections of the Merger Agreement to reflect the right to use certain Trademarks and Trade Secrets by Tauriga, (iv) add a covenant that the Company will cover the costs related to Pilus Energy’s intellectual property following the consummation of the Merger, (v) add a covenant that Tauriga shall establish a stock option plan for BR, (vi) add a guarantee that key man insurance is in place by the closing of the Merger, (vi) address a plan for management of Pilus Energy following the merger, and (vii) revise the Merger Agreement to reflect the Assignment (and ownership) of certain Pilus Energy intellectual property, rather than the granting of a License to use such intellectual property.

In connection with the closing of the merger, BR, Jason E. Barkeloo, the Chief Executive Officer of BR, Hassett, Harrison and each member of Pilus Energy entered a Release and Covenant Not to Sue in favor of the Company, and a Standstill and Voting Agreement with the Company, agreeing to restrictions on acquisition of additional Company capital stock, transactions involving Company or proxy solicitations. The BR and Pilus Energy members that were not previously a party to the Merger Agreement (at the time of initial signing on November 25, 2013), also signed a Joinder Agreement binding them to the terms of the Merger Agreement prior to the Closing.

Subsequent to December 31, 2013, the Company issued 54,557,827 shares in connection with the Conversion of Convertible Notes and issued 67,014,000 in connection with consulting agreements.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

1. Nature of Business and Going Concern (Details Narrative) (USD $)
3 Months Ended 9 Months Ended 25 Months Ended

Dec. 31, 2013

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nature Of Business And Going Concern Details Narrative

Net operating losses $ 1,599,159 $ 3,592,683 $ 5,489,199 $ 8,207,636 $ 21,230,874

Stock-based compensation (3,101,043) (2,924,227) (11,498,376)

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership $ (885,000) $ (2,714,049) $ (3,533,214)

X

- Details

Name: TAUG_NatureOfBusinessAndGoingConcernDetailsNarrativeAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership

+ References

No definition available.

+ Details

Name: TAUG_TherapiesLtd.ForFutureStockOwnership

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 40 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Details 1)
9 Months Ended

Dec. 31, 2013

Volatility 168.32%

Risk-free rate 1.27%

Expected life 5 years

StockOptions [Member]

Volatility 220.00%

Risk-free rate 1.87%

Dividend rate 0.00%

Expected life 10 years

Warrant [Member]

Volatility, Minimum 241.65%

Volatility, Maximum 244.92%

Risk-free rate, Minimum 0.41%

Risk-free rate, Maximum 1.34%

Dividend rate 0.00%

Expected life 3 years

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 41 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended 25 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (5,489,199) $ (8,207,636) $ (21,230,874)

Adjustments to reconcile net loss to cash provided by (used in) operating activities:

Stock based compensation 3,101,043 2,924,227 11,498,376

Shares issued in Settlement Agreement 153,000

Impairment of advances to Immunovative Therapies, LTD, for future stock ownership 2,665,050 3,533,214

Amortization of debt discount to interest expense 539,001 3,410 562,817

Depreciation and amortization 48,083 8,245 94,670

Loss on conversion of debt 321,000 321,000

Decrease (increase) in assets

Other receivables 5,915 (109,900) (1,991)

Prepaid expense 19,534 (14,928) 16,758

Increase (decrease) in liabilities

Accounts Payable 85,435 147,524 232,977

Accrued salaries and wages 7,846

Accrued interest 53,339 (31,600) 41,191

Accrued expense (4,611) 96,678 86,277

Accrued professional fees (184,703) (98,832) (96,437)

Related party payables 90,000 (96,884)

Cash used in operating activities (1,505,163) (2,519,916) (4,885,906)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of Equipment (5,134) (2,940) (28,954)

Purchase of intangible assets-domain name (7,893) (7,893)

Purchase of license (168,750) (168,750)

Advance to acquire Pilus Energy, LLC (70,000) (70,000)

Advances to Immunovative Therapies LTD, for future stock ownership (2,665,050) (3,533,214)

Cash used in investing activities (243,884) (2,675,883) (3,808,811)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from notes payable 136,425 150,000 361,425

Repayment of note payable to Chief Executive Officer (52,364) (125,503)

Sale of Common Stock 141,350 5,191,123 7,402,827

Proceeds from convertible debentures 1,378,713 1,553,713

Commisions paid on sale of common stock (643,956) (643,956)

Cash provided by financing activities 1,656,488 4,644,803 8,548,506

Foreign Currency Translation Effect 7,153 2,243 34,296

Net increase / (decrease) in cash (85,406) (548,753) (85,406)

CASH, BEGINNING OF PERIOD 143,034 619,624 169,543

CASH, END OF PERIOD 57,628 70,871 57,628

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Interest and Taxes Paid

NON CASH ITEMS

Conversion of accounts payable to common stock (65,000) (95,559)

Conversion of convetible notes payable to common stock (1,378,354) (179,572) (1,557,926)

Issuance of common stock to settle commissions on private placement offering (689,000) (689,000)

Conversion of accrued interest on Caete Invest & Trade, S.A. to common stock (46,247) (46,247)

Purchase of intangible asset-domain with commons stock (25,000) (25,000)

Investments in available for sale securities (250,000) (250,000)

Impairment of available for sale securities (200,000) (200,000)

Comprehensive loss 200,000 200,000

Investment in Green Hygienics, Inc. (106,250) (106,250)

Issuance of common stock 778 88 876

Additional paid-in-capital 2,788,242 1,004,731 3,823,522

Beneficial Conversion Feature (848,014) (37,500) (940,405)

Additional paid in capital 848,014 37,500 940,405

Deferred financing costs 85,435 85,435

Licensing agreement - Warrant $ (1,139,851) $ (1,139,851)

X

- Definition

Additional paid in capital

+ References

No definition available.

+ Details

Name: TAUG_AdditionalPaidInCapital1

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_AdvancesToImmunovativeTherapiesLtdForFutureStockOwnership

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_AdvanceToAcquirePilusEnergyLlc

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_AmortizationOfDebtDiscountsToInterestExpense

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Beneficial Conversion Feature

+ References

No definition available.

+ Details

Name: TAUG_BeneficialConversion

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

CommisionsPaidOnSaleOfCommonStock

+ References

No definition available.

+ Details

Name: TAUG_CommisionsPaidOnSaleOfCommonStock

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ComprehensiveLoss

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Conversion of accounts payable to common stock

+ References

No definition available.

+ Details

Name: TAUG_ConversionOfAccountsPayableToCommonStock

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_DeferredFinancingCosts

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Impairment of advances to Immunovative Therapies, LTD, for future stock ownership

+ References

No definition available.

+ Details

Name: TAUG_ImpairmentOfAdvances

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_ImpairmentOfAvailableForSaleSecurities

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Accrued professional fees

+ References

No definition available.

+ Details

Name: TAUG_IncreaseDecreaseInAccruedProfessionalFees

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Interest and Taxes Paid

+ References

No definition available.

+ Details

Name: TAUG_InterestAndTaxesPaid

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_InvestmentInGreenHygienicsInc.

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_InvestmentsInAvailableForSaleSecurities

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_IssuanceOfCommonStockToSettleCommissionsOnPrivatePlacementOffering

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_LicensingAgreementWarrant

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_LossOnConversionOfDebt

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_PurchaseOfIntangibleAssetdomainWithCommonsStock

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

PurchaseOfIntangibleAssetsdomainName

+ References

No definition available.

+ Details

Name: TAUG_PurchaseOfIntangibleAssetsdomainName

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_PurchaseOfLicense

Namespace Prefix: TAUG_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of other increase (decrease) in additional paid in capital (APIC).

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow for acquisition of machinery and equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireMachineryAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Intangible Assets
9 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

4. Intangible Assets

Intangible assets consist of the cost of: (1) a license fee with Green Hygienics, Inc. (see Notes 1, 5 and 8). The Company has paid cash of $143,750 and the chief executive officer contributed 2,500,000 shares of the Company's common stock valued at $106,250 for a total license fee value of $250,000 and (2) A strategic alliance agreement to utilize technology owned by Bacterial Robotics in the cleansing of nuclear wastewater created by the operation of a nuclear power plant. The company paid cash of $25,000 and issued a warrant for up to 75,000,000 shares of the Company's common stock valued at $1,139,851. The Company’s intangible assets are as follows:

December 31, March 31,

2013 2013 Estimated Life

Licensing fee $ 1,414,851 $ - 5 years

Less: accumulated amortization 41,420 -

$ 1,373,431 $ -

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Details 2) (USD $)
9 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Stockholders Equity Deficit Details 2

Number of Options Outstanding 10,000,000 10,000,000

Number of Options Granted

Number of Options Exercised

Number of Options Forfeited

Number of Options Exercisable 10,000,000

Weighted Average Exercise Price Outstanding $ 0.1 $ 0.1

Weighted Average Exercise Price Granted

Weighted Average Exercise Price Exercised

Weighted Average Exercise Price Forfeited

Weighted Average Exercise Price Exercisable $ 0.1

Weighted Average Remaining Contractual Life (in years) Outstanding 8 years 11 months 1 day

Weighted Average Remaining Contractual Life (in years) Exercisable 8 years 11 months 1 day

Aggregate Intrinsic Value Outstanding $ 400,000 $ 400,000

Aggregate Intrinsic Value Granted

Aggregate Intrinsic Value Exercised

Aggregate Intrinsic Value Forfeited/canceled

Aggregate Intrinsic Value Exercisable $ 400,000

X

- Details

Name: TAUG_Disclosure8.StockholdersEquityDeficitDetails2Abstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 39 232 1 false 8 0 false 4 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://imun.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0002 - Statement - Consoldiated Balance Sheets (Unaudited) Sheet http://imun.com/role/ConsoldiatedBalanceSheets Consoldiated Balance Sheets (Unaudited) false false R3.htm 0003 - Statement - Consoldiated Balance Sheets (Parenthetical) Sheet http://imun.com/role/ConsoldiatedBalanceSheetsParenthetical Consoldiated Balance Sheets (Parenthetical) false false R4.htm 0004 - Statement - Consoldiated Statements of Operations (Unaudited) Sheet http://imun.com/role/ConsoldiatedStatementsOfOperations Consoldiated Statements of Operations (Unaudited) false false R5.htm 0005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://imun.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 0006 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) Sheet http://imun.com/role/ConsolidatedStatementOfStockholdersDeficit Consolidated Statement of Stockholders' Equity (Deficit) false false R7.htm 0007 - Disclosure - 1. Nature of Business and Going Concern Sheet http://imun.com/role/NatureOfBusinessAndGoingConcern 1. Nature of Business and Going Concern false false R8.htm 0008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://imun.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies false false R9.htm 0009 - Disclosure - 3. Equipment Sheet http://imun.com/role/Equipment 3. Equipment false false R10.htm 0010 - Disclosure - 4. Intangible Assets Sheet http://imun.com/role/IntangibleAssets 4. Intangible Assets false false R11.htm 0011 - Disclosure - 5. License Agreement Sheet http://imun.com/role/LicenseAgreement 5. License Agreement false false R12.htm 0012 - Disclosure - 6. Convertible Notes and Notes Payable Notes http://imun.com/role/ConvertibleNotesAndNotesPayable 6. Convertible Notes and Notes Payable false false R13.htm 0013 - Disclosure - 7. Related Parties Sheet http://imun.com/role/RelatedParties 7. Related Parties false false R14.htm 0014 - Disclosure - 8. Stockholders' Equity (Deficit) Sheet http://imun.com/role/StockholdersEquityDeficit 8. Stockholders' Equity (Deficit) false false R15.htm 0015 - Disclosure - 9. Commitments Sheet http://imun.com/role/CommitmentsAndContingencies 9. Commitments false false R16.htm 0016 - Disclosure - 10. Subsequent Events Sheet http://imun.com/role/SubsequentEvents 10. Subsequent Events false false R17.htm 0017 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://imun.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) false false R18.htm 0018 - Disclosure - 3. Equipment (Tables) Sheet http://imun.com/role/EquipmentTables 3. Equipment (Tables) false false R19.htm 0019 - Disclosure - 4. Intangible Assets (Tables) Sheet http://imun.com/role/IntangibleAssetsTables 4. Intangible Assets (Tables) false false R20.htm 0020 - Disclosure - 8. Stockholders' Equity (Deficit) (Tables) Sheet http://imun.com/role/StockholdersEquityDeficitTables 8. Stockholders' Equity (Deficit) (Tables) false false R21.htm 0021 - Disclosure - 1. Nature of Business and Going Concern (Details Narrative) Sheet http://imun.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative 1. Nature of Business and Going Concern (Details Narrative) false false R22.htm 0022 - Disclosure - 3. Equipment (Details) Sheet http://imun.com/role/EquipmentDetails 3. Equipment (Details) false false R23.htm 0023 - Disclosure - 4. Intangible Assets (Details) Sheet http://imun.com/role/IntangibleAssetsDetails 4. Intangible Assets (Details) false false R24.htm 0024 - Disclosure - 4. Intangible Assets (Details Narrative) Sheet http://imun.com/role/IntangibleAssetsDetailsNarrative 4. Intangible Assets (Details Narrative) false false R25.htm 0025 - Disclosure - 8. Stockholders' Equity (Deficit) (Details) Sheet http://imun.com/role/StockholdersEquityDeficitDetails 8. Stockholders' Equity (Deficit) (Details) false false R26.htm 0026 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 1) Sheet http://imun.com/role/StockholdersEquityDeficitDetails1 8. Stockholders' Equity (Deficit) (Details 1) false false R27.htm 0027 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 2) Sheet http://imun.com/role/StockholdersEquityDeficitDetails2 8. Stockholders' Equity (Deficit) (Details 2) false false R28.htm 0028 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 3) Sheet http://imun.com/role/StockholdersEquityDeficitDetails3 8. Stockholders' Equity (Deficit) (Details 3) false false R29.htm 0029 - Disclosure - 8. Stockholders' Equity (Deficit) (Details 4) Sheet http://imun.com/role/StockholdersEquityDeficitDetails4 8. Stockholders' Equity (Deficit) (Details 4) false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - Consoldiated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 11, 2011' Process Flow-Through: 0003 - Statement - Consoldiated Balance Sheets (Parenthetical) Process Flow-Through: 0004 - Statement - Consoldiated Statements of Operations (Unaudited) Process Flow-Through: 0005 - Statement - Consolidated Statements of Cash Flows (Unaudited) taug-20131231.xml taug-20131231.xsd taug-20131231_cal.xml taug-20131231_def.xml taug-20131231_lab.xml taug-20131231_pre.xml true true XML 45 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Stockholders' Equity (Deficit) (Tables)
9 Months Ended

Dec. 31, 2013

Notes to Financial Statements

Warrants

Number of

Warrants

Exercise

Price

Expiration

Date

Balance March 31, 2013 394,465 $ 0.75 8/2014

Exercised -

Balance December 31, 2013 394,465

Pricing model to value Stock Options
The warrants were valued utilizing the following assumption employing the Black-Scholes Pricing Model:

Volatility 241.65% to 244.92%

Risk-free rate 1.34% to 0.41%

Dividend -

Expected life of warrants 3

Stock Options

Volatility 220 %

Expected dividend rate -

Expected life of options in years 10

Risk-free rate 1.87 %

Stock Options

Weighted

Weighted Average

Average Remaining Aggregate

Exercise Number of Contractual Intrinsic

Options Price Shares Term Value

Balance March 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

Options granted - - - -

Options exercised - - - -

Options cancelled/forfeited - - - -

Balance at December 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

Exercisable at December 31, 2013 $ 0.10 10,000,000 8.92 $ 400,000

Summary of warrant activity

Volatility 168.32 %

Expected dividend rate -

Expected life of warrant in years 5

Risk-free rate 1.27 %

Number of Warrants Outstanding Exercise Price Exercise Date

Balance March 31, 2013 - - -

Granted - October 29, 2013 75,000,000 $ 10.026 October 29, 2018

Exercised -

Cancelled -

Balance December 31, 2013 75,000,000

X

- Details

Name: TAUG_NotesToFinancialStatementsAbstract

Namespace Prefix: TAUG_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TAUG_SummaryOfWarrantActivity

Namespace Prefix: TAUG_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

8. Stockholders' Equity (Deficit) (Details 3)	9 Months Ended
8. Stockholders' Equity (Deficit) (Details 3)	Dec. 31, 2013
Stockholders Equity Deficit Details 3
Volatility	168.32%
Expected life	5 years
Risk-free rate	1.27%

Consoldiated Balance Sheets (Unaudited) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Current assets:
Cash	$ 57,628	$ 143,034
Other receivables	1,991	7,906
Investments - available for sale securities	50,000
Prepaid expense		19,534
Total current assets	109,619	170,474
Equipment, net of depreciation	26,853	28,382
Other assets:
Deferred financing costs	85,434
Advance to acquire Pilus Energy LLC	70,000
Lincense agreements, net of amortization	1,373,431
Total assets	1,665,337	198,856
CURRENT LIABILITIES
Notes payable	96,425	225,000
Convertible notes, net of discounts	558,773	106,425
Accounts payable	302,488	277,053
Accrued interest	51,343	8,004
Accrued expenses	143,737	148,348
Accrued professional fees	233,965	418,668
Total current liabilities	1,386,731	1,183,498
Stockholders' equity (deficit)
Common stock, par value $0.00001; 1,000,000,000 shares authorized, 401,366,096 and 226,449,077 issued and outstanding at December 31, 2013 and March 31, 2013	4,013	2,264
Additional paid-in capital	37,943,812	31,000,267
Accumulated deficit from prior operations	(16,244,237)	(16,244,237)
Accumulated deficit during development stage	(21,230,874)	(15,741,675)
Accumulated other comprehensive loss	(194,108)	(1,261)
Total stockholders' deficit	278,606	(984,642)
Total liabilties and stockholders' equity (deficit)	$ 1,665,337	$ 198,856

Consolidated Statement of Stockholders' Equity (Deficit) (USD $)	Common Stock	Additional Paid-In Capital	Deficit accumulated from prior operations	Deficit accumulated during the development stage	Accumulatedothercomprehensiveincomeloss	Total
Beginning Balance, Amount at Mar. 31, 2012	$ 1,166	$ 20,770,505	$ (16,244,237)	$ (4,595,168)	$ (2,243)	$ (69,977)
Beginning Balance, Shares at Mar. 31, 2012	116,667,888
Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Shares	48,844,286
Sale of common stock under private placement agreements at $0.10 to $0.15 per share, Amount	489	5,190,633				5,191,122
Amendment to former chief executive officer's employment agreement at $0.10 per share, Shares	2,500,000
Amendment to former chief executive officer's employment agreement at $0.10 per share, Amount	25	249,975				250,000
Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Shares	2,500,000
Issuance of shares under consulting contract for strategic planning officer at $0.10 per share, Amount	25	249,975				250,000
Issuance of shares to purchase domain name at $0.125 per share, Shares	200,000
Issuance of shares to purchase domain name at $0.125 per share, Amount	2	24,998				25,000
Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period A net of vesting amortization, Shares	30,878,983
Issuance of shares under consulting contracts at $0.10 to $0.29 per share during the period, net of vesting amortization, Amount	308	4,505,881				4,506,189
Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Shares	2,720,000
Issuance of shares to convert Caete Invest & Trade, S.A. debt under conversion agreement, Amount	27	225,792				225,819
Conversion of accounts payable at $0.10 per share, Shares	1,592,920
Conversion of accounts payable at $0.10 per share, Amount	16	95,559				95,575
Stock issued for commissions under private placement agreements, Shares	5,335,000
Stock issued for commissions under private placement agreements, Amount	53	688,947				689,000
Commission expense paid with stock issuances under private placements		(689,000)				(689,000)
Commission paid under private placement agreements in cash		(643,956)				(643,956)
Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares	2,500,000
Issuance of shares to CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount	25	624,975				625,000
Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, shares	2,500,000
Issuance of shares to former CEO under employment contract for achieving capital raise goal of $7,500,000 at $0.25 per share, amount	25	624,975				625,000
Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, shares	360,000
Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, amount	4	47,396				47,400
Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, shares	200,000
Issuance of shares to JMJ Financial to obtain loan at $0.15 per share, amount	2	29,998				30,000
Beneficial conversion feature related to JMJ financial		92,391				92,391
Issuance of shares to CEO as signing bonus under employment contract at $0.20 per share, shares	1,500,000
Issuance of shares to CEO as signing bonus under employment contract at $0.20 per share, amount	15	299,985				300,000
Issuance of shares to CEO as additional compensation at $0.04 per share, shares	4,000,000
Issuance of shares to CEO as additional compensation at $0.04 per share, amount	40	159,960				160,000
Issuance of shares to CFO under consulting agreement at $0.06 to $0.20 per share, shares	2,000,000
Issuance of shares to CFO under consulting agreement at $0.06 to $0.20 per share, amount	20	246,480				246,500
Issuance of shares to company attorneys for services rendered at $0.10 to $0.25 per share, shares	2,150,000
Issuance of shares to company attorneys for services rendered at $0.10 to $0.25 per share, amount	22	287,478				287,500
Consulting contract vesting amortization adjustment		(2,082,680)				(2,082,680)
Translation adjustment				(11,146,507)		(11,146,507)
Ending Balance, Amount at Mar. 31, 2013	2,264	31,000,267	(16,244,237)	(15,741,675)	(1,261)	(984,642)
Ending Balance, Shares at Mar. 31, 2013	226,449,077
Issuance of shares to CEO in lieu of salary at a price of $0.04 to $0.24 per share, amount						36,000
Issuance of shares to former chief financial officer at $0.04 to $0.07 per share, shares	360,000
Issuance of shares to former chief financial officer at $0.04 to $0.07 per share, amount	4	15,896				15,900
Issuance of shares for cash at $0.01 to $0.06 per share, shares	4,569,848
Issuance of shares for cash at $0.01 to $0.06 per share, amount	46	141,304				141,350
Issuance of shares to chief executive officer at $0.02 to $0.08 per share, shares	7,790,000
Issuance of shares to chief executive officer at $0.02 to $0.08 per share, amount	79	465,921				466,000
Issuance of shares to chief operating officer at $0.02 to $0.09 per share, shares	5,250,000
Issuance of shares to chief operating officer at $0.02 to $0.09 per share, amount	53	342,447				342,500
Issuance of shares to convert convertible debt at $0.02 to $0.09 per share, shares	63,635,121
Issuance of shares to convert convertible debt at $0.02 to $0.09 per share, amount	636	1,202,718				1,203,354
Issuance of shares to consultants at $0.02 to $0.09 per share, shares	80,461,224
Issuance of shares to consultants at $0.02 to $0.09 per share, amount	803	2,134,435				2,135,238
Contribution of 2,500,000 shares by chief executive officer to finalize licensing agreement at $0.04		106,250				106,250
Issuance of shares to settle accounts payable at $0.04 per share, shares	1,500,000
Issuance of shares to settle accounts payable at $0.04 per share, amount	15	59,985				60,000
Issuance of shares for loan commitment fee at $0.03 per share, shares	7,000,000
Issuance of shares for loan commitment fee at $0.03 per share, amount	70	209,930				210,000
Issuance of shares for available for sale investments $0.06 per share, shares	4,347,826
Issuance of shares for available for sale investments $0.06 per share, amount	43	249,957				250,000
Beneficial conversion feature of convertible		848,014				848,014
Stock-based compensation vesting		26,837				26,837
Strategic alliance warrant valuation		1,139,851				1,139,851
Impairment of available for sale securities					(200,000)	(200,000)
Translation adjustment					7,153	7,153
Net loss					(5,489,199)	(5,489,199)
Ending Balance, Amount at Dec. 31, 2013	$ 4,013	$ 37,943,812	$ (16,244,237)	$ (21,230,874)	$ (194,108)	$ 278,606
Ending Balance, Shares at Dec. 31, 2013	401,363,096

3. Equipment (Details) (USD $)	9 Months Ended
3. Equipment (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Equipment Details
Computer and office equipment	$ 55,085	$ 49,951
Less: accumulated depreciation	28,232	21,569
Equipment, Net	$ 26,853	$ 28,382
Computer and office equipment useful life	5 years

4. Intangible Assets (Details Narrative) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Intangible Assets Details Narrative
Intangible Assets - domain name	$ 1,373,431

Consoldiated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Mar. 31, 2013
STOCKHOLDERS' DEFICIT
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, Authorized	1,000,000,000	1,000,000,000
Common stock, Issued	401,363,096	226,449,077
Common stock, outstanding	401,363,096	226,449,077

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]
Nature of Business	The Company, prior to December 12, 2011, was involved in the business of exploiting new technologies for the production of clean energy. The Company is now moving in the direction of a diversified biotechnology company which includes medical devices and the development of proprietary drug compounds. The mission of the company is to acquire a diversified portfolio of medical technologies. In May 2011, the Company had entered into an exclusive memorandum of understanding with Immunovative Therapies, Ltd. (“ITL”) (an Israeli company) whereby the Company would acquire a subsidiary of ITL. On December 12, 2011, the Company terminated this memorandum of understanding and entered into a License Agreement (the “License Agreement”) with ITL, pursuant to which the Company received an immediate exclusive and worldwide license to commercialize all the Licensed Products based on ITL’s current and future patents and a patent in-licensed from the University of Arizona. The license granted covered two experimental products for the treatment of cancer in clinical development called AlloStim TM and Allo Vax TM (“Licensed Products”). On May 8, 2012, the Company changed its name to Immunovative, Inc. to better reflect its new direction on the development and commercialization of the next generation of immunotherapy treatments. On January 8, 2013, the Company received from ITL, a notice by which ITL purported to terminate the License Agreement dated December 9, 2011 between the Company and ITL (the “ITL Notice”), along with alleged damages. It is the Company’s position that ITL breached the License Agreement by delivering the ITL Notice and, that prior to the ITL Notice, the License Agreement was in full force and, on January 17, 2013, and that the Company had complied in all material respects with the License Agreement and therefore the Company believes that there are no damages to ITL. As such, on January 17, 2013, the Company filed a lawsuit against ITL, which included the request for various injunctive relief against ITL for damages stemming from this breach. On February 19, 2013, the Company and ITL entered into a settlement agreement whereby the parties have agreed to the following: (1) the Company will submit a letter to the Court advising the Court that the parties have reached a settlement and that the Company is withdrawing its motion, (2) ITL will pay the Company $20,000, (3) ITL will issue to the Company, ITL’s share capital equivalent to 9% of the issued and outstanding shares of ITL, (4) the Company will change its name and (5) the settling parties agree that the license agreement will be terminated. On March 13, 2013, the Company changed its name to Tauriga Sciences, Inc. to better reflect its new direction. The Company traded under the symbol “TAUG” beginning on April 9, 2013. On May 31, 2013, the Company signed a Licensing Agreement with Green Hygienics, Inc. (“GHI”) to enable the Company on an exclusive basis for North America, to market and sell 100% tree-free, bamboo-based, biodegradable, hospital grade wipes, as well as other similar products. The Company contracted to pay $250,000 for the licensing rights and issued 4,347,826 shares of common stock of the Company to GHI whereas GHI’s parent company, Green Innovations Ltd. (“GNIN”) has issued the Company 625,000 shares of common stock of GNIN. The Company paid $143,730 in cash to GHI and, in lieu of the remaining $106,270 to be paid in cash, the chief executive officer issued from his personal holdings of Company stock to GHI an additional 2,500,000 shares of common stock of the Company. The shares issued by the chief executive officer were recorded as a capital contribution. See Notes 4, 5, and 8. On October 29, 2013, the Company entered into a strategic alliance agreement with Bacterial Robotics, LLC (Bacterial Robotics), hereinafter referred to as the “Parties”. Bacterial Robotics owns certain patents and/or other intellectual property related to the development of genetically modified micro-organisms (GMOs) and GMOs tailored to perform one of more specific functions, one such GMO being adopted to clean polluting molecules from wastewater, such GMO being referred to herein as the existing BoctoBot Technology (the BR Technology). Bacterial Robotics is developing a whitepaper to deliver to the Company for acceptance. Upon acceptance by the Company, the Parties will form a strategic relationship through the formation of a joint venture in which the Company will be the majority and controlling owner which will use the NuclearBot Technology to further the growth of the nuclear wastewater treatment market. The intent is for Bacterial Robotics to issue a 10 year license agreement. On November 25, 2013, the Company executed a definitive agreement to acquire Pilus Energy, LLC (“Pilus”), a Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater (The wastewater is a $10 billion industry). Pilus is converging digester, fermenter, scrubber, and other proven technologies into a scalable Electrogenic Bioreactor (“EBR”) platform. This transformative technology is the basis of the Pilus Cell™. The EBR harnesses genetically enhanced bacteria, also known as bacterial robots, or BactoBots™, that remediate water, harvest direct current (“DC”) electricity, and produce economically important gases. The EBR accomplishes this through bacterial metabolism, specifically cellular respiration of nearly four hundred carbon and nitrogen molecules. Pilus’ highly metabolic bacteria are non-pathogenic. Because of the mediated biofilm formation, these wastewater-to-value BactoBots resist heavy metal poisoning, swings of pH, and survive in a 4-to-45 degree Celsius temperature range. Additionally, the BactoBots are anaerobically and aerobically active, even with low BOD/COD. On January 28, 2014, the acquisition was completed. Pilus will operate as a wholly-owned subsidiary of the Company. As a condition of the acquisition, Pilus will get one seat on the board of directors, and the shareholders of Pilus will receive 100,000,000 shares of common stock of the Company, which represented a fair market value of approximately $2,000,000. In addition, the Company paid Bacterial Robotics, LLC (“BRLLC”), formerly the parent company of Pilus, $50,000 at closing. In total, the Company paid BRLLC $125,000, which is inclusive of fees contractually owed for strategic alliance, definitive agreement, and the completion of Pilus.
Basis of presentation	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year. These unaudited consolidated financial statements should be read in conjunction with our 2013 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on June 12, 2013.
Going Concern	As indicated in the accompanying consolidated financial statements, the Company has incurred net operating losses of $5,489,199 for the nine months ended December 31, 2013. Since inception of development stage, the Company has incurred net losses of $21,230,874. Management’s plans include the raising of capital through equity markets to fund future operations and cultivating new license agreements or acquiring ownership in medical companies. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreement or ownership interests in medical companies and generate adequate revenues, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currency Translation	Commencing with the quarter ended June 30, 2012, the Company considers the U.S. dollar to be its functional currency. Prior to March 31, 2012, the Company considered the Canadian dollar to be its functional currency. Assets and liabilities were translated into U.S. dollars at year-end exchange rates. Statement of operations amounts were translated using the average rate during the year. Gains and losses resulting from translating foreign currency financial statements were included in accumulated other comprehensive gain or loss, a separate component of stockholders’ deficit.
Cash Equivalents	For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less.
Equipment and Depreciation	Equipment is stated at cost and is depreciated using the straight line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.
Intangible Assets	Intangible asset, consisting of a licensing fee, is stated at cost and has been determined to have a five year life based on the terms of the licensing agreement.
Consolidated Financial Statements	The financial statements include the accounts and activities of Tauriga Sciences, Inc. and its wholly-owned Canadian subsidiary, Tauriga Canada, Inc. (formerly known as Immunovative Canada, Inc.) All inter-company transactions have been eliminated in consolidation.
Net Loss Per Common Share	The Company computes per share amounts in accordance with ASC Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods. A fully diluted calculation is not presented since the results would be anti-dilutive.
Stock-Based Compensation	The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders’ equity/(deficit) over the applicable service periods through the vesting dates based on the fair value of the options or warrants at the end of each period. The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterparty’s performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.
Comprehensive Income	The Company has adopted ASC 211-05 effective January 1, 2012 which requires entities to report comprehensive income within a continuous statement of comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.
Income Taxes	The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.
Impairment of Long-Lived Assets	Long-lived assets, primarily fixed assets and intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Research and development	The Company expenses research and development costs as incurred.
Fair Value Measurements	ASC 820 Fair Value Measurements defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosure about fair value measurements. The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable: Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities); Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). Financial instruments classified as Level 1 - quoted prices in active markets include cash. These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts payable, accrued expenses and due to related parties.
Uncertainty in Income Taxes	Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does meet the more-likely-than-not threshold as of December 31, 2013.
Recent Accounting Pronouncements	Management does not believe any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying consolidated financial statements.

Document and Entity Information	9 Months Ended
Document and Entity Information	Dec. 31, 2013	Feb. 18, 2014
Document And Entity Information
Entity Registrant Name	TAURIGA SCIENCES, INC.
Entity Central Index Key	0001142790
Document Type	10-Q
Document Period End Date	Dec. 31, 2013
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		522,934,923
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014

Consoldiated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		25 Months Ended
	Dec. 31, 2013	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING EXPENSES
General and Administrative	$ 1,162,138	$ 2,703,686	$ 4,460,880	$ 5,479,420	$ 16,602,528
Impairment of advances to Immunovative Therapies, Ltd. for future stock ownership		885,000		2,714,049	3,533,214
Depreciation and amortization expense	32,077	587	48,084	8,245	94,671
Total operating expenses	1,194,215	3,589,273	4,508,964	8,201,714	20,230,413
Loss from operations	(1,194,215)	(3,589,273)	(4,508,964)	(8,201,714)	(20,230,413)
Other income (expense)
Interest expense	(7,540)	(3,410)	(57,839)	(5,922)	(74,249)
Loss on conversion of debt			(321,000)		(321,000)
Gain on settlement of law suit					20,000
Amortization of debt discount	(397,404)		(601,396)		(625,212)
Total other income (expense)	(404,944)	(3,410)	(980,235)	(5,922)	(1,000,461)
Net loss	(1,599,159)	(3,592,683)	(5,489,199)	(8,207,636)	(21,230,874)
Other comprehensive income (loss)
Translation adjustment	5,627	(5,706)	7,153		7,153
Impairment on available for sale investments	(77,500)		(200,000)		(200,000)
Total other comprehensive income (loss)	(71,873)	(5,706)	(192,847)		(192,847)
Comprehensive loss	$ (1,671,032)	$ (3,598,389)	$ (5,682,046)	$ (8,207,636)	$ (21,423,721)
Net loss per share (basic and diluted)	$ 0.00	$ (0.02)	$ (0.02)	$ (0.05)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and diluted	347,748,207	196,957,424	258,387,696	156,677,929

4. Intangible Assets (Details) (USD $)	9 Months Ended
4. Intangible Assets (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Intangible Assets Details
Licensing fee	$ 1,414,851
Less: accumulated amortization	41,420
Intangible Asset	$ 1,373,431
Intangible Asset Estimated Life	5 years

7. Related Parties	9 Months Ended
7. Related Parties	Dec. 31, 2013
Notes to Financial Statements
7. Related Parties	On May 31, 2013, the Company executed a licensing agreement with GHI (see Notes 1, 4, 5 and 8). The Company’s former CFO, Bruce Harmon, is the CFO and Chairman of GNIN, the parent company of GHI.